data_2l35_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2l35 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.7 t . . . . . 0 N--CA 1.462 0.15 0 CA-C-O 120.509 0.195 . . . . 0.0 110.489 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.442 ' N ' ' HG1' ' A' ' 3' ' ' THR . 27.1 m 34.22 31.47 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.142 0.496 . . . . 0.0 111.159 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.557 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.5 OUTLIER -84.82 -44.09 0.69 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.262 179.317 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.557 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.0 Cg_exo -45.37 -43.94 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 122.731 2.287 . . . . 0.0 112.871 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 70.55 -50.45 0.82 Allowed Glycine 0 N--CA 1.464 0.502 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.473 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.8 t -52.8 -35.13 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.9 mt -55.35 -41.7 72.85 Favored 'General case' 0 C--O 1.238 0.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -58.35 -37.58 75.48 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 177.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.3 -27.96 68.49 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.81 -39.03 79.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.9 t -62.08 -51.32 73.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.846 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.47 -43.04 89.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.72 -38.87 92.75 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.466 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 51.2 t0 -65.57 -46.59 78.88 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.916 0.389 . . . . 0.0 110.685 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.5 tp -56.31 -51.36 68.52 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.766 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 m -65.63 -27.32 41.2 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.323 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.578 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.84 -57.33 13.13 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.515 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -56.98 -42.47 80.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.113 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -65.7 -37.73 80.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.288 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.57 -54.47 19.6 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.404 -178.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 21.2 mm -66.21 -44.72 91.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.484 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.78 -39.59 77.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.911 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.0 tp -68.52 -34.5 75.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.023 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.58 -50.72 72.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.624 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -68.05 -39.42 81.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -60.58 -33.69 73.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -55.67 -50.09 71.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.75 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.0 tp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.6 -179.959 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.862 0.363 . . . . 0.0 110.361 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 m -57.53 -26.7 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.459 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.0 tp -46.26 -29.12 1.49 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.655 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -55.56 -48.82 68.34 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.472 ' CD1' ' H ' ' A' ' 41' ' ' ILE . 2.0 mp -56.6 -40.77 71.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.002 0.429 . . . . 0.0 110.104 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.486 ' N ' ' CD1' ' A' ' 42' ' ' ILE . 1.9 mp -64.9 -41.22 91.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.205 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.7 t -58.1 -51.79 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.618 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.5 pt -63.14 -39.89 86.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.91 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.0 t -64.71 -30.68 50.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.171 -0.612 . . . . 0.0 109.83 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -71.21 -47.69 55.9 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.937 -178.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.8 p -67.73 -30.49 48.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.626 -178.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.51 -53.3 16.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.377 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.431 ' O ' ' OG1' ' A' ' 53' ' ' THR . 7.1 m -57.98 -47.1 83.99 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.256 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.5 m -71.11 -28.83 34.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.881 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 35.0 tp -67.36 -55.7 12.71 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 119.882 -0.727 . . . . 0.0 110.821 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.466 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.0 OUTLIER -64.8 -45.27 86.98 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.099 179.614 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 49' ' ' THR . 59.4 m -60.77 -45.16 95.42 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -178.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.492 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.4 mt -73.45 -43.25 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -177.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 m -76.89 -33.13 20.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.365 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.6 tp -79.47 -41.62 27.12 Favored 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 25.9 mt -64.09 -62.11 5.72 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 119.047 -1.061 . . . . 0.0 113.23 -176.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.492 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 7.0 Cg_endo -47.35 -27.14 6.59 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 121.924 1.749 . . . . 0.0 112.504 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -90.24 -65.62 1.0 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 120.384 -0.527 . . . . 0.0 109.809 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.485 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? . . . . . 0 CA--C 1.532 0.256 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.649 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.505 ' O ' ' N ' ' B' ' 7' ' ' GLY . 32.6 m . . . . . 0 CA--C 1.521 -0.135 0 CA-C-O 120.745 0.307 . . . . 0.0 110.685 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.555 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -38.7 -59.21 1.41 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.177 179.848 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -64.38 13.86 0.09 OUTLIER 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 121.528 1.486 . . . . 0.0 111.783 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.555 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -113.01 -66.92 0.49 Allowed Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -51.92 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 9.6 mt -57.82 -39.15 76.93 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.72 76.89 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 108.112 -1.069 . . . . 0.0 108.112 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.88 -30.96 79.38 Favored Glycine 0 CA--C 1.522 0.519 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.099 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 50.5 mm -66.23 -43.34 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 C-N-CA 120.079 -0.648 . . . . 0.0 109.769 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.29 -42.0 89.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.87 -42.6 89.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.706 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.85 -39.25 97.26 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -61.51 -40.47 94.72 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -62.88 -44.93 94.79 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.102 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.4 -44.34 92.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.301 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 69.8 mt -66.54 -30.3 70.58 Favored 'General case' 0 C--O 1.225 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 110.212 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 21.8 m -62.58 -50.2 72.25 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.239 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 71.8 t -70.42 -43.28 78.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.554 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.45 -53.06 60.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.823 0.344 . . . . 0.0 111.194 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 76.3 mt -59.45 -50.64 79.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.965 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.39 38.14 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -57.25 -39.39 75.49 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.11 -35.37 78.5 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.133 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.97 -47.05 95.0 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -63.02 -40.43 97.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.125 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -55.67 -44.67 77.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.438 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 28.3 tp . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.216 179.942 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 5' ' ' SER . 8.3 p . . . . . 0 N--CA 1.461 0.107 0 CA-C-O 120.551 0.215 . . . . 0.0 110.621 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' A' ' 3' ' ' THR . 27.2 m 33.86 34.6 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.198 0.523 . . . . 0.0 111.239 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.578 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -84.94 -42.97 0.68 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.335 179.308 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 5' ' ' SER . 75.5 Cg_exo -46.38 -44.1 20.93 Favored 'Trans proline' 0 N--CA 1.495 1.598 0 C-N-CA 122.745 2.297 . . . . 0.0 112.807 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 70.55 -48.33 0.75 Allowed Glycine 0 N--CA 1.464 0.518 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' PRO . 62.5 t -53.87 -36.38 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 50.1 mt -55.07 -40.99 70.95 Favored 'General case' 0 C--O 1.238 0.461 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -58.2 -37.96 75.82 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.34 -28.02 66.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 178.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.402 HG23 ' N ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.8 -41.05 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.304 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.402 ' N ' HG23 ' A' ' 12' ' ' ILE . 57.4 t -60.0 -53.09 53.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 121.467 0.651 . . . . 0.0 109.573 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -58.62 -34.63 51.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.964 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.32 -34.79 90.38 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -69.25 -44.7 71.42 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.8 tp -66.9 -51.27 57.4 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.42 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 m -59.65 -35.02 57.14 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.328 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.8 tp -64.39 -52.84 56.21 Favored 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.537 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 15.0 m -50.48 -49.83 54.24 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.901 -0.319 . . . . 0.0 111.439 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.6 p -70.73 -31.06 44.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 120.197 -0.601 . . . . 0.0 112.464 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -67.73 -54.6 18.03 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.586 -179.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 27.5 mt -63.96 -50.47 77.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.387 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.27 -41.53 68.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.351 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 29.6 tp -63.58 -42.53 98.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.09 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.9 -48.22 70.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.342 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.1 t -63.85 -39.85 86.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.606 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -59.01 -48.02 83.09 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -61.06 -48.53 81.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.683 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.573 -179.859 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 . . . . . 0 C--O 1.23 0.045 0 CA-C-O 121.022 0.439 . . . . 0.0 110.452 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 16.4 m -63.49 -23.52 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.773 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.0 tp -44.03 -28.11 0.44 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.14 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -60.78 -49.51 77.85 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.471 ' CD1' ' H ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -49.09 76.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.09 0.472 . . . . 0.0 109.989 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.482 ' N ' ' CD1' ' A' ' 42' ' ' ILE . 2.0 mp -61.33 -31.4 50.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.981 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.9 t -62.26 -50.99 69.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.438 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.6 pt -66.11 -35.79 75.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.141 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.6 t -67.05 -40.1 84.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.448 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.14 -44.73 75.42 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.841 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.6 p -69.48 -28.71 39.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.817 -178.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.75 -51.76 25.15 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.772 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.421 ' O ' ' OG1' ' A' ' 53' ' ' THR . 19.7 p -60.09 -40.85 91.03 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.537 -0.465 . . . . 0.0 110.756 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.37 -41.09 78.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.648 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 21.5 tp -65.47 -54.91 21.64 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.793 -179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 56' ' ' LEU . 0.6 OUTLIER -58.58 -43.21 89.4 Favored 'General case' 0 C--O 1.219 -0.518 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.727 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 49' ' ' THR . 99.1 m -60.38 -50.74 72.39 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 112.238 0.459 . . . . 0.0 112.238 -179.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.495 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.3 mt -69.23 -43.95 80.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -177.537 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.526 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.6 m -76.21 -31.18 20.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.148 -0.621 . . . . 0.0 111.85 -178.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.407 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 8.6 tp -75.71 -37.96 58.99 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.23 -51.41 78.48 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.56 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.495 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 59.3 Cg_endo -72.71 -28.73 13.61 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.54 1.493 . . . . 0.0 111.283 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.3 m-30 -67.32 -53.88 25.68 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.131 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.49 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.332 -0.166 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.379 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' B' ' 7' ' ' GLY . 25.4 m . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.991 0.424 . . . . 0.0 110.336 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.555 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -39.59 -62.15 0.89 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.429 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -62.2 10.61 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.154 1.903 . . . . 0.0 112.388 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.555 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.19 -65.52 0.29 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -60.7 -51.96 67.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 121.215 0.531 . . . . 0.0 110.285 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.6 mt -60.49 -34.38 73.97 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.59 -35.93 73.2 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.2 -40.65 98.18 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.685 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 45.5 mm -58.0 -45.7 87.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.986 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.3 m -57.29 -44.69 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.251 179.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.96 -41.42 76.93 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.3 -41.72 98.5 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -60.36 -41.4 93.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.359 . . . . 0.0 110.213 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.8 tp -61.2 -43.95 98.06 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.046 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -57.85 -47.97 84.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.048 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 74.7 mt -61.43 -36.28 79.92 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.013 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -57.63 -43.78 85.1 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.215 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -69.24 -47.15 75.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.733 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.0 mp -62.08 -51.9 66.09 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.105 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 61.0 mt -57.58 -50.3 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.9 -45.17 40.94 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 121.256 0.551 . . . . 0.0 109.942 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 4.9 tp -65.19 -30.08 70.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.119 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.17 -50.07 67.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.219 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -64.1 -38.28 82.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 C-N-CA 120.406 -0.518 . . . . 0.0 109.879 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -61.45 -43.11 99.44 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -60.62 -47.09 87.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.676 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.466 -179.706 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 5' ' ' SER . 5.4 p . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.531 0.205 . . . . 0.0 110.629 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.606 ' H ' ' HG ' ' B' ' 5' ' ' SER . 34.8 m 36.62 26.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.252 0.549 . . . . 0.0 111.212 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.62 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 1.6 t -81.74 -35.43 0.75 Allowed Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.61 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.62 ' CD ' ' N ' ' A' ' 5' ' ' SER . 84.2 Cg_exo -49.45 -41.49 43.7 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.336 2.024 . . . . 0.0 112.554 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.91 -47.01 0.98 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.483 ' H ' ' C ' ' A' ' 6' ' ' PRO . 58.1 t -59.28 -40.64 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -54.37 -43.03 70.99 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.12 -37.6 69.66 Favored 'General case' 0 C--O 1.233 0.184 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.08 -27.46 68.93 Favored Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.3 -38.53 79.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 80.8 t -64.21 -50.89 74.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.15 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.8 t -59.58 -46.1 93.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.18 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.53 -29.2 71.13 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.989 -0.845 . . . . 0.0 110.989 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.524 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 53.3 t0 -67.45 -52.64 37.11 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 110.387 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.3 tp -60.35 -41.23 93.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.127 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.5 -26.45 31.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 37.3 tp -71.43 -57.42 4.45 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.84 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.0 t -62.3 -40.43 96.26 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.145 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.5 t -69.32 -43.82 80.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.662 -179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -60.54 -51.6 68.75 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.333 -178.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 63.7 mt -63.08 -42.48 96.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.942 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -43.88 78.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.96 0.41 . . . . 0.0 110.324 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.96 -36.24 82.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.47 -50.79 71.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.795 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.3 m -69.21 -32.56 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.48 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -61.93 -41.31 97.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.716 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -61.73 -45.39 94.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.651 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.5 tp . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.561 -179.879 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.736 0.303 . . . . 0.0 110.563 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 63.5 t -68.17 -28.74 42.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.636 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.509 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.6 mm? -63.77 -31.29 72.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -62.23 -50.28 66.56 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.3 mt -58.19 -44.3 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.092 0.473 . . . . 0.0 110.453 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.14 -38.65 82.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.471 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.5 m -59.94 -52.16 66.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.736 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.3 pt -62.11 -42.39 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.649 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.4 t -60.66 -35.24 62.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.0 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.6 -39.16 77.41 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.529 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -68.69 -30.46 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.622 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.18 -52.1 25.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.981 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -44.77 90.78 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.622 -0.431 . . . . 0.0 111.8 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.0 m -68.17 -40.32 82.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.563 -179.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 49.5 tp -63.33 -45.81 89.54 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.456 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.524 ' NZ ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -62.03 -49.97 73.9 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.742 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.4 p -62.66 -47.54 83.24 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.605 0.595 . . . . 0.0 112.605 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.482 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 87.4 mt -64.03 -46.05 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.559 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 10.0 m -76.36 -34.62 25.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.153 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.3 tt -68.27 -35.27 77.63 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 113.574 0.954 . . . . 0.0 113.574 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.4 mp -65.42 -52.74 43.33 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 119.456 -0.898 . . . . 0.0 112.127 -177.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 57.6 Cg_endo -71.7 -29.57 15.69 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 121.591 1.527 . . . . 0.0 111.466 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.559 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.7 m-30 -64.28 -48.53 75.37 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.226 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.47 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 N--CA 1.463 0.195 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.428 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' B' ' 7' ' ' GLY . 30.0 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.839 0.352 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.606 ' HG ' ' H ' ' A' ' 4' ' ' VAL . 0.4 OUTLIER -38.49 -64.2 0.49 Allowed Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.584 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.4 Cg_endo -59.31 6.22 0.1 OUTLIER 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.328 2.019 . . . . 0.0 112.296 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -117.78 -66.29 0.34 Allowed Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -60.68 -51.95 67.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-O 121.091 0.472 . . . . 0.0 110.11 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 49.4 mt -57.66 -37.2 73.0 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.23 -34.48 68.63 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -36.49 91.48 Favored Glycine 0 CA--C 1.524 0.649 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.328 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 11.3 mt -65.42 -41.39 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 119.496 -0.882 . . . . 0.0 109.394 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 m -57.69 -44.2 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -54.29 -50.34 57.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.169 -0.613 . . . . 0.0 109.677 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.17 -31.97 66.57 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' OD1' ' A' ' 16' ' ' ASP . 30.5 t0 -69.38 -41.04 77.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.774 0.321 . . . . 0.0 110.835 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -61.49 -52.39 64.7 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 121.008 0.432 . . . . 0.0 110.402 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -58.42 -39.12 73.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.128 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.3 mt -60.85 -53.08 61.72 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.61 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 8.3 m -48.26 -45.84 35.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.528 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 91.8 t -65.37 -33.83 66.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.723 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.9 tp -68.23 -53.76 22.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.49 -179.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 mm -60.83 -47.16 94.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 C-N-CA 120.658 -0.417 . . . . 0.0 109.931 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.12 -45.04 68.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.045 0.45 . . . . 0.0 109.835 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 31.0 tp -58.93 -38.73 79.65 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.18 -38.27 90.51 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.298 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -61.04 -47.75 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.031 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -61.9 -40.88 96.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.048 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -57.21 -48.47 78.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.491 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.8 tp . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.389 -179.977 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 5' ' ' SER . 81.6 p . . . . . 0 C--O 1.23 0.056 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.431 ' N ' ' OG ' ' B' ' 5' ' ' SER . 34.2 m 34.78 32.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 121.158 0.504 . . . . 0.0 111.323 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -81.04 -46.34 1.17 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.093 179.292 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.527 ' C ' ' H ' ' A' ' 8' ' ' VAL . 50.8 Cg_exo -43.27 -43.78 10.24 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.814 2.343 . . . . 0.0 112.996 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.93 -46.88 0.76 Allowed Glycine 0 N--CA 1.463 0.464 0 N-CA-C 108.932 -1.667 . . . . 0.0 108.932 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.2 t -55.53 -38.95 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.6 mt -55.8 -36.79 67.79 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.57 -37.68 84.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -29.21 71.06 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 178.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.69 -42.89 93.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 96.4 t -57.86 -51.13 74.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.3 t -58.47 -30.21 40.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.931 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.43 -38.44 90.99 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -68.2 -44.67 75.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.037 0.446 . . . . 0.0 110.226 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 tp -58.54 -51.38 70.13 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.932 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.6 m -65.0 -29.59 47.85 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.716 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.4 -59.57 5.19 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 120.046 -0.662 . . . . 0.0 109.402 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 70.5 p -52.2 -43.21 64.08 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.005 179.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.27 -30.02 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 112.103 0.408 . . . . 0.0 112.103 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.7 -55.21 9.2 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.18 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.429 HD12 HG22 ' A' ' 23' ' ' ILE . 54.5 mt -68.64 -41.01 82.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.254 -0.578 . . . . 0.0 110.352 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.2 -42.83 95.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.138 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -67.82 -32.39 72.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.737 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.45 -51.1 70.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.641 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.5 m -66.54 -36.98 78.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.413 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -60.16 -45.62 92.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.644 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.3 t80 -64.79 -41.12 96.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.745 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.74 -179.791 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.939 0.4 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 20.8 m -68.33 -25.95 32.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -46.43 -30.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.655 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.64 -49.81 62.34 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.404 HG21 HD11 ' A' ' 41' ' ' ILE . 16.7 mm -58.12 -44.85 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.026 0.441 . . . . 0.0 110.51 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.9 mt -63.43 -36.88 77.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.569 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 65.6 m -61.04 -51.47 69.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.506 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 9.7 pt -62.66 -43.36 98.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.935 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -58.69 -44.0 88.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.019 0.437 . . . . 0.0 110.233 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.62 -36.06 83.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.701 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.8 t -65.84 -34.08 67.91 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-O 121.087 0.47 . . . . 0.0 109.833 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.515 ' C ' ' HZ1' ' A' ' 52' ' ' LYS . . . -68.45 -53.81 21.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.382 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 6.3 m -55.49 -49.22 73.12 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.075 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.3 m -70.51 -26.34 28.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.617 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 27.6 tp -65.98 -56.06 13.57 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.867 -179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.515 ' HZ1' ' C ' ' A' ' 48' ' ' ALA . 1.4 mppt? -65.16 -44.38 88.71 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.394 -0.522 . . . . 0.0 110.244 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.8 m -60.7 -44.97 95.92 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.474 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.0 mt -74.05 -41.73 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.23 -32.54 19.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.254 -178.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 tp -78.41 -44.22 25.39 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.9 mt -59.81 -61.9 6.96 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 119.278 -0.969 . . . . 0.0 113.039 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.474 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -49.31 -26.55 11.7 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 C-N-CA 122.135 1.89 . . . . 0.0 112.233 -179.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -92.27 -64.8 1.06 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.487 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 CA--C 1.53 0.194 0 C-N-CA 120.132 -0.627 . . . . 0.0 110.196 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.833 0.349 . . . . 0.0 110.326 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.551 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -41.84 -64.69 0.61 Allowed Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.179 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.5 Cg_endo -60.33 6.22 0.12 Allowed 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 122.257 1.971 . . . . 0.0 111.956 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.46 -65.11 0.28 Allowed Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.486 ' CG2' ' N ' ' B' ' 9' ' ' LEU . 16.1 m -59.94 -52.16 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.483 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.486 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 39.1 mt -54.16 -39.11 66.27 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.72 71.36 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.66 -34.53 88.88 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.896 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.54 -46.96 88.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.302 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -53.56 -42.47 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.047 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 84.2 t -57.92 -44.72 87.16 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.907 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.52 -37.47 94.21 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -61.81 -41.99 98.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 0.0 110.142 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 58.4 tp -61.28 -44.38 97.32 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.35 -41.53 87.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.007 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 20.5 mt -64.55 -35.5 81.19 Favored 'General case' 0 C--O 1.225 -0.208 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.064 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 96.0 m -61.79 -48.83 78.86 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.632 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 61.7 t -68.42 -47.64 76.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.525 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 29.2 tp -60.86 -51.9 67.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.303 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 79.0 mt -57.65 -50.61 76.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.02 37.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.024 0.44 . . . . 0.0 109.934 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.21 -41.03 78.67 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.74 -37.21 83.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.403 179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.41 -46.51 95.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -61.46 -41.02 96.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.177 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 45.0 t80 -59.34 -44.51 92.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.61 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 30.1 tp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.28 -179.859 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.459 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.14 0 N-CA-C 110.385 -0.228 . . . . 0.0 110.385 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' A' ' 3' ' ' THR . 26.9 m 33.11 34.84 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.082 0.468 . . . . 0.0 111.637 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -86.91 -41.57 0.54 Allowed Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.304 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.2 Cg_exo -47.9 -45.03 25.86 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.659 2.239 . . . . 0.0 112.703 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.76 -49.21 0.82 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.491 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.0 t -54.96 -41.72 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 71.4 mt -55.22 -37.9 67.75 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.09 -36.9 75.92 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -61.14 -28.87 69.74 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 178.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -66.6 -40.89 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.51 -50.44 80.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.71 179.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.1 t -58.29 -44.62 88.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.713 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.51 -36.55 78.01 Favored Glycine 0 CA--C 1.525 0.674 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.037 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.528 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.2 t0 -65.21 -48.66 72.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.904 0.383 . . . . 0.0 110.592 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 28.7 tp -55.53 -51.64 66.36 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.716 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 m -64.36 -28.72 45.51 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 C-N-CA 120.213 -0.595 . . . . 0.0 110.801 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.26 -56.87 15.61 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.946 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.3 m -55.14 -42.39 72.99 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.415 179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.48 -29.05 44.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.829 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.47 -53.86 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.193 -178.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.8 mt -66.15 -42.81 91.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.402 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.25 -39.5 90.55 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.992 0.425 . . . . 0.0 110.429 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 33.0 tp -69.14 -37.54 78.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.041 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.61 -50.4 73.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 26.0 m -67.63 -35.69 73.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.634 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -60.31 -41.83 94.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.528 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -65.77 -38.75 89.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.721 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.9 tp . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.539 -179.698 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.871 0.367 . . . . 0.0 110.401 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.0 m -69.17 -23.94 27.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.74 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.437 ' CD1' ' H ' ' A' ' 39' ' ' LEU . 9.3 mp -46.06 -35.93 5.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.594 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.79 -46.47 89.9 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 58.8 mt -59.2 -38.29 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.016 0.436 . . . . 0.0 110.6 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.4 mm -67.41 -39.45 82.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -61.46 -52.12 65.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.616 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.1 pt -61.62 -44.67 99.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.905 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.8 t -56.72 -43.53 79.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.519 -0.472 . . . . 0.0 109.792 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 64.9 mt -65.21 -32.66 74.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.188 -179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.12 -36.15 76.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.14 -51.13 41.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.145 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.434 ' O ' ' OG1' ' A' ' 53' ' ' THR . 14.3 m -56.57 -48.45 77.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.455 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.8 m -71.36 -28.52 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 64.8 tp -67.74 -54.74 16.88 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.839 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.528 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 2.1 mptp? -65.24 -44.84 86.89 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.42 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 49' ' ' THR . 23.9 m -61.09 -47.19 87.46 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.486 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.1 mt -70.93 -42.95 77.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.533 ' O ' ' CD2' ' A' ' 59' ' ' PHE . 16.5 m -75.68 -36.58 34.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.509 -178.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -71.85 -39.28 69.81 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 -178.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.468 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 1.4 mp -60.39 -50.44 85.72 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.371 0.878 . . . . 0.0 113.371 -177.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.486 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 7.4 Cg_endo -50.65 -43.96 42.99 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 CA-C-N 120.718 1.292 . . . . 0.0 111.64 -178.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.533 ' CD2' ' O ' ' A' ' 55' ' ' VAL . 24.2 m-85 -74.56 -68.01 0.58 Allowed 'General case' 0 N--CA 1.433 -1.275 0 CA-C-O 120.742 0.306 . . . . 0.0 110.665 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.475 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 C--N 1.331 -0.215 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.298 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' B' ' 7' ' ' GLY . 4.7 t . . . . . 0 N--CA 1.465 0.316 0 CA-C-O 120.436 0.16 . . . . 0.0 111.23 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.523 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -33.14 -61.43 0.36 Allowed Pre-proline 0 CA--C 1.535 0.366 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.58 9.39 0.12 Allowed 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.052 1.835 . . . . 0.0 112.194 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' VAL . . . -120.69 -63.85 0.25 Allowed Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.964 -0.454 . . . . 0.0 111.964 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' B' ' 11' ' ' GLY . 35.2 m -61.52 -55.28 25.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 C-N-CA 120.224 -0.591 . . . . 0.0 110.607 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.415 ' H ' ' CG2' ' B' ' 8' ' ' VAL . 40.8 mt -53.51 -38.1 63.41 Favored 'General case' 0 C--O 1.244 0.788 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.2 -36.71 71.19 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 177.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.86 -35.75 91.78 Favored Glycine 0 CA--C 1.522 0.472 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.976 179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . 0.423 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.5 mp -65.03 -46.25 92.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.572 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.01 -44.49 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 C-N-CA 118.97 -1.092 . . . . 0.0 109.0 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.18 -43.99 77.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.793 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.08 -36.67 92.68 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -60.65 -46.23 91.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.107 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -49.35 77.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.622 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 70.0 t -54.04 -45.31 64.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.12 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 91.9 mt -60.19 -50.94 71.68 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.967 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -44.97 -49.44 11.18 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.484 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -62.9 -37.64 79.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.547 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.0 tp -63.74 -50.3 69.64 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.642 -179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 24.4 mm -58.85 -46.11 91.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -52.41 -48.7 65.55 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 32.3 tp -56.17 -37.09 69.08 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -37.45 87.32 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.24 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.81 -47.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -61.2 -40.7 94.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.22 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -58.51 -44.8 89.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.557 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.0 tp . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.405 -179.806 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 5' ' ' SER . 60.4 p . . . . . 0 N--CA 1.462 0.166 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.47 ' N ' ' OG ' ' B' ' 5' ' ' SER . 30.4 m 34.85 29.95 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.219 0.533 . . . . 0.0 111.065 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.619 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -91.26 -38.67 0.38 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.215 179.057 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.3 Cg_exo -48.18 -42.19 33.44 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.429 2.086 . . . . 0.0 112.551 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.07 -47.14 0.8 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 108.863 -1.695 . . . . 0.0 108.863 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.529 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -56.53 -40.85 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.0 mt -55.69 -35.39 65.98 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.63 -37.8 87.75 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 177.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.23 -29.12 70.4 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 178.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.27 -42.58 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.9 t -57.07 -51.89 63.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.103 0.478 . . . . 0.0 109.971 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.4 t -59.2 -43.17 88.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.952 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -36.35 88.08 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.466 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -66.32 -49.75 65.94 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.826 0.346 . . . . 0.0 110.523 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 23.0 tp -54.82 -51.02 67.14 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.83 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.5 m -65.18 -29.12 46.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.995 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -61.12 -58.86 6.6 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.999 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -54.9 -40.48 69.84 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.604 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.9 t -69.57 -30.02 43.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.22 -54.34 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.103 -178.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 22.0 mt -68.14 -41.53 84.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.535 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.36 -41.76 94.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.444 . . . . 0.0 110.094 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.0 tp -68.2 -32.85 73.36 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.909 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.62 -51.09 70.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.627 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.56 -36.36 77.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.506 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -60.64 -46.25 90.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.506 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -69.0 -45.9 69.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.78 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.2 tp . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.552 -179.81 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.855 0.36 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 21.9 m -65.77 -24.7 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.697 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.42 ' CD1' ' H ' ' A' ' 39' ' ' LEU . 10.2 mp -45.91 -29.22 1.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.404 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.18 -47.48 81.1 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.58 -38.76 72.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.932 0.396 . . . . 0.0 110.598 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.5 ' N ' ' CD1' ' A' ' 42' ' ' ILE . 1.9 mp -67.13 -43.14 88.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.168 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -58.54 -51.25 70.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.875 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.9 pt -63.04 -45.02 99.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.814 -179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.59 -36.36 53.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.633 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -38.43 80.79 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.348 -179.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.82 -31.99 56.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.166 -0.614 . . . . 0.0 109.682 -179.383 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.61 -52.36 21.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.482 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.4 ' O ' ' OG1' ' A' ' 53' ' ' THR . 4.6 m -58.81 -45.26 90.33 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.512 -178.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -71.51 -31.45 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 56.0 tp -68.07 -53.47 25.32 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 119.816 -0.754 . . . . 0.0 110.954 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.448 ' CD ' ' N ' ' A' ' 52' ' ' LYS . 11.8 mptt -63.5 -47.12 83.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.732 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 49' ' ' THR . 64.1 p -65.23 -41.92 93.91 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.455 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 97.5 mt -71.52 -46.65 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -177.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.1 m -74.72 -34.95 35.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.645 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.2 tp -78.35 -41.04 34.64 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.471 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 37.2 mt -53.48 -52.95 62.06 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.471 ' HD2' ' N ' ' A' ' 57' ' ' ILE . 9.3 Cg_endo -51.1 -44.16 44.09 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 121.228 1.285 . . . . 0.0 112.386 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -75.98 -57.17 4.03 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.532 0.283 0 C-N-CA 120.637 -0.425 . . . . 0.0 109.996 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.438 ' CG2' ' N ' ' B' ' 5' ' ' SER . 18.4 m . . . . . 0 N--CA 1.461 0.121 0 CA-C-O 120.687 0.28 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.602 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -45.9 -64.81 0.8 Allowed Pre-proline 0 CA--C 1.533 0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.608 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.439 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 10.5 Cg_endo -52.95 2.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 121.872 1.715 . . . . 0.0 112.283 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.602 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -99.99 -68.76 0.87 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -65.25 -49.61 77.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.826 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.2 mt -55.32 -39.9 70.51 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.17 89.24 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.5 -29.88 74.8 Favored Glycine 0 CA--C 1.52 0.404 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.159 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -69.09 -47.52 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 C-N-CA 119.661 -0.816 . . . . 0.0 108.976 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -53.86 -42.3 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 118.674 -1.21 . . . . 0.0 108.811 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.58 -42.34 91.22 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.992 179.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.9 -38.45 96.11 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -61.34 -43.2 99.28 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.7 tp -61.16 -46.98 88.29 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.811 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -58.63 -45.49 90.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 89.4 mt -60.87 -50.35 73.77 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.872 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.9 m -45.74 -50.23 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.471 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.28 -36.88 77.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.617 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.1 tp -63.72 -50.67 68.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.571 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 28.6 mm -59.39 -44.27 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.27 -47.11 69.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.211 0.529 . . . . 0.0 109.654 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.93 -38.93 76.81 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.63 87.87 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.258 179.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 73.1 t -60.47 -47.31 93.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -61.2 -40.93 95.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.192 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -58.79 -47.3 85.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.717 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 26.3 tp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.43 -179.785 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.2 t . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.639 0.256 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.468 ' H ' ' CB ' ' B' ' 5' ' ' SER . 26.9 m 34.68 34.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.228 0.537 . . . . 0.0 111.248 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.621 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -86.57 -37.43 0.52 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.36 179.067 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.621 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.1 Cg_exo -48.71 -41.2 38.45 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.359 2.04 . . . . 0.0 112.512 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.72 -47.21 0.74 Allowed Glycine 0 N--CA 1.463 0.491 0 N-CA-C 108.795 -1.722 . . . . 0.0 108.795 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.518 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.8 t -55.0 -38.24 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.001 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 68.0 mt -55.32 -39.51 70.03 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.05 -38.45 79.4 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 177.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.63 -26.89 67.29 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -68.04 -42.18 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.86 -54.11 39.89 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.733 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.6 t -58.49 -30.25 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.798 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.44 -38.8 93.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.531 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.1 t0 -67.62 -45.88 74.15 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.232 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.0 tp -57.65 -51.01 71.26 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -66.05 -28.71 44.59 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.774 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -60.19 -56.99 14.76 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 120.297 -0.561 . . . . 0.0 109.545 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.3 m -57.99 -41.79 83.78 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.292 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.57 -36.76 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.973 0.36 . . . . 0.0 111.973 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.08 -55.36 12.79 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 121.056 -0.258 . . . . 0.0 111.254 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.9 mt -66.42 -44.4 90.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.723 -179.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.29 -43.97 88.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.134 0.492 . . . . 0.0 110.231 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.4 tp -67.12 -30.92 71.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.939 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.55 -51.07 68.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -36.11 76.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.365 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -61.82 -48.69 79.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.546 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 61.2 t80 -70.35 -48.47 56.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.669 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.7 tp . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.51 -179.816 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.6 m -62.64 -27.26 42.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.677 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -48.78 -29.38 4.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.921 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.0 -47.96 83.15 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.454 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 1.9 mp -55.62 -45.8 79.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.9 0.381 . . . . 0.0 110.079 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.481 ' N ' ' CD1' ' A' ' 42' ' ' ILE . 1.9 mp -65.22 -29.48 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.429 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.7 m -65.33 -49.27 70.05 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.4 pt -68.87 -39.2 79.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.473 -179.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.2 t -61.76 -43.05 96.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.125 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -69.02 -35.93 77.19 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.593 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.58 -32.92 59.08 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.954 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.01 -49.93 32.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.476 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.43 ' H ' ' HG1' ' A' ' 49' ' ' THR . 2.6 m -59.55 -48.62 80.94 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.2 -179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.8 m -64.53 -37.56 80.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.867 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 35.3 tp -63.07 -44.15 96.6 Favored 'General case' 0 C--O 1.224 -0.246 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.296 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.531 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 3.8 mptp? -59.79 -52.98 63.16 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.49 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.8 m -63.85 -46.46 84.93 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 -178.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 84.9 mt -62.7 -47.5 92.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.531 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 5.5 m -76.47 -35.91 27.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 120.327 -0.549 . . . . 0.0 111.024 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.5 tt -65.24 -33.07 75.13 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 113.091 0.775 . . . . 0.0 113.091 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.7 mt -66.75 -54.79 20.24 Favored Pre-proline 0 CA--C 1.544 0.75 0 C-N-CA 119.549 -0.86 . . . . 0.0 112.692 -178.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 55.9 Cg_endo -70.09 -28.57 23.5 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.726 1.617 . . . . 0.0 111.033 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.98 -52.0 64.67 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.523 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.446 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.7 mm? . . . . . 0 C--N 1.331 -0.224 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.507 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' B' ' 7' ' ' GLY . 28.3 m . . . . . 0 C--O 1.23 0.047 0 CA-C-O 120.943 0.401 . . . . 0.0 110.433 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.559 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -38.67 -62.86 0.65 Allowed Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.505 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -59.93 6.99 0.09 OUTLIER 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.197 1.931 . . . . 0.0 112.229 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.559 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -116.99 -66.44 0.37 Allowed Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -58.2 -51.88 65.62 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 121.007 0.432 . . . . 0.0 110.3 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 32.2 mt -56.79 -38.42 72.5 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.23 67.19 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.13 -36.84 93.42 Favored Glycine 0 CA--C 1.522 0.498 0 CA-C-N 114.135 -1.393 . . . . 0.0 110.884 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 19.6 mt -63.96 -42.53 96.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.567 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 m -56.64 -46.05 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.833 178.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.8 t -52.44 -45.12 45.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 C-N-CA 120.081 -0.647 . . . . 0.0 109.474 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.3 -37.45 91.91 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -60.58 -47.0 88.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.094 0.474 . . . . 0.0 110.175 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.5 tp -56.61 -47.22 80.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.155 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -56.35 -45.54 81.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.272 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 30.0 mt -59.67 -52.84 63.78 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.588 -0.445 . . . . 0.0 109.977 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.1 m -44.64 -47.4 10.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.574 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -63.45 -38.43 82.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.485 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 39.7 tp -64.58 -54.86 25.37 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.67 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 8.5 mm -55.13 -47.48 77.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.893 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -50.98 -49.14 60.78 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 121.118 0.485 . . . . 0.0 109.781 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -55.86 -36.46 67.58 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.76 -37.72 88.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.19 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -60.62 -47.69 91.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -62.35 -40.04 95.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.053 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -59.14 -43.8 92.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.551 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.9 tp . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.462 -179.935 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.1 t . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.62 0.248 . . . . 0.0 110.448 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 3' ' ' THR . 29.5 m 32.23 34.44 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.561 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -85.49 -40.77 0.62 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.442 179.345 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 90.1 Cg_exo -47.77 -43.01 29.97 Favored 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.695 2.264 . . . . 0.0 112.801 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 69.98 -52.18 0.75 Allowed Glycine 0 N--CA 1.465 0.568 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 6' ' ' PRO . 63.1 t -50.73 -36.12 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 177.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 36.2 mt -55.4 -40.93 72.03 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.524 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -56.18 -39.07 71.8 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 177.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.9 -27.53 67.03 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -69.03 -37.15 76.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.1 t -65.6 -52.65 48.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.22 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.4 t -59.77 -42.63 89.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.138 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.43 73.14 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.346 -0.701 . . . . 0.0 111.346 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -69.94 -54.08 14.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.771 0.319 . . . . 0.0 110.487 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 50.2 tp -61.05 -40.71 94.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.204 0.526 . . . . 0.0 109.815 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.6 t -69.23 -27.63 35.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.272 -179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 tp -72.16 -55.87 6.54 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.802 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 m -62.51 -39.09 92.4 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.235 -0.586 . . . . 0.0 110.975 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.85 -39.36 75.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.658 -0.246 . . . . 0.0 111.521 -179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.3 -52.8 56.77 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.387 -178.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -65.67 -43.7 93.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.363 -179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -40.21 81.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.023 0.439 . . . . 0.0 110.404 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -71.1 -35.82 71.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.258 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.75 -50.19 70.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.996 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 29.6 m -69.17 -33.84 60.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.357 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -63.39 -45.26 91.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.456 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -61.18 -50.83 71.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.428 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 28.7 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.25 179.758 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.9 tp10 . . . . . 0 CA--C 1.529 0.15 0 CA-C-O 120.985 0.422 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.2 m -56.63 -26.54 23.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.544 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.9 tp -47.79 -32.57 6.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.643 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.0 -53.16 42.55 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.9 mm -56.38 -46.41 81.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-O 121.055 0.455 . . . . 0.0 110.436 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.41 HD13 HG22 ' A' ' 42' ' ' ILE . 95.7 mt -55.02 -45.25 76.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.171 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.7 t -60.12 -41.14 92.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.041 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 5.3 mm -57.44 -53.9 37.98 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.278 0.561 . . . . 0.0 111.125 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 p -64.65 -27.64 43.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.184 -0.606 . . . . 0.0 110.279 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.9 -46.42 74.95 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.276 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.7 p -67.61 -33.44 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.626 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.59 -44.62 77.69 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.633 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.5 p -66.56 -52.06 49.69 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.836 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.3 m -65.35 -37.33 79.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.244 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.1 tt -65.35 -42.19 93.1 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.591 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 14.6 tptm -62.98 -52.43 63.04 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.884 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 75.5 p -65.95 -44.02 86.23 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 112.807 0.669 . . . . 0.0 112.807 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.477 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 88.5 mt -64.93 -45.97 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.538 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.3 m -77.64 -36.34 22.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.135 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.1 tt -67.27 -31.93 72.6 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.5 mm -67.74 -54.19 18.44 Favored Pre-proline 0 CA--C 1.544 0.729 0 C-N-CA 119.663 -0.815 . . . . 0.0 112.669 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 53.7 Cg_endo -69.54 -28.05 26.77 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 121.729 1.619 . . . . 0.0 111.0 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.81 -54.62 36.17 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.6 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.458 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.523 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.7 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.761 0.315 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.448 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -40.21 -63.93 0.64 Allowed Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.783 -179.071 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 30.8 Cg_endo -61.6 0.73 0.97 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.099 1.866 . . . . 0.0 112.02 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.448 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -107.29 -64.02 0.59 Allowed Glycine 0 N--CA 1.466 0.7 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.522 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 0.2 OUTLIER -64.11 -50.95 74.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.091 0.472 . . . . 0.0 109.859 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.38 -38.96 81.84 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.19 -32.77 66.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -38.34 93.91 Favored Glycine 0 CA--C 1.525 0.713 0 CA-C-N 114.449 -1.251 . . . . 0.0 111.625 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 8.2 mt -65.73 -42.31 92.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 C-N-CA 119.555 -0.858 . . . . 0.0 109.61 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.5 m -55.75 -45.27 79.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.0 t -53.73 -50.18 52.9 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.674 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.46 -31.22 62.83 Favored Glycine 0 CA--C 1.527 0.844 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -70.93 -40.38 72.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.742 0.306 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 tp -61.53 -51.39 68.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -59.03 -44.43 91.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.353 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 26.8 mt -58.45 -51.94 67.73 Favored 'General case' 0 C--O 1.227 -0.117 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.925 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -48.07 -50.85 26.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 0.0 110.456 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.2 t -60.82 -31.26 49.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.137 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 13.9 tp -67.86 -44.74 76.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.894 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 28.4 mm -61.53 -51.23 75.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.035 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.86 -42.25 75.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.144 0.497 . . . . 0.0 109.92 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.2 tp -60.02 -37.38 79.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.709 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.81 94.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.204 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -60.13 -48.11 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.059 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -63.66 -38.95 93.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.221 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 44.0 t80 -58.26 -46.96 85.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.8 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.227 179.974 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.462 0.137 0 CA-C-O 120.598 0.237 . . . . 0.0 110.374 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.498 ' N ' ' OG ' ' B' ' 5' ' ' SER . 26.8 m 34.61 31.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.173 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.616 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -85.71 -38.33 0.58 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.432 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.616 ' CD ' ' N ' ' A' ' 5' ' ' SER . 97.9 Cg_exo -48.43 -42.4 34.77 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 122.405 2.07 . . . . 0.0 112.572 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.28 -48.39 0.71 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' PRO . 76.7 t -53.68 -35.94 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 177.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.0 mt -54.84 -41.88 71.27 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.67 -37.98 77.21 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 177.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.82 -26.02 64.63 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -70.9 -38.38 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.6 t -61.42 -54.6 32.79 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-O 121.355 0.598 . . . . 0.0 109.521 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 t -60.57 -36.26 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.284 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.11 -38.75 96.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -67.92 -47.75 67.86 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.889 0.376 . . . . 0.0 110.382 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.697 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 23.5 tp -58.91 -50.67 73.15 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.044 -179.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -68.33 -26.33 33.56 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.292 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.764 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.5 mt -62.81 -54.99 30.47 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.469 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.1 m -60.39 -43.99 96.1 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.298 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 98.6 t -62.75 -49.36 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.33 -53.51 53.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.143 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.1 mt -58.8 -44.34 90.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.159 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.13 -38.02 81.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.286 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.39 -48.05 74.23 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.93 -46.85 64.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.512 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.2 t -62.06 -45.21 99.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -55.22 -43.67 74.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.636 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -59.21 -48.47 81.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.3 tt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.435 179.951 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.778 0.323 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.7 m -56.34 -24.48 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.41 ' CD1' ' H ' ' A' ' 39' ' ' LEU . 10.1 mp -46.9 -32.54 3.87 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.394 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 -50.89 42.7 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 61.0 mt -60.74 -41.05 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.669 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 82.1 mt -66.27 -39.44 84.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.398 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.4 t -60.53 -50.83 71.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.794 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 8.3 pt -64.51 -44.11 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -57.52 -42.97 82.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.128 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.68 -39.71 91.59 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.694 -178.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.24 -30.24 49.67 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.067 0 C-N-CA 120.396 -0.521 . . . . 0.0 109.658 -179.21 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.73 -50.18 32.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.546 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.7 m -58.5 -47.04 85.44 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.352 -0.539 . . . . 0.0 111.108 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.7 m -69.0 -44.69 81.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.596 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 37.9 tp -53.41 -51.81 61.38 Favored 'General case' 0 CA--C 1.519 -0.218 0 C-N-CA 120.114 -0.634 . . . . 0.0 110.302 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.697 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 3.4 mmmm -60.45 -43.94 96.34 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.825 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.2 m -59.68 -49.82 76.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.483 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 2.8 mp -70.97 -44.84 75.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.519 ' O ' ' CD1' ' A' ' 59' ' ' PHE . 6.0 m -74.92 -34.18 32.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.887 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.404 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 10.8 tp -75.33 -37.33 60.79 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -178.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.1 mt -57.59 -52.64 72.81 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.483 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 49.5 Cg_endo -69.59 -27.58 27.11 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.434 1.423 . . . . 0.0 111.216 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.519 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.4 m-30 -63.98 -56.37 15.63 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.28 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.516 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.331 -0.234 0 CA-C-O 120.932 0.396 . . . . 0.0 110.096 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.418 ' O ' ' N ' ' B' ' 7' ' ' GLY . 26.6 m . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.767 0.318 . . . . 0.0 110.456 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.568 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -40.49 -62.75 0.87 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.213 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -61.85 11.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 122.09 1.86 . . . . 0.0 112.235 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.568 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.74 -66.14 0.28 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -50.86 78.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-O 121.055 0.455 . . . . 0.0 110.224 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.8 mt -60.13 -37.14 79.16 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.52 -34.15 66.73 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.02 -43.4 97.41 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.946 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 42.6 mm -57.82 -41.72 80.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.195 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.3 m -60.75 -43.02 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.395 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -57.44 -47.2 85.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 120.338 -0.545 . . . . 0.0 109.913 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.37 -36.3 90.68 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -63.18 -41.19 99.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.147 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.9 tp -61.77 -45.73 92.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.917 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.91 -48.0 82.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.384 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 49.9 mt -61.24 -49.13 78.36 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.105 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -46.1 -50.33 15.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.504 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 97.1 t -66.01 -31.72 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.501 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.6 tp -66.22 -51.83 53.78 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.482 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 20.9 mm -61.4 -50.71 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.3 -44.35 61.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.176 0.512 . . . . 0.0 109.677 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.33 -38.47 80.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.478 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.0 91.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.088 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 84.1 t -60.86 -46.0 97.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.987 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -60.84 -41.74 96.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.162 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -58.02 -49.99 74.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.409 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 19.9 mt . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.406 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.6 t . . . . . 0 N--CA 1.462 0.125 0 CA-C-O 120.574 0.226 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.406 ' C ' ' O ' ' A' ' 3' ' ' THR . 27.1 m 34.11 34.3 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.502 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.593 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -78.24 -41.15 1.95 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.469 179.402 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 5' ' ' SER . 78.7 Cg_exo -47.57 -41.98 29.57 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.727 2.285 . . . . 0.0 112.748 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.26 -47.37 0.85 Allowed Glycine 0 N--CA 1.462 0.416 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -179.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.52 ' H ' ' C ' ' A' ' 6' ' ' PRO . 70.8 t -56.1 -39.47 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.5 mt -55.86 -38.1 69.66 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.23 -38.51 83.63 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.13 -29.76 71.96 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.42 -42.87 94.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.6 t -57.81 -51.64 67.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.8 t -57.79 -30.12 36.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.758 178.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.35 -38.12 86.84 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -68.03 -43.79 77.95 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.87 0.367 . . . . 0.0 110.648 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 27.5 tp -63.5 -48.72 76.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.417 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.9 m -65.49 -29.81 48.26 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.124 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.961 -179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -66.35 -56.43 11.13 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.72 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.5 m -52.9 -50.68 63.42 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.987 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -70.28 -27.61 32.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 19.7 tp -66.9 -56.57 9.7 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.003 -179.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 61.2 mt -70.39 -43.23 78.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.596 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.23 -39.51 79.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.979 0.418 . . . . 0.0 110.152 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.79 -40.3 83.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.81 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.72 -50.9 67.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.866 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.4 m -67.98 -34.32 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.63 -0.428 . . . . 0.0 110.59 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -60.24 -44.54 95.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.696 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -66.49 -48.97 68.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.219 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.887 0.375 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.53 -25.68 38.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.704 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 58.3 tp -46.41 -29.61 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.817 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.98 -50.57 57.3 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.471 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 1.8 mp -56.79 -48.07 81.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.954 0.407 . . . . 0.0 109.931 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.8 mt -63.58 -29.99 48.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.618 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.3 t -64.85 -47.28 78.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.356 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.5 pt -71.11 -35.43 58.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.323 . . . . 0.0 111.54 -179.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 64.9 t -67.78 -43.85 86.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.196 -0.602 . . . . 0.0 110.36 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -72.04 -37.52 69.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.72 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.2 p -69.4 -31.81 50.82 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.113 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.878 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.38 -52.14 20.28 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.586 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.421 ' H ' ' HG1' ' A' ' 49' ' ' THR . 3.8 m -60.22 -42.48 95.25 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.566 -178.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -71.42 -32.98 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.518 -0.473 . . . . 0.0 112.066 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.403 ' CD1' ' C ' ' A' ' 51' ' ' LEU . 0.9 OUTLIER -68.05 -56.55 8.46 Favored 'General case' 0 CA--C 1.521 -0.146 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.388 -179.694 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.31 -47.68 84.85 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.569 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 96.1 m -61.02 -44.55 97.25 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 95.3 mt -72.33 -43.53 64.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 113.736 1.013 . . . . 0.0 113.736 -177.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -78.68 -33.72 16.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.171 -0.611 . . . . 0.0 111.565 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -77.86 -39.88 41.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.441 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 13.0 mm -59.75 -54.32 56.88 Favored Pre-proline 0 CA--C 1.541 0.623 0 N-CA-C 113.198 0.814 . . . . 0.0 113.198 -177.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.485 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 16.7 Cg_endo -56.45 -35.76 96.8 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 121.484 1.456 . . . . 0.0 112.045 -179.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -77.28 -61.01 2.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.532 0.251 0 C-N-CA 120.488 -0.485 . . . . 0.0 109.98 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.887 0.375 . . . . 0.0 110.138 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.557 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -45.39 -63.27 1.27 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.861 179.592 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.5 Cg_endo -59.51 7.43 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.227 1.951 . . . . 0.0 112.35 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -114.05 -66.17 0.45 Allowed Glycine 0 N--CA 1.468 0.772 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.415 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 11.5 p -63.58 -47.92 89.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.995 0.426 . . . . 0.0 110.306 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.415 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 33.3 mt -56.74 -38.11 71.94 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.3 -39.09 81.9 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.17 75.74 Favored Glycine 0 CA--C 1.523 0.561 0 CA-C-N 114.491 -1.231 . . . . 0.0 110.786 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mm -67.32 -46.13 84.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.063 -0.655 . . . . 0.0 109.615 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -55.6 -43.74 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 118.88 -1.128 . . . . 0.0 108.58 178.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 87.5 t -56.51 -47.92 81.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.294 -0.563 . . . . 0.0 109.542 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -55.5 -30.94 56.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -70.88 -41.91 70.71 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.645 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mp -60.48 -51.55 68.99 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 120.885 0.374 . . . . 0.0 110.196 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -58.7 -45.78 90.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.398 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 51.8 mt -59.42 -34.91 73.06 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.934 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.8 m -64.27 -41.39 96.94 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.295 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.84 -51.19 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.706 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.3 mp -64.28 -51.4 63.71 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.712 0.291 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 82.4 mt -58.63 -51.49 71.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.07 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.6 -48.0 39.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.16 0.505 . . . . 0.0 109.812 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 34.2 tp -57.02 -35.75 69.64 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.1 -36.37 84.07 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.078 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 45.5 t -60.8 -48.07 90.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -64.42 -37.24 86.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.238 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -59.92 -46.49 89.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.682 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 tp . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.318 -179.836 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 11.6 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.572 0.225 . . . . 0.0 110.426 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.47 ' H ' ' HG ' ' B' ' 5' ' ' SER . 27.0 m 34.64 36.93 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.339 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.484 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -79.36 -48.23 1.52 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.317 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.536 ' C ' ' H ' ' A' ' 8' ' ' VAL . 46.7 Cg_exo -42.87 -43.42 9.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 122.699 2.266 . . . . 0.0 112.757 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.47 -46.66 0.87 Allowed Glycine 0 N--CA 1.463 0.433 0 N-CA-C 108.84 -1.704 . . . . 0.0 108.84 -179.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.536 ' H ' ' C ' ' A' ' 6' ' ' PRO . 74.3 t -57.75 -38.73 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.7 mt -55.62 -38.69 69.81 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.22 89.59 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.62 -29.22 66.51 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.87 -43.23 89.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -50.83 74.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 179.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.6 t -57.27 -39.86 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.471 178.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.22 -36.81 91.75 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.62 -47.84 71.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.967 0.413 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -55.53 -51.74 66.04 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.726 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -65.14 -29.15 46.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.373 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.83 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.18 -58.04 10.25 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.738 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.1 m -56.09 -42.37 76.65 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.51 -32.03 56.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.78 -53.9 13.69 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.404 -178.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.9 mt -67.83 -43.17 86.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.365 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.62 -42.94 97.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.891 0.377 . . . . 0.0 110.158 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 30.4 tp -65.56 -42.55 91.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.184 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.51 -48.58 71.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.661 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -64.51 -44.28 96.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.701 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -56.6 -37.58 70.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.662 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -59.91 -48.92 79.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.647 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.1 tp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.489 -179.994 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.856 0.36 . . . . 0.0 110.483 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.3 m -57.87 -28.28 32.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.561 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.6 tt -49.32 -37.72 25.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.545 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.53 -48.15 76.42 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 92.7 mt -59.63 -40.61 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.064 0.459 . . . . 0.0 110.49 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 91.6 mt -66.84 -35.98 76.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.467 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.3 m -64.18 -51.93 61.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.543 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.5 pt -61.86 -44.53 98.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.966 -179.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.47 -43.38 82.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 120.452 -0.499 . . . . 0.0 109.822 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 70.5 mt -66.04 -32.14 73.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.201 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.26 -35.78 74.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.412 -0.515 . . . . 0.0 109.658 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.98 -49.05 55.48 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.265 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.3 p -58.92 -48.2 82.32 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.511 -179.325 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 m -71.31 -28.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.603 -179.058 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.2 tt -67.12 -53.12 33.69 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.888 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 37.5 mttp -65.42 -44.83 86.16 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.82 0.343 . . . . 0.0 110.649 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.9 m -63.22 -42.53 99.26 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.515 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 93.8 mt -75.36 -41.96 43.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -76.59 -28.62 17.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 120.028 -0.669 . . . . 0.0 111.304 -179.058 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.1 tp -84.82 -47.13 10.68 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.2 -59.38 13.19 Favored Pre-proline 0 N--CA 1.473 0.708 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -175.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.515 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -52.02 -27.49 28.93 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 121.392 1.394 . . . . 0.0 111.992 -178.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 26.4 m-85 -90.19 -65.94 0.97 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.494 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.2 mm? . . . . . 0 CA--C 1.53 0.205 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.29 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.419 ' O ' ' N ' ' B' ' 7' ' ' GLY . 35.4 m . . . . . 0 N--CA 1.462 0.136 0 CA-C-O 120.855 0.359 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.582 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -62.77 0.98 Allowed Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.908 179.786 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 31.2 Cg_endo -62.43 12.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.209 1.939 . . . . 0.0 111.995 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.582 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -125.45 -65.61 0.18 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.465 -0.654 . . . . 0.0 111.465 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.472 ' CG2' ' N ' ' B' ' 9' ' ' LEU . 18.1 m -60.09 -49.47 83.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.073 0.463 . . . . 0.0 110.461 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.472 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 28.9 mt -57.41 -42.63 82.67 Favored 'General case' 0 C--O 1.238 0.484 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.66 -37.19 65.42 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 177.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.16 -28.73 73.32 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.347 178.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.2 -43.62 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.377 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -58.86 -42.34 85.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 119.11 -1.036 . . . . 0.0 108.741 178.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.8 t -56.39 -47.42 81.47 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.86 -32.15 65.67 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -69.1 -41.75 77.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.804 0.335 . . . . 0.0 110.689 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 36.9 tp -61.07 -53.07 61.72 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.491 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -58.56 -39.85 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.139 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 25.6 mt -60.79 -52.72 63.9 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.733 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.5 m -47.14 -50.56 20.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.877 0.37 . . . . 0.0 110.21 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 60.0 t -61.95 -31.19 50.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.419 179.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 15.5 tp -68.37 -48.19 65.41 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 18.0 mm -60.64 -44.34 96.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.08 -48.19 79.18 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 121.184 0.516 . . . . 0.0 109.752 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -57.69 -34.93 69.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.55 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.81 -39.39 93.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.081 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -60.59 -45.83 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -62.52 -39.03 92.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -60.4 -44.46 95.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.618 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.0 tp . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.369 -179.848 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.553 ' C ' ' H ' ' A' ' 5' ' ' SER . 41.7 p . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.791 0.329 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.456 ' N ' ' OG1' ' A' ' 3' ' ' THR . 10.6 m -69.24 37.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.958 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.18 -40.76 16.17 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.509 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.4 Cg_exo -46.66 -40.53 24.1 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.531 2.154 . . . . 0.0 112.45 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.24 -47.24 0.67 Allowed Glycine 0 N--CA 1.464 0.507 0 N-CA-C 109.125 -1.59 . . . . 0.0 109.125 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.521 ' H ' ' C ' ' A' ' 6' ' ' PRO . 72.7 t -56.26 -39.82 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.612 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.7 mt -55.96 -38.36 70.25 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.4 -36.1 77.32 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.78 -27.5 70.16 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.65 -42.01 86.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -59.95 -50.93 78.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.997 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.4 t -59.21 -42.32 86.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.904 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.03 -37.1 91.12 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.472 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 59.2 t0 -66.36 -47.4 73.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 110.359 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -55.59 -51.48 67.0 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.884 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.7 m -65.67 -29.02 45.73 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.712 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.38 -58.85 6.83 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.613 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.5 p -56.32 -42.91 78.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.286 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -64.59 -33.82 65.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.845 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.86 -52.86 25.3 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.049 -0.261 . . . . 0.0 111.168 -178.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.4 mt -66.36 -43.79 91.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.349 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.8 -42.29 88.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.081 0.467 . . . . 0.0 110.07 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.6 tp -67.97 -31.27 70.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.034 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.81 -51.28 67.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.764 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.4 m -65.07 -37.52 80.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.432 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -60.98 -48.69 80.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.549 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 78.6 t80 -71.17 -50.97 27.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 tt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.178 -179.749 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.899 0.38 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.1 m -67.09 -26.0 35.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.485 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.5 tp -45.87 -27.69 0.93 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.727 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.427 ' O ' ' OG ' ' A' ' 43' ' ' SER . . . -58.72 -48.28 85.84 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.96 -44.51 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.098 0.475 . . . . 0.0 110.664 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.493 ' N ' ' CD1' ' A' ' 42' ' ' ILE . 1.8 mp -66.18 -27.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.529 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 40' ' ' GLY . 24.0 p -70.66 -50.48 36.28 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 10.5 pt -65.0 -44.85 95.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -63.93 -41.75 93.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.555 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 28.9 mt -65.2 -36.09 83.1 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.525 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.8 t -67.16 -35.55 74.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.076 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.46 -49.76 62.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.339 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 44.4 p -62.41 -50.57 70.97 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.876 -178.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -39.01 83.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -178.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 33.6 tp -65.09 -40.74 95.03 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.598 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.472 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -65.66 -52.17 53.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.753 0.311 . . . . 0.0 110.995 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 m -67.87 -37.34 81.68 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.533 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 89.9 mt -72.28 -44.32 63.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 -177.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 m -78.49 -31.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.055 -0.658 . . . . 0.0 111.388 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 4.3 tp -79.01 -39.92 32.8 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -177.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.2 mp -72.42 -60.04 2.3 Favored Pre-proline 0 N--CA 1.475 0.817 0 N-CA-C 113.796 1.036 . . . . 0.0 113.796 -176.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.533 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 9.4 Cg_endo -50.72 -25.4 15.05 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 121.736 1.624 . . . . 0.0 112.218 -178.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -88.26 -67.34 0.84 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.507 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? . . . . . 0 C--O 1.231 0.122 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.166 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 13.8 m . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.815 0.34 . . . . 0.0 110.572 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.553 ' HG ' ' N ' ' B' ' 6' ' ' PRO . 0.3 OUTLIER -37.75 -65.16 0.38 Allowed Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.923 -179.605 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.553 ' N ' ' HG ' ' B' ' 5' ' ' SER . 28.6 Cg_endo -60.43 6.14 0.12 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.323 2.015 . . . . 0.0 112.145 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -118.46 -64.5 0.3 Allowed Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' B' ' 9' ' ' LEU . 14.3 m -60.84 -52.18 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 120.572 -0.451 . . . . 0.0 110.343 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.481 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 36.6 mt -54.29 -40.04 67.5 Favored 'General case' 0 C--O 1.246 0.904 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.79 -35.41 70.76 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 177.07 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -63.62 -34.2 89.31 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.374 -1.284 . . . . 0.0 111.137 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.77 -45.87 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.333 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.53 -46.25 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 C-N-CA 119.095 -1.042 . . . . 0.0 108.856 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.4 t -53.26 -46.41 56.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.21 0.529 . . . . 0.0 109.627 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.78 -40.77 93.41 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -56.92 -46.37 82.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.709 0.29 . . . . 0.0 110.505 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -58.87 -45.12 90.93 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.3 t -56.34 -47.95 80.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.055 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 98.3 mt -59.13 -39.74 83.3 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.002 179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 15.8 m -56.78 -40.13 75.32 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.402 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 89.2 t -67.87 -51.72 47.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.831 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -62.11 -51.68 66.93 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.159 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 61.0 mt -56.87 -50.01 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.55 -0.46 . . . . 0.0 109.998 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -49.13 -46.41 44.98 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.79 -40.02 75.16 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.026 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.64 86.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.404 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.9 -48.06 89.19 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -64.08 -37.89 89.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.277 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -59.88 -51.03 71.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.641 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 20.9 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.393 179.861 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 5' ' ' SER . 28.6 p . . . . . 0 C--O 1.231 0.113 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.464 ' N ' ' OG ' ' B' ' 5' ' ' SER . 32.7 m 37.21 26.74 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.203 0.525 . . . . 0.0 111.03 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.627 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.6 OUTLIER -79.72 -35.47 0.96 Allowed Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.684 179.006 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.627 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.7 Cg_exo -49.56 -42.85 41.3 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.158 1.906 . . . . 0.0 112.529 179.81 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.81 -46.61 0.94 Allowed Glycine 0 CA--C 1.521 0.426 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.514 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -58.97 -40.1 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.59 -38.78 69.85 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.47 -38.91 82.05 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 177.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.04 -28.21 65.99 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.84 -43.62 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.2 t -55.77 -53.93 32.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -57.61 -36.95 56.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.69 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.08 -39.6 95.99 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.405 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 64.6 t0 -65.1 -46.92 79.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.896 0.379 . . . . 0.0 110.407 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.0 tp -55.74 -50.85 69.27 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -67.76 -25.68 33.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.008 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.57 -56.76 14.88 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 119.984 -0.687 . . . . 0.0 109.396 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -58.52 -44.5 89.55 Favored 'General case' 0 N--CA 1.456 -0.16 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.171 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.73 -32.88 59.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.1 tp -70.34 -54.5 12.29 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 -178.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.402 HG23 HD11 ' A' ' 23' ' ' ILE . 11.5 mm -70.28 -41.58 78.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.314 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.69 -40.3 87.39 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.022 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 32.7 tp -67.6 -37.48 82.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.626 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.18 -51.08 69.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.739 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -67.16 -36.19 76.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 C-N-CA 120.312 -0.555 . . . . 0.0 110.563 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -58.4 -44.38 88.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -66.28 -44.27 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.704 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.615 -179.803 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.908 0.385 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.8 m -69.67 -25.17 28.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.704 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 44.5 tp -46.13 -29.5 1.56 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.854 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.8 -52.82 47.99 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.447 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -40.27 58.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.919 0.39 . . . . 0.0 110.14 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.0 mm -64.54 -41.7 93.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.721 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 11.2 t -59.47 -51.79 68.36 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.69 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.1 tt -61.76 -43.88 97.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.31 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.7 t -55.99 -43.11 74.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.121 0.486 . . . . 0.0 109.951 179.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -68.22 -30.8 69.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.935 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.4 t -68.29 -34.36 65.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.816 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.54 -48.15 42.61 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.474 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.418 ' H ' ' HG1' ' A' ' 49' ' ' THR . 2.8 m -60.13 -46.75 88.57 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.201 -179.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.7 m -68.4 -37.19 77.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 120.652 -0.419 . . . . 0.0 111.115 -179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.7 -41.11 92.76 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.271 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.419 ' NZ ' ' CD1' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -62.96 -53.19 57.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.431 -179.899 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.8 p -63.59 -46.86 83.89 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -61.64 -51.72 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.567 ' O ' ' CD1' ' A' ' 59' ' ' PHE . 5.0 m -73.62 -29.79 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.174 -178.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.401 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 6.5 tt -70.91 -29.95 66.15 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -178.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 mt -61.95 -55.1 44.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.287 -178.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.71 -28.63 43.86 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.518 1.479 . . . . 0.0 111.503 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.2 m-30 -56.55 -47.07 80.25 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.349 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.478 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 N--CA 1.462 0.135 0 C-N-CA 120.846 -0.342 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.472 ' CG1' ' N ' ' B' ' 5' ' ' SER . 14.8 p . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 120.805 0.336 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.53 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.7 OUTLIER -43.31 -64.48 0.75 Allowed Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.515 179.835 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 19.4 Cg_endo -56.86 1.75 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.325 2.017 . . . . 0.0 112.341 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -112.05 -67.05 0.52 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.527 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 6.8 m -59.24 -48.05 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.154 0.502 . . . . 0.0 110.275 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.465 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 43.6 mt -57.35 -42.15 81.46 Favored 'General case' 0 C--O 1.242 0.696 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.57 -33.46 45.91 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 176.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -37.22 94.17 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.292 178.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.1 tp -58.4 -43.82 87.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.672 -0.811 . . . . 0.0 108.956 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -59.93 -46.81 93.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 119.256 -0.977 . . . . 0.0 109.487 179.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.5 -45.58 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 120.256 -0.577 . . . . 0.0 109.841 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.77 -39.25 96.48 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -59.58 -47.83 84.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.685 0.279 . . . . 0.0 110.712 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -57.79 -45.43 86.07 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -54.83 -46.64 75.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.419 ' CD1' ' NZ ' ' A' ' 52' ' ' LYS . 23.5 mt -61.69 -47.08 86.94 Favored 'General case' 0 C--O 1.223 -0.302 0 C-N-CA 120.659 -0.417 . . . . 0.0 110.295 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.5 m -48.03 -50.73 26.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.8 0.333 . . . . 0.0 110.686 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 99.9 t -61.89 -44.13 98.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.936 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 12.2 tp -59.16 -45.3 91.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.18 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 4.6 mm -59.52 -49.78 82.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.87 -45.38 30.29 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.332 0.586 . . . . 0.0 109.83 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.76 -35.36 80.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.34 -55.32 35.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.167 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -57.86 -37.04 58.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.4 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 43.1 t80 -59.66 -43.76 93.81 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.82 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -61.15 -41.82 97.44 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.571 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 8.5 mp . . . . . 0 C--N 1.329 -0.299 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 5' ' ' SER . 32.7 p . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.621 0.248 . . . . 0.0 110.424 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.659 ' H ' ' HG ' ' B' ' 5' ' ' SER . 27.0 m 34.59 34.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.442 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -83.98 -40.09 0.73 Allowed Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.361 179.061 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 5' ' ' SER . 86.7 Cg_exo -48.1 -42.73 32.23 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.606 2.204 . . . . 0.0 112.655 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.86 -46.85 0.75 Allowed Glycine 0 N--CA 1.463 0.438 0 N-CA-C 108.865 -1.694 . . . . 0.0 108.865 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.515 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.6 t -55.27 -38.57 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 82.0 mt -55.38 -38.97 69.56 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.182 -1.007 . . . . 0.0 108.388 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.88 -39.86 86.72 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.51 -27.72 63.93 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.53 -42.89 83.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.197 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -56.45 -53.22 43.17 Favored 'Isoleucine or valine' 0 C--O 1.242 0.684 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.7 t -56.92 -39.67 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.357 178.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -54.71 -41.23 74.08 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 61.4 t0 -64.77 -45.85 84.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 110.299 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.637 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 20.8 tp -55.45 -51.08 68.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.894 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -68.53 -24.05 28.8 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.905 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -56.7 14.69 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.032 -0.667 . . . . 0.0 109.382 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 53.6 m -61.36 -47.36 86.22 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.507 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.8 t -64.4 -34.32 68.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.4 tp -69.22 -54.28 15.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.609 -178.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 64.7 mt -67.57 -41.73 86.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.501 -0.479 . . . . 0.0 110.388 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.01 91.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.138 0.494 . . . . 0.0 110.026 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -67.57 -34.49 77.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.828 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.89 -51.36 70.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.757 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.65 -36.65 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.569 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -59.36 -41.69 89.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.872 0.367 . . . . 0.0 110.577 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -59.42 -46.87 87.49 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.656 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.4 tp . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -179.892 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 65.5 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.814 0.34 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.2 m -49.24 -26.67 2.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.6 tp -48.21 -28.62 3.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.715 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.38 -51.62 57.55 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.475 ' CD1' ' H ' ' A' ' 41' ' ' ILE . 1.9 mp -52.68 -49.94 43.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.027 0.441 . . . . 0.0 110.012 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.63 -27.58 43.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.727 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -67.01 -45.52 77.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.432 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.441 HG22 HD12 ' A' ' 44' ' ' ILE . 22.1 pt -71.83 -34.58 51.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.139 -179.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.3 t -68.38 -46.4 80.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.572 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -69.77 -37.75 76.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.643 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.22 -31.56 47.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.777 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.19 51.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.378 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.9 p -62.38 -43.36 99.0 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.953 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.99 -43.74 97.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.556 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.91 -53.39 47.18 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.018 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.637 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 0.7 OUTLIER -47.21 -51.99 17.03 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.909 179.924 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 31.4 p -59.13 -46.73 87.58 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 87.1 mt -59.82 -52.52 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.58 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 26.7 m -75.31 -30.89 23.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.258 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.7 tt -66.65 -32.79 74.34 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.424 HD13 HG21 ' A' ' 57' ' ' ILE . 7.4 mt -68.16 -54.23 16.37 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.479 -178.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.38 -28.44 18.09 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 121.799 1.666 . . . . 0.0 111.566 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.58 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -60.68 -45.43 94.2 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.342 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 121.017 0.437 . . . . 0.0 110.141 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' B' ' 7' ' ' GLY . 21.2 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.897 0.379 . . . . 0.0 110.314 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.659 ' HG ' ' H ' ' A' ' 4' ' ' VAL . 0.1 OUTLIER -40.02 -62.78 0.81 Allowed Pre-proline 0 CA--C 1.536 0.407 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.952 179.763 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.9 Cg_endo -61.02 9.88 0.07 OUTLIER 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.138 1.892 . . . . 0.0 112.073 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.556 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -123.64 -66.24 0.21 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.524 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 15.9 m -58.8 -51.74 68.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 CA-C-O 121.094 0.473 . . . . 0.0 110.61 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.474 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 40.5 mt -56.51 -40.04 74.32 Favored 'General case' 0 C--O 1.242 0.663 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.24 -36.97 61.66 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.16 -34.45 89.12 Favored Glycine 0 CA--C 1.523 0.565 0 CA-C-N 114.425 -1.261 . . . . 0.0 110.447 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.52 -42.26 95.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 C-N-CA 119.701 -0.799 . . . . 0.0 109.341 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -59.86 -44.42 94.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.32 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 83.9 t -51.23 -47.52 33.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.615 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.11 93.88 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -58.78 -45.16 90.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.857 0.361 . . . . 0.0 110.488 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.7 tp -56.77 -45.73 81.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.021 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.42 -46.77 82.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.204 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 14.2 mt -60.25 -39.74 87.84 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.062 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.2 m -57.68 -40.59 79.77 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.388 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.5 t -66.41 -51.8 53.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.474 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 11.1 mp -62.53 -52.95 61.41 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 120.939 -0.304 . . . . 0.0 111.274 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 61.9 mt -56.84 -51.33 69.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.111 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.94 -46.46 32.23 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.088 0.47 . . . . 0.0 109.857 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.91 -39.31 74.19 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.83 -38.51 91.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.455 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.53 -47.19 89.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -63.75 -41.37 98.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.206 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -56.44 -46.54 80.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.1 tp . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.32 -179.763 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 8.4 p . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.613 0.244 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 35.8 m 35.08 36.38 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.346 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -82.23 -40.19 0.92 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.377 179.133 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 72.4 Cg_exo -46.41 -40.45 22.72 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.647 2.232 . . . . 0.0 112.58 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.408 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 70.31 -48.09 0.7 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.493 ' H ' ' C ' ' A' ' 6' ' ' PRO . 71.3 t -53.83 -39.28 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 81.2 mt -56.05 -37.99 69.99 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -61.59 -33.08 73.27 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 177.245 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -63.37 -32.24 83.48 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -67.2 -41.98 87.46 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 42.5 t -59.29 -55.17 25.41 Favored 'Isoleucine or valine' 0 C--O 1.241 0.613 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.481 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 95.7 t -61.02 -36.86 75.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.498 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.48 -40.47 99.14 Favored Glycine 0 C--O 1.224 -0.513 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -64.16 -51.26 64.68 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.008 0.433 . . . . 0.0 110.281 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 tp -56.86 -47.34 80.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.848 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.44 -28.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.758 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.53 -56.64 12.74 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.68 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.4 m -56.09 -40.4 73.59 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.649 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.33 -32.52 57.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.727 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.41 -55.23 9.55 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.15 -178.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.408 HD11 HG21 ' A' ' 23' ' ' ILE . 80.0 mt -66.66 -43.65 90.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.574 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.41 -41.38 89.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.217 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.2 tp -69.18 -31.79 70.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.273 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.72 -50.51 68.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.799 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -66.32 -38.1 81.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.472 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -61.83 -46.52 89.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.575 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -69.46 -49.13 57.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.744 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.3 tp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.464 -179.977 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.6 tp10 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.839 0.352 . . . . 0.0 110.573 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.7 t -65.59 -28.98 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.581 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 tp -60.74 -29.29 69.28 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.78 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -54.64 -49.55 60.9 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.8 mm -55.38 -48.51 76.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.028 0.442 . . . . 0.0 110.651 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 74.2 mt -61.53 -34.96 63.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.483 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.9 m -61.53 -51.7 67.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.692 -179.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 12.4 pt -63.06 -42.22 95.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.924 -179.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 71.7 t -60.24 -43.99 94.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.375 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.09 -34.7 79.03 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 50.4 t -66.78 -34.73 71.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.76 -47.98 64.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.457 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 4.5 m -60.87 -48.73 80.47 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.711 -0.396 . . . . 0.0 111.494 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.91 -33.83 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -178.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 49.3 tp -65.69 -52.59 50.22 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.269 -0.572 . . . . 0.0 110.744 -179.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.29 -50.53 72.63 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.312 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 48.5 p -60.34 -43.12 96.75 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.421 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 90.4 mt -72.95 -44.52 57.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.362 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -177.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.4 m -77.04 -28.34 16.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.384 -178.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.0 tp -82.58 -39.44 22.26 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 114.566 1.321 . . . . 0.0 114.566 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 mm -75.45 -63.79 0.64 Allowed Pre-proline 0 N--CA 1.475 0.824 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.421 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 12.2 Cg_endo -53.09 -38.68 80.91 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.766 1.644 . . . . 0.0 112.146 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -67.33 -59.63 3.25 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 121.055 -0.258 . . . . 0.0 110.666 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.531 0.219 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.864 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.462 0.15 0 CA-C-O 120.953 0.406 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 5' ' ' SER . . . . . 0.534 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -40.51 -63.99 0.65 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.37 179.803 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 17.9 Cg_endo -57.9 3.62 0.12 Allowed 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.27 1.98 . . . . 0.0 112.231 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -115.14 -68.07 0.44 Allowed Glycine 0 CA--C 1.527 0.83 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' B' ' 11' ' ' GLY . 7.4 m -58.19 -52.55 57.35 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.214 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.5 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 42.1 mt -54.84 -31.76 59.76 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.86 -36.34 72.2 Favored 'General case' 0 C--O 1.244 0.775 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -66.71 -30.93 77.04 Favored Glycine 0 CA--C 1.528 0.875 0 CA-C-N 113.768 -1.56 . . . . 0.0 111.319 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . 0.465 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.2 mp -71.32 -39.8 72.71 Favored 'Isoleucine or valine' 0 C--N 1.34 0.194 0 C-N-CA 119.684 -0.807 . . . . 0.0 109.4 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.5 m -57.92 -44.44 86.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.3 t -59.48 -48.85 85.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 CA-C-O 121.18 0.514 . . . . 0.0 110.267 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -34.85 81.27 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -65.76 -39.41 91.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.878 0.37 . . . . 0.0 110.154 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.91 -47.41 86.51 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.86 -35.17 74.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.895 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.59 -48.78 71.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.482 -179.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 99.6 m -59.76 -44.24 93.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.884 0.374 . . . . 0.0 110.542 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.2 t -63.98 -40.72 90.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -59.01 -51.06 71.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.821 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 66.6 mt -59.06 -48.02 88.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.995 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.53 -46.85 39.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.03 0.443 . . . . 0.0 109.925 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -58.05 -40.48 81.04 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.65 -37.08 80.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.281 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 50.3 t -62.26 -42.28 94.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 61.5 t80 -63.19 -38.92 93.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.981 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -60.99 -41.07 95.77 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.742 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.7 tp . . . . . 0 C--N 1.329 -0.294 0 C-N-CA 120.829 -0.349 . . . . 0.0 110.278 -179.858 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 40.4 t . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.1 m -160.56 170.17 21.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.575 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.7 t -152.07 145.23 24.61 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.489 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.442 ' N ' ' HG1' ' A' ' 3' ' ' THR . 27.1 m 34.22 31.47 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.142 0.496 . . . . 0.0 111.159 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.557 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.5 OUTLIER -84.82 -44.09 0.69 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.262 179.317 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.557 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.0 Cg_exo -45.37 -43.94 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 122.731 2.287 . . . . 0.0 112.871 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 70.55 -50.45 0.82 Allowed Glycine 0 N--CA 1.464 0.502 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.473 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.8 t -52.8 -35.13 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.9 mt -55.35 -41.7 72.85 Favored 'General case' 0 C--O 1.238 0.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -58.35 -37.58 75.48 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 177.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.3 -27.96 68.49 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.81 -39.03 79.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.9 t -62.08 -51.32 73.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.846 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.47 -43.04 89.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.72 -38.87 92.75 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.466 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 51.2 t0 -65.57 -46.59 78.88 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.916 0.389 . . . . 0.0 110.685 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.5 tp -56.31 -51.36 68.52 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.766 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 m -65.63 -27.32 41.2 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.323 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.578 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.84 -57.33 13.13 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.515 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -56.98 -42.47 80.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.113 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -65.7 -37.73 80.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.288 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.57 -54.47 19.6 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.404 -178.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 21.2 mm -66.21 -44.72 91.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.484 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.78 -39.59 77.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.911 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.0 tp -68.52 -34.5 75.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.023 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.58 -50.72 72.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.624 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -68.05 -39.42 81.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -60.58 -33.69 73.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -55.67 -50.09 71.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.75 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.0 tp -67.94 -43.61 78.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.6 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.96 41.73 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -163.7 67.76 0.18 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.599 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.442 ' N ' ' CD1' ' A' ' 33' ' ' LEU . 9.9 mp 46.31 87.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.41 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 165.25 -34.14 0.25 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 61.3 p -74.93 -19.01 60.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.779 0.323 . . . . 0.0 110.555 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 58.99 177.95 0.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.397 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 53.96 15.23 0.81 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.361 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 m -57.53 -26.7 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.459 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.0 tp -46.26 -29.12 1.49 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.655 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -55.56 -48.82 68.34 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.472 ' CD1' ' H ' ' A' ' 41' ' ' ILE . 2.0 mp -56.6 -40.77 71.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.002 0.429 . . . . 0.0 110.104 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.486 ' N ' ' CD1' ' A' ' 42' ' ' ILE . 1.9 mp -64.9 -41.22 91.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.205 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.7 t -58.1 -51.79 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.618 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.5 pt -63.14 -39.89 86.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.91 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.0 t -64.71 -30.68 50.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.171 -0.612 . . . . 0.0 109.83 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -71.21 -47.69 55.9 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.937 -178.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.8 p -67.73 -30.49 48.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.626 -178.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.51 -53.3 16.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.377 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.431 ' O ' ' OG1' ' A' ' 53' ' ' THR . 7.1 m -57.98 -47.1 83.99 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.256 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.5 m -71.11 -28.83 34.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.881 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 35.0 tp -67.36 -55.7 12.71 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 119.882 -0.727 . . . . 0.0 110.821 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.466 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.0 OUTLIER -64.8 -45.27 86.98 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.099 179.614 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 49' ' ' THR . 59.4 m -60.77 -45.16 95.42 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -178.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.492 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.4 mt -73.45 -43.25 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -177.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 m -76.89 -33.13 20.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.365 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.6 tp -79.47 -41.62 27.12 Favored 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.428 ' O ' ' CB ' ' A' ' 61' ' ' GLU . 25.9 mt -64.09 -62.11 5.72 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 119.047 -1.061 . . . . 0.0 113.23 -176.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.492 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 7.0 Cg_endo -47.35 -27.14 6.59 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 121.924 1.749 . . . . 0.0 112.504 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -90.24 -65.62 1.0 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 120.384 -0.527 . . . . 0.0 109.809 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.485 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? -57.16 -15.99 6.88 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.649 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.428 ' CB ' ' O ' ' A' ' 57' ' ' ILE . 34.7 tt0 -77.94 139.61 39.2 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.657 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -67.94 85.9 0.23 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.436 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 60.9 t30 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.576 -179.857 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 85.8 m . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.414 ' O ' ' OG1' ' B' ' 3' ' ' THR . 18.5 t -71.72 -24.28 61.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.538 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' B' ' 2' ' ' SER . 36.3 p 52.28 100.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.669 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.505 ' O ' ' N ' ' B' ' 7' ' ' GLY . 32.6 m -79.15 -42.72 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.685 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.555 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -38.7 -59.21 1.41 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.177 179.848 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -64.38 13.86 0.09 OUTLIER 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 121.528 1.486 . . . . 0.0 111.783 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.555 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -113.01 -66.92 0.49 Allowed Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -51.92 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 9.6 mt -57.82 -39.15 76.93 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.72 76.89 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 108.112 -1.069 . . . . 0.0 108.112 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.88 -30.96 79.38 Favored Glycine 0 CA--C 1.522 0.519 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.099 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 50.5 mm -66.23 -43.34 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 C-N-CA 120.079 -0.648 . . . . 0.0 109.769 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.29 -42.0 89.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.87 -42.6 89.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.706 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.85 -39.25 97.26 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -61.51 -40.47 94.72 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -62.88 -44.93 94.79 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.102 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.4 -44.34 92.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.301 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 69.8 mt -66.54 -30.3 70.58 Favored 'General case' 0 C--O 1.225 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 110.212 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 21.8 m -62.58 -50.2 72.25 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.239 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 71.8 t -70.42 -43.28 78.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.554 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.45 -53.06 60.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.823 0.344 . . . . 0.0 111.194 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 76.3 mt -59.45 -50.64 79.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.965 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.39 38.14 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -57.25 -39.39 75.49 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.11 -35.37 78.5 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.133 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.97 -47.05 95.0 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -63.02 -40.43 97.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.125 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -55.67 -44.67 77.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.438 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 28.3 tp -59.88 -44.07 94.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.216 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 70.72 140.87 0.19 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 . . . . . 0 C--N 1.328 -0.352 0 CA-C-O 120.844 0.354 . . . . 0.0 110.532 -179.932 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 42.3 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.5 t -161.09 125.25 3.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.537 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 5' ' ' SER . 8.3 p -83.62 163.29 20.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.621 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.409 ' C ' ' O ' ' A' ' 3' ' ' THR . 27.2 m 33.86 34.6 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.198 0.523 . . . . 0.0 111.239 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.578 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -84.94 -42.97 0.68 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.335 179.308 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 5' ' ' SER . 75.5 Cg_exo -46.38 -44.1 20.93 Favored 'Trans proline' 0 N--CA 1.495 1.598 0 C-N-CA 122.745 2.297 . . . . 0.0 112.807 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 70.55 -48.33 0.75 Allowed Glycine 0 N--CA 1.464 0.518 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' PRO . 62.5 t -53.87 -36.38 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 50.1 mt -55.07 -40.99 70.95 Favored 'General case' 0 C--O 1.238 0.461 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -58.2 -37.96 75.82 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.34 -28.02 66.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 178.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.402 HG23 ' N ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.8 -41.05 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.304 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.402 ' N ' HG23 ' A' ' 12' ' ' ILE . 57.4 t -60.0 -53.09 53.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 121.467 0.651 . . . . 0.0 109.573 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -58.62 -34.63 51.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.964 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.32 -34.79 90.38 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -69.25 -44.7 71.42 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.8 tp -66.9 -51.27 57.4 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.42 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 m -59.65 -35.02 57.14 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.328 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.8 tp -64.39 -52.84 56.21 Favored 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.537 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 15.0 m -50.48 -49.83 54.24 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.901 -0.319 . . . . 0.0 111.439 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.6 p -70.73 -31.06 44.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 120.197 -0.601 . . . . 0.0 112.464 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -67.73 -54.6 18.03 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.586 -179.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 27.5 mt -63.96 -50.47 77.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.387 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.27 -41.53 68.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.351 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 29.6 tp -63.58 -42.53 98.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.09 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.9 -48.22 70.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.342 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.1 t -63.85 -39.85 86.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.606 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -59.01 -48.02 83.09 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -61.06 -48.53 81.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.683 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.7 tp -66.7 -39.35 88.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.573 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -76.99 -106.45 0.15 Allowed Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 60.61 80.64 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.86 0.362 . . . . 0.0 110.475 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.466 ' CD1' ' N ' ' A' ' 33' ' ' LEU . 9.4 mp 55.22 179.34 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.4 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.61 1.33 90.5 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 69.8 p -151.72 -4.3 0.27 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.735 0.302 . . . . 0.0 110.488 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 46.37 -162.09 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.597 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 54.25 31.44 14.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.452 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 16.4 m -63.49 -23.52 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.773 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.0 tp -44.03 -28.11 0.44 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.14 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -60.78 -49.51 77.85 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.471 ' CD1' ' H ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -49.09 76.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.09 0.472 . . . . 0.0 109.989 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.482 ' CD1' ' N ' ' A' ' 42' ' ' ILE . 2.0 mp -61.33 -31.4 50.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.981 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.9 t -62.26 -50.99 69.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.438 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.6 pt -66.11 -35.79 75.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.141 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.6 t -67.05 -40.1 84.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.448 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.14 -44.73 75.42 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.841 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.6 p -69.48 -28.71 39.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.817 -178.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.75 -51.76 25.15 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.772 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.421 ' O ' ' OG1' ' A' ' 53' ' ' THR . 19.7 p -60.09 -40.85 91.03 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.537 -0.465 . . . . 0.0 110.756 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.37 -41.09 78.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.648 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 21.5 tp -65.47 -54.91 21.64 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.793 -179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 56' ' ' LEU . 0.6 OUTLIER -58.58 -43.21 89.4 Favored 'General case' 0 C--O 1.219 -0.518 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.727 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 49' ' ' THR . 99.1 m -60.38 -50.74 72.39 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 112.238 0.459 . . . . 0.0 112.238 -179.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.495 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.3 mt -69.23 -43.95 80.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -177.537 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.526 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.6 m -76.21 -31.18 20.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.148 -0.621 . . . . 0.0 111.85 -178.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.407 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 8.6 tp -75.71 -37.96 58.99 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.23 -51.41 78.48 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.56 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.495 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 59.3 Cg_endo -72.71 -28.73 13.61 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.54 1.493 . . . . 0.0 111.283 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.3 m-30 -67.32 -53.88 25.68 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.131 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.49 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -78.36 21.98 0.34 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.379 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.454 ' H ' ' C ' ' A' ' 59' ' ' PHE . 89.4 mt-10 -148.66 159.51 44.04 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.523 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . 0.49 ' OE1' ' ND2' ' A' ' 63' ' ' ASN . 7.8 tm0? -68.09 -41.63 81.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.378 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.49 ' ND2' ' OE1' ' A' ' 62' ' ' GLN . 2.5 p30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.549 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.526 ' O ' ' N ' ' B' ' 3' ' ' THR . 10.3 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.419 ' O ' ' OG1' ' B' ' 3' ' ' THR . 6.4 t 62.21 -70.93 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.614 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.526 ' N ' ' O ' ' B' ' 1' ' ' CYS . 8.3 p 57.84 63.62 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.84 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' B' ' 7' ' ' GLY . 25.4 m -75.3 -34.66 31.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.336 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.555 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -39.59 -62.15 0.89 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.429 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -62.2 10.61 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.154 1.903 . . . . 0.0 112.388 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.555 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.19 -65.52 0.29 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -60.7 -51.96 67.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 121.215 0.531 . . . . 0.0 110.285 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.6 mt -60.49 -34.38 73.97 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.59 -35.93 73.2 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.2 -40.65 98.18 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.685 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 45.5 mm -58.0 -45.7 87.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.986 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.3 m -57.29 -44.69 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.251 179.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.96 -41.42 76.93 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.3 -41.72 98.5 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -60.36 -41.4 93.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.359 . . . . 0.0 110.213 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.8 tp -61.2 -43.95 98.06 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.046 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -57.85 -47.97 84.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.048 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 74.7 mt -61.43 -36.28 79.92 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.013 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -57.63 -43.78 85.1 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.215 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -69.24 -47.15 75.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.733 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.0 mp -62.08 -51.9 66.09 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.105 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 61.0 mt -57.58 -50.3 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.9 -45.17 40.94 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 121.256 0.551 . . . . 0.0 109.942 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 4.9 tp -65.19 -30.08 70.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.119 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.17 -50.07 67.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.219 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -64.1 -38.28 82.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 C-N-CA 120.406 -0.518 . . . . 0.0 109.879 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -61.45 -43.11 99.44 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -60.62 -47.09 87.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.676 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 4.9 tp -61.06 -40.68 94.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.466 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -165.83 -89.23 0.07 OUTLIER Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.8 ttt85 . . . . . 0 C--N 1.328 -0.348 0 CA-C-O 120.778 0.323 . . . . 0.0 110.481 179.959 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 47.5 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.6 t -158.59 114.15 2.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.635 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 5' ' ' SER . 5.4 p -82.68 174.7 10.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.629 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.606 ' H ' ' HG ' ' B' ' 5' ' ' SER . 34.8 m 36.62 26.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.252 0.549 . . . . 0.0 111.212 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.62 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 1.6 t -81.74 -35.43 0.75 Allowed Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.61 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.62 ' CD ' ' N ' ' A' ' 5' ' ' SER . 84.2 Cg_exo -49.45 -41.49 43.7 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.336 2.024 . . . . 0.0 112.554 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.91 -47.01 0.98 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.483 ' H ' ' C ' ' A' ' 6' ' ' PRO . 58.1 t -59.28 -40.64 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -54.37 -43.03 70.99 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.12 -37.6 69.66 Favored 'General case' 0 C--O 1.233 0.184 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.08 -27.46 68.93 Favored Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.3 -38.53 79.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 80.8 t -64.21 -50.89 74.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.15 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.8 t -59.58 -46.1 93.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.18 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.53 -29.2 71.13 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.989 -0.845 . . . . 0.0 110.989 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.524 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 53.3 t0 -67.45 -52.64 37.11 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 110.387 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.3 tp -60.35 -41.23 93.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.127 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.5 -26.45 31.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 37.3 tp -71.43 -57.42 4.45 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.84 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.0 t -62.3 -40.43 96.26 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.145 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.5 t -69.32 -43.82 80.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.662 -179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -60.54 -51.6 68.75 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.333 -178.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 63.7 mt -63.08 -42.48 96.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.942 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -43.88 78.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.96 0.41 . . . . 0.0 110.324 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.96 -36.24 82.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.47 -50.79 71.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.795 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.3 m -69.21 -32.56 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.48 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -61.93 -41.31 97.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.716 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -61.73 -45.39 94.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.651 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.04 -43.66 98.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.561 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.19 156.19 52.96 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -162.54 89.67 0.69 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.78 0.324 . . . . 0.0 110.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.7 mt 51.75 38.18 22.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.567 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 176.32 111.95 0.3 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.527 ' HG1' ' H ' ' A' ' 36' ' ' ALA . 4.4 t -161.04 173.63 14.93 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.787 0.327 . . . . 0.0 110.634 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.527 ' H ' ' HG1' ' A' ' 35' ' ' THR . . . -74.2 106.43 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.581 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 36' ' ' ALA . 50.1 mt-10 49.85 100.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.563 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 63.5 t -68.17 -28.74 42.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.636 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.509 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.6 mm? -63.77 -31.29 72.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -62.23 -50.28 66.56 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.3 mt -58.19 -44.3 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.092 0.473 . . . . 0.0 110.453 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.14 -38.65 82.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.471 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.5 m -59.94 -52.16 66.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.736 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.3 pt -62.11 -42.39 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.649 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.4 t -60.66 -35.24 62.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.0 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.6 -39.16 77.41 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.529 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -68.69 -30.46 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.622 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.18 -52.1 25.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.981 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -44.77 90.78 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.622 -0.431 . . . . 0.0 111.8 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.0 m -68.17 -40.32 82.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.563 -179.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 49.5 tp -63.33 -45.81 89.54 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.456 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.524 ' NZ ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -62.03 -49.97 73.9 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.742 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.4 p -62.66 -47.54 83.24 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.605 0.595 . . . . 0.0 112.605 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.482 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 87.4 mt -64.03 -46.05 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.559 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 10.0 m -76.36 -34.62 25.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.153 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.3 tt -68.27 -35.27 77.63 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 113.574 0.954 . . . . 0.0 113.574 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.4 mp -65.42 -52.74 43.33 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 119.456 -0.898 . . . . 0.0 112.127 -177.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 57.6 Cg_endo -71.7 -29.57 15.69 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 121.591 1.527 . . . . 0.0 111.466 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.559 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.7 m-30 -64.28 -48.53 75.37 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.226 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.47 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -84.12 26.34 0.76 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.428 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -139.82 147.54 40.88 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.347 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.2 mm-40 -73.03 143.95 47.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.65 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 18.8 p30 . . . . . 0 C--N 1.331 -0.211 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.848 179.947 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 9.9 m . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 40.4 m -159.74 -35.33 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.371 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p 45.78 72.86 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.922 179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' B' ' 7' ' ' GLY . 30.0 m -81.78 -43.44 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.349 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.606 ' HG ' ' H ' ' A' ' 4' ' ' VAL . 0.4 OUTLIER -38.49 -64.2 0.49 Allowed Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.584 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.4 Cg_endo -59.31 6.22 0.1 OUTLIER 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.328 2.019 . . . . 0.0 112.296 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -117.78 -66.29 0.34 Allowed Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -60.68 -51.95 67.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-O 121.091 0.472 . . . . 0.0 110.11 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 49.4 mt -57.66 -37.2 73.0 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.23 -34.48 68.63 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -36.49 91.48 Favored Glycine 0 CA--C 1.524 0.649 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.328 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 11.3 mt -65.42 -41.39 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 119.496 -0.882 . . . . 0.0 109.394 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 m -57.69 -44.2 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -54.29 -50.34 57.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.169 -0.613 . . . . 0.0 109.677 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.17 -31.97 66.57 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' OD1' ' A' ' 16' ' ' ASP . 30.5 t0 -69.38 -41.04 77.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.774 0.321 . . . . 0.0 110.835 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -61.49 -52.39 64.7 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 121.008 0.432 . . . . 0.0 110.402 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -58.42 -39.12 73.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.128 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.3 mt -60.85 -53.08 61.72 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.61 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 8.3 m -48.26 -45.84 35.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.528 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 91.8 t -65.37 -33.83 66.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.723 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.9 tp -68.23 -53.76 22.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.49 -179.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 mm -60.83 -47.16 94.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 C-N-CA 120.658 -0.417 . . . . 0.0 109.931 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.12 -45.04 68.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.045 0.45 . . . . 0.0 109.835 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 31.0 tp -58.93 -38.73 79.65 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.18 -38.27 90.51 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.298 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -61.04 -47.75 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.031 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -61.9 -40.88 96.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.048 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -57.21 -48.47 78.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.491 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.8 tp -61.97 -43.14 99.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.389 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.17 120.59 0.01 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 . . . . . 0 C--N 1.328 -0.335 0 CA-C-O 120.771 0.32 . . . . 0.0 110.58 -179.985 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 10.5 m . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.8 m -160.59 67.59 0.34 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.735 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 5' ' ' SER . 81.6 p -82.41 160.51 22.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.314 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.431 ' N ' ' OG ' ' B' ' 5' ' ' SER . 34.2 m 34.78 32.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 121.158 0.504 . . . . 0.0 111.323 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -81.04 -46.34 1.17 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.093 179.292 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.527 ' C ' ' H ' ' A' ' 8' ' ' VAL . 50.8 Cg_exo -43.27 -43.78 10.24 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.814 2.343 . . . . 0.0 112.996 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.93 -46.88 0.76 Allowed Glycine 0 N--CA 1.463 0.464 0 N-CA-C 108.932 -1.667 . . . . 0.0 108.932 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.2 t -55.53 -38.95 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.6 mt -55.8 -36.79 67.79 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.57 -37.68 84.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -29.21 71.06 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 178.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.69 -42.89 93.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 96.4 t -57.86 -51.13 74.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.3 t -58.47 -30.21 40.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.931 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.43 -38.44 90.99 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -68.2 -44.67 75.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.037 0.446 . . . . 0.0 110.226 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 tp -58.54 -51.38 70.13 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.932 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.6 m -65.0 -29.59 47.85 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.716 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.4 -59.57 5.19 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 120.046 -0.662 . . . . 0.0 109.402 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 70.5 p -52.2 -43.21 64.08 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.005 179.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.27 -30.02 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 112.103 0.408 . . . . 0.0 112.103 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.7 -55.21 9.2 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.18 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.429 HD12 HG22 ' A' ' 23' ' ' ILE . 54.5 mt -68.64 -41.01 82.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.254 -0.578 . . . . 0.0 110.352 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.2 -42.83 95.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.138 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -67.82 -32.39 72.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.737 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.45 -51.1 70.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.641 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.5 m -66.54 -36.98 78.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.413 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -60.16 -45.62 92.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.644 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.3 t80 -64.79 -41.12 96.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.745 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.15 -41.29 92.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.74 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -48.2 147.39 4.71 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -171.77 71.69 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.53 ' CD1' ' N ' ' A' ' 33' ' ' LEU . 7.7 mp 51.01 62.94 2.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.321 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -172.96 1.43 0.03 OUTLIER Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.1 t -73.35 177.95 4.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.742 0.306 . . . . 0.0 110.519 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -158.28 134.1 9.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.551 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 55.62 65.22 1.52 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.551 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 20.8 m -68.33 -25.95 32.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -46.43 -30.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.655 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.64 -49.81 62.34 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.404 HG21 HD11 ' A' ' 41' ' ' ILE . 16.7 mm -58.12 -44.85 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.026 0.441 . . . . 0.0 110.51 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.9 mt -63.43 -36.88 77.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.569 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 65.6 m -61.04 -51.47 69.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.506 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 9.7 pt -62.66 -43.36 98.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.935 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -58.69 -44.0 88.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.019 0.437 . . . . 0.0 110.233 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.62 -36.06 83.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.701 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.8 t -65.84 -34.08 67.91 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-O 121.087 0.47 . . . . 0.0 109.833 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.515 ' C ' ' HZ1' ' A' ' 52' ' ' LYS . . . -68.45 -53.81 21.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.382 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 6.3 m -55.49 -49.22 73.12 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.075 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.3 m -70.51 -26.34 28.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.617 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 27.6 tp -65.98 -56.06 13.57 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.867 -179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.515 ' HZ1' ' C ' ' A' ' 48' ' ' ALA . 1.4 mppt? -65.16 -44.38 88.71 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.394 -0.522 . . . . 0.0 110.244 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.8 m -60.7 -44.97 95.92 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.474 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.0 mt -74.05 -41.73 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.23 -32.54 19.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.254 -178.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 tp -78.41 -44.22 25.39 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.452 ' O ' ' N ' ' A' ' 61' ' ' GLU . 33.9 mt -59.81 -61.9 6.96 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 119.278 -0.969 . . . . 0.0 113.039 -176.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.474 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -49.31 -26.55 11.7 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 C-N-CA 122.135 1.89 . . . . 0.0 112.233 -179.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -92.27 -64.8 1.06 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.487 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -60.4 -11.09 5.81 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.132 -0.627 . . . . 0.0 110.196 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 57' ' ' ILE . 31.5 mm-40 -135.02 110.56 9.15 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.928 0.394 . . . . 0.0 110.543 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -72.4 -36.95 68.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.477 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 17.8 m120 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.525 179.984 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.424 ' O ' ' OG ' ' B' ' 2' ' ' SER . 22.2 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.424 ' OG ' ' O ' ' B' ' 1' ' ' CYS . 3.3 p 72.58 -53.1 0.7 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.449 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.413 ' N ' ' OG ' ' B' ' 2' ' ' SER . 64.9 p 45.37 61.44 2.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.813 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 22.4 m -72.28 -37.21 58.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.326 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.551 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -41.84 -64.69 0.61 Allowed Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.179 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.5 Cg_endo -60.33 6.22 0.12 Allowed 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 122.257 1.971 . . . . 0.0 111.956 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.46 -65.11 0.28 Allowed Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.486 ' CG2' ' N ' ' B' ' 9' ' ' LEU . 16.1 m -59.94 -52.16 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.483 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.486 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 39.1 mt -54.16 -39.11 66.27 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.72 71.36 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.66 -34.53 88.88 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.896 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.54 -46.96 88.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.302 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -53.56 -42.47 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.047 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 84.2 t -57.92 -44.72 87.16 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.907 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.52 -37.47 94.21 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -61.81 -41.99 98.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 0.0 110.142 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 58.4 tp -61.28 -44.38 97.32 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.35 -41.53 87.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.007 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 20.5 mt -64.55 -35.5 81.19 Favored 'General case' 0 C--O 1.225 -0.208 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.064 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 96.0 m -61.79 -48.83 78.86 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.632 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 61.7 t -68.42 -47.64 76.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.525 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 29.2 tp -60.86 -51.9 67.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.303 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 79.0 mt -57.65 -50.61 76.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.02 37.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.024 0.44 . . . . 0.0 109.934 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.21 -41.03 78.67 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.74 -37.21 83.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.403 179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.41 -46.51 95.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -61.46 -41.02 96.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.177 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 45.0 t80 -59.34 -44.51 92.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.61 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 30.1 tp -55.87 -41.83 74.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.28 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 78.89 161.16 19.74 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 64.3 mtp85 . . . . . 0 C--N 1.331 -0.236 0 CA-C-O 120.787 0.327 . . . . 0.0 110.572 179.997 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' B' ' 1' ' ' CYS . 55.9 m . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.0 t -76.7 115.52 16.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.668 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.459 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.6 OUTLIER -82.48 169.73 16.04 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.385 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' A' ' 3' ' ' THR . 26.9 m 33.11 34.84 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.082 0.468 . . . . 0.0 111.637 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -86.91 -41.57 0.54 Allowed Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.304 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.2 Cg_exo -47.9 -45.03 25.86 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.659 2.239 . . . . 0.0 112.703 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.76 -49.21 0.82 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.491 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.0 t -54.96 -41.72 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 71.4 mt -55.22 -37.9 67.75 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.09 -36.9 75.92 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -61.14 -28.87 69.74 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 178.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -66.6 -40.89 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.51 -50.44 80.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.71 179.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.1 t -58.29 -44.62 88.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.713 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.51 -36.55 78.01 Favored Glycine 0 CA--C 1.525 0.674 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.037 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.528 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.2 t0 -65.21 -48.66 72.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.904 0.383 . . . . 0.0 110.592 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 28.7 tp -55.53 -51.64 66.36 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.716 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 m -64.36 -28.72 45.51 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 C-N-CA 120.213 -0.595 . . . . 0.0 110.801 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.26 -56.87 15.61 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.946 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.3 m -55.14 -42.39 72.99 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.415 179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.48 -29.05 44.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.829 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.47 -53.86 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.193 -178.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.8 mt -66.15 -42.81 91.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.402 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.25 -39.5 90.55 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.992 0.425 . . . . 0.0 110.429 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 33.0 tp -69.14 -37.54 78.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.041 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.61 -50.4 73.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 26.0 m -67.63 -35.69 73.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.634 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -60.31 -41.83 94.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.528 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -65.77 -38.75 89.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.721 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.9 tp -59.78 -43.33 94.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.539 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.98 115.69 4.58 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.9 mmt85 -81.21 44.89 0.8 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.76 0.314 . . . . 0.0 110.482 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.4 mt 58.75 158.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.487 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.58 12.15 84.78 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 29.0 p -78.57 -11.8 59.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.779 0.323 . . . . 0.0 110.496 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 52.46 -175.13 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.539 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 47.36 22.78 0.29 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.401 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.0 m -69.17 -23.94 27.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.74 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.437 ' CD1' ' H ' ' A' ' 39' ' ' LEU . 9.3 mp -46.06 -35.93 5.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.594 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.79 -46.47 89.9 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 58.8 mt -59.2 -38.29 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.016 0.436 . . . . 0.0 110.6 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.4 mm -67.41 -39.45 82.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -61.46 -52.12 65.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.616 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.1 pt -61.62 -44.67 99.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.905 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.8 t -56.72 -43.53 79.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.519 -0.472 . . . . 0.0 109.792 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 64.9 mt -65.21 -32.66 74.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.188 -179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.12 -36.15 76.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.14 -51.13 41.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.145 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.434 ' O ' ' OG1' ' A' ' 53' ' ' THR . 14.3 m -56.57 -48.45 77.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.455 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.8 m -71.36 -28.52 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 64.8 tp -67.74 -54.74 16.88 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.839 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.528 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 2.1 mptp? -65.24 -44.84 86.89 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.42 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 49' ' ' THR . 23.9 m -61.09 -47.19 87.46 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.486 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.1 mt -70.93 -42.95 77.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.533 ' O ' ' CD2' ' A' ' 59' ' ' PHE . 16.5 m -75.68 -36.58 34.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.509 -178.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -71.85 -39.28 69.81 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 -178.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.499 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.4 mp -60.39 -50.44 85.72 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.371 0.878 . . . . 0.0 113.371 -177.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.486 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 7.4 Cg_endo -50.65 -43.96 42.99 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 CA-C-N 120.718 1.292 . . . . 0.0 111.64 -178.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.533 ' CD2' ' O ' ' A' ' 55' ' ' VAL . 24.2 m-85 -74.56 -68.01 0.58 Allowed 'General case' 0 N--CA 1.433 -1.275 0 CA-C-O 120.742 0.306 . . . . 0.0 110.665 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.475 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -53.24 -22.62 7.13 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.298 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ILE . 66.1 mm-40 -143.92 111.05 5.77 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.86 0.362 . . . . 0.0 110.268 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -72.84 -31.27 64.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.684 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.2 p30 . . . . . 0 C--N 1.332 -0.194 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.811 -179.917 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.572 ' N ' ' SG ' ' A' ' 1' ' ' CYS . 23.9 p . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.56 ' C ' ' H ' ' B' ' 4' ' ' VAL . 8.1 t 60.22 -75.0 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.647 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.527 ' N ' ' O ' ' B' ' 1' ' ' CYS . 5.9 m 67.69 -30.59 0.17 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.488 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.56 ' H ' ' C ' ' B' ' 2' ' ' SER . 4.7 t 64.57 -66.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.818 -0.174 . . . . 0.0 111.23 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.523 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -33.14 -61.43 0.36 Allowed Pre-proline 0 CA--C 1.535 0.366 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.58 9.39 0.12 Allowed 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.052 1.835 . . . . 0.0 112.194 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' VAL . . . -120.69 -63.85 0.25 Allowed Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.964 -0.454 . . . . 0.0 111.964 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' B' ' 11' ' ' GLY . 35.2 m -61.52 -55.28 25.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 C-N-CA 120.224 -0.591 . . . . 0.0 110.607 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.415 ' H ' ' CG2' ' B' ' 8' ' ' VAL . 40.8 mt -53.51 -38.1 63.41 Favored 'General case' 0 C--O 1.244 0.788 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.2 -36.71 71.19 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 177.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.86 -35.75 91.78 Favored Glycine 0 CA--C 1.522 0.472 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.976 179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . 0.423 ' CD1' ' N ' ' B' ' 12' ' ' ILE . 1.5 mp -65.03 -46.25 92.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.572 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.01 -44.49 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 C-N-CA 118.97 -1.092 . . . . 0.0 109.0 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.18 -43.99 77.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.793 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.08 -36.67 92.68 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -60.65 -46.23 91.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.107 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -49.35 77.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.622 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 70.0 t -54.04 -45.31 64.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.12 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 91.9 mt -60.19 -50.94 71.68 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.967 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -44.97 -49.44 11.18 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.484 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -62.9 -37.64 79.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.547 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.0 tp -63.74 -50.3 69.64 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.642 -179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 24.4 mm -58.85 -46.11 91.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -52.41 -48.7 65.55 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 32.3 tp -56.17 -37.09 69.08 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -37.45 87.32 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.24 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.81 -47.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -61.2 -40.7 94.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.22 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -58.51 -44.8 89.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.557 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.0 tp -58.17 -40.61 81.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.405 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.99 150.38 8.21 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.784 0.326 . . . . 0.0 110.549 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 45.4 m . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.5 m -80.89 70.74 7.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.653 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 5' ' ' SER . 60.4 p -148.97 132.2 16.45 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.363 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.47 ' N ' ' OG ' ' B' ' 5' ' ' SER . 30.4 m 34.85 29.95 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.219 0.533 . . . . 0.0 111.065 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.619 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -91.26 -38.67 0.38 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.215 179.057 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.3 Cg_exo -48.18 -42.19 33.44 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.429 2.086 . . . . 0.0 112.551 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.07 -47.14 0.8 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 108.863 -1.695 . . . . 0.0 108.863 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.529 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -56.53 -40.85 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.0 mt -55.69 -35.39 65.98 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.63 -37.8 87.75 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 177.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.23 -29.12 70.4 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 178.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.27 -42.58 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.9 t -57.07 -51.89 63.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.103 0.478 . . . . 0.0 109.971 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.4 t -59.2 -43.17 88.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.952 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -36.35 88.08 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.466 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -66.32 -49.75 65.94 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.826 0.346 . . . . 0.0 110.523 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 23.0 tp -54.82 -51.02 67.14 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.83 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.5 m -65.18 -29.12 46.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.995 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -61.12 -58.86 6.6 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.999 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -54.9 -40.48 69.84 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.604 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.9 t -69.57 -30.02 43.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.22 -54.34 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.103 -178.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 22.0 mt -68.14 -41.53 84.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.535 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.36 -41.76 94.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.444 . . . . 0.0 110.094 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.0 tp -68.2 -32.85 73.36 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.909 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.62 -51.09 70.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.627 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.56 -36.36 77.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.506 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -60.64 -46.25 90.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.506 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -69.0 -45.9 69.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.78 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.2 tp -61.34 -43.72 98.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.552 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -82.25 79.26 1.89 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -63.41 82.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.467 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.479 ' CD1' ' N ' ' A' ' 33' ' ' LEU . 9.2 mp 45.48 64.15 1.53 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.4 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -73.73 -152.31 2.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.425 ' O ' ' O ' ' A' ' 36' ' ' ALA . 9.5 t -72.55 177.95 4.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.767 0.318 . . . . 0.0 110.536 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.5 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . -60.27 -139.57 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.498 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 54.56 8.0 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.5 ' H ' ' C ' ' A' ' 36' ' ' ALA . 21.9 m -65.77 -24.7 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.697 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.42 ' CD1' ' H ' ' A' ' 39' ' ' LEU . 10.2 mp -45.91 -29.22 1.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.404 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.18 -47.48 81.1 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.58 -38.76 72.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.932 0.396 . . . . 0.0 110.598 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.5 ' CD1' ' N ' ' A' ' 42' ' ' ILE . 1.9 mp -67.13 -43.14 88.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.168 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -58.54 -51.25 70.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.875 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.9 pt -63.04 -45.02 99.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.814 -179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.59 -36.36 53.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.633 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -38.43 80.79 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.348 -179.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.82 -31.99 56.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.166 -0.614 . . . . 0.0 109.682 -179.383 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.61 -52.36 21.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.482 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.4 ' O ' ' OG1' ' A' ' 53' ' ' THR . 4.6 m -58.81 -45.26 90.33 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.512 -178.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -71.51 -31.45 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 56.0 tp -68.07 -53.47 25.32 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 119.816 -0.754 . . . . 0.0 110.954 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 52' ' ' LYS . 11.8 mptt -63.5 -47.12 83.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.732 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 49' ' ' THR . 64.1 p -65.23 -41.92 93.91 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.455 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 97.5 mt -71.52 -46.65 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -177.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.1 m -74.72 -34.95 35.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.645 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.2 tp -78.35 -41.04 34.64 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.471 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 37.2 mt -53.48 -52.95 62.06 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.471 ' HD2' ' N ' ' A' ' 57' ' ' ILE . 9.3 Cg_endo -51.1 -44.16 44.09 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 121.228 1.285 . . . . 0.0 112.386 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -75.98 -57.17 4.03 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -45.29 -38.23 5.47 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 120.637 -0.425 . . . . 0.0 109.996 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -81.61 110.61 17.14 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.529 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -69.76 -23.71 63.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.496 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 30.0 m120 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.498 -179.991 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.415 ' O ' ' O ' ' B' ' 2' ' ' SER . 24.2 m . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.415 ' O ' ' O ' ' B' ' 1' ' ' CYS . 16.3 m 55.76 108.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.491 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 30.8 p -68.69 143.25 54.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.501 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.438 ' CG2' ' N ' ' B' ' 5' ' ' SER . 18.4 m -147.37 -46.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.602 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -45.9 -64.81 0.8 Allowed Pre-proline 0 CA--C 1.533 0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.608 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.439 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 10.5 Cg_endo -52.95 2.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 121.872 1.715 . . . . 0.0 112.283 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.602 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -99.99 -68.76 0.87 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -65.25 -49.61 77.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.826 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.2 mt -55.32 -39.9 70.51 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.17 89.24 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.5 -29.88 74.8 Favored Glycine 0 CA--C 1.52 0.404 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.159 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -69.09 -47.52 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 C-N-CA 119.661 -0.816 . . . . 0.0 108.976 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -53.86 -42.3 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 118.674 -1.21 . . . . 0.0 108.811 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.58 -42.34 91.22 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.992 179.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.9 -38.45 96.11 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -61.34 -43.2 99.28 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.7 tp -61.16 -46.98 88.29 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.811 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -58.63 -45.49 90.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 89.4 mt -60.87 -50.35 73.77 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.872 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.9 m -45.74 -50.23 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.471 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.28 -36.88 77.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.617 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.1 tp -63.72 -50.67 68.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.571 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 28.6 mm -59.39 -44.27 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.27 -47.11 69.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.211 0.529 . . . . 0.0 109.654 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.93 -38.93 76.81 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.63 87.87 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.258 179.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 73.1 t -60.47 -47.31 93.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -61.2 -40.93 95.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.192 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -58.79 -47.3 85.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.717 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 26.3 tp -59.17 -46.88 87.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.43 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.95 112.32 0.75 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 . . . . . 0 C--N 1.328 -0.366 0 CA-C-O 120.827 0.346 . . . . 0.0 110.47 179.975 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.0 t . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.3 p -73.29 151.01 41.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.545 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.2 t -163.1 165.0 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.613 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.468 ' H ' ' CB ' ' B' ' 5' ' ' SER . 26.9 m 34.68 34.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.228 0.537 . . . . 0.0 111.248 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.621 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -86.57 -37.43 0.52 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.36 179.067 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.621 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.1 Cg_exo -48.71 -41.2 38.45 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.359 2.04 . . . . 0.0 112.512 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.72 -47.21 0.74 Allowed Glycine 0 N--CA 1.463 0.491 0 N-CA-C 108.795 -1.722 . . . . 0.0 108.795 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.518 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.8 t -55.0 -38.24 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.001 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 68.0 mt -55.32 -39.51 70.03 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.05 -38.45 79.4 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 177.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.63 -26.89 67.29 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -68.04 -42.18 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.86 -54.11 39.89 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.733 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.6 t -58.49 -30.25 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.798 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.44 -38.8 93.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.531 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.1 t0 -67.62 -45.88 74.15 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.232 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.0 tp -57.65 -51.01 71.26 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -66.05 -28.71 44.59 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.774 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -60.19 -56.99 14.76 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 120.297 -0.561 . . . . 0.0 109.545 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.3 m -57.99 -41.79 83.78 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.292 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.57 -36.76 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.973 0.36 . . . . 0.0 111.973 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.08 -55.36 12.79 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 121.056 -0.258 . . . . 0.0 111.254 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.9 mt -66.42 -44.4 90.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.723 -179.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.29 -43.97 88.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.134 0.492 . . . . 0.0 110.231 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.4 tp -67.12 -30.92 71.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.939 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.55 -51.07 68.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -36.11 76.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.365 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -61.82 -48.69 79.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.546 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 61.2 t80 -70.35 -48.47 56.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.669 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.7 tp -62.59 -42.89 99.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.51 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.72 112.37 4.93 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -72.84 149.51 43.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.798 0.332 . . . . 0.0 110.423 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.531 ' CD2' ' N ' ' A' ' 33' ' ' LEU . 3.2 mm? -73.73 109.86 7.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.215 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 160.88 43.31 0.02 OUTLIER Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -165.05 132.02 2.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.627 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.42 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . -73.26 -140.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.455 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 47.24 19.02 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.474 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.42 ' N ' ' C ' ' A' ' 36' ' ' ALA . 19.6 m -62.64 -27.26 42.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.677 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -48.78 -29.38 4.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.921 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.0 -47.96 83.15 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.454 ' CD1' ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.62 -45.8 79.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.9 0.381 . . . . 0.0 110.079 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.481 ' CD1' ' N ' ' A' ' 42' ' ' ILE . 1.9 mp -65.22 -29.48 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.429 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.7 m -65.33 -49.27 70.05 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.4 pt -68.87 -39.2 79.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.473 -179.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.2 t -61.76 -43.05 96.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.125 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -69.02 -35.93 77.19 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.593 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.58 -32.92 59.08 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.954 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.01 -49.93 32.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.476 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.43 ' H ' ' HG1' ' A' ' 49' ' ' THR . 2.6 m -59.55 -48.62 80.94 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.2 -179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.8 m -64.53 -37.56 80.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.867 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 35.3 tp -63.07 -44.15 96.6 Favored 'General case' 0 C--O 1.224 -0.246 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.296 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.531 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 3.8 mptp? -59.79 -52.98 63.16 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.49 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.8 m -63.85 -46.46 84.93 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 -178.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 84.9 mt -62.7 -47.5 92.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.531 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 5.5 m -76.47 -35.91 27.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 120.327 -0.549 . . . . 0.0 111.024 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.5 tt -65.24 -33.07 75.13 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 113.091 0.775 . . . . 0.0 113.091 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.438 ' O ' ' OE1' ' A' ' 61' ' ' GLU . 9.7 mt -66.75 -54.79 20.24 Favored Pre-proline 0 CA--C 1.544 0.75 0 C-N-CA 119.549 -0.86 . . . . 0.0 112.692 -178.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' A' ' 61' ' ' GLU . 55.9 Cg_endo -70.09 -28.57 23.5 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.726 1.617 . . . . 0.0 111.033 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.98 -52.0 64.67 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.523 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.446 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.7 mm? -79.21 -3.01 43.69 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.507 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 57' ' ' ILE . 56.9 mp0 -145.01 109.22 4.83 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.281 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 89.3 mm-40 -62.97 -41.64 99.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.554 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.616 -179.938 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 77.5 m . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.402 ' O ' ' OG1' ' B' ' 3' ' ' THR . 5.1 m 53.92 18.08 1.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.588 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.402 ' OG1' ' O ' ' B' ' 2' ' ' SER . 28.1 p 52.83 94.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.818 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' B' ' 7' ' ' GLY . 28.3 m -74.52 -38.95 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.433 179.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.559 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -38.67 -62.86 0.65 Allowed Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.505 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -59.93 6.99 0.09 OUTLIER 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.197 1.931 . . . . 0.0 112.229 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.559 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -116.99 -66.44 0.37 Allowed Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -58.2 -51.88 65.62 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 121.007 0.432 . . . . 0.0 110.3 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 32.2 mt -56.79 -38.42 72.5 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.23 67.19 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.13 -36.84 93.42 Favored Glycine 0 CA--C 1.522 0.498 0 CA-C-N 114.135 -1.393 . . . . 0.0 110.884 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 19.6 mt -63.96 -42.53 96.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.567 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 m -56.64 -46.05 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.833 178.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.8 t -52.44 -45.12 45.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 C-N-CA 120.081 -0.647 . . . . 0.0 109.474 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.3 -37.45 91.91 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -60.58 -47.0 88.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.094 0.474 . . . . 0.0 110.175 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.5 tp -56.61 -47.22 80.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.155 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -56.35 -45.54 81.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.272 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 30.0 mt -59.67 -52.84 63.78 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.588 -0.445 . . . . 0.0 109.977 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.1 m -44.64 -47.4 10.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.574 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -63.45 -38.43 82.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.485 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 39.7 tp -64.58 -54.86 25.37 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.67 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 8.5 mm -55.13 -47.48 77.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.893 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -50.98 -49.14 60.78 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 121.118 0.485 . . . . 0.0 109.781 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -55.86 -36.46 67.58 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.76 -37.72 88.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.19 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -60.62 -47.69 91.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -62.35 -40.04 95.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.053 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -59.14 -43.8 92.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.551 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.9 tp -59.75 -43.09 94.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.462 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 74.98 142.76 0.89 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 22.0 ttm105 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.783 0.325 . . . . 0.0 110.533 -179.913 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 2' ' ' SER . 31.1 t . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.483 ' N ' ' SG ' ' A' ' 1' ' ' CYS . 42.8 m 51.66 54.95 10.1 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.608 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.1 t -67.39 145.58 54.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.448 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 3' ' ' THR . 29.5 m 32.23 34.44 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.561 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -85.49 -40.77 0.62 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.442 179.345 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 90.1 Cg_exo -47.77 -43.01 29.97 Favored 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.695 2.264 . . . . 0.0 112.801 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 69.98 -52.18 0.75 Allowed Glycine 0 N--CA 1.465 0.568 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 6' ' ' PRO . 63.1 t -50.73 -36.12 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 177.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 36.2 mt -55.4 -40.93 72.03 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.524 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -56.18 -39.07 71.8 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 177.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.9 -27.53 67.03 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -69.03 -37.15 76.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.1 t -65.6 -52.65 48.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.22 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.4 t -59.77 -42.63 89.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.138 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.43 73.14 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.346 -0.701 . . . . 0.0 111.346 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -69.94 -54.08 14.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.771 0.319 . . . . 0.0 110.487 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 50.2 tp -61.05 -40.71 94.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.204 0.526 . . . . 0.0 109.815 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.6 t -69.23 -27.63 35.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.272 -179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 tp -72.16 -55.87 6.54 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.802 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 m -62.51 -39.09 92.4 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.235 -0.586 . . . . 0.0 110.975 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.85 -39.36 75.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.658 -0.246 . . . . 0.0 111.521 -179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.3 -52.8 56.77 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.387 -178.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -65.67 -43.7 93.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.363 -179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -40.21 81.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.023 0.439 . . . . 0.0 110.404 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -71.1 -35.82 71.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.258 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.75 -50.19 70.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.996 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 29.6 m -69.17 -33.84 60.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.357 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -63.39 -45.26 91.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.456 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -61.18 -50.83 71.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.428 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' GLY . 28.7 mt -70.05 -34.82 73.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.25 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 30' ' ' LEU . . . -55.99 -160.23 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -159.8 127.12 4.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.835 0.35 . . . . 0.0 110.722 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.477 ' C ' ' H ' ' A' ' 35' ' ' THR . 0.2 OUTLIER -84.17 -177.61 6.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.126 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' H ' ' A' ' 36' ' ' ALA . . . 74.62 -15.93 3.42 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.477 ' H ' ' C ' ' A' ' 33' ' ' LEU . 11.4 t -80.44 23.72 0.49 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.809 0.338 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.469 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . 51.17 -171.58 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.9 tp10 58.2 7.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.119 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.469 ' H ' ' C ' ' A' ' 36' ' ' ALA . 27.2 m -56.63 -26.54 23.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.544 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.9 tp -47.79 -32.57 6.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.643 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.0 -53.16 42.55 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.9 mm -56.38 -46.41 81.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-O 121.055 0.455 . . . . 0.0 110.436 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.41 HD13 HG22 ' A' ' 42' ' ' ILE . 95.7 mt -55.02 -45.25 76.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.171 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.7 t -60.12 -41.14 92.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.041 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 5.3 mm -57.44 -53.9 37.98 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.278 0.561 . . . . 0.0 111.125 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 p -64.65 -27.64 43.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.184 -0.606 . . . . 0.0 110.279 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.9 -46.42 74.95 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.276 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.7 p -67.61 -33.44 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.626 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.59 -44.62 77.69 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.633 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.5 p -66.56 -52.06 49.69 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.836 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.3 m -65.35 -37.33 79.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.244 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.1 tt -65.35 -42.19 93.1 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.591 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 14.6 tptm -62.98 -52.43 63.04 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.884 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 75.5 p -65.95 -44.02 86.23 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 112.807 0.669 . . . . 0.0 112.807 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.477 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 88.5 mt -64.93 -45.97 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.538 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.3 m -77.64 -36.34 22.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.135 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.1 tt -67.27 -31.93 72.6 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.5 mm -67.74 -54.19 18.44 Favored Pre-proline 0 CA--C 1.544 0.729 0 C-N-CA 119.663 -0.815 . . . . 0.0 112.669 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 53.7 Cg_endo -69.54 -28.05 26.77 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 121.729 1.619 . . . . 0.0 111.0 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.81 -54.62 36.17 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.6 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.458 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -76.36 -20.99 56.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.523 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 58' ' ' PRO . 69.3 mm-40 -99.65 115.26 29.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.461 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -67.05 -67.18 0.47 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.569 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.522 179.98 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.466 ' O ' ' OG1' ' B' ' 3' ' ' THR . 32.9 p -163.36 102.9 0.95 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.394 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.472 ' OG1' ' N ' ' B' ' 4' ' ' VAL . 44.7 p 57.19 -101.95 0.14 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.864 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.472 ' N ' ' OG1' ' B' ' 3' ' ' THR . 7.7 t 66.33 -79.79 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.254 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.448 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -40.21 -63.93 0.64 Allowed Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.783 -179.071 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 30.8 Cg_endo -61.6 0.73 0.97 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.099 1.866 . . . . 0.0 112.02 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.448 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -107.29 -64.02 0.59 Allowed Glycine 0 N--CA 1.466 0.7 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.522 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 0.2 OUTLIER -64.11 -50.95 74.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.091 0.472 . . . . 0.0 109.859 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.38 -38.96 81.84 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.19 -32.77 66.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -38.34 93.91 Favored Glycine 0 CA--C 1.525 0.713 0 CA-C-N 114.449 -1.251 . . . . 0.0 111.625 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 8.2 mt -65.73 -42.31 92.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 C-N-CA 119.555 -0.858 . . . . 0.0 109.61 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.5 m -55.75 -45.27 79.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.0 t -53.73 -50.18 52.9 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.674 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.46 -31.22 62.83 Favored Glycine 0 CA--C 1.527 0.844 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -70.93 -40.38 72.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.742 0.306 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 tp -61.53 -51.39 68.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -59.03 -44.43 91.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.353 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 26.8 mt -58.45 -51.94 67.73 Favored 'General case' 0 C--O 1.227 -0.117 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.925 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -48.07 -50.85 26.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 0.0 110.456 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.2 t -60.82 -31.26 49.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.137 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 13.9 tp -67.86 -44.74 76.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.894 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 28.4 mm -61.53 -51.23 75.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.035 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.86 -42.25 75.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.144 0.497 . . . . 0.0 109.92 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.2 tp -60.02 -37.38 79.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.709 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.81 94.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.204 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 87.3 t -60.13 -48.11 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.059 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -63.66 -38.95 93.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.221 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 44.0 t80 -58.26 -46.96 85.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.6 -40.28 96.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.227 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 84.73 176.97 51.05 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 82.1 mtt85 . . . . . 0 C--N 1.329 -0.309 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 -179.966 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 53.8 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.549 ' HG ' ' CB ' ' A' ' 5' ' ' SER . 17.6 p -52.87 113.07 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.58 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.0 OUTLIER -87.28 167.38 14.14 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.374 179.844 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.498 ' N ' ' OG ' ' B' ' 5' ' ' SER . 26.8 m 34.61 31.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.173 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.616 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -85.71 -38.33 0.58 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.432 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.616 ' CD ' ' N ' ' A' ' 5' ' ' SER . 97.9 Cg_exo -48.43 -42.4 34.77 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 122.405 2.07 . . . . 0.0 112.572 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.28 -48.39 0.71 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' PRO . 76.7 t -53.68 -35.94 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 177.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.0 mt -54.84 -41.88 71.27 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.67 -37.98 77.21 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 177.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.82 -26.02 64.63 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -70.9 -38.38 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.6 t -61.42 -54.6 32.79 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-O 121.355 0.598 . . . . 0.0 109.521 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 t -60.57 -36.26 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.284 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.11 -38.75 96.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -67.92 -47.75 67.86 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.889 0.376 . . . . 0.0 110.382 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.697 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 23.5 tp -58.91 -50.67 73.15 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.044 -179.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -68.33 -26.33 33.56 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.292 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.764 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.5 mt -62.81 -54.99 30.47 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.469 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.1 m -60.39 -43.99 96.1 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.298 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 98.6 t -62.75 -49.36 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.33 -53.51 53.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.143 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.1 mt -58.8 -44.34 90.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.159 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.13 -38.02 81.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.286 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.39 -48.05 74.23 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.93 -46.85 64.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.512 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.2 t -62.06 -45.21 99.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -55.22 -43.67 74.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.636 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -59.21 -48.47 81.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.3 tt -64.35 -43.17 95.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.435 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.431 ' C ' ' H ' ' A' ' 33' ' ' LEU . . . -65.01 94.99 0.19 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -76.89 41.84 0.29 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.838 0.351 . . . . 0.0 110.587 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.535 ' CD2' ' N ' ' A' ' 33' ' ' LEU . 3.3 mm? 48.69 -175.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.92 -20.17 3.9 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.441 ' H ' ' C ' ' A' ' 33' ' ' LEU . 3.3 t -80.42 -12.7 59.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.823 0.344 . . . . 0.0 110.449 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.421 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . 49.76 -143.83 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.467 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 48.63 17.96 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.48 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.421 ' N ' ' C ' ' A' ' 36' ' ' ALA . 23.7 m -56.34 -24.48 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.41 ' CD1' ' H ' ' A' ' 39' ' ' LEU . 10.1 mp -46.9 -32.54 3.87 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.394 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 -50.89 42.7 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 61.0 mt -60.74 -41.05 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.669 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 82.1 mt -66.27 -39.44 84.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.398 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.4 t -60.53 -50.83 71.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.794 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 8.3 pt -64.51 -44.11 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -57.52 -42.97 82.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.128 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.68 -39.71 91.59 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.694 -178.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.24 -30.24 49.67 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.067 0 C-N-CA 120.396 -0.521 . . . . 0.0 109.658 -179.21 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.73 -50.18 32.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.546 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.7 m -58.5 -47.04 85.44 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.352 -0.539 . . . . 0.0 111.108 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.7 m -69.0 -44.69 81.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.596 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 37.9 tp -53.41 -51.81 61.38 Favored 'General case' 0 CA--C 1.519 -0.218 0 C-N-CA 120.114 -0.634 . . . . 0.0 110.302 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.697 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 3.4 mmmm -60.45 -43.94 96.34 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.825 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.2 m -59.68 -49.82 76.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.483 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 2.8 mp -70.97 -44.84 75.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.519 ' O ' ' CD1' ' A' ' 59' ' ' PHE . 6.0 m -74.92 -34.18 32.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.887 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.404 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 10.8 tp -75.33 -37.33 60.79 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -178.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.1 mt -57.59 -52.64 72.81 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 49.5 Cg_endo -69.59 -27.58 27.11 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.434 1.423 . . . . 0.0 111.216 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.519 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.4 m-30 -63.98 -56.37 15.63 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.28 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.516 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -77.7 18.79 0.42 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.932 0.396 . . . . 0.0 110.096 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.469 ' H ' ' C ' ' A' ' 59' ' ' PHE . 32.9 tp10 -173.25 78.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.598 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -55.47 -46.3 76.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.647 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 16.2 p30 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.508 -179.982 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 25.7 p -66.02 -46.94 76.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.467 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 71.2 p 43.18 45.49 4.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.103 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.418 ' O ' ' N ' ' B' ' 7' ' ' GLY . 26.6 m -73.93 -33.27 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.767 0.318 . . . . 0.0 110.456 179.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.568 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -40.49 -62.75 0.87 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.213 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -61.85 11.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 122.09 1.86 . . . . 0.0 112.235 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.568 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.74 -66.14 0.28 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -50.86 78.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-O 121.055 0.455 . . . . 0.0 110.224 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.8 mt -60.13 -37.14 79.16 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.52 -34.15 66.73 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.02 -43.4 97.41 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.946 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 42.6 mm -57.82 -41.72 80.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.195 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.3 m -60.75 -43.02 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.395 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -57.44 -47.2 85.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 120.338 -0.545 . . . . 0.0 109.913 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.37 -36.3 90.68 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -63.18 -41.19 99.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.147 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.9 tp -61.77 -45.73 92.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.917 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.91 -48.0 82.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.384 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 49.9 mt -61.24 -49.13 78.36 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.105 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -46.1 -50.33 15.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.504 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 97.1 t -66.01 -31.72 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.501 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.6 tp -66.22 -51.83 53.78 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.482 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 20.9 mm -61.4 -50.71 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.3 -44.35 61.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.176 0.512 . . . . 0.0 109.677 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.33 -38.47 80.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.478 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.0 91.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.088 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 84.1 t -60.86 -46.0 97.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.987 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -60.84 -41.74 96.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.162 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -58.02 -49.99 74.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.409 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 19.9 mt -63.48 -39.01 93.33 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 76.97 -140.99 25.61 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-O 120.86 0.362 . . . . 0.0 110.361 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.1 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.2 p -79.4 151.41 30.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.638 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.6 t -87.91 159.54 18.31 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.474 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.406 ' C ' ' O ' ' A' ' 3' ' ' THR . 27.1 m 34.11 34.3 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.502 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.593 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -78.24 -41.15 1.95 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.469 179.402 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 5' ' ' SER . 78.7 Cg_exo -47.57 -41.98 29.57 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.727 2.285 . . . . 0.0 112.748 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.26 -47.37 0.85 Allowed Glycine 0 N--CA 1.462 0.416 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -179.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.52 ' H ' ' C ' ' A' ' 6' ' ' PRO . 70.8 t -56.1 -39.47 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.5 mt -55.86 -38.1 69.66 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.23 -38.51 83.63 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.13 -29.76 71.96 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.42 -42.87 94.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.6 t -57.81 -51.64 67.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.8 t -57.79 -30.12 36.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.758 178.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.35 -38.12 86.84 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -68.03 -43.79 77.95 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.87 0.367 . . . . 0.0 110.648 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 27.5 tp -63.5 -48.72 76.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.417 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.9 m -65.49 -29.81 48.26 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.124 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.961 -179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -66.35 -56.43 11.13 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.72 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.5 m -52.9 -50.68 63.42 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.987 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -70.28 -27.61 32.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 19.7 tp -66.9 -56.57 9.7 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.003 -179.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 61.2 mt -70.39 -43.23 78.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.596 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.23 -39.51 79.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.979 0.418 . . . . 0.0 110.152 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.79 -40.3 83.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.81 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.72 -50.9 67.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.866 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.4 m -67.98 -34.32 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.63 -0.428 . . . . 0.0 110.59 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -60.24 -44.54 95.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.696 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -66.49 -48.97 68.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -50.48 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.219 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -60.25 133.9 50.48 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.515 ' C ' ' H ' ' A' ' 34' ' ' GLY . 40.0 ttm180 -76.28 154.59 35.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.541 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 16.0 mt -72.2 38.28 0.07 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.692 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.515 ' H ' ' C ' ' A' ' 32' ' ' ARG . . . -179.2 99.07 0.12 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.402 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.1 t -165.09 17.01 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.811 0.338 . . . . 0.0 110.522 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.408 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . 47.39 -170.36 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.55 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 52.1 14.09 0.31 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.45 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.408 ' H ' ' C ' ' A' ' 36' ' ' ALA . 17.0 m -63.53 -25.68 38.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.704 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 58.3 tp -46.41 -29.61 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.817 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.98 -50.57 57.3 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.471 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 1.8 mp -56.79 -48.07 81.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.954 0.407 . . . . 0.0 109.931 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.8 mt -63.58 -29.99 48.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.618 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.3 t -64.85 -47.28 78.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.356 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.5 pt -71.11 -35.43 58.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.323 . . . . 0.0 111.54 -179.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 64.9 t -67.78 -43.85 86.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.196 -0.602 . . . . 0.0 110.36 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -72.04 -37.52 69.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.72 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.2 p -69.4 -31.81 50.82 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.113 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.878 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.38 -52.14 20.28 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.586 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.421 ' H ' ' HG1' ' A' ' 49' ' ' THR . 3.8 m -60.22 -42.48 95.25 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.566 -178.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -71.42 -32.98 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.518 -0.473 . . . . 0.0 112.066 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.403 ' CD1' ' C ' ' A' ' 51' ' ' LEU . 0.9 OUTLIER -68.05 -56.55 8.46 Favored 'General case' 0 CA--C 1.521 -0.146 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.388 -179.694 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.31 -47.68 84.85 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.569 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 96.1 m -61.02 -44.55 97.25 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 95.3 mt -72.33 -43.53 64.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 113.736 1.013 . . . . 0.0 113.736 -177.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -78.68 -33.72 16.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.171 -0.611 . . . . 0.0 111.565 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -77.86 -39.88 41.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.441 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 13.0 mm -59.75 -54.32 56.88 Favored Pre-proline 0 CA--C 1.541 0.623 0 N-CA-C 113.198 0.814 . . . . 0.0 113.198 -177.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.485 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 16.7 Cg_endo -56.45 -35.76 96.8 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 121.484 1.456 . . . . 0.0 112.045 -179.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -77.28 -61.01 2.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.1 -40.41 23.34 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 120.488 -0.485 . . . . 0.0 109.98 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -78.74 118.28 20.66 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.828 0.347 . . . . 0.0 110.681 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -70.25 138.8 51.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.574 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--N 1.331 -0.222 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.937 -179.987 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 39.4 m . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 15.0 m -75.92 81.41 2.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.283 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 19.2 p -73.14 166.21 23.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.654 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.83 -42.79 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.138 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.557 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -45.39 -63.27 1.27 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.861 179.592 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.5 Cg_endo -59.51 7.43 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.227 1.951 . . . . 0.0 112.35 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -114.05 -66.17 0.45 Allowed Glycine 0 N--CA 1.468 0.772 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.415 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 11.5 p -63.58 -47.92 89.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.995 0.426 . . . . 0.0 110.306 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.415 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 33.3 mt -56.74 -38.11 71.94 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.3 -39.09 81.9 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.17 75.74 Favored Glycine 0 CA--C 1.523 0.561 0 CA-C-N 114.491 -1.231 . . . . 0.0 110.786 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mm -67.32 -46.13 84.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.063 -0.655 . . . . 0.0 109.615 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -55.6 -43.74 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 118.88 -1.128 . . . . 0.0 108.58 178.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 87.5 t -56.51 -47.92 81.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.294 -0.563 . . . . 0.0 109.542 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -55.5 -30.94 56.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -70.88 -41.91 70.71 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.645 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mp -60.48 -51.55 68.99 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 120.885 0.374 . . . . 0.0 110.196 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -58.7 -45.78 90.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.398 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 51.8 mt -59.42 -34.91 73.06 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.934 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.8 m -64.27 -41.39 96.94 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.295 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.84 -51.19 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.706 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.3 mp -64.28 -51.4 63.71 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.712 0.291 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 82.4 mt -58.63 -51.49 71.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.07 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.6 -48.0 39.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.16 0.505 . . . . 0.0 109.812 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 34.2 tp -57.02 -35.75 69.64 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.1 -36.37 84.07 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.078 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 45.5 t -60.8 -48.07 90.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -64.42 -37.24 86.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.238 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -59.92 -46.49 89.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.682 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 tp -60.18 -41.45 92.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.318 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 162.52 -119.13 0.86 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.739 0.304 . . . . 0.0 110.371 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.9 p -77.45 156.99 30.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.653 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 11.6 p -81.63 169.28 17.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.426 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.47 ' H ' ' HG ' ' B' ' 5' ' ' SER . 27.0 m 34.64 36.93 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.339 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.484 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -79.36 -48.23 1.52 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.317 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.536 ' C ' ' H ' ' A' ' 8' ' ' VAL . 46.7 Cg_exo -42.87 -43.42 9.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 122.699 2.266 . . . . 0.0 112.757 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.47 -46.66 0.87 Allowed Glycine 0 N--CA 1.463 0.433 0 N-CA-C 108.84 -1.704 . . . . 0.0 108.84 -179.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.536 ' H ' ' C ' ' A' ' 6' ' ' PRO . 74.3 t -57.75 -38.73 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.7 mt -55.62 -38.69 69.81 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.22 89.59 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.62 -29.22 66.51 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.87 -43.23 89.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -50.83 74.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 179.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.6 t -57.27 -39.86 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.471 178.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.22 -36.81 91.75 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.62 -47.84 71.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.967 0.413 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -55.53 -51.74 66.04 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.726 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -65.14 -29.15 46.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.373 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.83 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.18 -58.04 10.25 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.738 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.1 m -56.09 -42.37 76.65 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.51 -32.03 56.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.78 -53.9 13.69 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.404 -178.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.9 mt -67.83 -43.17 86.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.365 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.62 -42.94 97.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.891 0.377 . . . . 0.0 110.158 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 30.4 tp -65.56 -42.55 91.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.184 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.51 -48.58 71.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.661 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -64.51 -44.28 96.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.701 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -56.6 -37.58 70.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.662 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -59.91 -48.92 79.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.647 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.1 tp -67.88 -38.41 83.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.489 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -43.32 -69.38 0.66 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.401 ' O ' ' O ' ' A' ' 33' ' ' LEU . 32.7 ttm180 47.42 65.28 1.3 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.774 0.321 . . . . 0.0 110.575 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.495 ' C ' ' H ' ' A' ' 35' ' ' THR . 9.3 mp 52.94 171.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.329 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.18 -24.17 1.37 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.495 ' H ' ' C ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -64.17 -34.37 77.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.796 0.332 . . . . 0.0 110.497 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 51.88 -169.34 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.45 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 48.89 28.68 2.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.483 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.3 m -57.87 -28.28 32.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.561 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.6 tt -49.32 -37.72 25.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.545 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.53 -48.15 76.42 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 92.7 mt -59.63 -40.61 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.064 0.459 . . . . 0.0 110.49 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 91.6 mt -66.84 -35.98 76.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.467 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.3 m -64.18 -51.93 61.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.543 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.5 pt -61.86 -44.53 98.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.966 -179.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.47 -43.38 82.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 120.452 -0.499 . . . . 0.0 109.822 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 70.5 mt -66.04 -32.14 73.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.201 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.26 -35.78 74.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.412 -0.515 . . . . 0.0 109.658 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.98 -49.05 55.48 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.265 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.3 p -58.92 -48.2 82.32 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.511 -179.325 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 m -71.31 -28.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.603 -179.058 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.2 tt -67.12 -53.12 33.69 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.888 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 37.5 mttp -65.42 -44.83 86.16 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.82 0.343 . . . . 0.0 110.649 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.9 m -63.22 -42.53 99.26 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.515 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 93.8 mt -75.36 -41.96 43.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -76.59 -28.62 17.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 120.028 -0.669 . . . . 0.0 111.304 -179.058 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.1 tp -84.82 -47.13 10.68 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.476 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.3 mp -62.2 -59.38 13.19 Favored Pre-proline 0 N--CA 1.473 0.708 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -175.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.515 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -52.02 -27.49 28.93 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 121.392 1.394 . . . . 0.0 111.992 -178.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 26.4 m-85 -90.19 -65.94 0.97 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.494 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.2 mm? -59.61 -17.75 35.84 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.29 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ILE . 69.5 mm-40 -141.5 148.9 40.17 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.895 0.379 . . . . 0.0 110.731 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -69.41 -33.59 73.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.544 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.3 t-20 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 -179.96 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.525 ' O ' ' N ' ' B' ' 3' ' ' THR . 97.4 m . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 9.0 t 59.82 -75.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.58 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.525 ' N ' ' O ' ' B' ' 1' ' ' CYS . 26.3 p 45.97 -169.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.727 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.419 ' O ' ' N ' ' B' ' 7' ' ' GLY . 35.4 m -150.91 -29.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.242 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.582 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -62.77 0.98 Allowed Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.908 179.786 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 31.2 Cg_endo -62.43 12.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.209 1.939 . . . . 0.0 111.995 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.582 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -125.45 -65.61 0.18 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.465 -0.654 . . . . 0.0 111.465 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.472 ' CG2' ' N ' ' B' ' 9' ' ' LEU . 18.1 m -60.09 -49.47 83.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.073 0.463 . . . . 0.0 110.461 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.472 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 28.9 mt -57.41 -42.63 82.67 Favored 'General case' 0 C--O 1.238 0.484 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.66 -37.19 65.42 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 177.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.16 -28.73 73.32 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.347 178.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.2 -43.62 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.377 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -58.86 -42.34 85.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 119.11 -1.036 . . . . 0.0 108.741 178.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.8 t -56.39 -47.42 81.47 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.86 -32.15 65.67 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -69.1 -41.75 77.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.804 0.335 . . . . 0.0 110.689 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 36.9 tp -61.07 -53.07 61.72 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.491 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -58.56 -39.85 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.139 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 25.6 mt -60.79 -52.72 63.9 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.733 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.5 m -47.14 -50.56 20.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.877 0.37 . . . . 0.0 110.21 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 60.0 t -61.95 -31.19 50.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.419 179.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 15.5 tp -68.37 -48.19 65.41 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 18.0 mm -60.64 -44.34 96.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.08 -48.19 79.18 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 121.184 0.516 . . . . 0.0 109.752 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -57.69 -34.93 69.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.55 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.81 -39.39 93.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.081 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -60.59 -45.83 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -62.52 -39.03 92.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -60.4 -44.46 95.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.618 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.0 tp -59.16 -43.38 92.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.369 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.81 116.15 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 50.9 ttm-85 . . . . . 0 C--N 1.328 -0.359 0 CA-C-O 120.737 0.303 . . . . 0.0 110.594 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.7 p -170.03 131.79 1.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.802 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.553 ' C ' ' H ' ' A' ' 5' ' ' SER . 41.7 p -80.89 -72.33 0.42 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.456 ' N ' ' OG1' ' A' ' 3' ' ' THR . 10.6 m -69.24 37.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.958 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.18 -40.76 16.17 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.509 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.4 Cg_exo -46.66 -40.53 24.1 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.531 2.154 . . . . 0.0 112.45 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.24 -47.24 0.67 Allowed Glycine 0 N--CA 1.464 0.507 0 N-CA-C 109.125 -1.59 . . . . 0.0 109.125 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.521 ' H ' ' C ' ' A' ' 6' ' ' PRO . 72.7 t -56.26 -39.82 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.612 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.7 mt -55.96 -38.36 70.25 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.4 -36.1 77.32 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.78 -27.5 70.16 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.65 -42.01 86.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -59.95 -50.93 78.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.997 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.4 t -59.21 -42.32 86.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.904 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.03 -37.1 91.12 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.472 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 59.2 t0 -66.36 -47.4 73.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 110.359 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -55.59 -51.48 67.0 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.884 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.7 m -65.67 -29.02 45.73 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.712 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.38 -58.85 6.83 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.613 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.5 p -56.32 -42.91 78.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.286 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -64.59 -33.82 65.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.845 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.86 -52.86 25.3 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.049 -0.261 . . . . 0.0 111.168 -178.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.4 mt -66.36 -43.79 91.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.349 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.8 -42.29 88.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.081 0.467 . . . . 0.0 110.07 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.6 tp -67.97 -31.27 70.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.034 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.81 -51.28 67.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.764 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.4 ' O ' ' N ' ' A' ' 31' ' ' GLY . 14.4 m -65.07 -37.52 80.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -60.98 -48.69 80.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.549 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 78.6 t80 -71.17 -50.97 27.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 tt -63.65 -51.0 67.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.178 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 27' ' ' VAL . . . -71.08 165.32 53.28 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.7 ttm180 -157.94 88.36 0.96 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.822 0.344 . . . . 0.0 110.315 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.534 ' CD2' ' N ' ' A' ' 33' ' ' LEU . 3.3 mm? 49.58 75.68 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.201 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.99 -154.89 5.32 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.433 ' O ' ' N ' ' A' ' 37' ' ' GLU . 67.5 p -50.96 163.19 0.21 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.783 0.325 . . . . 0.0 110.513 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.85 70.11 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.621 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.433 ' N ' ' O ' ' A' ' 35' ' ' THR . 27.8 tp10 -163.78 49.01 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.478 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.1 m -67.09 -26.0 35.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.485 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.5 tp -45.87 -27.69 0.93 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.727 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.427 ' O ' ' OG ' ' A' ' 43' ' ' SER . . . -58.72 -48.28 85.84 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.96 -44.51 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.098 0.475 . . . . 0.0 110.664 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.493 ' CD1' ' N ' ' A' ' 42' ' ' ILE . 1.8 mp -66.18 -27.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.529 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 40' ' ' GLY . 24.0 p -70.66 -50.48 36.28 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 10.5 pt -65.0 -44.85 95.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -63.93 -41.75 93.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.555 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 28.9 mt -65.2 -36.09 83.1 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.525 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.8 t -67.16 -35.55 74.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.076 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.46 -49.76 62.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.339 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 44.4 p -62.41 -50.57 70.97 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.876 -178.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -39.01 83.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -178.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 33.6 tp -65.09 -40.74 95.03 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.598 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.472 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -65.66 -52.17 53.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.753 0.311 . . . . 0.0 110.995 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 m -67.87 -37.34 81.68 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.533 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 89.9 mt -72.28 -44.32 63.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 -177.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.9 m -78.49 -31.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.055 -0.658 . . . . 0.0 111.388 -179.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 4.3 tp -79.01 -39.92 32.8 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -177.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.438 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.2 mp -72.42 -60.04 2.3 Favored Pre-proline 0 N--CA 1.475 0.817 0 N-CA-C 113.796 1.036 . . . . 0.0 113.796 -176.237 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.533 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 9.4 Cg_endo -50.72 -25.4 15.05 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 121.736 1.624 . . . . 0.0 112.218 -178.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -88.26 -67.34 0.84 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.507 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? -59.93 -13.38 10.82 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.166 179.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.438 ' N ' ' O ' ' A' ' 57' ' ' ILE . 68.8 mt-10 -147.13 137.15 23.24 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -65.56 -44.34 87.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.552 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.563 -179.979 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.486 ' C ' ' H ' ' B' ' 3' ' ' THR . 68.6 m . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.403 ' O ' ' C ' ' B' ' 3' ' ' THR . 22.7 t 56.16 7.94 0.35 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.486 ' H ' ' C ' ' B' ' 1' ' ' CYS . 0.5 OUTLIER 31.98 61.5 0.31 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.665 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 13.8 m -76.05 -37.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.572 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.553 ' HG ' ' N ' ' B' ' 6' ' ' PRO . 0.3 OUTLIER -37.75 -65.16 0.38 Allowed Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.923 -179.605 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.553 ' N ' ' HG ' ' B' ' 5' ' ' SER . 28.6 Cg_endo -60.43 6.14 0.12 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.323 2.015 . . . . 0.0 112.145 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -118.46 -64.5 0.3 Allowed Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' B' ' 9' ' ' LEU . 14.3 m -60.84 -52.18 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 120.572 -0.451 . . . . 0.0 110.343 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.481 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 36.6 mt -54.29 -40.04 67.5 Favored 'General case' 0 C--O 1.246 0.904 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.79 -35.41 70.76 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 177.07 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -63.62 -34.2 89.31 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.374 -1.284 . . . . 0.0 111.137 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.6 mp -65.77 -45.87 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.333 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.53 -46.25 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 C-N-CA 119.095 -1.042 . . . . 0.0 108.856 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.4 t -53.26 -46.41 56.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.21 0.529 . . . . 0.0 109.627 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.78 -40.77 93.41 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -56.92 -46.37 82.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.709 0.29 . . . . 0.0 110.505 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -58.87 -45.12 90.93 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.3 t -56.34 -47.95 80.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.055 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 98.3 mt -59.13 -39.74 83.3 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.002 179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 15.8 m -56.78 -40.13 75.32 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.402 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 89.2 t -67.87 -51.72 47.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.831 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -62.11 -51.68 66.93 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.159 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 61.0 mt -56.87 -50.01 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.55 -0.46 . . . . 0.0 109.998 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -49.13 -46.41 44.98 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.79 -40.02 75.16 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.026 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.64 86.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.404 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.9 -48.06 89.19 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -64.08 -37.89 89.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.277 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -59.88 -51.03 71.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.641 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 20.9 mt -67.29 -42.36 83.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.393 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 158.8 156.01 7.85 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.361 . . . . 0.0 110.512 -179.885 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 55.6 m . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.3 p -167.46 113.86 0.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.782 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 5' ' ' SER . 28.6 p -79.7 -177.24 5.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.368 179.817 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.464 ' N ' ' OG ' ' B' ' 5' ' ' SER . 32.7 m 37.21 26.74 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.203 0.525 . . . . 0.0 111.03 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.627 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.6 OUTLIER -79.72 -35.47 0.96 Allowed Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.684 179.006 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.627 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.7 Cg_exo -49.56 -42.85 41.3 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.158 1.906 . . . . 0.0 112.529 179.81 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.81 -46.61 0.94 Allowed Glycine 0 CA--C 1.521 0.426 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.514 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -58.97 -40.1 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.59 -38.78 69.85 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.47 -38.91 82.05 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 177.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.04 -28.21 65.99 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.84 -43.62 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.2 t -55.77 -53.93 32.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -57.61 -36.95 56.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.69 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.08 -39.6 95.99 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.405 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 64.6 t0 -65.1 -46.92 79.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.896 0.379 . . . . 0.0 110.407 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.0 tp -55.74 -50.85 69.27 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -67.76 -25.68 33.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.008 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.57 -56.76 14.88 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 119.984 -0.687 . . . . 0.0 109.396 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -58.52 -44.5 89.55 Favored 'General case' 0 N--CA 1.456 -0.16 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.171 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.73 -32.88 59.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.1 tp -70.34 -54.5 12.29 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 -178.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.402 HG23 HD11 ' A' ' 23' ' ' ILE . 11.5 mm -70.28 -41.58 78.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.314 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.69 -40.3 87.39 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.022 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 32.7 tp -67.6 -37.48 82.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.626 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.18 -51.08 69.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.739 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -67.16 -36.19 76.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 C-N-CA 120.312 -0.555 . . . . 0.0 110.563 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -58.4 -44.38 88.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -66.28 -44.27 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.704 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -62.3 -44.73 95.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.615 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -73.29 137.12 23.31 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -172.26 95.33 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.857 0.36 . . . . 0.0 110.437 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.528 ' N ' ' CD1' ' A' ' 33' ' ' LEU . 7.4 mp 47.63 76.8 0.1 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.417 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -175.15 -65.68 0.05 OUTLIER Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.25 -28.11 68.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.728 0.299 . . . . 0.0 110.563 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 61.85 173.74 0.12 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.531 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 55.99 58.04 4.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.435 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.8 m -69.67 -25.17 28.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.704 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 44.5 tp -46.13 -29.5 1.56 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.854 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.8 -52.82 47.99 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.447 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -40.27 58.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.919 0.39 . . . . 0.0 110.14 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.0 mm -64.54 -41.7 93.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.721 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 11.2 t -59.47 -51.79 68.36 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.69 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.1 tt -61.76 -43.88 97.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.31 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.7 t -55.99 -43.11 74.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.121 0.486 . . . . 0.0 109.951 179.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -68.22 -30.8 69.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.935 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.4 t -68.29 -34.36 65.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.816 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.54 -48.15 42.61 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.474 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.418 ' H ' ' HG1' ' A' ' 49' ' ' THR . 2.8 m -60.13 -46.75 88.57 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.201 -179.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.7 m -68.4 -37.19 77.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 120.652 -0.419 . . . . 0.0 111.115 -179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.7 -41.11 92.76 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.271 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.419 ' NZ ' ' CD1' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -62.96 -53.19 57.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.431 -179.899 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.8 p -63.59 -46.86 83.89 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -61.64 -51.72 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.567 ' O ' ' CD1' ' A' ' 59' ' ' PHE . 5.0 m -73.62 -29.79 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.174 -178.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.401 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 6.5 tt -70.91 -29.95 66.15 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -178.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 mt -61.95 -55.1 44.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.287 -178.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.71 -28.63 43.86 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.518 1.479 . . . . 0.0 111.503 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.2 m-30 -56.55 -47.07 80.25 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.349 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.478 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -82.48 26.68 0.55 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 120.846 -0.342 . . . . 0.0 110.437 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -141.2 163.09 33.89 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.892 0.377 . . . . 0.0 110.465 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 -67.44 -26.4 66.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.537 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 65.6 m-20 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.685 -179.972 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.43 ' O ' ' O ' ' B' ' 3' ' ' THR . 41.5 t -59.54 -46.12 89.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.507 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.43 ' O ' ' O ' ' B' ' 2' ' ' SER . 43.8 p 47.36 100.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.83 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.472 ' CG1' ' N ' ' B' ' 5' ' ' SER . 14.8 p -143.37 -50.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.303 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.53 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.7 OUTLIER -43.31 -64.48 0.75 Allowed Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.515 179.835 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 19.4 Cg_endo -56.86 1.75 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.325 2.017 . . . . 0.0 112.341 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -112.05 -67.05 0.52 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.527 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 6.8 m -59.24 -48.05 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.154 0.502 . . . . 0.0 110.275 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.465 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 43.6 mt -57.35 -42.15 81.46 Favored 'General case' 0 C--O 1.242 0.696 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.57 -33.46 45.91 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 176.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -37.22 94.17 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.292 178.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.1 tp -58.4 -43.82 87.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.672 -0.811 . . . . 0.0 108.956 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -59.93 -46.81 93.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 119.256 -0.977 . . . . 0.0 109.487 179.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.5 -45.58 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 120.256 -0.577 . . . . 0.0 109.841 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.77 -39.25 96.48 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -59.58 -47.83 84.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.685 0.279 . . . . 0.0 110.712 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -57.79 -45.43 86.07 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -54.83 -46.64 75.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.419 ' CD1' ' NZ ' ' A' ' 52' ' ' LYS . 23.5 mt -61.69 -47.08 86.94 Favored 'General case' 0 C--O 1.223 -0.302 0 C-N-CA 120.659 -0.417 . . . . 0.0 110.295 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.5 m -48.03 -50.73 26.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.8 0.333 . . . . 0.0 110.686 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 99.9 t -61.89 -44.13 98.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.936 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 12.2 tp -59.16 -45.3 91.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.18 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 4.6 mm -59.52 -49.78 82.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.87 -45.38 30.29 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.332 0.586 . . . . 0.0 109.83 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.76 -35.36 80.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.34 -55.32 35.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.167 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -57.86 -37.04 58.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.4 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 43.1 t80 -59.66 -43.76 93.81 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.82 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -61.15 -41.82 97.44 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.571 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 8.5 mp -59.17 -40.11 84.59 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.23 150.69 5.7 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.362 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 21.1 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 94.5 p -56.85 132.03 51.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.632 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 5' ' ' SER . 32.7 p -83.24 168.17 16.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.424 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.659 ' H ' ' HG ' ' B' ' 5' ' ' SER . 27.0 m 34.59 34.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.442 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -83.98 -40.09 0.73 Allowed Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.361 179.061 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 5' ' ' SER . 86.7 Cg_exo -48.1 -42.73 32.23 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.606 2.204 . . . . 0.0 112.655 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.86 -46.85 0.75 Allowed Glycine 0 N--CA 1.463 0.438 0 N-CA-C 108.865 -1.694 . . . . 0.0 108.865 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.515 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.6 t -55.27 -38.57 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 82.0 mt -55.38 -38.97 69.56 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.182 -1.007 . . . . 0.0 108.388 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.88 -39.86 86.72 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.51 -27.72 63.93 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.53 -42.89 83.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.197 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -56.45 -53.22 43.17 Favored 'Isoleucine or valine' 0 C--O 1.242 0.684 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.7 t -56.92 -39.67 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.357 178.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -54.71 -41.23 74.08 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 61.4 t0 -64.77 -45.85 84.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 110.299 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.637 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 20.8 tp -55.45 -51.08 68.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.894 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -68.53 -24.05 28.8 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.905 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -56.7 14.69 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.032 -0.667 . . . . 0.0 109.382 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 53.6 m -61.36 -47.36 86.22 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.507 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.8 t -64.4 -34.32 68.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.4 tp -69.22 -54.28 15.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.609 -178.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 64.7 mt -67.57 -41.73 86.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.501 -0.479 . . . . 0.0 110.388 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.01 91.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.138 0.494 . . . . 0.0 110.026 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -67.57 -34.49 77.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.828 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.89 -51.36 70.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.757 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.65 -36.65 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.569 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -59.36 -41.69 89.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.872 0.367 . . . . 0.0 110.577 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -59.42 -46.87 87.49 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.656 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.51 -45.34 91.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.13 149.62 49.67 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -159.31 69.16 0.44 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.779 0.323 . . . . 0.0 110.499 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.479 ' CD1' ' N ' ' A' ' 33' ' ' LEU . 9.1 mp 51.17 78.3 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.306 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -170.62 -51.58 0.04 OUTLIER Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.2 t -59.3 132.21 53.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.787 0.327 . . . . 0.0 110.721 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -86.23 -179.29 6.68 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.589 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 65.5 mm-40 52.82 32.97 13.24 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.591 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.2 m -49.24 -26.67 2.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.6 tp -48.21 -28.62 3.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.715 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.38 -51.62 57.55 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.475 ' CD1' ' H ' ' A' ' 41' ' ' ILE . 1.9 mp -52.68 -49.94 43.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.027 0.441 . . . . 0.0 110.012 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.63 -27.58 43.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.727 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -67.01 -45.52 77.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.432 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.441 HG22 HD12 ' A' ' 44' ' ' ILE . 22.1 pt -71.83 -34.58 51.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.139 -179.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.3 t -68.38 -46.4 80.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.572 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -69.77 -37.75 76.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.643 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.22 -31.56 47.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.777 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.19 51.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.378 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.9 p -62.38 -43.36 99.0 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.953 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.99 -43.74 97.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.556 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.91 -53.39 47.18 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.018 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.637 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 0.7 OUTLIER -47.21 -51.99 17.03 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.909 179.924 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 31.4 p -59.13 -46.73 87.58 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 87.1 mt -59.82 -52.52 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.58 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 26.7 m -75.31 -30.89 23.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.258 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.7 tt -66.65 -32.79 74.34 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.424 HD13 HG21 ' A' ' 57' ' ' ILE . 7.4 mt -68.16 -54.23 16.37 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.479 -178.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.38 -28.44 18.09 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 121.799 1.666 . . . . 0.0 111.566 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.58 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -60.68 -45.43 94.2 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.342 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.59 -24.01 53.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.017 0.437 . . . . 0.0 110.141 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 73.7 mm-40 -97.28 168.37 10.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.694 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -60.6 -46.77 89.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.416 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 22.2 p-10 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.583 179.965 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' N ' ' B' ' 2' ' ' SER . 29.7 p . . . . . 0 N--CA 1.488 1.458 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.446 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 60.7 p -53.66 -64.23 0.89 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.442 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.443 ' N ' ' OG ' ' B' ' 2' ' ' SER . 32.1 p 43.23 53.13 5.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' B' ' 7' ' ' GLY . 21.2 m -76.08 -39.31 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.314 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.659 ' HG ' ' H ' ' A' ' 4' ' ' VAL . 0.1 OUTLIER -40.02 -62.78 0.81 Allowed Pre-proline 0 CA--C 1.536 0.407 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.952 179.763 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.9 Cg_endo -61.02 9.88 0.07 OUTLIER 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.138 1.892 . . . . 0.0 112.073 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.556 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -123.64 -66.24 0.21 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.524 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 15.9 m -58.8 -51.74 68.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 CA-C-O 121.094 0.473 . . . . 0.0 110.61 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.474 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 40.5 mt -56.51 -40.04 74.32 Favored 'General case' 0 C--O 1.242 0.663 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.24 -36.97 61.66 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.16 -34.45 89.12 Favored Glycine 0 CA--C 1.523 0.565 0 CA-C-N 114.425 -1.261 . . . . 0.0 110.447 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.52 -42.26 95.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 C-N-CA 119.701 -0.799 . . . . 0.0 109.341 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -59.86 -44.42 94.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.32 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 83.9 t -51.23 -47.52 33.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.615 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.11 93.88 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -58.78 -45.16 90.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.857 0.361 . . . . 0.0 110.488 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.7 tp -56.77 -45.73 81.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.021 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.42 -46.77 82.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.204 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 14.2 mt -60.25 -39.74 87.84 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.062 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.2 m -57.68 -40.59 79.77 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.388 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.5 t -66.41 -51.8 53.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.474 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 11.1 mp -62.53 -52.95 61.41 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 120.939 -0.304 . . . . 0.0 111.274 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 61.9 mt -56.84 -51.33 69.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.111 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.94 -46.46 32.23 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.088 0.47 . . . . 0.0 109.857 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.91 -39.31 74.19 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.83 -38.51 91.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.455 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.53 -47.19 89.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -63.75 -41.37 98.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.206 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -56.44 -46.54 80.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.1 tp -58.05 -45.5 86.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.32 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.63 -100.14 0.15 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . 0.526 ' C ' ' HE ' ' B' ' 32' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 110.264 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.0 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.0 m -157.07 136.47 12.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.555 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 8.4 p -80.91 -165.1 0.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.497 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 35.8 m 35.08 36.38 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.346 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -82.23 -40.19 0.92 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.377 179.133 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 72.4 Cg_exo -46.41 -40.45 22.72 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.647 2.232 . . . . 0.0 112.58 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.408 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 70.31 -48.09 0.7 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.493 ' H ' ' C ' ' A' ' 6' ' ' PRO . 71.3 t -53.83 -39.28 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 81.2 mt -56.05 -37.99 69.99 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -61.59 -33.08 73.27 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 177.245 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -63.37 -32.24 83.48 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -67.2 -41.98 87.46 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 42.5 t -59.29 -55.17 25.41 Favored 'Isoleucine or valine' 0 C--O 1.241 0.613 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.481 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 95.7 t -61.02 -36.86 75.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.498 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.48 -40.47 99.14 Favored Glycine 0 C--O 1.224 -0.513 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -64.16 -51.26 64.68 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.008 0.433 . . . . 0.0 110.281 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 tp -56.86 -47.34 80.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.848 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.44 -28.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.758 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.53 -56.64 12.74 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.68 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.4 m -56.09 -40.4 73.59 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.649 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.33 -32.52 57.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.727 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.41 -55.23 9.55 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.15 -178.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.408 HD11 HG21 ' A' ' 23' ' ' ILE . 80.0 mt -66.66 -43.65 90.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.574 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.41 -41.38 89.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.217 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.2 tp -69.18 -31.79 70.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.273 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.72 -50.51 68.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.799 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -66.32 -38.1 81.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.472 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -61.83 -46.52 89.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.575 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -69.46 -49.13 57.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.744 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.3 tp -62.65 -43.63 98.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.464 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -73.68 124.65 8.77 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -80.09 41.33 0.51 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 0.0 110.544 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 8.8 tp 52.69 82.27 0.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.518 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 164.7 107.79 0.21 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.656 ' HG1' ' N ' ' A' ' 36' ' ' ALA . 4.4 t -158.63 177.02 11.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.78 0.324 . . . . 0.0 110.626 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.656 ' N ' ' HG1' ' A' ' 35' ' ' THR . . . -52.26 -104.13 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.6 tp10 -83.14 95.33 8.06 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.573 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.7 t -65.59 -28.98 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.581 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 tp -60.74 -29.29 69.28 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.78 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -54.64 -49.55 60.9 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.8 mm -55.38 -48.51 76.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.028 0.442 . . . . 0.0 110.651 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 74.2 mt -61.53 -34.96 63.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.483 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.9 m -61.53 -51.7 67.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.692 -179.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 12.4 pt -63.06 -42.22 95.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.924 -179.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 71.7 t -60.24 -43.99 94.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.375 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.09 -34.7 79.03 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 50.4 t -66.78 -34.73 71.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.76 -47.98 64.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.457 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 4.5 m -60.87 -48.73 80.47 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.711 -0.396 . . . . 0.0 111.494 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.91 -33.83 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -178.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 49.3 tp -65.69 -52.59 50.22 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.269 -0.572 . . . . 0.0 110.744 -179.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.29 -50.53 72.63 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.312 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 48.5 p -60.34 -43.12 96.75 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.421 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 90.4 mt -72.95 -44.52 57.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.362 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -177.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.4 m -77.04 -28.34 16.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.384 -178.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.0 tp -82.58 -39.44 22.26 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 114.566 1.321 . . . . 0.0 114.566 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 mm -75.45 -63.79 0.64 Allowed Pre-proline 0 N--CA 1.475 0.824 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.421 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 12.2 Cg_endo -53.09 -38.68 80.91 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.766 1.644 . . . . 0.0 112.146 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -67.33 -59.63 3.25 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 121.055 -0.258 . . . . 0.0 110.666 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.05 -48.04 81.32 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.864 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -74.55 156.53 36.74 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.848 0.356 . . . . 0.0 110.632 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -155.55 -35.81 0.09 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.477 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.5 p30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.525 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 14.4 m -75.33 172.93 11.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.441 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 2.8 t -156.01 147.56 22.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.64 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -148.61 -40.77 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.249 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.534 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -40.51 -63.99 0.65 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.37 179.803 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 17.9 Cg_endo -57.9 3.62 0.12 Allowed 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.27 1.98 . . . . 0.0 112.231 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -115.14 -68.07 0.44 Allowed Glycine 0 CA--C 1.527 0.83 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' B' ' 11' ' ' GLY . 7.4 m -58.19 -52.55 57.35 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.214 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.5 ' N ' ' CG2' ' B' ' 8' ' ' VAL . 42.1 mt -54.84 -31.76 59.76 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.86 -36.34 72.2 Favored 'General case' 0 C--O 1.244 0.775 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -66.71 -30.93 77.04 Favored Glycine 0 CA--C 1.528 0.875 0 CA-C-N 113.768 -1.56 . . . . 0.0 111.319 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . 0.465 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.2 mp -71.32 -39.8 72.71 Favored 'Isoleucine or valine' 0 C--N 1.34 0.194 0 C-N-CA 119.684 -0.807 . . . . 0.0 109.4 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.5 m -57.92 -44.44 86.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.3 t -59.48 -48.85 85.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 CA-C-O 121.18 0.514 . . . . 0.0 110.267 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -34.85 81.27 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -65.76 -39.41 91.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.878 0.37 . . . . 0.0 110.154 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.91 -47.41 86.51 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.86 -35.17 74.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.895 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.59 -48.78 71.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.482 -179.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 99.6 m -59.76 -44.24 93.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.884 0.374 . . . . 0.0 110.542 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.2 t -63.98 -40.72 90.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -59.01 -51.06 71.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.821 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 66.6 mt -59.06 -48.02 88.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.995 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.53 -46.85 39.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.03 0.443 . . . . 0.0 109.925 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -58.05 -40.48 81.04 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.65 -37.08 80.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.281 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 50.3 t -62.26 -42.28 94.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 61.5 t80 -63.19 -38.92 93.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.981 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -60.99 -41.07 95.77 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.742 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.7 tp -48.19 -39.21 20.22 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.829 -0.349 . . . . 0.0 110.278 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 77.34 92.63 0.25 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.844 0.354 . . . . 0.0 110.504 179.953 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.7 t . . . . . 0 N--CA 1.462 0.15 0 CA-C-O 120.509 0.195 . . . . 0.0 110.489 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.474 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.22 31.47 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.142 0.496 . . . . 0.0 111.159 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.557 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.5 OUTLIER -84.82 -44.09 0.69 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.262 179.317 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.557 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.0 Cg_exo -45.37 -43.94 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 122.731 2.287 . . . . 0.0 112.871 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -50.45 0.82 Allowed Glycine 0 N--CA 1.464 0.502 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' PRO . 75.8 t -52.8 -35.13 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.9 mt -55.35 -41.7 72.85 Favored 'General case' 0 C--O 1.238 0.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.35 -37.58 75.48 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 177.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.3 -27.96 68.49 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.453 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -68.81 -39.03 79.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.9 t -62.08 -51.32 73.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.846 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.47 -43.04 89.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.72 -38.87 92.75 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.466 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 51.2 t0 -65.57 -46.59 78.88 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.916 0.389 . . . . 0.0 110.685 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.5 tp -56.31 -51.36 68.52 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.766 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 m -65.63 -27.32 41.2 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.323 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.578 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.84 -57.33 13.13 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.515 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -56.98 -42.47 80.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.113 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -65.7 -37.73 80.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.288 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -67.57 -54.47 19.6 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.404 -178.539 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 21.2 mm -66.21 -44.72 91.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.484 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.78 -39.59 77.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.911 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.0 tp -68.52 -34.5 75.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.023 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.58 -50.72 72.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.624 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -68.05 -39.42 81.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -60.58 -33.69 73.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -55.67 -50.09 71.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.75 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.0 tp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.6 -179.959 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.862 0.363 . . . . 0.0 110.361 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 m -57.53 -26.7 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.459 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.0 tp -46.26 -29.12 1.49 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.655 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -55.56 -48.82 68.34 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.666 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.0 mp -56.6 -40.77 71.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.002 0.429 . . . . 0.0 110.104 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -64.9 -41.22 91.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.205 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.7 t -58.1 -51.79 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.618 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.423 ' H ' HG12 ' A' ' 44' ' ' ILE . 6.5 pt -63.14 -39.89 86.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.91 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.0 t -64.71 -30.68 50.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.171 -0.612 . . . . 0.0 109.83 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.559 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -71.21 -47.69 55.9 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.937 -178.905 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.8 p -67.73 -30.49 48.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.626 -178.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.458 ' HB2' HD22 ' B' ' 19' ' ' LEU . . . -70.51 -53.3 16.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.377 -179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.1 m -57.98 -47.1 83.99 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.256 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.5 m -71.11 -28.83 34.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.881 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.606 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.0 tp -67.36 -55.7 12.71 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 119.882 -0.727 . . . . 0.0 110.821 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.466 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.0 OUTLIER -64.8 -45.27 86.98 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.099 179.614 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -60.77 -45.16 95.42 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -178.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.492 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.4 mt -73.45 -43.25 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -177.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.1 m -76.89 -33.13 20.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.365 -178.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.6 tp -79.47 -41.62 27.12 Favored 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 25.9 mt -64.09 -62.11 5.72 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 119.047 -1.061 . . . . 0.0 113.23 -176.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.492 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 7.0 Cg_endo -47.35 -27.14 6.59 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 121.924 1.749 . . . . 0.0 112.504 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.431 ' CD1' HG21 ' B' ' 8' ' ' VAL . 0.9 OUTLIER -90.24 -65.62 1.0 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 120.384 -0.527 . . . . 0.0 109.809 179.52 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.485 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? . . . . . 0 CA--C 1.532 0.256 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.649 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.527 HG23 ' N ' ' B' ' 5' ' ' SER . 32.6 m . . . . . 0 CA--C 1.521 -0.135 0 CA-C-O 120.745 0.307 . . . . 0.0 110.685 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.527 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.1 OUTLIER -38.7 -59.21 1.41 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.177 179.848 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.419 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 33.6 Cg_endo -64.38 13.86 0.09 OUTLIER 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 121.528 1.486 . . . . 0.0 111.783 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -113.01 -66.92 0.49 Allowed Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.431 HG21 ' CD1' ' A' ' 59' ' ' PHE . 0.0 OUTLIER -67.15 -51.92 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 9.6 mt -57.82 -39.15 76.93 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.419 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -58.07 -38.72 76.89 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 108.112 -1.069 . . . . 0.0 108.112 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.88 -30.96 79.38 Favored Glycine 0 CA--C 1.522 0.519 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.099 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 50.5 mm -66.23 -43.34 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 C-N-CA 120.079 -0.648 . . . . 0.0 109.769 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.453 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.9 OUTLIER -60.29 -42.0 89.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.838 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.87 -42.6 89.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.706 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.85 -39.25 97.26 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -61.51 -40.47 94.72 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -62.88 -44.93 94.79 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.102 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.4 -44.34 92.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.301 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.458 HD22 ' HB2' ' A' ' 48' ' ' ALA . 69.8 mt -66.54 -30.3 70.58 Favored 'General case' 0 C--O 1.225 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 110.212 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 21.8 m -62.58 -50.2 72.25 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.239 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 71.8 t -70.42 -43.28 78.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.554 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.45 -53.06 60.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.823 0.344 . . . . 0.0 111.194 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.47 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 76.3 mt -59.45 -50.64 79.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.965 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.39 38.14 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -57.25 -39.39 75.49 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.11 -35.37 78.5 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.133 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.97 -47.05 95.0 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -63.02 -40.43 97.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.125 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -55.67 -44.67 77.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.438 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 28.3 tp . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.216 179.942 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 5' ' ' SER . 8.3 p . . . . . 0 N--CA 1.461 0.107 0 CA-C-O 120.551 0.215 . . . . 0.0 110.621 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.2 m 33.86 34.6 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.198 0.523 . . . . 0.0 111.239 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.578 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -84.94 -42.97 0.68 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.335 179.308 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 5' ' ' SER . 75.5 Cg_exo -46.38 -44.1 20.93 Favored 'Trans proline' 0 N--CA 1.495 1.598 0 C-N-CA 122.745 2.297 . . . . 0.0 112.807 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.496 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -48.33 0.75 Allowed Glycine 0 N--CA 1.464 0.518 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.462 ' H ' ' C ' ' A' ' 6' ' ' PRO . 62.5 t -53.87 -36.38 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' HG22 ' A' ' 12' ' ' ILE . 50.1 mt -55.07 -40.99 70.95 Favored 'General case' 0 C--O 1.238 0.461 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.2 -37.96 75.82 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.49 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.34 -28.02 66.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 178.147 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.427 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -67.8 -41.05 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.304 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 57.4 t -60.0 -53.09 53.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 121.467 0.651 . . . . 0.0 109.573 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.8 t -58.62 -34.63 51.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.964 179.277 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.32 -34.79 90.38 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -69.25 -44.7 71.42 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.8 tp -66.9 -51.27 57.4 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.42 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 14' ' ' VAL . 22.6 m -59.65 -35.02 57.14 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.328 -179.596 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.401 HD23 ' OD1' ' B' ' 16' ' ' ASP . 40.8 tp -64.39 -52.84 56.21 Favored 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.537 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.528 HG21 ' CB ' ' A' ' 48' ' ' ALA . 15.0 m -50.48 -49.83 54.24 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.901 -0.319 . . . . 0.0 111.439 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.6 p -70.73 -31.06 44.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 120.197 -0.601 . . . . 0.0 112.464 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.527 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.3 OUTLIER -67.73 -54.6 18.03 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.586 -179.47 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 27.5 mt -63.96 -50.47 77.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.387 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.27 -41.53 68.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.351 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 29.6 tp -63.58 -42.53 98.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.09 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.9 -48.22 70.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.342 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.1 t -63.85 -39.85 86.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.606 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -59.01 -48.02 83.09 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -61.06 -48.53 81.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.683 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.573 -179.859 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 . . . . . 0 C--O 1.23 0.045 0 CA-C-O 121.022 0.439 . . . . 0.0 110.452 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 16.4 m -63.49 -23.52 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.773 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.0 tp -44.03 -28.11 0.44 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.14 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -60.78 -49.51 77.85 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.667 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -49.09 76.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.09 0.472 . . . . 0.0 109.989 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.683 ' N ' HD12 ' A' ' 42' ' ' ILE . 2.0 mp -61.33 -31.4 50.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.981 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.9 t -62.26 -50.99 69.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.438 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.6 pt -66.11 -35.79 75.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.141 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.6 t -67.05 -40.1 84.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.448 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 46' ' ' LEU . 0.8 OUTLIER -68.14 -44.73 75.42 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.841 -178.94 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.6 p -69.48 -28.71 39.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.817 -178.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.528 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -70.75 -51.76 25.15 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.772 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.7 p -60.09 -40.85 91.03 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.537 -0.465 . . . . 0.0 110.756 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.37 -41.09 78.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.648 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 55' ' ' VAL . 21.5 tp -65.47 -54.91 21.64 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.793 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 56' ' ' LEU . 0.6 OUTLIER -58.58 -43.21 89.4 Favored 'General case' 0 C--O 1.219 -0.518 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.727 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 99.1 m -60.38 -50.74 72.39 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 112.238 0.459 . . . . 0.0 112.238 -179.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.495 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.3 mt -69.23 -43.95 80.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -177.537 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.526 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.6 m -76.21 -31.18 20.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.148 -0.621 . . . . 0.0 111.85 -178.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.407 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 8.6 tp -75.71 -37.96 58.99 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.23 -51.41 78.48 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.56 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.495 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 59.3 Cg_endo -72.71 -28.73 13.61 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.54 1.493 . . . . 0.0 111.283 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.3 m-30 -67.32 -53.88 25.68 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.131 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.491 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.332 -0.166 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.379 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.431 ' O ' HG22 ' B' ' 8' ' ' VAL . 25.4 m . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.991 0.424 . . . . 0.0 110.336 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.518 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -39.59 -62.15 0.89 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.429 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -62.2 10.61 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.154 1.903 . . . . 0.0 112.388 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.19 -65.52 0.29 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.431 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.0 OUTLIER -60.7 -51.96 67.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 121.215 0.531 . . . . 0.0 110.285 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.6 mt -60.49 -34.38 73.97 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.478 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -58.59 -35.93 73.2 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.2 -40.65 98.18 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.685 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 45.5 mm -58.0 -45.7 87.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.986 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.427 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -57.29 -44.69 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.251 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.96 -41.42 76.93 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.3 -41.72 98.5 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' HD23 ' A' ' 19' ' ' LEU . 24.5 t0 -60.36 -41.4 93.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.359 . . . . 0.0 110.213 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.8 tp -61.2 -43.95 98.06 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.046 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -57.85 -47.97 84.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.048 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 74.7 mt -61.43 -36.28 79.92 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.013 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -57.63 -43.78 85.1 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.215 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -69.24 -47.15 75.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.733 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.0 mp -62.08 -51.9 66.09 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.105 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.449 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -57.58 -50.3 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.9 -45.17 40.94 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 121.256 0.551 . . . . 0.0 109.942 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 4.9 tp -65.19 -30.08 70.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.119 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.17 -50.07 67.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.219 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -64.1 -38.28 82.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 C-N-CA 120.406 -0.518 . . . . 0.0 109.879 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -61.45 -43.11 99.44 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -60.62 -47.09 87.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.676 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.466 -179.706 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 5' ' ' SER . 5.4 p . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.531 0.205 . . . . 0.0 110.629 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.462 ' N ' ' OG ' ' B' ' 5' ' ' SER . 34.8 m 36.62 26.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.252 0.549 . . . . 0.0 111.212 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.62 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 1.6 t -81.74 -35.43 0.75 Allowed Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.61 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.62 ' CD ' ' N ' ' A' ' 5' ' ' SER . 84.2 Cg_exo -49.45 -41.49 43.7 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.336 2.024 . . . . 0.0 112.554 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.517 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.91 -47.01 0.98 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' PRO . 58.1 t -59.28 -40.64 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.35 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 12' ' ' ILE . 3.4 mm? -54.37 -43.03 70.99 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -56.12 -37.6 69.66 Favored 'General case' 0 C--O 1.233 0.184 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.725 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.08 -27.46 68.93 Favored Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.508 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -68.3 -38.53 79.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.409 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 80.8 t -64.21 -50.89 74.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.15 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.8 t -59.58 -46.1 93.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.18 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.53 -29.2 71.13 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.989 -0.845 . . . . 0.0 110.989 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.512 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 53.3 t0 -67.45 -52.64 37.11 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 110.387 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.3 tp -60.35 -41.23 93.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.127 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.5 -26.45 31.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.468 HD23 ' OD1' ' B' ' 16' ' ' ASP . 37.3 tp -71.43 -57.42 4.45 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.84 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.444 HG23 ' N ' ' A' ' 21' ' ' VAL . 14.0 t -62.3 -40.43 96.26 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.145 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.444 ' N ' HG23 ' A' ' 20' ' ' THR . 53.5 t -69.32 -43.82 80.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.662 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -60.54 -51.6 68.75 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.333 -178.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 63.7 mt -63.08 -42.48 96.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.942 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -43.88 78.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.96 0.41 . . . . 0.0 110.324 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.96 -36.24 82.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.47 -50.79 71.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.795 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.3 m -69.21 -32.56 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.48 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -61.93 -41.31 97.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.716 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -61.73 -45.39 94.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.651 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.5 tp . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.561 -179.879 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.736 0.303 . . . . 0.0 110.563 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 63.5 t -68.17 -28.74 42.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.636 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.6 mm? -63.77 -31.29 72.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -62.23 -50.28 66.56 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.3 mt -58.19 -44.3 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.092 0.473 . . . . 0.0 110.453 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.14 -38.65 82.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.471 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.5 m -59.94 -52.16 66.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.736 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.3 pt -62.11 -42.39 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.649 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.4 t -60.66 -35.24 62.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.0 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.553 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.5 OUTLIER -69.6 -39.16 77.41 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.529 -179.181 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -68.69 -30.46 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.622 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.18 -52.1 25.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.981 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -44.77 90.78 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.622 -0.431 . . . . 0.0 111.8 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.0 m -68.17 -40.32 82.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.563 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.619 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.5 tp -63.33 -45.81 89.54 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.456 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.512 ' NZ ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -62.03 -49.97 73.9 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.742 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.637 ' O ' HD13 ' A' ' 57' ' ' ILE . 25.4 p -62.66 -47.54 83.24 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.605 0.595 . . . . 0.0 112.605 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.482 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 87.4 mt -64.03 -46.05 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.619 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.0 m -76.36 -34.62 25.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.153 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.3 tt -68.27 -35.27 77.63 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 113.574 0.954 . . . . 0.0 113.574 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.637 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -65.42 -52.74 43.33 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 119.456 -0.898 . . . . 0.0 112.127 -177.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 57.6 Cg_endo -71.7 -29.57 15.69 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 121.591 1.527 . . . . 0.0 111.466 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.559 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.7 m-30 -64.28 -48.53 75.37 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.226 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 N--CA 1.463 0.195 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.428 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.536 HG23 ' N ' ' B' ' 5' ' ' SER . 30.0 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.839 0.352 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.536 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.4 OUTLIER -38.49 -64.2 0.49 Allowed Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.584 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.4 Cg_endo -59.31 6.22 0.1 OUTLIER 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.328 2.019 . . . . 0.0 112.296 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -117.78 -66.29 0.34 Allowed Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.451 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -60.68 -51.95 67.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-O 121.091 0.472 . . . . 0.0 110.11 -179.871 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 49.4 mt -57.66 -37.2 73.0 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.23 -34.48 68.63 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 177.337 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -36.49 91.48 Favored Glycine 0 CA--C 1.524 0.649 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.328 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 11.3 mt -65.42 -41.39 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 119.496 -0.882 . . . . 0.0 109.394 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.508 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.4 m -57.69 -44.2 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.462 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -54.29 -50.34 57.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.169 -0.613 . . . . 0.0 109.677 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.17 -31.97 66.57 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.468 ' OD1' HD23 ' A' ' 19' ' ' LEU . 30.5 t0 -69.38 -41.04 77.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.774 0.321 . . . . 0.0 110.835 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -61.49 -52.39 64.7 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 121.008 0.432 . . . . 0.0 110.402 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -58.42 -39.12 73.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.128 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.3 mt -60.85 -53.08 61.72 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.61 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.453 ' OG1' HD21 ' A' ' 19' ' ' LEU . 8.3 m -48.26 -45.84 35.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.528 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 91.8 t -65.37 -33.83 66.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.723 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.9 tp -68.23 -53.76 22.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.49 -179.212 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 mm -60.83 -47.16 94.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 C-N-CA 120.658 -0.417 . . . . 0.0 109.931 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.12 -45.04 68.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.045 0.45 . . . . 0.0 109.835 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 31.0 tp -58.93 -38.73 79.65 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.18 -38.27 90.51 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.298 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -61.04 -47.75 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.031 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -61.9 -40.88 96.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.048 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -57.21 -48.47 78.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.491 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.8 tp . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.389 -179.977 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 5' ' ' SER . 81.6 p . . . . . 0 C--O 1.23 0.056 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.467 ' H ' ' CB ' ' B' ' 5' ' ' SER . 34.2 m 34.78 32.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 121.158 0.504 . . . . 0.0 111.323 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -81.04 -46.34 1.17 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.093 179.292 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 5' ' ' SER . 50.8 Cg_exo -43.27 -43.78 10.24 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.814 2.343 . . . . 0.0 112.996 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.93 -46.88 0.76 Allowed Glycine 0 N--CA 1.463 0.464 0 N-CA-C 108.932 -1.667 . . . . 0.0 108.932 -179.241 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.2 t -55.53 -38.95 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.096 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.4 HD23 ' HA ' ' A' ' 9' ' ' LEU . 87.6 mt -55.8 -36.79 67.79 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.013 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.57 -37.68 84.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -29.21 71.06 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 178.198 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.69 -42.89 93.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 96.4 t -57.86 -51.13 74.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.3 t -58.47 -30.21 40.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.931 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.43 -38.44 90.99 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -68.2 -44.67 75.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.037 0.446 . . . . 0.0 110.226 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 tp -58.54 -51.38 70.13 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.932 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.6 m -65.0 -29.59 47.85 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.716 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -60.4 -59.57 5.19 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 120.046 -0.662 . . . . 0.0 109.402 179.523 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.45 HG21 ' HB1' ' A' ' 48' ' ' ALA . 70.5 p -52.2 -43.21 64.08 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.005 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.27 -30.02 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 112.103 0.408 . . . . 0.0 112.103 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.7 -55.21 9.2 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.18 -178.869 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 54.5 mt -68.64 -41.01 82.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.254 -0.578 . . . . 0.0 110.352 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.2 -42.83 95.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.138 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -67.82 -32.39 72.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.737 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.45 -51.1 70.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.641 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.5 m -66.54 -36.98 78.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.413 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -60.16 -45.62 92.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.644 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.3 t80 -64.79 -41.12 96.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.745 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.74 -179.791 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.939 0.4 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 20.8 m -68.33 -25.95 32.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -46.43 -30.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.655 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.64 -49.81 62.34 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -58.12 -44.85 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.026 0.441 . . . . 0.0 110.51 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.9 mt -63.43 -36.88 77.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.569 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 47' ' ' VAL . 65.6 m -61.04 -51.47 69.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.506 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.407 HG12 ' H ' ' A' ' 44' ' ' ILE . 9.7 pt -62.66 -43.36 98.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.935 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -58.69 -44.0 88.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.019 0.437 . . . . 0.0 110.233 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -64.62 -36.06 83.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.701 -179.355 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 43' ' ' SER . 53.8 t -65.84 -34.08 67.91 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-O 121.087 0.47 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.602 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -68.45 -53.81 21.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.382 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 6.3 m -55.49 -49.22 73.12 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.075 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 46' ' ' LEU . 13.3 m -70.51 -26.34 28.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.617 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.668 ' O ' HG22 ' A' ' 55' ' ' VAL . 27.6 tp -65.98 -56.06 13.57 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.867 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.602 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 1.4 mppt? -65.16 -44.38 88.71 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.394 -0.522 . . . . 0.0 110.244 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.8 m -60.7 -44.97 95.92 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.474 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.0 mt -74.05 -41.73 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 51' ' ' LEU . 18.9 m -77.23 -32.54 19.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.254 -178.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 tp -78.41 -44.22 25.39 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.9 mt -59.81 -61.9 6.96 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 119.278 -0.969 . . . . 0.0 113.039 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.474 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -49.31 -26.55 11.7 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 C-N-CA 122.135 1.89 . . . . 0.0 112.233 -179.307 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.663 ' CG ' HG11 ' B' ' 8' ' ' VAL . 2.8 m-85 -92.27 -64.8 1.06 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.499 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 CA--C 1.53 0.194 0 C-N-CA 120.132 -0.627 . . . . 0.0 110.196 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.433 HG23 ' N ' ' B' ' 5' ' ' SER . 22.4 m . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.833 0.349 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.503 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -41.84 -64.69 0.61 Allowed Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.179 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.5 Cg_endo -60.33 6.22 0.12 Allowed 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 122.257 1.971 . . . . 0.0 111.956 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.503 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.46 -65.11 0.28 Allowed Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.663 HG11 ' CG ' ' A' ' 59' ' ' PHE . 16.1 m -59.94 -52.16 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.483 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.636 ' N ' HG23 ' B' ' 8' ' ' VAL . 39.1 mt -54.16 -39.11 66.27 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.27 -36.72 71.36 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.66 -34.53 88.88 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.896 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.426 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.54 -46.96 88.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.302 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -53.56 -42.47 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.047 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 84.2 t -57.92 -44.72 87.16 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.907 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.52 -37.47 94.21 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -61.81 -41.99 98.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 0.0 110.142 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 58.4 tp -61.28 -44.38 97.32 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.35 -41.53 87.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.007 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.464 HD22 ' HB2' ' A' ' 48' ' ' ALA . 20.5 mt -64.55 -35.5 81.19 Favored 'General case' 0 C--O 1.225 -0.208 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.064 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 96.0 m -61.79 -48.83 78.86 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.632 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 61.7 t -68.42 -47.64 76.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.525 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 29.2 tp -60.86 -51.9 67.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.303 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 79.0 mt -57.65 -50.61 76.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.02 37.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.024 0.44 . . . . 0.0 109.934 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.53 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.21 -41.03 78.67 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.113 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.74 -37.21 83.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.403 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.41 -46.51 95.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -61.46 -41.02 96.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.177 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 45.0 t80 -59.34 -44.51 92.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.61 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 30.1 tp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.28 -179.859 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.459 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.14 0 N-CA-C 110.385 -0.228 . . . . 0.0 110.385 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 26.9 m 33.11 34.84 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.082 0.468 . . . . 0.0 111.637 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -86.91 -41.57 0.54 Allowed Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.304 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.2 Cg_exo -47.9 -45.03 25.86 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.659 2.239 . . . . 0.0 112.703 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.76 -49.21 0.82 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 -179.383 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 6' ' ' PRO . 69.0 t -54.96 -41.72 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 71.4 mt -55.22 -37.9 67.75 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.09 -36.9 75.92 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.371 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -61.14 -28.87 69.74 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 178.115 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -66.6 -40.89 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.51 -50.44 80.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.71 179.368 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.1 t -58.29 -44.62 88.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.713 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.51 -36.55 78.01 Favored Glycine 0 CA--C 1.525 0.674 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.037 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.2 t0 -65.21 -48.66 72.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.904 0.383 . . . . 0.0 110.592 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 28.7 tp -55.53 -51.64 66.36 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.716 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 m -64.36 -28.72 45.51 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 C-N-CA 120.213 -0.595 . . . . 0.0 110.801 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.424 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -61.26 -56.87 15.61 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.946 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.3 m -55.14 -42.39 72.99 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.415 179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.48 -29.05 44.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.829 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.47 -53.86 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.193 -178.757 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.516 ' CG2' HG21 ' B' ' 23' ' ' ILE . 11.8 mt -66.15 -42.81 91.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.402 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.25 -39.5 90.55 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.992 0.425 . . . . 0.0 110.429 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 33.0 tp -69.14 -37.54 78.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.041 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.61 -50.4 73.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 26.0 m -67.63 -35.69 73.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.634 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -60.31 -41.83 94.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.528 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -65.77 -38.75 89.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.721 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.9 tp . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.539 -179.698 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.871 0.367 . . . . 0.0 110.401 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.0 m -69.17 -23.94 27.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.74 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.566 HD12 ' N ' ' A' ' 39' ' ' LEU . 9.3 mp -46.06 -35.93 5.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.594 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.79 -46.47 89.9 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 58.8 mt -59.2 -38.29 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.016 0.436 . . . . 0.0 110.6 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.4 mm -67.41 -39.45 82.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -61.46 -52.12 65.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.616 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.401 HG22 HD21 ' B' ' 22' ' ' LEU . 7.1 pt -61.62 -44.67 99.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.905 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.8 t -56.72 -43.53 79.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.519 -0.472 . . . . 0.0 109.792 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.458 ' O ' HG22 ' A' ' 50' ' ' VAL . 64.9 mt -65.21 -32.66 74.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.188 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.12 -36.15 76.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.14 -51.13 41.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.145 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.3 m -56.57 -48.45 77.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.455 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 46' ' ' LEU . 12.8 m -71.36 -28.52 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -178.785 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.682 ' O ' HG22 ' A' ' 55' ' ' VAL . 64.8 tp -67.74 -54.74 16.88 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.839 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.504 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 2.1 mptp? -65.24 -44.84 86.89 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.42 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.642 ' O ' HD13 ' A' ' 57' ' ' ILE . 23.9 m -61.09 -47.19 87.46 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.486 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.1 mt -70.93 -42.95 77.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 51' ' ' LEU . 16.5 m -75.68 -36.58 34.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.509 -178.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -71.85 -39.28 69.81 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 -178.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -60.39 -50.44 85.72 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.371 0.878 . . . . 0.0 113.371 -177.569 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.486 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 7.4 Cg_endo -50.65 -43.96 42.99 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 CA-C-N 120.718 1.292 . . . . 0.0 111.64 -178.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.71 ' CG ' HG11 ' B' ' 8' ' ' VAL . 24.2 m-85 -74.56 -68.01 0.58 Allowed 'General case' 0 N--CA 1.433 -1.275 0 CA-C-O 120.742 0.306 . . . . 0.0 110.665 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.485 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 C--N 1.331 -0.215 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.298 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.481 ' O ' ' N ' ' B' ' 7' ' ' GLY . 4.7 t . . . . . 0 N--CA 1.465 0.316 0 CA-C-O 120.436 0.16 . . . . 0.0 111.23 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.505 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -33.14 -61.43 0.36 Allowed Pre-proline 0 CA--C 1.535 0.366 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.58 9.39 0.12 Allowed 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.052 1.835 . . . . 0.0 112.194 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -120.69 -63.85 0.25 Allowed Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.964 -0.454 . . . . 0.0 111.964 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.71 HG11 ' CG ' ' A' ' 59' ' ' PHE . 35.2 m -61.52 -55.28 25.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 C-N-CA 120.224 -0.591 . . . . 0.0 110.607 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.8 mt -53.51 -38.1 63.41 Favored 'General case' 0 C--O 1.244 0.788 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.451 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.2 -36.71 71.19 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 177.309 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.86 -35.75 91.78 Favored Glycine 0 CA--C 1.522 0.472 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.976 179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.47 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.5 mp -65.03 -46.25 92.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.572 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.01 -44.49 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 C-N-CA 118.97 -1.092 . . . . 0.0 109.0 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.18 -43.99 77.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.793 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.08 -36.67 92.68 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -60.65 -46.23 91.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.107 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.474 ' O ' HD13 ' B' ' 17' ' ' LEU . 0.2 OUTLIER -58.22 -49.35 77.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.622 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 70.0 t -54.04 -45.31 64.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.12 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 91.9 mt -60.19 -50.94 71.68 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.967 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -44.97 -49.44 11.18 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.484 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -62.9 -37.64 79.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.547 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' LEU . . . . . 0.401 HD21 HG22 ' A' ' 44' ' ' ILE . 20.0 tp -63.74 -50.3 69.64 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.516 HG21 ' CG2' ' A' ' 23' ' ' ILE . 24.4 mm -58.85 -46.11 91.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -52.41 -48.7 65.55 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 32.3 tp -56.17 -37.09 69.08 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.39 -37.45 87.32 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.24 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.81 -47.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -61.2 -40.7 94.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.22 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -58.51 -44.8 89.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.557 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.0 tp . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.405 -179.806 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 5' ' ' SER . 60.4 p . . . . . 0 N--CA 1.462 0.166 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.465 ' H ' ' CB ' ' B' ' 5' ' ' SER . 30.4 m 34.85 29.95 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.219 0.533 . . . . 0.0 111.065 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.619 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -91.26 -38.67 0.38 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.215 179.057 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.3 Cg_exo -48.18 -42.19 33.44 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.429 2.086 . . . . 0.0 112.551 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.07 -47.14 0.8 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 108.863 -1.695 . . . . 0.0 108.863 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -56.53 -40.85 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.0 mt -55.69 -35.39 65.98 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -62.63 -37.8 87.75 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 177.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.23 -29.12 70.4 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 178.26 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.27 -42.58 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.9 t -57.07 -51.89 63.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.103 0.478 . . . . 0.0 109.971 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.4 t -59.2 -43.17 88.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.952 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -36.35 88.08 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.466 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -66.32 -49.75 65.94 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.826 0.346 . . . . 0.0 110.523 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.407 ' O ' HG23 ' A' ' 21' ' ' VAL . 23.0 tp -54.82 -51.02 67.14 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.83 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.5 m -65.18 -29.12 46.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.995 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -61.12 -58.86 6.6 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.999 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -54.9 -40.48 69.84 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.604 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 17' ' ' LEU . 89.9 t -69.57 -30.02 43.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.22 -54.34 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.103 -178.575 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.465 HG22 HG21 ' B' ' 23' ' ' ILE . 22.0 mt -68.14 -41.53 84.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.535 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.36 -41.76 94.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.444 . . . . 0.0 110.094 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.0 tp -68.2 -32.85 73.36 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.909 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.62 -51.09 70.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.627 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.56 -36.36 77.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.506 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -60.64 -46.25 90.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.506 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -69.0 -45.9 69.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.78 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.2 tp . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.552 -179.81 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.855 0.36 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 21.9 m -65.77 -24.7 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.697 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.562 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.2 mp -45.91 -29.22 1.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.404 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.18 -47.48 81.1 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.58 -38.76 72.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.932 0.396 . . . . 0.0 110.598 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -67.13 -43.14 88.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.168 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -58.54 -51.25 70.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.875 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.405 HG22 HD21 ' B' ' 22' ' ' LEU . 7.9 pt -63.04 -45.02 99.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.814 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.59 -36.36 53.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.633 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.532 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -68.55 -38.43 80.79 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.348 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.82 -31.99 56.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.166 -0.614 . . . . 0.0 109.682 -179.383 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.61 -52.36 21.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.482 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.424 ' O ' HG23 ' A' ' 53' ' ' THR . 4.6 m -58.81 -45.26 90.33 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.512 -178.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.51 -31.45 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -179.093 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.604 ' O ' HG22 ' A' ' 55' ' ' VAL . 56.0 tp -68.07 -53.47 25.32 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 119.816 -0.754 . . . . 0.0 110.954 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 52' ' ' LYS . 11.8 mptt -63.5 -47.12 83.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.732 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 49' ' ' THR . 64.1 p -65.23 -41.92 93.91 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.455 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 97.5 mt -71.52 -46.65 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -177.553 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 51' ' ' LEU . 8.1 m -74.72 -34.95 35.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.645 -178.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.2 tp -78.35 -41.04 34.64 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.488 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 37.2 mt -53.48 -52.95 62.06 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 57' ' ' ILE . 9.3 Cg_endo -51.1 -44.16 44.09 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 121.228 1.285 . . . . 0.0 112.386 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.485 ' CG ' HG11 ' B' ' 8' ' ' VAL . 9.1 m-85 -75.98 -57.17 4.03 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.532 0.283 0 C-N-CA 120.637 -0.425 . . . . 0.0 109.996 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.564 HG23 ' N ' ' B' ' 5' ' ' SER . 18.4 m . . . . . 0 N--CA 1.461 0.121 0 CA-C-O 120.687 0.28 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.57 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -45.9 -64.81 0.8 Allowed Pre-proline 0 CA--C 1.533 0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.608 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 10.5 Cg_endo -52.95 2.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 121.872 1.715 . . . . 0.0 112.283 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.57 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -99.99 -68.76 0.87 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.485 HG11 ' CG ' ' A' ' 59' ' ' PHE . 0.1 OUTLIER -65.25 -49.61 77.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.826 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.2 mt -55.32 -39.9 70.51 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -61.21 -39.17 89.24 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.5 -29.88 74.8 Favored Glycine 0 CA--C 1.52 0.404 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.159 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -69.09 -47.52 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 C-N-CA 119.661 -0.816 . . . . 0.0 108.976 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -53.86 -42.3 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 118.674 -1.21 . . . . 0.0 108.811 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.58 -42.34 91.22 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.992 179.032 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.9 -38.45 96.11 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -61.34 -43.2 99.28 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.7 tp -61.16 -46.98 88.29 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.811 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -58.63 -45.49 90.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 89.4 mt -60.87 -50.35 73.77 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.872 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.9 m -45.74 -50.23 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.471 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.28 -36.88 77.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.617 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' LEU . . . . . 0.405 HD21 HG22 ' A' ' 44' ' ' ILE . 36.1 tp -63.72 -50.67 68.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.571 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 23' ' ' ILE . 28.6 mm -59.39 -44.27 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.27 -47.11 69.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.211 0.529 . . . . 0.0 109.654 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.535 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.93 -38.93 76.81 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.184 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.44 -38.63 87.87 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.258 179.323 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 73.1 t -60.47 -47.31 93.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -61.2 -40.93 95.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.192 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -58.79 -47.3 85.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.717 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 26.3 tp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.43 -179.785 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.2 t . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.639 0.256 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.533 ' H ' ' CB ' ' B' ' 5' ' ' SER . 26.9 m 34.68 34.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.228 0.537 . . . . 0.0 111.248 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.621 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -86.57 -37.43 0.52 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.36 179.067 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.621 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.1 Cg_exo -48.71 -41.2 38.45 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.359 2.04 . . . . 0.0 112.512 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.532 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.72 -47.21 0.74 Allowed Glycine 0 N--CA 1.463 0.491 0 N-CA-C 108.795 -1.722 . . . . 0.0 108.795 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.8 t -55.0 -38.24 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.001 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 9' ' ' LEU . 68.0 mt -55.32 -39.51 70.03 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.532 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.05 -38.45 79.4 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.63 -26.89 67.29 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -68.04 -42.18 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.86 -54.11 39.89 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.733 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.6 t -58.49 -30.25 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.798 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.44 -38.8 93.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.475 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.1 t0 -67.62 -45.88 74.15 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.232 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.0 tp -57.65 -51.01 71.26 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -66.05 -28.71 44.59 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.774 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.518 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -60.19 -56.99 14.76 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 120.297 -0.561 . . . . 0.0 109.545 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.531 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.3 m -57.99 -41.79 83.78 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.292 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.57 -36.76 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.973 0.36 . . . . 0.0 111.973 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.08 -55.36 12.79 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 121.056 -0.258 . . . . 0.0 111.254 -178.526 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.9 mt -66.42 -44.4 90.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.723 -179.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.29 -43.97 88.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.134 0.492 . . . . 0.0 110.231 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.4 tp -67.12 -30.92 71.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.939 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.55 -51.07 68.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -36.11 76.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.365 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -61.82 -48.69 79.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.546 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 61.2 t80 -70.35 -48.47 56.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.669 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.7 tp . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.51 -179.816 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.6 m -62.64 -27.26 42.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.677 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -48.78 -29.38 4.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.921 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.0 -47.96 83.15 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.62 -45.8 79.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.9 0.381 . . . . 0.0 110.079 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.686 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -65.22 -29.48 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.429 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.7 m -65.33 -49.27 70.05 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.543 HD12 HD12 ' B' ' 23' ' ' ILE . 24.4 pt -68.87 -39.2 79.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.473 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.2 t -61.76 -43.05 96.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.125 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.487 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -69.02 -35.93 77.19 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.593 -179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.58 -32.92 59.08 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.954 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.531 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.01 -49.93 32.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -59.55 -48.62 80.94 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.2 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.8 m -64.53 -37.56 80.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.867 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.575 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.3 tp -63.07 -44.15 96.6 Favored 'General case' 0 C--O 1.224 -0.246 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.296 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.475 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 3.8 mptp? -59.79 -52.98 63.16 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.49 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.8 m -63.85 -46.46 84.93 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 -178.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 84.9 mt -62.7 -47.5 92.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.5 m -76.47 -35.91 27.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 120.327 -0.549 . . . . 0.0 111.024 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.5 tt -65.24 -33.07 75.13 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 113.091 0.775 . . . . 0.0 113.091 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.7 mt -66.75 -54.79 20.24 Favored Pre-proline 0 CA--C 1.544 0.75 0 C-N-CA 119.549 -0.86 . . . . 0.0 112.692 -178.03 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 55.9 Cg_endo -70.09 -28.57 23.5 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.726 1.617 . . . . 0.0 111.033 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.98 -52.0 64.67 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.523 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.446 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.7 mm? . . . . . 0 C--N 1.331 -0.224 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.507 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.463 HG23 ' N ' ' B' ' 5' ' ' SER . 28.3 m . . . . . 0 C--O 1.23 0.047 0 CA-C-O 120.943 0.401 . . . . 0.0 110.433 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.533 ' CB ' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -38.67 -62.86 0.65 Allowed Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.505 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -59.93 6.99 0.09 OUTLIER 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.197 1.931 . . . . 0.0 112.229 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -116.99 -66.44 0.37 Allowed Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.45 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -58.2 -51.88 65.62 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 121.007 0.432 . . . . 0.0 110.3 -179.898 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 32.2 mt -56.79 -38.42 72.5 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.68 -34.23 67.19 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.067 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.13 -36.84 93.42 Favored Glycine 0 CA--C 1.522 0.498 0 CA-C-N 114.135 -1.393 . . . . 0.0 110.884 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 19.6 mt -63.96 -42.53 96.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.567 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.403 HG13 ' H ' ' B' ' 13' ' ' VAL . 1.1 m -56.64 -46.05 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.833 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.8 t -52.44 -45.12 45.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 C-N-CA 120.081 -0.647 . . . . 0.0 109.474 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.3 -37.45 91.91 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -60.58 -47.0 88.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.094 0.474 . . . . 0.0 110.175 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.5 tp -56.61 -47.22 80.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.155 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -56.35 -45.54 81.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.272 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 30.0 mt -59.67 -52.84 63.78 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.588 -0.445 . . . . 0.0 109.977 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.1 m -44.64 -47.4 10.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.574 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -63.45 -38.43 82.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.485 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 39.7 tp -64.58 -54.86 25.37 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.67 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.543 HD12 HD12 ' A' ' 44' ' ' ILE . 8.5 mm -55.13 -47.48 77.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.893 -179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -50.98 -49.14 60.78 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 121.118 0.485 . . . . 0.0 109.781 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -55.86 -36.46 67.58 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.76 -37.72 88.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.19 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -60.62 -47.69 91.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -62.35 -40.04 95.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.053 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -59.14 -43.8 92.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.551 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.9 tp . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.462 -179.935 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.1 t . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.62 0.248 . . . . 0.0 110.448 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.502 ' H ' ' HB2' ' B' ' 5' ' ' SER . 29.5 m 32.23 34.44 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.561 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -85.49 -40.77 0.62 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.442 179.345 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 90.1 Cg_exo -47.77 -43.01 29.97 Favored 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.695 2.264 . . . . 0.0 112.801 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 69.98 -52.18 0.75 Allowed Glycine 0 N--CA 1.465 0.568 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' PRO . 63.1 t -50.73 -36.12 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 177.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.412 ' O ' HG22 ' A' ' 12' ' ' ILE . 36.2 mt -55.4 -40.93 72.03 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.524 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -56.18 -39.07 71.8 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 177.437 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.9 -27.53 67.03 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.444 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -69.03 -37.15 76.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.398 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.1 t -65.6 -52.65 48.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.22 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.4 t -59.77 -42.63 89.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.138 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.43 73.14 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.346 -0.701 . . . . 0.0 111.346 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -69.94 -54.08 14.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.771 0.319 . . . . 0.0 110.487 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.42 ' O ' HG23 ' A' ' 21' ' ' VAL . 50.2 tp -61.05 -40.71 94.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.204 0.526 . . . . 0.0 109.815 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.6 t -69.23 -27.63 35.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.272 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 tp -72.16 -55.87 6.54 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.802 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 m -62.51 -39.09 92.4 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.235 -0.586 . . . . 0.0 110.975 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 17' ' ' LEU . 94.6 t -70.85 -39.36 75.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.658 -0.246 . . . . 0.0 111.521 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.3 -52.8 56.77 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.387 -178.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.486 HG22 HG21 ' B' ' 23' ' ' ILE . 50.2 mt -65.67 -43.7 93.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.363 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -40.21 81.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.023 0.439 . . . . 0.0 110.404 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -71.1 -35.82 71.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.258 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.75 -50.19 70.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.996 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.435 HG11 ' CG2' ' B' ' 27' ' ' VAL . 29.6 m -69.17 -33.84 60.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.357 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -63.39 -45.26 91.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.456 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -61.18 -50.83 71.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.428 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 28.7 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.25 179.758 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.9 tp10 . . . . . 0 CA--C 1.529 0.15 0 CA-C-O 120.985 0.422 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.2 m -56.63 -26.54 23.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.544 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.9 tp -47.79 -32.57 6.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.643 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.0 -53.16 42.55 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.9 mm -56.38 -46.41 81.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-O 121.055 0.455 . . . . 0.0 110.436 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 95.7 mt -55.02 -45.25 76.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.171 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.7 t -60.12 -41.14 92.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.041 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 47' ' ' VAL . 5.3 mm -57.44 -53.9 37.98 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.278 0.561 . . . . 0.0 111.125 -179.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 p -64.65 -27.64 43.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.184 -0.606 . . . . 0.0 110.279 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.534 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.2 OUTLIER -66.9 -46.42 74.95 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.276 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 44' ' ' ILE . 3.7 p -67.61 -33.44 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.626 -179.327 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.59 -44.62 77.69 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.633 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.5 p -66.56 -52.06 49.69 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.836 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 46' ' ' LEU . 25.3 m -65.35 -37.33 79.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.244 -179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.666 ' O ' HG22 ' A' ' 55' ' ' VAL . 6.1 tt -65.35 -42.19 93.1 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.591 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 14.6 tptm -62.98 -52.43 63.04 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.884 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 75.5 p -65.95 -44.02 86.23 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 112.807 0.669 . . . . 0.0 112.807 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.477 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 88.5 mt -64.93 -45.97 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.3 m -77.64 -36.34 22.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.135 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.1 tt -67.27 -31.93 72.6 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.401 HD13 ' HA ' ' A' ' 57' ' ' ILE . 3.5 mm -67.74 -54.19 18.44 Favored Pre-proline 0 CA--C 1.544 0.729 0 C-N-CA 119.663 -0.815 . . . . 0.0 112.669 -178.009 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 53.7 Cg_endo -69.54 -28.05 26.77 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 121.729 1.619 . . . . 0.0 111.0 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.81 -54.62 36.17 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.6 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.458 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.523 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.499 ' O ' HG22 ' B' ' 8' ' ' VAL . 7.7 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.761 0.315 . . . . 0.0 111.254 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.502 ' HB2' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -40.21 -63.93 0.64 Allowed Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.783 -179.071 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.523 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 30.8 Cg_endo -61.6 0.73 0.97 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.099 1.866 . . . . 0.0 112.02 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -107.29 -64.02 0.59 Allowed Glycine 0 N--CA 1.466 0.7 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.522 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 0.2 OUTLIER -64.11 -50.95 74.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.091 0.472 . . . . 0.0 109.859 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.38 -38.96 81.84 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -57.19 -32.77 66.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -38.34 93.91 Favored Glycine 0 CA--C 1.525 0.713 0 CA-C-N 114.449 -1.251 . . . . 0.0 111.625 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 8.2 mt -65.73 -42.31 92.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 C-N-CA 119.555 -0.858 . . . . 0.0 109.61 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.444 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.5 m -55.75 -45.27 79.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.0 t -53.73 -50.18 52.9 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.674 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.46 -31.22 62.83 Favored Glycine 0 CA--C 1.527 0.844 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -70.93 -40.38 72.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.742 0.306 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 tp -61.53 -51.39 68.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -59.03 -44.43 91.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.353 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 26.8 mt -58.45 -51.94 67.73 Favored 'General case' 0 C--O 1.227 -0.117 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.925 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -48.07 -50.85 26.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 0.0 110.456 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.2 t -60.82 -31.26 49.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.137 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 13.9 tp -67.86 -44.74 76.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.894 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.486 HG21 HG22 ' A' ' 23' ' ' ILE . 28.4 mm -61.53 -51.23 75.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.035 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.86 -42.25 75.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.144 0.497 . . . . 0.0 109.92 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.2 tp -60.02 -37.38 79.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.709 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.81 94.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.204 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.435 ' CG2' HG11 ' A' ' 27' ' ' VAL . 87.3 t -60.13 -48.11 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.059 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -63.66 -38.95 93.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.221 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 44.0 t80 -58.26 -46.96 85.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.8 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.227 179.974 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.462 0.137 0 CA-C-O 120.598 0.237 . . . . 0.0 110.374 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.453 ' N ' ' OG ' ' B' ' 5' ' ' SER . 26.8 m 34.61 31.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.173 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.616 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -85.71 -38.33 0.58 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.432 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.616 ' CD ' ' N ' ' A' ' 5' ' ' SER . 97.9 Cg_exo -48.43 -42.4 34.77 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 122.405 2.07 . . . . 0.0 112.572 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.28 -48.39 0.71 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 6' ' ' PRO . 76.7 t -53.68 -35.94 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 177.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.424 ' O ' HG22 ' A' ' 12' ' ' ILE . 34.0 mt -54.84 -41.88 71.27 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.175 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.67 -37.98 77.21 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.82 -26.02 64.63 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.506 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -70.9 -38.38 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.6 t -61.42 -54.6 32.79 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-O 121.355 0.598 . . . . 0.0 109.521 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.401 ' O ' HG22 ' A' ' 18' ' ' VAL . 14.9 t -60.57 -36.26 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.284 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.11 -38.75 96.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -67.92 -47.75 67.86 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.889 0.376 . . . . 0.0 110.382 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.805 ' N ' ' HZ1' ' A' ' 52' ' ' LYS . 23.5 tp -58.91 -50.67 73.15 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.044 -179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.401 HG22 ' O ' ' A' ' 14' ' ' VAL . 16.9 m -68.33 -26.33 33.56 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.292 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.764 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.5 mt -62.81 -54.99 30.47 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.469 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.421 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.1 m -60.39 -43.99 96.1 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.298 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 17' ' ' LEU . 98.6 t -62.75 -49.36 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.511 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -62.33 -53.51 53.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.143 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.45 ' CG2' HG21 ' B' ' 23' ' ' ILE . 59.1 mt -58.8 -44.34 90.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.159 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.13 -38.02 81.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.286 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -65.39 -48.05 74.23 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.642 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.93 -46.85 64.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.512 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.2 t -62.06 -45.21 99.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -55.22 -43.67 74.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.636 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -59.21 -48.47 81.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.3 tt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.435 179.951 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.778 0.323 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.7 m -56.34 -24.48 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.563 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.1 mp -46.9 -32.54 3.87 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.394 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 -50.89 42.7 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 61.0 mt -60.74 -41.05 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.669 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 82.1 mt -66.27 -39.44 84.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.398 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.4 t -60.53 -50.83 71.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.794 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 8.3 pt -64.51 -44.11 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -57.52 -42.97 82.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.128 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.68 -39.71 91.59 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.694 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.24 -30.24 49.67 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.067 0 C-N-CA 120.396 -0.521 . . . . 0.0 109.658 -179.21 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.421 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.73 -50.18 32.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.546 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.7 m -58.5 -47.04 85.44 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.352 -0.539 . . . . 0.0 111.108 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.526 HG23 ' N ' ' A' ' 51' ' ' LEU . 26.7 m -69.0 -44.69 81.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.596 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.572 ' O ' HG22 ' A' ' 55' ' ' VAL . 37.9 tp -53.41 -51.81 61.38 Favored 'General case' 0 CA--C 1.519 -0.218 0 C-N-CA 120.114 -0.634 . . . . 0.0 110.302 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.805 ' HZ1' ' N ' ' A' ' 17' ' ' LEU . 3.4 mmmm -60.45 -43.94 96.34 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.825 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.2 m -59.68 -49.82 76.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.483 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 2.8 mp -70.97 -44.84 75.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.572 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.0 m -74.92 -34.18 32.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.887 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.404 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 10.8 tp -75.33 -37.33 60.79 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -178.559 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.1 mt -57.59 -52.64 72.81 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.483 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 49.5 Cg_endo -69.59 -27.58 27.11 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.434 1.423 . . . . 0.0 111.216 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.519 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.4 m-30 -63.98 -56.37 15.63 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.28 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.55 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.331 -0.234 0 CA-C-O 120.932 0.396 . . . . 0.0 110.096 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.401 ' O ' HG22 ' B' ' 8' ' ' VAL . 26.6 m . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.767 0.318 . . . . 0.0 110.456 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.528 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -40.49 -62.75 0.87 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.213 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -61.85 11.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 122.09 1.86 . . . . 0.0 112.235 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.74 -66.14 0.28 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.401 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.2 OUTLIER -61.85 -50.86 78.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-O 121.055 0.455 . . . . 0.0 110.224 -179.807 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.8 mt -60.13 -37.14 79.16 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.52 -34.15 66.73 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.02 -43.4 97.41 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.946 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 42.6 mm -57.82 -41.72 80.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.195 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.506 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -60.75 -43.02 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.395 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -57.44 -47.2 85.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 120.338 -0.545 . . . . 0.0 109.913 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.37 -36.3 90.68 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -63.18 -41.19 99.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.147 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.9 tp -61.77 -45.73 92.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.917 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.91 -48.0 82.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.384 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 49.9 mt -61.24 -49.13 78.36 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.105 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -46.1 -50.33 15.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.504 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 97.1 t -66.01 -31.72 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.501 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.6 tp -66.22 -51.83 53.78 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.482 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.45 HG21 ' CG2' ' A' ' 23' ' ' ILE . 20.9 mm -61.4 -50.71 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.3 -44.35 61.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.176 0.512 . . . . 0.0 109.677 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.33 -38.47 80.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.478 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.43 -39.0 91.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.088 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 84.1 t -60.86 -46.0 97.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.987 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -60.84 -41.74 96.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.162 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -58.02 -49.99 74.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.409 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 19.9 mt . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.406 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.6 t . . . . . 0 N--CA 1.462 0.125 0 CA-C-O 120.574 0.226 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.41 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.11 34.3 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.502 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.593 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -78.24 -41.15 1.95 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.469 179.402 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 5' ' ' SER . 78.7 Cg_exo -47.57 -41.98 29.57 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.727 2.285 . . . . 0.0 112.748 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.548 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.26 -47.37 0.85 Allowed Glycine 0 N--CA 1.462 0.416 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -179.226 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.477 ' H ' ' C ' ' A' ' 6' ' ' PRO . 70.8 t -56.1 -39.47 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 9' ' ' LEU . 72.5 mt -55.86 -38.1 69.66 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.23 -38.51 83.63 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.024 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.13 -29.76 71.96 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.42 -42.87 94.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.478 ' HA ' HG21 ' B' ' 12' ' ' ILE . 60.6 t -57.81 -51.64 67.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 84.8 t -57.79 -30.12 36.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.758 178.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.35 -38.12 86.84 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -68.03 -43.79 77.95 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.87 0.367 . . . . 0.0 110.648 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 27.5 tp -63.5 -48.72 76.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.417 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 14' ' ' VAL . 31.9 m -65.49 -29.81 48.26 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.124 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.961 -179.352 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.526 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.6 OUTLIER -66.35 -56.43 11.13 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.72 179.641 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.669 HG21 ' CB ' ' A' ' 48' ' ' ALA . 10.5 m -52.9 -50.68 63.42 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.987 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -70.28 -27.61 32.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 19.7 tp -66.9 -56.57 9.7 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.003 -179.13 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 61.2 mt -70.39 -43.23 78.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.596 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.23 -39.51 79.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.979 0.418 . . . . 0.0 110.152 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.79 -40.3 83.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.81 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.72 -50.9 67.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.866 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.4 m -67.98 -34.32 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.63 -0.428 . . . . 0.0 110.59 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -60.24 -44.54 95.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.696 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -66.49 -48.97 68.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 30' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.219 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.887 0.375 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.53 -25.68 38.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.704 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 58.3 tp -46.41 -29.61 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.817 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.98 -50.57 57.3 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.646 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.8 mp -56.79 -48.07 81.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.954 0.407 . . . . 0.0 109.931 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.8 mt -63.58 -29.99 48.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.618 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.3 t -64.85 -47.28 78.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.356 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.5 pt -71.11 -35.43 58.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.323 . . . . 0.0 111.54 -179.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 64.9 t -67.78 -43.85 86.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.196 -0.602 . . . . 0.0 110.36 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.528 ' O ' HG22 ' A' ' 50' ' ' VAL . 3.3 mm? -72.04 -37.52 69.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.72 -179.284 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.2 p -69.4 -31.81 50.82 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.113 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.878 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.669 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.38 -52.14 20.28 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.586 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.8 m -60.22 -42.48 95.25 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.566 -178.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.42 -32.98 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.518 -0.473 . . . . 0.0 112.066 -179.063 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.546 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -68.05 -56.55 8.46 Favored 'General case' 0 CA--C 1.521 -0.146 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.388 -179.694 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.31 -47.68 84.85 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.569 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 96.1 m -61.02 -44.55 97.25 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 95.3 mt -72.33 -43.53 64.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 113.736 1.013 . . . . 0.0 113.736 -177.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.7 m -78.68 -33.72 16.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.171 -0.611 . . . . 0.0 111.565 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -77.86 -39.88 41.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.453 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 13.0 mm -59.75 -54.32 56.88 Favored Pre-proline 0 CA--C 1.541 0.623 0 N-CA-C 113.198 0.814 . . . . 0.0 113.198 -177.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.485 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 16.7 Cg_endo -56.45 -35.76 96.8 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 121.484 1.456 . . . . 0.0 112.045 -179.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -77.28 -61.01 2.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.549 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.532 0.251 0 C-N-CA 120.488 -0.485 . . . . 0.0 109.98 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 27.8 m . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.887 0.375 . . . . 0.0 110.138 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.529 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -45.39 -63.27 1.27 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.861 179.592 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.5 Cg_endo -59.51 7.43 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.227 1.951 . . . . 0.0 112.35 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -114.05 -66.17 0.45 Allowed Glycine 0 N--CA 1.468 0.772 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.589 HG13 ' N ' ' B' ' 9' ' ' LEU . 11.5 p -63.58 -47.92 89.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.995 0.426 . . . . 0.0 110.306 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.589 ' N ' HG13 ' B' ' 8' ' ' VAL . 33.3 mt -56.74 -38.11 71.94 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.3 -39.09 81.9 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.17 75.74 Favored Glycine 0 CA--C 1.523 0.561 0 CA-C-N 114.491 -1.231 . . . . 0.0 110.786 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.478 HG21 ' HA ' ' A' ' 13' ' ' VAL . 49.8 mm -67.32 -46.13 84.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.063 -0.655 . . . . 0.0 109.615 179.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -55.6 -43.74 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 118.88 -1.128 . . . . 0.0 108.58 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 87.5 t -56.51 -47.92 81.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.294 -0.563 . . . . 0.0 109.542 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -55.5 -30.94 56.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -70.88 -41.91 70.71 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.645 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mp -60.48 -51.55 68.99 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 120.885 0.374 . . . . 0.0 110.196 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.403 HG13 ' N ' ' B' ' 19' ' ' LEU . 2.6 p -58.7 -45.78 90.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.398 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.403 ' N ' HG13 ' B' ' 18' ' ' VAL . 51.8 mt -59.42 -34.91 73.06 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.934 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.8 m -64.27 -41.39 96.94 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.295 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.84 -51.19 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.706 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' LEU . . . . . 0.413 ' N ' HD12 ' B' ' 22' ' ' LEU . 10.3 mp -64.28 -51.4 63.71 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.712 0.291 . . . . 0.0 111.052 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.517 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 82.4 mt -58.63 -51.49 71.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.07 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.6 -48.0 39.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.16 0.505 . . . . 0.0 109.812 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 34.2 tp -57.02 -35.75 69.64 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.1 -36.37 84.07 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.078 179.314 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 45.5 t -60.8 -48.07 90.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -64.42 -37.24 86.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.238 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -59.92 -46.49 89.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.682 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 tp . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.318 -179.836 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 11.6 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.572 0.225 . . . . 0.0 110.426 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.478 ' H ' ' CB ' ' B' ' 5' ' ' SER . 27.0 m 34.64 36.93 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.339 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.484 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -79.36 -48.23 1.52 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.317 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' A' ' 8' ' ' VAL . 46.7 Cg_exo -42.87 -43.42 9.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 122.699 2.266 . . . . 0.0 112.757 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.47 -46.66 0.87 Allowed Glycine 0 N--CA 1.463 0.433 0 N-CA-C 108.84 -1.704 . . . . 0.0 108.84 -179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' PRO . 74.3 t -57.75 -38.73 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.7 mt -55.62 -38.69 69.81 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.27 -40.22 89.59 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.62 -29.22 66.51 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.407 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -66.87 -43.23 89.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.086 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -50.83 74.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 179.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.6 t -57.27 -39.86 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.471 178.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.22 -36.81 91.75 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.62 -47.84 71.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.967 0.413 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 21' ' ' VAL . 41.1 tp -55.53 -51.74 66.04 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.726 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -65.14 -29.15 46.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.373 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.83 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.432 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -60.18 -58.04 10.25 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.738 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.1 m -56.09 -42.37 76.65 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 17' ' ' LEU . 87.4 t -66.51 -32.03 56.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.78 -53.9 13.69 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.404 -178.694 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.9 mt -67.83 -43.17 86.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.365 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.62 -42.94 97.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.891 0.377 . . . . 0.0 110.158 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 30.4 tp -65.56 -42.55 91.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.184 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.51 -48.58 71.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.661 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -64.51 -44.28 96.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.701 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -56.6 -37.58 70.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.662 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -59.91 -48.92 79.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.647 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.1 tp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.489 -179.994 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.856 0.36 . . . . 0.0 110.483 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.3 m -57.87 -28.28 32.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.561 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.6 tt -49.32 -37.72 25.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.545 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.53 -48.15 76.42 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 92.7 mt -59.63 -40.61 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.064 0.459 . . . . 0.0 110.49 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 91.6 mt -66.84 -35.98 76.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.467 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.3 m -64.18 -51.93 61.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.543 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.5 pt -61.86 -44.53 98.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.966 -179.27 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.47 -43.38 82.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 120.452 -0.499 . . . . 0.0 109.822 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.506 ' O ' HG22 ' A' ' 50' ' ' VAL . 70.5 mt -66.04 -32.14 73.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.201 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.26 -35.78 74.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.412 -0.515 . . . . 0.0 109.658 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.54 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -69.98 -49.05 55.48 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.265 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.3 p -58.92 -48.2 82.32 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.511 -179.325 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.506 HG22 ' O ' ' A' ' 46' ' ' LEU . 14.5 m -71.31 -28.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.603 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.672 ' O ' HG22 ' A' ' 55' ' ' VAL . 5.2 tt -67.12 -53.12 33.69 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.888 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.54 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 37.5 mttp -65.42 -44.83 86.16 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.82 0.343 . . . . 0.0 110.649 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.9 m -63.22 -42.53 99.26 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.515 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 93.8 mt -75.36 -41.96 43.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.672 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.5 m -76.59 -28.62 17.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 120.028 -0.669 . . . . 0.0 111.304 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.1 tp -84.82 -47.13 10.68 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.2 -59.38 13.19 Favored Pre-proline 0 N--CA 1.473 0.708 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -175.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.515 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -52.02 -27.49 28.93 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 121.392 1.394 . . . . 0.0 111.992 -178.742 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.546 ' CD1' HG11 ' B' ' 8' ' ' VAL . 26.4 m-85 -90.19 -65.94 0.97 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.494 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.2 mm? . . . . . 0 CA--C 1.53 0.205 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.29 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.462 0.136 0 CA-C-O 120.855 0.359 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.551 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -62.77 0.98 Allowed Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.908 179.786 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 31.2 Cg_endo -62.43 12.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.209 1.939 . . . . 0.0 111.995 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -125.45 -65.61 0.18 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.465 -0.654 . . . . 0.0 111.465 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.623 HG23 ' N ' ' B' ' 9' ' ' LEU . 18.1 m -60.09 -49.47 83.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.073 0.463 . . . . 0.0 110.461 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.623 ' N ' HG23 ' B' ' 8' ' ' VAL . 28.9 mt -57.41 -42.63 82.67 Favored 'General case' 0 C--O 1.238 0.484 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.66 -37.19 65.42 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 177.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.16 -28.73 73.32 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.347 178.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.2 -43.62 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.377 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.407 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.6 OUTLIER -58.86 -42.34 85.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 119.11 -1.036 . . . . 0.0 108.741 178.773 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.8 t -56.39 -47.42 81.47 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.323 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.86 -32.15 65.67 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.25 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -69.1 -41.75 77.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.804 0.335 . . . . 0.0 110.689 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 36.9 tp -61.07 -53.07 61.72 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.491 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -58.56 -39.85 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.139 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.428 HD22 ' HB2' ' A' ' 48' ' ' ALA . 25.6 mt -60.79 -52.72 63.9 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.733 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.5 m -47.14 -50.56 20.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.877 0.37 . . . . 0.0 110.21 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 60.0 t -61.95 -31.19 50.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.419 179.432 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 15.5 tp -68.37 -48.19 65.41 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.412 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 18.0 mm -60.64 -44.34 96.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.08 -48.19 79.18 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 121.184 0.516 . . . . 0.0 109.752 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -57.69 -34.93 69.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.55 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.81 -39.39 93.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.081 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -60.59 -45.83 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -62.52 -39.03 92.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -60.4 -44.46 95.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.618 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.0 tp . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.369 -179.848 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 5' ' ' SER . 41.7 p . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.791 0.329 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.456 ' N ' ' OG1' ' A' ' 3' ' ' THR . 10.6 m -69.24 37.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.958 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.18 -40.76 16.17 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.509 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.4 Cg_exo -46.66 -40.53 24.1 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.531 2.154 . . . . 0.0 112.45 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.24 -47.24 0.67 Allowed Glycine 0 N--CA 1.464 0.507 0 N-CA-C 109.125 -1.59 . . . . 0.0 109.125 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 72.7 t -56.26 -39.82 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.612 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.7 mt -55.96 -38.36 70.25 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.28 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.4 -36.1 77.32 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.78 -27.5 70.16 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.65 -42.01 86.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -59.95 -50.93 78.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.997 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.4 t -59.21 -42.32 86.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.904 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.03 -37.1 91.12 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.472 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 59.2 t0 -66.36 -47.4 73.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 110.359 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -55.59 -51.48 67.0 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.884 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.7 m -65.67 -29.02 45.73 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.712 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.475 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -59.38 -58.85 6.83 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.613 179.745 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.586 HG21 HD13 ' B' ' 19' ' ' LEU . 73.5 p -56.32 -42.91 78.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.286 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -64.59 -33.82 65.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.845 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.494 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.86 -52.86 25.3 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.049 -0.261 . . . . 0.0 111.168 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.4 mt -66.36 -43.79 91.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.349 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.8 -42.29 88.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.081 0.467 . . . . 0.0 110.07 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.6 tp -67.97 -31.27 70.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.034 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.81 -51.28 67.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.764 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.4 m -65.07 -37.52 80.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.432 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -60.98 -48.69 80.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.549 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 78.6 t80 -71.17 -50.97 27.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 30' ' ' LEU . 1.3 tt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.178 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.899 0.38 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.1 m -67.09 -26.0 35.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.485 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.5 tp -45.87 -27.69 0.93 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.727 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.72 -48.28 85.84 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.96 -44.51 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.098 0.475 . . . . 0.0 110.664 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.682 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.8 mp -66.18 -27.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.529 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.503 ' O ' HG23 ' A' ' 47' ' ' VAL . 24.0 p -70.66 -50.48 36.28 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.404 HG12 ' H ' ' A' ' 44' ' ' ILE . 10.5 pt -65.0 -44.85 95.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.032 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.417 HG13 ' N ' ' A' ' 46' ' ' LEU . 6.9 p -63.93 -41.75 93.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.555 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.543 ' O ' HG22 ' A' ' 50' ' ' VAL . 28.9 mt -65.2 -36.09 83.1 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 43' ' ' SER . 47.8 t -67.16 -35.55 74.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.076 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.46 -49.76 62.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.339 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 44.4 p -62.41 -50.57 70.97 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.876 -178.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 46' ' ' LEU . 15.8 m -66.04 -39.01 83.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.719 ' O ' HG22 ' A' ' 55' ' ' VAL . 33.6 tp -65.09 -40.74 95.03 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.598 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.472 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -65.66 -52.17 53.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.753 0.311 . . . . 0.0 110.995 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 m -67.87 -37.34 81.68 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.533 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 89.9 mt -72.28 -44.32 63.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 -177.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.9 m -78.49 -31.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.055 -0.658 . . . . 0.0 111.388 -179.323 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 4.3 tp -79.01 -39.92 32.8 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -177.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.2 mp -72.42 -60.04 2.3 Favored Pre-proline 0 N--CA 1.475 0.817 0 N-CA-C 113.796 1.036 . . . . 0.0 113.796 -176.237 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.533 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 9.4 Cg_endo -50.72 -25.4 15.05 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 121.736 1.624 . . . . 0.0 112.218 -178.8 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.533 ' CD1' HG11 ' B' ' 8' ' ' VAL . 1.9 m-85 -88.26 -67.34 0.84 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.54 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? . . . . . 0 C--O 1.231 0.122 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.166 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.434 HG23 ' N ' ' B' ' 5' ' ' SER . 13.8 m . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.815 0.34 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.509 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -37.75 -65.16 0.38 Allowed Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.923 -179.605 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 28.6 Cg_endo -60.43 6.14 0.12 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.323 2.015 . . . . 0.0 112.145 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -118.46 -64.5 0.3 Allowed Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.628 HG23 ' N ' ' B' ' 9' ' ' LEU . 14.3 m -60.84 -52.18 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 120.572 -0.451 . . . . 0.0 110.343 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.628 ' N ' HG23 ' B' ' 8' ' ' VAL . 36.6 mt -54.29 -40.04 67.5 Favored 'General case' 0 C--O 1.246 0.904 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.425 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.79 -35.41 70.76 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 11' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -63.62 -34.2 89.31 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.374 -1.284 . . . . 0.0 111.137 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.435 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.77 -45.87 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.333 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.53 -46.25 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 C-N-CA 119.095 -1.042 . . . . 0.0 108.856 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.4 t -53.26 -46.41 56.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.21 0.529 . . . . 0.0 109.627 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.78 -40.77 93.41 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.275 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -56.92 -46.37 82.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.709 0.29 . . . . 0.0 110.505 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -58.87 -45.12 90.93 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.3 t -56.34 -47.95 80.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.055 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.586 HD13 HG21 ' A' ' 20' ' ' THR . 98.3 mt -59.13 -39.74 83.3 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.002 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 15.8 m -56.78 -40.13 75.32 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.402 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 89.2 t -67.87 -51.72 47.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.831 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -62.11 -51.68 66.93 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.159 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.446 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -56.87 -50.01 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.55 -0.46 . . . . 0.0 109.998 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -49.13 -46.41 44.98 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.308 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.525 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.79 -40.02 75.16 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.026 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.446 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.25 -37.64 86.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.404 179.47 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.9 -48.06 89.19 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -64.08 -37.89 89.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.277 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -59.88 -51.03 71.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.641 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 20.9 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.393 179.861 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 5' ' ' SER . 28.6 p . . . . . 0 C--O 1.231 0.113 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.452 ' H ' ' CB ' ' B' ' 5' ' ' SER . 32.7 m 37.21 26.74 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.203 0.525 . . . . 0.0 111.03 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.627 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.6 OUTLIER -79.72 -35.47 0.96 Allowed Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.684 179.006 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.627 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.7 Cg_exo -49.56 -42.85 41.3 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.158 1.906 . . . . 0.0 112.529 179.81 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.539 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.81 -46.61 0.94 Allowed Glycine 0 CA--C 1.521 0.426 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.474 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -58.97 -40.1 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.59 -38.78 69.85 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.47 -38.91 82.05 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 177.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.04 -28.21 65.99 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.84 -43.62 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.078 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.2 t -55.77 -53.93 32.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -57.61 -36.95 56.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.69 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.08 -39.6 95.99 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -65.1 -46.92 79.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.896 0.379 . . . . 0.0 110.407 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.0 tp -55.74 -50.85 69.27 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -67.76 -25.68 33.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.008 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.57 -56.76 14.88 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 119.984 -0.687 . . . . 0.0 109.396 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.522 HG21 ' CB ' ' A' ' 48' ' ' ALA . 6.7 m -58.52 -44.5 89.55 Favored 'General case' 0 N--CA 1.456 -0.16 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.171 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.73 -32.88 59.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.1 tp -70.34 -54.5 12.29 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 -178.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.546 HG22 HG21 ' B' ' 23' ' ' ILE . 11.5 mm -70.28 -41.58 78.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.314 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.69 -40.3 87.39 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.022 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 32.7 tp -67.6 -37.48 82.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.626 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.18 -51.08 69.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.739 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -67.16 -36.19 76.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 C-N-CA 120.312 -0.555 . . . . 0.0 110.563 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -58.4 -44.38 88.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -66.28 -44.27 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.704 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.615 -179.803 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.908 0.385 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.8 m -69.67 -25.17 28.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.704 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 44.5 tp -46.13 -29.5 1.56 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.854 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.8 -52.82 47.99 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.645 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -40.27 58.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.919 0.39 . . . . 0.0 110.14 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.0 mm -64.54 -41.7 93.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.721 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 11.2 t -59.47 -51.79 68.36 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.69 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.1 tt -61.76 -43.88 97.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.31 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 41' ' ' ILE . 55.7 t -55.99 -43.11 74.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.121 0.486 . . . . 0.0 109.951 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -68.22 -30.8 69.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.935 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.4 t -68.29 -34.36 65.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.816 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.522 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.54 -48.15 42.61 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.474 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.8 m -60.13 -46.75 88.57 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.201 -179.04 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.7 m -68.4 -37.19 77.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 120.652 -0.419 . . . . 0.0 111.115 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.644 ' O ' HG22 ' A' ' 55' ' ' VAL . 34.1 tp -65.7 -41.11 92.76 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.271 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.419 ' NZ ' ' CD1' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -62.96 -53.19 57.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.431 -179.899 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.8 p -63.59 -46.86 83.89 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -61.64 -51.72 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.0 m -73.62 -29.79 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.174 -178.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.401 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 6.5 tt -70.91 -29.95 66.15 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -178.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 mt -61.95 -55.1 44.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.287 -178.713 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.71 -28.63 43.86 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.518 1.479 . . . . 0.0 111.503 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.2 m-30 -56.55 -47.07 80.25 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.349 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.478 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 N--CA 1.462 0.135 0 C-N-CA 120.846 -0.342 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.627 HG13 ' N ' ' B' ' 5' ' ' SER . 14.8 p . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 120.805 0.336 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.627 ' N ' HG13 ' B' ' 4' ' ' VAL . 0.7 OUTLIER -43.31 -64.48 0.75 Allowed Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.515 179.835 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 19.4 Cg_endo -56.86 1.75 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.325 2.017 . . . . 0.0 112.341 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -112.05 -67.05 0.52 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.552 HG23 ' N ' ' B' ' 9' ' ' LEU . 6.8 m -59.24 -48.05 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.154 0.502 . . . . 0.0 110.275 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.552 ' N ' HG23 ' B' ' 8' ' ' VAL . 43.6 mt -57.35 -42.15 81.46 Favored 'General case' 0 C--O 1.242 0.696 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -52.57 -33.46 45.91 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 176.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -37.22 94.17 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.292 178.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.1 tp -58.4 -43.82 87.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.672 -0.811 . . . . 0.0 108.956 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.431 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.9 OUTLIER -59.93 -46.81 93.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 119.256 -0.977 . . . . 0.0 109.487 179.281 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.5 -45.58 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 120.256 -0.577 . . . . 0.0 109.841 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.77 -39.25 96.48 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -59.58 -47.83 84.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.685 0.279 . . . . 0.0 110.712 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -57.79 -45.43 86.07 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -54.83 -46.64 75.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.439 HD22 ' HB2' ' A' ' 48' ' ' ALA . 23.5 mt -61.69 -47.08 86.94 Favored 'General case' 0 C--O 1.223 -0.302 0 C-N-CA 120.659 -0.417 . . . . 0.0 110.295 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.5 m -48.03 -50.73 26.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.8 0.333 . . . . 0.0 110.686 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 99.9 t -61.89 -44.13 98.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.936 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 12.2 tp -59.16 -45.3 91.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.18 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.546 HG21 HG22 ' A' ' 23' ' ' ILE . 4.6 mm -59.52 -49.78 82.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.87 -45.38 30.29 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.332 0.586 . . . . 0.0 109.83 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.561 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -64.76 -35.36 80.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.317 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.34 -55.32 35.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -57.86 -37.04 58.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.4 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 43.1 t80 -59.66 -43.76 93.81 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.82 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -61.15 -41.82 97.44 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.571 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 8.5 mp . . . . . 0 C--N 1.329 -0.299 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 5' ' ' SER . 32.7 p . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.621 0.248 . . . . 0.0 110.424 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.447 ' H ' ' HB3' ' B' ' 5' ' ' SER . 27.0 m 34.59 34.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.442 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -83.98 -40.09 0.73 Allowed Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.361 179.061 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 5' ' ' SER . 86.7 Cg_exo -48.1 -42.73 32.23 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.606 2.204 . . . . 0.0 112.655 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.516 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.86 -46.85 0.75 Allowed Glycine 0 N--CA 1.463 0.438 0 N-CA-C 108.865 -1.694 . . . . 0.0 108.865 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.6 t -55.27 -38.57 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.423 HD23 ' HA ' ' A' ' 9' ' ' LEU . 82.0 mt -55.38 -38.97 69.56 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.182 -1.007 . . . . 0.0 108.388 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.88 -39.86 86.72 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.51 -27.72 63.93 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.359 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.53 -42.89 83.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.197 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -56.45 -53.22 43.17 Favored 'Isoleucine or valine' 0 C--O 1.242 0.684 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.7 t -56.92 -39.67 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.357 178.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -54.71 -41.23 74.08 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 61.4 t0 -64.77 -45.85 84.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 110.299 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.434 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 20.8 tp -55.45 -51.08 68.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.894 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -68.53 -24.05 28.8 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.905 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.07 -56.7 14.69 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.032 -0.667 . . . . 0.0 109.382 179.755 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 53.6 m -61.36 -47.36 86.22 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.507 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.8 t -64.4 -34.32 68.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.4 tp -69.22 -54.28 15.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.609 -178.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 64.7 mt -67.57 -41.73 86.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.501 -0.479 . . . . 0.0 110.388 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.01 91.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.138 0.494 . . . . 0.0 110.026 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -67.57 -34.49 77.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.828 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.89 -51.36 70.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.757 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.65 -36.65 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.569 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -59.36 -41.69 89.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.872 0.367 . . . . 0.0 110.577 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -59.42 -46.87 87.49 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.656 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.4 tp . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -179.892 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 65.5 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.814 0.34 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.2 m -49.24 -26.67 2.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.6 tp -48.21 -28.62 3.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.715 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.38 -51.62 57.55 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.647 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -52.68 -49.94 43.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.027 0.441 . . . . 0.0 110.012 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.63 -27.58 43.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.727 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -67.01 -45.52 77.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.432 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.1 pt -71.83 -34.58 51.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.139 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.3 t -68.38 -46.4 80.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.572 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.404 ' O ' HG23 ' A' ' 50' ' ' VAL . 3.4 mm? -69.77 -37.75 76.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.643 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.22 -31.56 47.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.777 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.19 51.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.378 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.9 p -62.38 -43.36 99.0 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.953 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 46' ' ' LEU . 85.1 t -63.99 -43.74 97.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.556 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.5 OUTLIER -64.91 -53.39 47.18 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.018 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.434 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 0.7 OUTLIER -47.21 -51.99 17.03 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.909 179.924 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 31.4 p -59.13 -46.73 87.58 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 87.1 mt -59.82 -52.52 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.58 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 26.7 m -75.31 -30.89 23.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.258 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.7 tt -66.65 -32.79 74.34 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.522 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 7.4 mt -68.16 -54.23 16.37 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.479 -178.415 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.38 -28.44 18.09 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 121.799 1.666 . . . . 0.0 111.566 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.58 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -60.68 -45.43 94.2 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.342 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 121.017 0.437 . . . . 0.0 110.141 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 21.2 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.897 0.379 . . . . 0.0 110.314 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.539 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -40.02 -62.78 0.81 Allowed Pre-proline 0 CA--C 1.536 0.407 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.952 179.763 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.9 Cg_endo -61.02 9.88 0.07 OUTLIER 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.138 1.892 . . . . 0.0 112.073 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -123.64 -66.24 0.21 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.613 HG23 ' N ' ' B' ' 9' ' ' LEU . 15.9 m -58.8 -51.74 68.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 CA-C-O 121.094 0.473 . . . . 0.0 110.61 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.5 mt -56.51 -40.04 74.32 Favored 'General case' 0 C--O 1.242 0.663 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -53.24 -36.97 61.66 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.143 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.16 -34.45 89.12 Favored Glycine 0 CA--C 1.523 0.565 0 CA-C-N 114.425 -1.261 . . . . 0.0 110.447 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.52 -42.26 95.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 C-N-CA 119.701 -0.799 . . . . 0.0 109.341 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.411 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.7 OUTLIER -59.86 -44.42 94.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.32 179.091 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 83.9 t -51.23 -47.52 33.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.615 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.11 93.88 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.161 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -58.78 -45.16 90.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.857 0.361 . . . . 0.0 110.488 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.7 tp -56.77 -45.73 81.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.021 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.42 -46.77 82.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.204 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 14.2 mt -60.25 -39.74 87.84 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.062 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.2 m -57.68 -40.59 79.77 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.388 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.5 t -66.41 -51.8 53.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.474 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 11.1 mp -62.53 -52.95 61.41 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 120.939 -0.304 . . . . 0.0 111.274 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.429 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.9 mt -56.84 -51.33 69.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.111 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.94 -46.46 32.23 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.088 0.47 . . . . 0.0 109.857 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.537 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.91 -39.31 74.19 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.999 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.429 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.83 -38.51 91.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.455 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.53 -47.19 89.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -63.75 -41.37 98.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.206 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -56.44 -46.54 80.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.1 tp . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.32 -179.763 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 8.4 p . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.613 0.244 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.432 ' H ' ' CB ' ' B' ' 5' ' ' SER . 35.8 m 35.08 36.38 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.346 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -82.23 -40.19 0.92 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.377 179.133 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 72.4 Cg_exo -46.41 -40.45 22.72 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.647 2.232 . . . . 0.0 112.58 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.549 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.31 -48.09 0.7 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.474 ' N ' ' O ' ' A' ' 6' ' ' PRO . 71.3 t -53.83 -39.28 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.465 HD23 HD12 ' A' ' 12' ' ' ILE . 81.2 mt -56.05 -37.99 69.99 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.59 -33.08 73.27 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 177.245 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -63.37 -32.24 83.48 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.723 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.732 HG21 HG12 ' B' ' 13' ' ' VAL . 70.8 mt -67.2 -41.98 87.46 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 42.5 t -59.29 -55.17 25.41 Favored 'Isoleucine or valine' 0 C--O 1.241 0.613 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.481 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.425 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.7 t -61.02 -36.86 75.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.498 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.48 -40.47 99.14 Favored Glycine 0 C--O 1.224 -0.513 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -64.16 -51.26 64.68 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.008 0.433 . . . . 0.0 110.281 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 tp -56.86 -47.34 80.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.848 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' VAL . 77.8 t -63.44 -28.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.758 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.461 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -64.53 -56.64 12.74 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.68 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.4 m -56.09 -40.4 73.59 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.649 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.33 -32.52 57.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.727 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.47 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.41 -55.23 9.55 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.15 -178.931 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 80.0 mt -66.66 -43.65 90.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.574 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.41 -41.38 89.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.217 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.2 tp -69.18 -31.79 70.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.273 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.72 -50.51 68.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.799 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -66.32 -38.1 81.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.472 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -61.83 -46.52 89.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.575 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -69.46 -49.13 57.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.744 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.3 tp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.464 -179.977 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.6 tp10 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.839 0.352 . . . . 0.0 110.573 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.7 t -65.59 -28.98 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.581 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 tp -60.74 -29.29 69.28 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.78 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -54.64 -49.55 60.9 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.8 mm -55.38 -48.51 76.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.028 0.442 . . . . 0.0 110.651 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 74.2 mt -61.53 -34.96 63.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.483 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.433 ' O ' HG23 ' A' ' 47' ' ' VAL . 13.9 m -61.53 -51.7 67.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.692 -179.241 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 12.4 pt -63.06 -42.22 95.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.924 -179.29 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 71.7 t -60.24 -43.99 94.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.375 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.09 -34.7 79.03 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 43' ' ' SER . 50.4 t -66.78 -34.73 71.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.76 -47.98 64.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.457 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 4.5 m -60.87 -48.73 80.47 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.711 -0.396 . . . . 0.0 111.494 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 46' ' ' LEU . 16.9 m -69.91 -33.83 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -178.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.635 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.3 tp -65.69 -52.59 50.22 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.269 -0.572 . . . . 0.0 110.744 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.29 -50.53 72.63 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.312 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 48.5 p -60.34 -43.12 96.75 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.421 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 90.4 mt -72.95 -44.52 57.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.362 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -177.658 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.635 HG22 ' O ' ' A' ' 51' ' ' LEU . 11.4 m -77.04 -28.34 16.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.384 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.0 tp -82.58 -39.44 22.26 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 114.566 1.321 . . . . 0.0 114.566 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 mm -75.45 -63.79 0.64 Allowed Pre-proline 0 N--CA 1.475 0.824 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.421 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 12.2 Cg_endo -53.09 -38.68 80.91 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.766 1.644 . . . . 0.0 112.146 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -67.33 -59.63 3.25 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 121.055 -0.258 . . . . 0.0 110.666 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.53 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.531 0.219 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.864 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 4' ' ' VAL . . . . . 0.512 HG23 ' N ' ' B' ' 5' ' ' SER . 18.2 m . . . . . 0 N--CA 1.462 0.15 0 CA-C-O 120.953 0.406 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 5' ' ' SER . . . . . 0.521 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -40.51 -63.99 0.65 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.37 179.803 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 17.9 Cg_endo -57.9 3.62 0.12 Allowed 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.27 1.98 . . . . 0.0 112.231 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 7' ' ' GLY . . . . . 0.767 ' O ' ' HB3' ' B' ' 10' ' ' ALA . . . -115.14 -68.07 0.44 Allowed Glycine 0 CA--C 1.527 0.83 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.622 HG23 ' N ' ' B' ' 9' ' ' LEU . 7.4 m -58.19 -52.55 57.35 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.214 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.622 ' N ' HG23 ' B' ' 8' ' ' VAL . 42.1 mt -54.84 -31.76 59.76 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.86 -36.34 72.2 Favored 'General case' 0 C--O 1.244 0.775 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.733 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 11' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -66.71 -30.93 77.04 Favored Glycine 0 CA--C 1.528 0.875 0 CA-C-N 113.768 -1.56 . . . . 0.0 111.319 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.465 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.2 mp -71.32 -39.8 72.71 Favored 'Isoleucine or valine' 0 C--N 1.34 0.194 0 C-N-CA 119.684 -0.807 . . . . 0.0 109.4 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.732 HG12 HG21 ' A' ' 12' ' ' ILE . 1.5 m -57.92 -44.44 86.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.3 t -59.48 -48.85 85.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 CA-C-O 121.18 0.514 . . . . 0.0 110.267 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -34.85 81.27 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -65.76 -39.41 91.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.878 0.37 . . . . 0.0 110.154 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.91 -47.41 86.51 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.86 -35.17 74.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.895 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.43 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -65.59 -48.78 71.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.482 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 99.6 m -59.76 -44.24 93.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.884 0.374 . . . . 0.0 110.542 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.2 t -63.98 -40.72 90.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -59.01 -51.06 71.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.821 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.438 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 66.6 mt -59.06 -48.02 88.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.995 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.53 -46.85 39.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.03 0.443 . . . . 0.0 109.925 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -58.05 -40.48 81.04 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.106 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.65 -37.08 80.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.281 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 50.3 t -62.26 -42.28 94.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 61.5 t80 -63.19 -38.92 93.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.981 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -60.99 -41.07 95.77 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.742 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.7 tp . . . . . 0 C--N 1.329 -0.294 0 C-N-CA 120.829 -0.349 . . . . 0.0 110.278 -179.858 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.667 ' HB2' ' H1 ' ' B' ' 1' ' ' CYS . 40.4 t . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.1 m -160.56 170.17 21.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.575 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.7 t -152.07 145.23 24.61 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.489 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.474 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.22 31.47 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.142 0.496 . . . . 0.0 111.159 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.557 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.5 OUTLIER -84.82 -44.09 0.69 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.262 179.317 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.557 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.0 Cg_exo -45.37 -43.94 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 122.731 2.287 . . . . 0.0 112.871 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -50.45 0.82 Allowed Glycine 0 N--CA 1.464 0.502 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' PRO . 75.8 t -52.8 -35.13 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.9 mt -55.35 -41.7 72.85 Favored 'General case' 0 C--O 1.238 0.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.35 -37.58 75.48 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 177.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.3 -27.96 68.49 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.453 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -68.81 -39.03 79.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.9 t -62.08 -51.32 73.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.846 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.47 -43.04 89.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.72 -38.87 92.75 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.466 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 51.2 t0 -65.57 -46.59 78.88 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.916 0.389 . . . . 0.0 110.685 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.5 tp -56.31 -51.36 68.52 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.766 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 m -65.63 -27.32 41.2 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.323 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.578 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.84 -57.33 13.13 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.515 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -56.98 -42.47 80.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.113 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -65.7 -37.73 80.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.288 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -67.57 -54.47 19.6 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.404 -178.539 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 21.2 mm -66.21 -44.72 91.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.484 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.78 -39.59 77.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.911 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.0 tp -68.52 -34.5 75.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.023 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.58 -50.72 72.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.624 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -68.05 -39.42 81.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -60.58 -33.69 73.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -55.67 -50.09 71.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.75 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.0 tp -67.94 -43.61 78.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.6 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.96 41.73 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -163.7 67.76 0.18 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.599 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.59 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.9 mp 46.31 87.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.41 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 165.25 -34.14 0.25 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 61.3 p -74.93 -19.01 60.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.779 0.323 . . . . 0.0 110.555 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 58.99 177.95 0.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.397 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 53.96 15.23 0.81 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.361 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 m -57.53 -26.7 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.459 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.0 tp -46.26 -29.12 1.49 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.655 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -55.56 -48.82 68.34 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.666 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.0 mp -56.6 -40.77 71.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.002 0.429 . . . . 0.0 110.104 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -64.9 -41.22 91.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.205 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.7 t -58.1 -51.79 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.618 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.423 ' H ' HG12 ' A' ' 44' ' ' ILE . 6.5 pt -63.14 -39.89 86.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.91 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.0 t -64.71 -30.68 50.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.171 -0.612 . . . . 0.0 109.83 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.559 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -71.21 -47.69 55.9 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.937 -178.905 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.8 p -67.73 -30.49 48.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.626 -178.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.458 ' HB2' HD22 ' B' ' 19' ' ' LEU . . . -70.51 -53.3 16.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.377 -179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.1 m -57.98 -47.1 83.99 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.256 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.5 m -71.11 -28.83 34.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.881 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.606 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.0 tp -67.36 -55.7 12.71 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 119.882 -0.727 . . . . 0.0 110.821 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.466 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.0 OUTLIER -64.8 -45.27 86.98 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.099 179.614 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -60.77 -45.16 95.42 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -178.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.492 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.4 mt -73.45 -43.25 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -177.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.1 m -76.89 -33.13 20.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.365 -178.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.6 tp -79.47 -41.62 27.12 Favored 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.428 ' O ' ' CB ' ' A' ' 61' ' ' GLU . 25.9 mt -64.09 -62.11 5.72 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 119.047 -1.061 . . . . 0.0 113.23 -176.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.492 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 7.0 Cg_endo -47.35 -27.14 6.59 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 121.924 1.749 . . . . 0.0 112.504 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.431 ' CD1' HG21 ' B' ' 8' ' ' VAL . 0.9 OUTLIER -90.24 -65.62 1.0 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 120.384 -0.527 . . . . 0.0 109.809 179.52 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.485 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? -57.16 -15.99 6.88 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.649 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.428 ' CB ' ' O ' ' A' ' 57' ' ' ILE . 34.7 tt0 -77.94 139.61 39.2 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.657 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -67.94 85.9 0.23 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.436 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 60.9 t30 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.576 -179.857 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.667 ' H1 ' ' HB2' ' A' ' 1' ' ' CYS . 85.8 m . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.406 ' O ' ' OG1' ' B' ' 3' ' ' THR . 18.5 t -71.72 -24.28 61.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.538 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.406 ' OG1' ' O ' ' B' ' 2' ' ' SER . 36.3 p 52.28 100.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.669 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.527 HG23 ' N ' ' B' ' 5' ' ' SER . 32.6 m -79.15 -42.72 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.685 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.527 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.1 OUTLIER -38.7 -59.21 1.41 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.177 179.848 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.419 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 33.6 Cg_endo -64.38 13.86 0.09 OUTLIER 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 121.528 1.486 . . . . 0.0 111.783 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -113.01 -66.92 0.49 Allowed Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.431 HG21 ' CD1' ' A' ' 59' ' ' PHE . 0.0 OUTLIER -67.15 -51.92 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 9.6 mt -57.82 -39.15 76.93 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.419 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -58.07 -38.72 76.89 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 108.112 -1.069 . . . . 0.0 108.112 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.88 -30.96 79.38 Favored Glycine 0 CA--C 1.522 0.519 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.099 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 50.5 mm -66.23 -43.34 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 C-N-CA 120.079 -0.648 . . . . 0.0 109.769 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.453 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.9 OUTLIER -60.29 -42.0 89.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.838 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.87 -42.6 89.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.706 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.85 -39.25 97.26 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -61.51 -40.47 94.72 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -62.88 -44.93 94.79 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.102 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.4 -44.34 92.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.301 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.458 HD22 ' HB2' ' A' ' 48' ' ' ALA . 69.8 mt -66.54 -30.3 70.58 Favored 'General case' 0 C--O 1.225 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 110.212 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 21.8 m -62.58 -50.2 72.25 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.239 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 71.8 t -70.42 -43.28 78.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.554 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.45 -53.06 60.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.823 0.344 . . . . 0.0 111.194 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.47 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 76.3 mt -59.45 -50.64 79.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.965 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.39 38.14 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -57.25 -39.39 75.49 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.11 -35.37 78.5 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.133 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.97 -47.05 95.0 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -63.02 -40.43 97.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.125 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -55.67 -44.67 77.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.438 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 28.3 tp -59.88 -44.07 94.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.216 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 70.72 140.87 0.19 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 . . . . . 0 C--N 1.328 -0.352 0 CA-C-O 120.844 0.354 . . . . 0.0 110.532 -179.932 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 42.3 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.5 t -161.09 125.25 3.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.537 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 5' ' ' SER . 8.3 p -83.62 163.29 20.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.621 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.2 m 33.86 34.6 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.198 0.523 . . . . 0.0 111.239 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.578 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -84.94 -42.97 0.68 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.335 179.308 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 5' ' ' SER . 75.5 Cg_exo -46.38 -44.1 20.93 Favored 'Trans proline' 0 N--CA 1.495 1.598 0 C-N-CA 122.745 2.297 . . . . 0.0 112.807 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.496 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -48.33 0.75 Allowed Glycine 0 N--CA 1.464 0.518 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.462 ' H ' ' C ' ' A' ' 6' ' ' PRO . 62.5 t -53.87 -36.38 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' HG22 ' A' ' 12' ' ' ILE . 50.1 mt -55.07 -40.99 70.95 Favored 'General case' 0 C--O 1.238 0.461 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.2 -37.96 75.82 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.49 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.34 -28.02 66.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 178.147 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.427 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -67.8 -41.05 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.304 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 57.4 t -60.0 -53.09 53.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 121.467 0.651 . . . . 0.0 109.573 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.8 t -58.62 -34.63 51.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.964 179.277 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.32 -34.79 90.38 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -69.25 -44.7 71.42 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.8 tp -66.9 -51.27 57.4 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.42 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 14' ' ' VAL . 22.6 m -59.65 -35.02 57.14 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.328 -179.596 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.401 HD23 ' OD1' ' B' ' 16' ' ' ASP . 40.8 tp -64.39 -52.84 56.21 Favored 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.537 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.528 HG21 ' CB ' ' A' ' 48' ' ' ALA . 15.0 m -50.48 -49.83 54.24 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.901 -0.319 . . . . 0.0 111.439 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.6 p -70.73 -31.06 44.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 120.197 -0.601 . . . . 0.0 112.464 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.527 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.3 OUTLIER -67.73 -54.6 18.03 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.586 -179.47 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 27.5 mt -63.96 -50.47 77.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.387 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.27 -41.53 68.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.351 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 29.6 tp -63.58 -42.53 98.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.09 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.9 -48.22 70.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.342 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.1 t -63.85 -39.85 86.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.606 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -59.01 -48.02 83.09 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -61.06 -48.53 81.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.683 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.7 tp -66.7 -39.35 88.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.573 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -76.99 -106.45 0.15 Allowed Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 60.61 80.64 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.86 0.362 . . . . 0.0 110.475 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.576 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.4 mp 55.22 179.34 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.4 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.61 1.33 90.5 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 69.8 p -151.72 -4.3 0.27 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.735 0.302 . . . . 0.0 110.488 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 46.37 -162.09 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.597 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 54.25 31.44 14.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.452 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 16.4 m -63.49 -23.52 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.773 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.0 tp -44.03 -28.11 0.44 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.14 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -60.78 -49.51 77.85 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.667 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -49.09 76.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.09 0.472 . . . . 0.0 109.989 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.683 ' N ' HD12 ' A' ' 42' ' ' ILE . 2.0 mp -61.33 -31.4 50.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.981 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.9 t -62.26 -50.99 69.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.438 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.6 pt -66.11 -35.79 75.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.141 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.6 t -67.05 -40.1 84.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.448 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 46' ' ' LEU . 0.8 OUTLIER -68.14 -44.73 75.42 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.841 -178.94 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.6 p -69.48 -28.71 39.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.817 -178.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.528 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -70.75 -51.76 25.15 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.772 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.7 p -60.09 -40.85 91.03 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.537 -0.465 . . . . 0.0 110.756 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.37 -41.09 78.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.648 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 55' ' ' VAL . 21.5 tp -65.47 -54.91 21.64 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.793 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 56' ' ' LEU . 0.6 OUTLIER -58.58 -43.21 89.4 Favored 'General case' 0 C--O 1.219 -0.518 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.727 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 99.1 m -60.38 -50.74 72.39 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 112.238 0.459 . . . . 0.0 112.238 -179.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.495 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.3 mt -69.23 -43.95 80.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -177.537 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.526 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.6 m -76.21 -31.18 20.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.148 -0.621 . . . . 0.0 111.85 -178.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.407 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 8.6 tp -75.71 -37.96 58.99 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.23 -51.41 78.48 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.56 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.495 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 59.3 Cg_endo -72.71 -28.73 13.61 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.54 1.493 . . . . 0.0 111.283 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.3 m-30 -67.32 -53.88 25.68 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.131 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.491 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -78.36 21.98 0.34 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.379 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 59' ' ' PHE . 89.4 mt-10 -148.66 159.51 44.04 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.523 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.49 ' OE1' ' ND2' ' A' ' 63' ' ' ASN . 7.8 tm0? -68.09 -41.63 81.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.378 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.49 ' ND2' ' OE1' ' A' ' 62' ' ' GLN . 2.5 p30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.549 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.526 ' O ' ' N ' ' B' ' 3' ' ' THR . 10.3 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.419 ' O ' ' OG1' ' B' ' 3' ' ' THR . 6.4 t 62.21 -70.93 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.614 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.526 ' N ' ' O ' ' B' ' 1' ' ' CYS . 8.3 p 57.84 63.62 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.84 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.431 ' O ' HG22 ' B' ' 8' ' ' VAL . 25.4 m -75.3 -34.66 31.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.336 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.518 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -39.59 -62.15 0.89 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.429 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -62.2 10.61 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.154 1.903 . . . . 0.0 112.388 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.19 -65.52 0.29 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.431 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.0 OUTLIER -60.7 -51.96 67.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 121.215 0.531 . . . . 0.0 110.285 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.6 mt -60.49 -34.38 73.97 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.478 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -58.59 -35.93 73.2 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.2 -40.65 98.18 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.685 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 45.5 mm -58.0 -45.7 87.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.986 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.427 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -57.29 -44.69 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.251 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.96 -41.42 76.93 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.3 -41.72 98.5 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' HD23 ' A' ' 19' ' ' LEU . 24.5 t0 -60.36 -41.4 93.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.359 . . . . 0.0 110.213 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.8 tp -61.2 -43.95 98.06 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.046 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -57.85 -47.97 84.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.048 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 74.7 mt -61.43 -36.28 79.92 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.013 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -57.63 -43.78 85.1 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.215 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -69.24 -47.15 75.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.733 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.0 mp -62.08 -51.9 66.09 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.105 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.449 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -57.58 -50.3 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.9 -45.17 40.94 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 121.256 0.551 . . . . 0.0 109.942 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 4.9 tp -65.19 -30.08 70.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.119 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.17 -50.07 67.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.219 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -64.1 -38.28 82.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 C-N-CA 120.406 -0.518 . . . . 0.0 109.879 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -61.45 -43.11 99.44 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -60.62 -47.09 87.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.676 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 4.9 tp -61.06 -40.68 94.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.466 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -165.83 -89.23 0.07 OUTLIER Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.8 ttt85 . . . . . 0 C--N 1.328 -0.348 0 CA-C-O 120.778 0.323 . . . . 0.0 110.481 179.959 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 47.5 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.6 t -158.59 114.15 2.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.635 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 5' ' ' SER . 5.4 p -82.68 174.7 10.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.629 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.462 ' N ' ' OG ' ' B' ' 5' ' ' SER . 34.8 m 36.62 26.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.252 0.549 . . . . 0.0 111.212 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.62 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 1.6 t -81.74 -35.43 0.75 Allowed Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.61 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.62 ' CD ' ' N ' ' A' ' 5' ' ' SER . 84.2 Cg_exo -49.45 -41.49 43.7 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.336 2.024 . . . . 0.0 112.554 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.517 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.91 -47.01 0.98 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' PRO . 58.1 t -59.28 -40.64 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.35 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 12' ' ' ILE . 3.4 mm? -54.37 -43.03 70.99 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -56.12 -37.6 69.66 Favored 'General case' 0 C--O 1.233 0.184 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.725 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.08 -27.46 68.93 Favored Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.508 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -68.3 -38.53 79.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.409 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 80.8 t -64.21 -50.89 74.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.15 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.8 t -59.58 -46.1 93.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.18 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.53 -29.2 71.13 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.989 -0.845 . . . . 0.0 110.989 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.512 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 53.3 t0 -67.45 -52.64 37.11 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 110.387 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.3 tp -60.35 -41.23 93.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.127 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.5 -26.45 31.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.468 HD23 ' OD1' ' B' ' 16' ' ' ASP . 37.3 tp -71.43 -57.42 4.45 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.84 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.444 HG23 ' N ' ' A' ' 21' ' ' VAL . 14.0 t -62.3 -40.43 96.26 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.145 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.444 ' N ' HG23 ' A' ' 20' ' ' THR . 53.5 t -69.32 -43.82 80.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.662 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -60.54 -51.6 68.75 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.333 -178.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 63.7 mt -63.08 -42.48 96.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.942 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -43.88 78.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.96 0.41 . . . . 0.0 110.324 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.96 -36.24 82.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.47 -50.79 71.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.795 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.3 m -69.21 -32.56 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.48 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -61.93 -41.31 97.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.716 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -61.73 -45.39 94.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.651 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.04 -43.66 98.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.561 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.19 156.19 52.96 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -162.54 89.67 0.69 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.78 0.324 . . . . 0.0 110.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.7 mt 51.75 38.18 22.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.567 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 176.32 111.95 0.3 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.4 t -161.04 173.63 14.93 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.787 0.327 . . . . 0.0 110.634 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.444 ' H ' HD13 ' B' ' 30' ' ' LEU . . . -74.2 106.43 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.581 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 36' ' ' ALA . 50.1 mt-10 49.85 100.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.563 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 63.5 t -68.17 -28.74 42.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.636 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.6 mm? -63.77 -31.29 72.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -62.23 -50.28 66.56 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.3 mt -58.19 -44.3 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.092 0.473 . . . . 0.0 110.453 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.14 -38.65 82.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.471 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.5 m -59.94 -52.16 66.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.736 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.3 pt -62.11 -42.39 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.649 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.4 t -60.66 -35.24 62.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.0 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.553 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.5 OUTLIER -69.6 -39.16 77.41 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.529 -179.181 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -68.69 -30.46 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.622 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.18 -52.1 25.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.981 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -44.77 90.78 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.622 -0.431 . . . . 0.0 111.8 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.0 m -68.17 -40.32 82.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.563 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.619 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.5 tp -63.33 -45.81 89.54 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.456 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.512 ' NZ ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -62.03 -49.97 73.9 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.742 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.637 ' O ' HD13 ' A' ' 57' ' ' ILE . 25.4 p -62.66 -47.54 83.24 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.605 0.595 . . . . 0.0 112.605 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.482 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 87.4 mt -64.03 -46.05 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.619 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.0 m -76.36 -34.62 25.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.153 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.3 tt -68.27 -35.27 77.63 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 113.574 0.954 . . . . 0.0 113.574 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.637 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -65.42 -52.74 43.33 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 119.456 -0.898 . . . . 0.0 112.127 -177.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 57.6 Cg_endo -71.7 -29.57 15.69 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 121.591 1.527 . . . . 0.0 111.466 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.559 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.7 m-30 -64.28 -48.53 75.37 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.226 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -84.12 26.34 0.76 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.428 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -139.82 147.54 40.88 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.347 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.2 mm-40 -73.03 143.95 47.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.65 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 18.8 p30 . . . . . 0 C--N 1.331 -0.211 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.848 179.947 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 9.9 m . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 40.4 m -159.74 -35.33 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.371 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p 45.78 72.86 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.922 179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.536 HG23 ' N ' ' B' ' 5' ' ' SER . 30.0 m -81.78 -43.44 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.349 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.536 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.4 OUTLIER -38.49 -64.2 0.49 Allowed Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.584 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.4 Cg_endo -59.31 6.22 0.1 OUTLIER 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.328 2.019 . . . . 0.0 112.296 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -117.78 -66.29 0.34 Allowed Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.451 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -60.68 -51.95 67.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-O 121.091 0.472 . . . . 0.0 110.11 -179.871 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 49.4 mt -57.66 -37.2 73.0 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.23 -34.48 68.63 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 177.337 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -36.49 91.48 Favored Glycine 0 CA--C 1.524 0.649 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.328 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 11.3 mt -65.42 -41.39 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 119.496 -0.882 . . . . 0.0 109.394 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.508 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.4 m -57.69 -44.2 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.462 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -54.29 -50.34 57.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.169 -0.613 . . . . 0.0 109.677 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.17 -31.97 66.57 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.468 ' OD1' HD23 ' A' ' 19' ' ' LEU . 30.5 t0 -69.38 -41.04 77.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.774 0.321 . . . . 0.0 110.835 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -61.49 -52.39 64.7 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 121.008 0.432 . . . . 0.0 110.402 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -58.42 -39.12 73.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.128 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.3 mt -60.85 -53.08 61.72 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.61 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.453 ' OG1' HD21 ' A' ' 19' ' ' LEU . 8.3 m -48.26 -45.84 35.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.528 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 91.8 t -65.37 -33.83 66.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.723 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.9 tp -68.23 -53.76 22.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.49 -179.212 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 mm -60.83 -47.16 94.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 C-N-CA 120.658 -0.417 . . . . 0.0 109.931 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.12 -45.04 68.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.045 0.45 . . . . 0.0 109.835 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 31.0 tp -58.93 -38.73 79.65 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.18 -38.27 90.51 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.298 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -61.04 -47.75 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.031 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -61.9 -40.88 96.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.048 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -57.21 -48.47 78.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.491 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' LEU . . . . . 0.444 HD13 ' H ' ' A' ' 36' ' ' ALA . 29.8 tp -61.97 -43.14 99.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.389 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.17 120.59 0.01 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 . . . . . 0 C--N 1.328 -0.335 0 CA-C-O 120.771 0.32 . . . . 0.0 110.58 -179.985 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 10.5 m . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.8 m -160.59 67.59 0.34 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.735 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 5' ' ' SER . 81.6 p -82.41 160.51 22.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.314 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.467 ' H ' ' CB ' ' B' ' 5' ' ' SER . 34.2 m 34.78 32.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 121.158 0.504 . . . . 0.0 111.323 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -81.04 -46.34 1.17 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.093 179.292 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 5' ' ' SER . 50.8 Cg_exo -43.27 -43.78 10.24 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.814 2.343 . . . . 0.0 112.996 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.93 -46.88 0.76 Allowed Glycine 0 N--CA 1.463 0.464 0 N-CA-C 108.932 -1.667 . . . . 0.0 108.932 -179.241 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.2 t -55.53 -38.95 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.096 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.4 HD23 ' HA ' ' A' ' 9' ' ' LEU . 87.6 mt -55.8 -36.79 67.79 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.013 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.57 -37.68 84.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -29.21 71.06 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 178.198 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.69 -42.89 93.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 96.4 t -57.86 -51.13 74.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.3 t -58.47 -30.21 40.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.931 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.43 -38.44 90.99 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -68.2 -44.67 75.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.037 0.446 . . . . 0.0 110.226 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 tp -58.54 -51.38 70.13 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.932 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.6 m -65.0 -29.59 47.85 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.716 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -60.4 -59.57 5.19 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 120.046 -0.662 . . . . 0.0 109.402 179.523 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.45 HG21 ' HB1' ' A' ' 48' ' ' ALA . 70.5 p -52.2 -43.21 64.08 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.005 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.27 -30.02 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 112.103 0.408 . . . . 0.0 112.103 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.7 -55.21 9.2 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.18 -178.869 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 54.5 mt -68.64 -41.01 82.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.254 -0.578 . . . . 0.0 110.352 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.2 -42.83 95.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.138 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -67.82 -32.39 72.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.737 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.45 -51.1 70.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.641 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.5 m -66.54 -36.98 78.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.413 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -60.16 -45.62 92.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.644 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.3 t80 -64.79 -41.12 96.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.745 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.15 -41.29 92.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.74 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -48.2 147.39 4.71 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -171.77 71.69 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 33' ' ' LEU . 7.7 mp 51.01 62.94 2.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.321 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -172.96 1.43 0.03 OUTLIER Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.1 t -73.35 177.95 4.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.742 0.306 . . . . 0.0 110.519 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -158.28 134.1 9.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.551 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 55.62 65.22 1.52 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.551 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 20.8 m -68.33 -25.95 32.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -46.43 -30.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.655 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.64 -49.81 62.34 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -58.12 -44.85 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.026 0.441 . . . . 0.0 110.51 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.9 mt -63.43 -36.88 77.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.569 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 47' ' ' VAL . 65.6 m -61.04 -51.47 69.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.506 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.407 HG12 ' H ' ' A' ' 44' ' ' ILE . 9.7 pt -62.66 -43.36 98.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.935 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -58.69 -44.0 88.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.019 0.437 . . . . 0.0 110.233 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -64.62 -36.06 83.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.701 -179.355 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 43' ' ' SER . 53.8 t -65.84 -34.08 67.91 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-O 121.087 0.47 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.602 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -68.45 -53.81 21.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.382 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 6.3 m -55.49 -49.22 73.12 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.075 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 46' ' ' LEU . 13.3 m -70.51 -26.34 28.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.617 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.668 ' O ' HG22 ' A' ' 55' ' ' VAL . 27.6 tp -65.98 -56.06 13.57 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.867 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.602 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 1.4 mppt? -65.16 -44.38 88.71 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.394 -0.522 . . . . 0.0 110.244 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.8 m -60.7 -44.97 95.92 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.474 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.0 mt -74.05 -41.73 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 51' ' ' LEU . 18.9 m -77.23 -32.54 19.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.254 -178.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 tp -78.41 -44.22 25.39 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.452 ' O ' ' N ' ' A' ' 61' ' ' GLU . 33.9 mt -59.81 -61.9 6.96 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 119.278 -0.969 . . . . 0.0 113.039 -176.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.474 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -49.31 -26.55 11.7 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 C-N-CA 122.135 1.89 . . . . 0.0 112.233 -179.307 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.663 ' CG ' HG11 ' B' ' 8' ' ' VAL . 2.8 m-85 -92.27 -64.8 1.06 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.499 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -60.4 -11.09 5.81 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.132 -0.627 . . . . 0.0 110.196 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 57' ' ' ILE . 31.5 mm-40 -135.02 110.56 9.15 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.928 0.394 . . . . 0.0 110.543 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -72.4 -36.95 68.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.477 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 17.8 m120 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.525 179.984 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.413 ' OG ' ' N ' ' B' ' 3' ' ' THR . 3.3 p 72.58 -53.1 0.7 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.449 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.413 ' N ' ' OG ' ' B' ' 2' ' ' SER . 64.9 p 45.37 61.44 2.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.813 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.433 HG23 ' N ' ' B' ' 5' ' ' SER . 22.4 m -72.28 -37.21 58.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.326 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.503 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -41.84 -64.69 0.61 Allowed Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.179 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.5 Cg_endo -60.33 6.22 0.12 Allowed 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 122.257 1.971 . . . . 0.0 111.956 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.503 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.46 -65.11 0.28 Allowed Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.663 HG11 ' CG ' ' A' ' 59' ' ' PHE . 16.1 m -59.94 -52.16 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.483 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.636 ' N ' HG23 ' B' ' 8' ' ' VAL . 39.1 mt -54.16 -39.11 66.27 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.27 -36.72 71.36 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.66 -34.53 88.88 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.896 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.426 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.54 -46.96 88.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.302 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -53.56 -42.47 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.047 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 84.2 t -57.92 -44.72 87.16 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.907 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.52 -37.47 94.21 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -61.81 -41.99 98.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 0.0 110.142 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 58.4 tp -61.28 -44.38 97.32 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.35 -41.53 87.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.007 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.464 HD22 ' HB2' ' A' ' 48' ' ' ALA . 20.5 mt -64.55 -35.5 81.19 Favored 'General case' 0 C--O 1.225 -0.208 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.064 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 96.0 m -61.79 -48.83 78.86 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.632 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 61.7 t -68.42 -47.64 76.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.525 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 29.2 tp -60.86 -51.9 67.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.303 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 79.0 mt -57.65 -50.61 76.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.02 37.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.024 0.44 . . . . 0.0 109.934 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.53 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.21 -41.03 78.67 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.113 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.74 -37.21 83.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.403 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.41 -46.51 95.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -61.46 -41.02 96.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.177 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 45.0 t80 -59.34 -44.51 92.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.61 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 30.1 tp -55.87 -41.83 74.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.28 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 78.89 161.16 19.74 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 64.3 mtp85 . . . . . 0 C--N 1.331 -0.236 0 CA-C-O 120.787 0.327 . . . . 0.0 110.572 179.997 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.527 ' SG ' ' N ' ' B' ' 1' ' ' CYS . 55.9 m . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.0 t -76.7 115.52 16.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.668 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.459 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.6 OUTLIER -82.48 169.73 16.04 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.385 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 26.9 m 33.11 34.84 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.082 0.468 . . . . 0.0 111.637 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -86.91 -41.57 0.54 Allowed Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.304 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.2 Cg_exo -47.9 -45.03 25.86 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.659 2.239 . . . . 0.0 112.703 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.76 -49.21 0.82 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 -179.383 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 6' ' ' PRO . 69.0 t -54.96 -41.72 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 71.4 mt -55.22 -37.9 67.75 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.09 -36.9 75.92 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.371 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -61.14 -28.87 69.74 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 178.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -66.6 -40.89 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.51 -50.44 80.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.71 179.368 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.1 t -58.29 -44.62 88.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.713 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.51 -36.55 78.01 Favored Glycine 0 CA--C 1.525 0.674 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.037 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.2 t0 -65.21 -48.66 72.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.904 0.383 . . . . 0.0 110.592 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 28.7 tp -55.53 -51.64 66.36 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.716 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 m -64.36 -28.72 45.51 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 C-N-CA 120.213 -0.595 . . . . 0.0 110.801 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.424 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -61.26 -56.87 15.61 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.946 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.3 m -55.14 -42.39 72.99 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.415 179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.48 -29.05 44.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.829 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.47 -53.86 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.193 -178.757 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.516 ' CG2' HG21 ' B' ' 23' ' ' ILE . 11.8 mt -66.15 -42.81 91.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.402 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.25 -39.5 90.55 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.992 0.425 . . . . 0.0 110.429 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 33.0 tp -69.14 -37.54 78.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.041 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.61 -50.4 73.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 26.0 m -67.63 -35.69 73.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.634 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -60.31 -41.83 94.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.528 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -65.77 -38.75 89.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.721 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.9 tp -59.78 -43.33 94.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.539 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.98 115.69 4.58 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.9 mmt85 -81.21 44.89 0.8 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.76 0.314 . . . . 0.0 110.482 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.4 mt 58.75 158.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.487 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.58 12.15 84.78 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 29.0 p -78.57 -11.8 59.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.779 0.323 . . . . 0.0 110.496 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 52.46 -175.13 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.539 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 47.36 22.78 0.29 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.401 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.0 m -69.17 -23.94 27.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.74 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.566 HD12 ' N ' ' A' ' 39' ' ' LEU . 9.3 mp -46.06 -35.93 5.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.594 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.79 -46.47 89.9 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 58.8 mt -59.2 -38.29 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.016 0.436 . . . . 0.0 110.6 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.4 mm -67.41 -39.45 82.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -61.46 -52.12 65.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.616 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.401 HG22 HD21 ' B' ' 22' ' ' LEU . 7.1 pt -61.62 -44.67 99.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.905 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.8 t -56.72 -43.53 79.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.519 -0.472 . . . . 0.0 109.792 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.458 ' O ' HG22 ' A' ' 50' ' ' VAL . 64.9 mt -65.21 -32.66 74.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.188 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.12 -36.15 76.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.14 -51.13 41.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.145 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.3 m -56.57 -48.45 77.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.455 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 46' ' ' LEU . 12.8 m -71.36 -28.52 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -178.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.682 ' O ' HG22 ' A' ' 55' ' ' VAL . 64.8 tp -67.74 -54.74 16.88 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.839 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.504 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 2.1 mptp? -65.24 -44.84 86.89 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.42 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.642 ' O ' HD13 ' A' ' 57' ' ' ILE . 23.9 m -61.09 -47.19 87.46 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.486 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.1 mt -70.93 -42.95 77.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 51' ' ' LEU . 16.5 m -75.68 -36.58 34.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.509 -178.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -71.85 -39.28 69.81 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 -178.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -60.39 -50.44 85.72 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.371 0.878 . . . . 0.0 113.371 -177.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.486 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 7.4 Cg_endo -50.65 -43.96 42.99 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 CA-C-N 120.718 1.292 . . . . 0.0 111.64 -178.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.71 ' CG ' HG11 ' B' ' 8' ' ' VAL . 24.2 m-85 -74.56 -68.01 0.58 Allowed 'General case' 0 N--CA 1.433 -1.275 0 CA-C-O 120.742 0.306 . . . . 0.0 110.665 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.485 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -53.24 -22.62 7.13 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.298 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 57' ' ' ILE . 66.1 mm-40 -143.92 111.05 5.77 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.86 0.362 . . . . 0.0 110.268 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -72.84 -31.27 64.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.684 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.2 p30 . . . . . 0 C--N 1.332 -0.194 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.811 -179.917 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.527 ' N ' ' SG ' ' A' ' 1' ' ' CYS . 23.9 p . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.528 ' C ' ' H ' ' B' ' 4' ' ' VAL . 8.1 t 60.22 -75.0 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.647 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.527 ' N ' ' O ' ' B' ' 1' ' ' CYS . 5.9 m 67.69 -30.59 0.17 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.488 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.528 ' H ' ' C ' ' B' ' 2' ' ' SER . 4.7 t 64.57 -66.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.818 -0.174 . . . . 0.0 111.23 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.505 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -33.14 -61.43 0.36 Allowed Pre-proline 0 CA--C 1.535 0.366 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.58 9.39 0.12 Allowed 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.052 1.835 . . . . 0.0 112.194 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -120.69 -63.85 0.25 Allowed Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.964 -0.454 . . . . 0.0 111.964 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.71 HG11 ' CG ' ' A' ' 59' ' ' PHE . 35.2 m -61.52 -55.28 25.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 C-N-CA 120.224 -0.591 . . . . 0.0 110.607 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.8 mt -53.51 -38.1 63.41 Favored 'General case' 0 C--O 1.244 0.788 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.451 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.2 -36.71 71.19 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 177.309 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.86 -35.75 91.78 Favored Glycine 0 CA--C 1.522 0.472 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.976 179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.47 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.5 mp -65.03 -46.25 92.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.572 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.01 -44.49 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 C-N-CA 118.97 -1.092 . . . . 0.0 109.0 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.18 -43.99 77.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.793 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.08 -36.67 92.68 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -60.65 -46.23 91.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.107 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.474 ' O ' HD13 ' B' ' 17' ' ' LEU . 0.2 OUTLIER -58.22 -49.35 77.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.622 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 70.0 t -54.04 -45.31 64.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.12 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 91.9 mt -60.19 -50.94 71.68 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.967 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -44.97 -49.44 11.18 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.484 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -62.9 -37.64 79.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.547 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' LEU . . . . . 0.401 HD21 HG22 ' A' ' 44' ' ' ILE . 20.0 tp -63.74 -50.3 69.64 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.516 HG21 ' CG2' ' A' ' 23' ' ' ILE . 24.4 mm -58.85 -46.11 91.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -52.41 -48.7 65.55 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 32.3 tp -56.17 -37.09 69.08 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.39 -37.45 87.32 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.24 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.81 -47.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -61.2 -40.7 94.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.22 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -58.51 -44.8 89.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.557 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.0 tp -58.17 -40.61 81.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.405 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.99 150.38 8.21 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.784 0.326 . . . . 0.0 110.549 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 45.4 m . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.5 m -80.89 70.74 7.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.653 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 5' ' ' SER . 60.4 p -148.97 132.2 16.45 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.363 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.465 ' H ' ' CB ' ' B' ' 5' ' ' SER . 30.4 m 34.85 29.95 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.219 0.533 . . . . 0.0 111.065 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.619 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -91.26 -38.67 0.38 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.215 179.057 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.3 Cg_exo -48.18 -42.19 33.44 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.429 2.086 . . . . 0.0 112.551 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.07 -47.14 0.8 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 108.863 -1.695 . . . . 0.0 108.863 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -56.53 -40.85 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.0 mt -55.69 -35.39 65.98 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -62.63 -37.8 87.75 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 177.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.23 -29.12 70.4 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 178.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.27 -42.58 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.9 t -57.07 -51.89 63.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.103 0.478 . . . . 0.0 109.971 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.4 t -59.2 -43.17 88.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.952 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -36.35 88.08 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.466 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -66.32 -49.75 65.94 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.826 0.346 . . . . 0.0 110.523 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.407 ' O ' HG23 ' A' ' 21' ' ' VAL . 23.0 tp -54.82 -51.02 67.14 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.83 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.5 m -65.18 -29.12 46.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.995 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -61.12 -58.86 6.6 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.999 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -54.9 -40.48 69.84 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.604 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 17' ' ' LEU . 89.9 t -69.57 -30.02 43.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.22 -54.34 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.103 -178.575 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.465 HG22 HG21 ' B' ' 23' ' ' ILE . 22.0 mt -68.14 -41.53 84.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.535 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.36 -41.76 94.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.444 . . . . 0.0 110.094 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.0 tp -68.2 -32.85 73.36 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.909 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.62 -51.09 70.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.627 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.56 -36.36 77.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.506 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -60.64 -46.25 90.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.506 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -69.0 -45.9 69.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.78 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.2 tp -61.34 -43.72 98.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.552 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -82.25 79.26 1.89 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -63.41 82.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.467 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.582 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.2 mp 45.48 64.15 1.53 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.4 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -73.73 -152.31 2.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.425 ' O ' ' O ' ' A' ' 36' ' ' ALA . 9.5 t -72.55 177.95 4.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.767 0.318 . . . . 0.0 110.536 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.472 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . -60.27 -139.57 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.498 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 54.56 8.0 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.472 ' H ' ' C ' ' A' ' 36' ' ' ALA . 21.9 m -65.77 -24.7 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.697 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.562 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.2 mp -45.91 -29.22 1.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.404 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.18 -47.48 81.1 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.58 -38.76 72.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.932 0.396 . . . . 0.0 110.598 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -67.13 -43.14 88.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.168 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -58.54 -51.25 70.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.875 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.405 HG22 HD21 ' B' ' 22' ' ' LEU . 7.9 pt -63.04 -45.02 99.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.814 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.59 -36.36 53.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.633 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.532 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -68.55 -38.43 80.79 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.348 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.82 -31.99 56.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.166 -0.614 . . . . 0.0 109.682 -179.383 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.61 -52.36 21.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.482 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.424 ' O ' HG23 ' A' ' 53' ' ' THR . 4.6 m -58.81 -45.26 90.33 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.512 -178.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.51 -31.45 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -179.093 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.604 ' O ' HG22 ' A' ' 55' ' ' VAL . 56.0 tp -68.07 -53.47 25.32 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 119.816 -0.754 . . . . 0.0 110.954 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 52' ' ' LYS . 11.8 mptt -63.5 -47.12 83.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.732 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 49' ' ' THR . 64.1 p -65.23 -41.92 93.91 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.455 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 97.5 mt -71.52 -46.65 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -177.553 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 51' ' ' LEU . 8.1 m -74.72 -34.95 35.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.645 -178.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.2 tp -78.35 -41.04 34.64 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.488 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 37.2 mt -53.48 -52.95 62.06 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 57' ' ' ILE . 9.3 Cg_endo -51.1 -44.16 44.09 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 121.228 1.285 . . . . 0.0 112.386 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.485 ' CG ' HG11 ' B' ' 8' ' ' VAL . 9.1 m-85 -75.98 -57.17 4.03 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -45.29 -38.23 5.47 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 120.637 -0.425 . . . . 0.0 109.996 179.494 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -81.61 110.61 17.14 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.529 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -69.76 -23.71 63.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.496 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 30.0 m120 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.498 -179.991 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.415 ' O ' ' O ' ' B' ' 2' ' ' SER . 24.2 m . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.415 ' O ' ' O ' ' B' ' 1' ' ' CYS . 16.3 m 55.76 108.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.491 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 30.8 p -68.69 143.25 54.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.501 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.564 HG23 ' N ' ' B' ' 5' ' ' SER . 18.4 m -147.37 -46.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.57 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -45.9 -64.81 0.8 Allowed Pre-proline 0 CA--C 1.533 0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.608 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 10.5 Cg_endo -52.95 2.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 121.872 1.715 . . . . 0.0 112.283 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.57 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -99.99 -68.76 0.87 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.485 HG11 ' CG ' ' A' ' 59' ' ' PHE . 0.1 OUTLIER -65.25 -49.61 77.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.826 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.2 mt -55.32 -39.9 70.51 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -61.21 -39.17 89.24 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.5 -29.88 74.8 Favored Glycine 0 CA--C 1.52 0.404 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.159 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -69.09 -47.52 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 C-N-CA 119.661 -0.816 . . . . 0.0 108.976 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -53.86 -42.3 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 118.674 -1.21 . . . . 0.0 108.811 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.58 -42.34 91.22 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.992 179.032 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.9 -38.45 96.11 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -61.34 -43.2 99.28 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.7 tp -61.16 -46.98 88.29 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.811 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -58.63 -45.49 90.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 89.4 mt -60.87 -50.35 73.77 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.872 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.9 m -45.74 -50.23 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.471 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.28 -36.88 77.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.617 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' LEU . . . . . 0.405 HD21 HG22 ' A' ' 44' ' ' ILE . 36.1 tp -63.72 -50.67 68.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.571 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 23' ' ' ILE . 28.6 mm -59.39 -44.27 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.27 -47.11 69.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.211 0.529 . . . . 0.0 109.654 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.535 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.93 -38.93 76.81 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.184 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.44 -38.63 87.87 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.258 179.323 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 73.1 t -60.47 -47.31 93.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -61.2 -40.93 95.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.192 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -58.79 -47.3 85.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.717 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 26.3 tp -59.17 -46.88 87.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.43 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.95 112.32 0.75 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 . . . . . 0 C--N 1.328 -0.366 0 CA-C-O 120.827 0.346 . . . . 0.0 110.47 179.975 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.0 t . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.3 p -73.29 151.01 41.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.545 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.2 t -163.1 165.0 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.613 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.533 ' H ' ' CB ' ' B' ' 5' ' ' SER . 26.9 m 34.68 34.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.228 0.537 . . . . 0.0 111.248 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.621 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -86.57 -37.43 0.52 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.36 179.067 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.621 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.1 Cg_exo -48.71 -41.2 38.45 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.359 2.04 . . . . 0.0 112.512 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.532 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.72 -47.21 0.74 Allowed Glycine 0 N--CA 1.463 0.491 0 N-CA-C 108.795 -1.722 . . . . 0.0 108.795 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.8 t -55.0 -38.24 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.001 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 9' ' ' LEU . 68.0 mt -55.32 -39.51 70.03 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.532 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.05 -38.45 79.4 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.63 -26.89 67.29 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -68.04 -42.18 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.86 -54.11 39.89 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.733 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.6 t -58.49 -30.25 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.798 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.44 -38.8 93.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.475 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.1 t0 -67.62 -45.88 74.15 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.232 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.0 tp -57.65 -51.01 71.26 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -66.05 -28.71 44.59 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.774 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.518 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -60.19 -56.99 14.76 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 120.297 -0.561 . . . . 0.0 109.545 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.531 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.3 m -57.99 -41.79 83.78 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.292 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.57 -36.76 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.973 0.36 . . . . 0.0 111.973 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.08 -55.36 12.79 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 121.056 -0.258 . . . . 0.0 111.254 -178.526 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.9 mt -66.42 -44.4 90.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.723 -179.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.29 -43.97 88.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.134 0.492 . . . . 0.0 110.231 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.4 tp -67.12 -30.92 71.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.939 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.55 -51.07 68.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -36.11 76.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.365 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -61.82 -48.69 79.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.546 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 61.2 t80 -70.35 -48.47 56.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.669 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.7 tp -62.59 -42.89 99.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.51 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.72 112.37 4.93 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -72.84 149.51 43.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.798 0.332 . . . . 0.0 110.423 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.589 HD22 ' N ' ' A' ' 33' ' ' LEU . 3.2 mm? -73.73 109.86 7.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.215 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 160.88 43.31 0.02 OUTLIER Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -165.05 132.02 2.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.627 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.42 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . -73.26 -140.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.455 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 47.24 19.02 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.474 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.42 ' N ' ' C ' ' A' ' 36' ' ' ALA . 19.6 m -62.64 -27.26 42.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.677 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -48.78 -29.38 4.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.921 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.0 -47.96 83.15 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.62 -45.8 79.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.9 0.381 . . . . 0.0 110.079 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.686 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -65.22 -29.48 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.429 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.7 m -65.33 -49.27 70.05 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.543 HD12 HD12 ' B' ' 23' ' ' ILE . 24.4 pt -68.87 -39.2 79.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.473 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.2 t -61.76 -43.05 96.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.125 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.487 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -69.02 -35.93 77.19 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.593 -179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.58 -32.92 59.08 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.954 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.531 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.01 -49.93 32.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -59.55 -48.62 80.94 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.2 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.8 m -64.53 -37.56 80.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.867 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.575 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.3 tp -63.07 -44.15 96.6 Favored 'General case' 0 C--O 1.224 -0.246 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.296 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.475 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 3.8 mptp? -59.79 -52.98 63.16 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.49 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.8 m -63.85 -46.46 84.93 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 -178.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 84.9 mt -62.7 -47.5 92.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.5 m -76.47 -35.91 27.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 120.327 -0.549 . . . . 0.0 111.024 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.5 tt -65.24 -33.07 75.13 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 113.091 0.775 . . . . 0.0 113.091 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.438 ' O ' ' OE1' ' A' ' 61' ' ' GLU . 9.7 mt -66.75 -54.79 20.24 Favored Pre-proline 0 CA--C 1.544 0.75 0 C-N-CA 119.549 -0.86 . . . . 0.0 112.692 -178.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' A' ' 61' ' ' GLU . 55.9 Cg_endo -70.09 -28.57 23.5 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.726 1.617 . . . . 0.0 111.033 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.98 -52.0 64.67 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.523 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.446 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.7 mm? -79.21 -3.01 43.69 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.507 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 57' ' ' ILE . 56.9 mp0 -145.01 109.22 4.83 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.281 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 89.3 mm-40 -62.97 -41.64 99.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.554 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.616 -179.938 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 77.5 m . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 5.1 m 53.92 18.08 1.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.588 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p 52.83 94.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.818 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.463 HG23 ' N ' ' B' ' 5' ' ' SER . 28.3 m -74.52 -38.95 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.433 179.686 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.533 ' CB ' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -38.67 -62.86 0.65 Allowed Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.505 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -59.93 6.99 0.09 OUTLIER 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.197 1.931 . . . . 0.0 112.229 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -116.99 -66.44 0.37 Allowed Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.45 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -58.2 -51.88 65.62 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 121.007 0.432 . . . . 0.0 110.3 -179.898 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 32.2 mt -56.79 -38.42 72.5 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.68 -34.23 67.19 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.13 -36.84 93.42 Favored Glycine 0 CA--C 1.522 0.498 0 CA-C-N 114.135 -1.393 . . . . 0.0 110.884 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 19.6 mt -63.96 -42.53 96.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.567 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.403 HG13 ' H ' ' B' ' 13' ' ' VAL . 1.1 m -56.64 -46.05 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.833 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.8 t -52.44 -45.12 45.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 C-N-CA 120.081 -0.647 . . . . 0.0 109.474 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.3 -37.45 91.91 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -60.58 -47.0 88.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.094 0.474 . . . . 0.0 110.175 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.5 tp -56.61 -47.22 80.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.155 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -56.35 -45.54 81.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.272 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 30.0 mt -59.67 -52.84 63.78 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.588 -0.445 . . . . 0.0 109.977 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.1 m -44.64 -47.4 10.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.574 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -63.45 -38.43 82.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.485 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 39.7 tp -64.58 -54.86 25.37 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.67 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.543 HD12 HD12 ' A' ' 44' ' ' ILE . 8.5 mm -55.13 -47.48 77.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.893 -179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -50.98 -49.14 60.78 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 121.118 0.485 . . . . 0.0 109.781 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -55.86 -36.46 67.58 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.76 -37.72 88.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.19 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -60.62 -47.69 91.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -62.35 -40.04 95.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.053 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -59.14 -43.8 92.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.551 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.9 tp -59.75 -43.09 94.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.462 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 74.98 142.76 0.89 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 22.0 ttm105 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.783 0.325 . . . . 0.0 110.533 -179.913 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 2' ' ' SER . 31.1 t . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.483 ' N ' ' SG ' ' A' ' 1' ' ' CYS . 42.8 m 51.66 54.95 10.1 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.608 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.1 t -67.39 145.58 54.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.448 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.502 ' H ' ' HB2' ' B' ' 5' ' ' SER . 29.5 m 32.23 34.44 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.561 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -85.49 -40.77 0.62 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.442 179.345 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 90.1 Cg_exo -47.77 -43.01 29.97 Favored 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.695 2.264 . . . . 0.0 112.801 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 69.98 -52.18 0.75 Allowed Glycine 0 N--CA 1.465 0.568 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' PRO . 63.1 t -50.73 -36.12 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 177.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.412 ' O ' HG22 ' A' ' 12' ' ' ILE . 36.2 mt -55.4 -40.93 72.03 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.524 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -56.18 -39.07 71.8 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 177.437 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.9 -27.53 67.03 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.444 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -69.03 -37.15 76.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.398 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.1 t -65.6 -52.65 48.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.22 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.4 t -59.77 -42.63 89.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.138 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.43 73.14 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.346 -0.701 . . . . 0.0 111.346 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -69.94 -54.08 14.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.771 0.319 . . . . 0.0 110.487 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.42 ' O ' HG23 ' A' ' 21' ' ' VAL . 50.2 tp -61.05 -40.71 94.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.204 0.526 . . . . 0.0 109.815 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.6 t -69.23 -27.63 35.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.272 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 tp -72.16 -55.87 6.54 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.802 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 m -62.51 -39.09 92.4 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.235 -0.586 . . . . 0.0 110.975 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 17' ' ' LEU . 94.6 t -70.85 -39.36 75.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.658 -0.246 . . . . 0.0 111.521 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.3 -52.8 56.77 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.387 -178.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.486 HG22 HG21 ' B' ' 23' ' ' ILE . 50.2 mt -65.67 -43.7 93.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.363 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -40.21 81.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.023 0.439 . . . . 0.0 110.404 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -71.1 -35.82 71.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.258 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.75 -50.19 70.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.996 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.435 HG11 ' CG2' ' B' ' 27' ' ' VAL . 29.6 m -69.17 -33.84 60.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.357 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -63.39 -45.26 91.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.456 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -61.18 -50.83 71.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.428 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' GLY . 28.7 mt -70.05 -34.82 73.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.25 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 30' ' ' LEU . . . -55.99 -160.23 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -159.8 127.12 4.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.835 0.35 . . . . 0.0 110.722 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.572 ' H ' HD23 ' A' ' 33' ' ' LEU . 0.2 OUTLIER -84.17 -177.61 6.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.126 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.62 -15.93 3.42 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.445 ' H ' ' C ' ' A' ' 33' ' ' LEU . 11.4 t -80.44 23.72 0.49 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.809 0.338 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.43 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . 51.17 -171.58 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.9 tp10 58.2 7.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.119 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.43 ' H ' ' C ' ' A' ' 36' ' ' ALA . 27.2 m -56.63 -26.54 23.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.544 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.9 tp -47.79 -32.57 6.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.643 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.0 -53.16 42.55 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.9 mm -56.38 -46.41 81.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-O 121.055 0.455 . . . . 0.0 110.436 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 95.7 mt -55.02 -45.25 76.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.171 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.7 t -60.12 -41.14 92.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.041 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 47' ' ' VAL . 5.3 mm -57.44 -53.9 37.98 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.278 0.561 . . . . 0.0 111.125 -179.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 p -64.65 -27.64 43.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.184 -0.606 . . . . 0.0 110.279 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.534 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.2 OUTLIER -66.9 -46.42 74.95 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.276 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 44' ' ' ILE . 3.7 p -67.61 -33.44 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.626 -179.327 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.59 -44.62 77.69 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.633 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.5 p -66.56 -52.06 49.69 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.836 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 46' ' ' LEU . 25.3 m -65.35 -37.33 79.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.244 -179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.666 ' O ' HG22 ' A' ' 55' ' ' VAL . 6.1 tt -65.35 -42.19 93.1 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.591 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 14.6 tptm -62.98 -52.43 63.04 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.884 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 75.5 p -65.95 -44.02 86.23 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 112.807 0.669 . . . . 0.0 112.807 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.477 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 88.5 mt -64.93 -45.97 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.3 m -77.64 -36.34 22.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.135 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.1 tt -67.27 -31.93 72.6 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.401 HD13 ' HA ' ' A' ' 57' ' ' ILE . 3.5 mm -67.74 -54.19 18.44 Favored Pre-proline 0 CA--C 1.544 0.729 0 C-N-CA 119.663 -0.815 . . . . 0.0 112.669 -178.009 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 53.7 Cg_endo -69.54 -28.05 26.77 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 121.729 1.619 . . . . 0.0 111.0 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.81 -54.62 36.17 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.6 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.458 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -76.36 -20.99 56.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.523 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 58' ' ' PRO . 69.3 mm-40 -99.65 115.26 29.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.461 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.6 mm100 -67.05 -67.18 0.47 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.569 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.522 179.98 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.51 ' O ' HG23 ' B' ' 4' ' ' VAL . 32.9 p -163.36 102.9 0.95 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.394 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.472 ' OG1' ' N ' ' B' ' 4' ' ' VAL . 44.7 p 57.19 -101.95 0.14 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.864 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.51 HG23 ' O ' ' B' ' 2' ' ' SER . 7.7 t 66.33 -79.79 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.254 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.502 ' HB2' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -40.21 -63.93 0.64 Allowed Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.783 -179.071 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.523 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 30.8 Cg_endo -61.6 0.73 0.97 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.099 1.866 . . . . 0.0 112.02 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -107.29 -64.02 0.59 Allowed Glycine 0 N--CA 1.466 0.7 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.522 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 0.2 OUTLIER -64.11 -50.95 74.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.091 0.472 . . . . 0.0 109.859 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.38 -38.96 81.84 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -57.19 -32.77 66.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -38.34 93.91 Favored Glycine 0 CA--C 1.525 0.713 0 CA-C-N 114.449 -1.251 . . . . 0.0 111.625 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 8.2 mt -65.73 -42.31 92.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 C-N-CA 119.555 -0.858 . . . . 0.0 109.61 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.444 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.5 m -55.75 -45.27 79.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.0 t -53.73 -50.18 52.9 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.674 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.46 -31.22 62.83 Favored Glycine 0 CA--C 1.527 0.844 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -70.93 -40.38 72.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.742 0.306 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 tp -61.53 -51.39 68.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -59.03 -44.43 91.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.353 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 26.8 mt -58.45 -51.94 67.73 Favored 'General case' 0 C--O 1.227 -0.117 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.925 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -48.07 -50.85 26.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 0.0 110.456 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.2 t -60.82 -31.26 49.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.137 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 13.9 tp -67.86 -44.74 76.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.894 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.486 HG21 HG22 ' A' ' 23' ' ' ILE . 28.4 mm -61.53 -51.23 75.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.035 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.86 -42.25 75.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.144 0.497 . . . . 0.0 109.92 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.2 tp -60.02 -37.38 79.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.709 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.81 94.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.204 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.435 ' CG2' HG11 ' A' ' 27' ' ' VAL . 87.3 t -60.13 -48.11 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.059 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -63.66 -38.95 93.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.221 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 44.0 t80 -58.26 -46.96 85.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.6 -40.28 96.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.227 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 84.73 176.97 51.05 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 82.1 mtt85 . . . . . 0 C--N 1.329 -0.309 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 -179.966 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 53.8 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.41 ' C ' ' HG ' ' A' ' 5' ' ' SER . 17.6 p -52.87 113.07 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.58 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.0 OUTLIER -87.28 167.38 14.14 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.374 179.844 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.453 ' N ' ' OG ' ' B' ' 5' ' ' SER . 26.8 m 34.61 31.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.173 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.616 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -85.71 -38.33 0.58 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.432 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.616 ' CD ' ' N ' ' A' ' 5' ' ' SER . 97.9 Cg_exo -48.43 -42.4 34.77 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 122.405 2.07 . . . . 0.0 112.572 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.28 -48.39 0.71 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 6' ' ' PRO . 76.7 t -53.68 -35.94 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 177.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.424 ' O ' HG22 ' A' ' 12' ' ' ILE . 34.0 mt -54.84 -41.88 71.27 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.175 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.67 -37.98 77.21 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.82 -26.02 64.63 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.506 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -70.9 -38.38 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.6 t -61.42 -54.6 32.79 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-O 121.355 0.598 . . . . 0.0 109.521 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.401 ' O ' HG22 ' A' ' 18' ' ' VAL . 14.9 t -60.57 -36.26 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.284 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.11 -38.75 96.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -67.92 -47.75 67.86 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.889 0.376 . . . . 0.0 110.382 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.805 ' N ' ' HZ1' ' A' ' 52' ' ' LYS . 23.5 tp -58.91 -50.67 73.15 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.044 -179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.401 HG22 ' O ' ' A' ' 14' ' ' VAL . 16.9 m -68.33 -26.33 33.56 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.292 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.764 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.5 mt -62.81 -54.99 30.47 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.469 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.421 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.1 m -60.39 -43.99 96.1 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.298 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 17' ' ' LEU . 98.6 t -62.75 -49.36 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.511 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -62.33 -53.51 53.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.143 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.45 ' CG2' HG21 ' B' ' 23' ' ' ILE . 59.1 mt -58.8 -44.34 90.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.159 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.13 -38.02 81.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.286 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -65.39 -48.05 74.23 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.642 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.93 -46.85 64.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.512 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.2 t -62.06 -45.21 99.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -55.22 -43.67 74.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.636 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -59.21 -48.47 81.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.3 tt -64.35 -43.17 95.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.435 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.01 94.99 0.19 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -76.89 41.84 0.29 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.838 0.351 . . . . 0.0 110.587 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.577 HD22 ' N ' ' A' ' 33' ' ' LEU . 3.3 mm? 48.69 -175.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.92 -20.17 3.9 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 35' ' ' THR . 3.3 t -80.42 -12.7 59.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.823 0.344 . . . . 0.0 110.449 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.421 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . 49.76 -143.83 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.467 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 48.63 17.96 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.48 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.421 ' N ' ' C ' ' A' ' 36' ' ' ALA . 23.7 m -56.34 -24.48 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.563 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.1 mp -46.9 -32.54 3.87 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.394 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 -50.89 42.7 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 61.0 mt -60.74 -41.05 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.669 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 82.1 mt -66.27 -39.44 84.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.398 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.4 t -60.53 -50.83 71.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.794 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 8.3 pt -64.51 -44.11 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -57.52 -42.97 82.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.128 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.68 -39.71 91.59 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.694 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.24 -30.24 49.67 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.067 0 C-N-CA 120.396 -0.521 . . . . 0.0 109.658 -179.21 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.421 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.73 -50.18 32.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.546 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.7 m -58.5 -47.04 85.44 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.352 -0.539 . . . . 0.0 111.108 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.526 HG23 ' N ' ' A' ' 51' ' ' LEU . 26.7 m -69.0 -44.69 81.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.596 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.572 ' O ' HG22 ' A' ' 55' ' ' VAL . 37.9 tp -53.41 -51.81 61.38 Favored 'General case' 0 CA--C 1.519 -0.218 0 C-N-CA 120.114 -0.634 . . . . 0.0 110.302 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.805 ' HZ1' ' N ' ' A' ' 17' ' ' LEU . 3.4 mmmm -60.45 -43.94 96.34 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.825 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.2 m -59.68 -49.82 76.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.483 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 2.8 mp -70.97 -44.84 75.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.572 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.0 m -74.92 -34.18 32.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.887 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.404 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 10.8 tp -75.33 -37.33 60.79 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -178.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.1 mt -57.59 -52.64 72.81 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 49.5 Cg_endo -69.59 -27.58 27.11 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.434 1.423 . . . . 0.0 111.216 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.519 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.4 m-30 -63.98 -56.37 15.63 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.28 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.55 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -77.7 18.79 0.42 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.932 0.396 . . . . 0.0 110.096 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.425 ' H ' ' C ' ' A' ' 59' ' ' PHE . 32.9 tp10 -173.25 78.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.598 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -55.47 -46.3 76.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.647 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 16.2 p30 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.508 -179.982 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 25.7 p -66.02 -46.94 76.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.467 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 71.2 p 43.18 45.49 4.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.103 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.401 ' O ' HG22 ' B' ' 8' ' ' VAL . 26.6 m -73.93 -33.27 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.767 0.318 . . . . 0.0 110.456 179.592 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.528 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -40.49 -62.75 0.87 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.213 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -61.85 11.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 122.09 1.86 . . . . 0.0 112.235 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.74 -66.14 0.28 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.401 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.2 OUTLIER -61.85 -50.86 78.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-O 121.055 0.455 . . . . 0.0 110.224 -179.807 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.8 mt -60.13 -37.14 79.16 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.52 -34.15 66.73 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.02 -43.4 97.41 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.946 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 42.6 mm -57.82 -41.72 80.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.195 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.506 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -60.75 -43.02 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.395 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -57.44 -47.2 85.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 120.338 -0.545 . . . . 0.0 109.913 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.37 -36.3 90.68 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -63.18 -41.19 99.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.147 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.9 tp -61.77 -45.73 92.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.917 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.91 -48.0 82.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.384 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 49.9 mt -61.24 -49.13 78.36 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.105 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -46.1 -50.33 15.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.504 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 97.1 t -66.01 -31.72 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.501 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.6 tp -66.22 -51.83 53.78 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.482 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.45 HG21 ' CG2' ' A' ' 23' ' ' ILE . 20.9 mm -61.4 -50.71 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.3 -44.35 61.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.176 0.512 . . . . 0.0 109.677 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.33 -38.47 80.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.478 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.43 -39.0 91.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.088 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 84.1 t -60.86 -46.0 97.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.987 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -60.84 -41.74 96.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.162 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -58.02 -49.99 74.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.409 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 19.9 mt -63.48 -39.01 93.33 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 76.97 -140.99 25.61 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-O 120.86 0.362 . . . . 0.0 110.361 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.1 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.2 p -79.4 151.41 30.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.638 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.6 t -87.91 159.54 18.31 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.474 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.41 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.11 34.3 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.502 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.593 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -78.24 -41.15 1.95 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.469 179.402 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 5' ' ' SER . 78.7 Cg_exo -47.57 -41.98 29.57 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.727 2.285 . . . . 0.0 112.748 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.548 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.26 -47.37 0.85 Allowed Glycine 0 N--CA 1.462 0.416 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -179.226 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.477 ' H ' ' C ' ' A' ' 6' ' ' PRO . 70.8 t -56.1 -39.47 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 9' ' ' LEU . 72.5 mt -55.86 -38.1 69.66 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.23 -38.51 83.63 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.024 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.13 -29.76 71.96 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.42 -42.87 94.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.478 ' HA ' HG21 ' B' ' 12' ' ' ILE . 60.6 t -57.81 -51.64 67.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 84.8 t -57.79 -30.12 36.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.758 178.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.35 -38.12 86.84 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -68.03 -43.79 77.95 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.87 0.367 . . . . 0.0 110.648 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 27.5 tp -63.5 -48.72 76.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.417 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 14' ' ' VAL . 31.9 m -65.49 -29.81 48.26 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.124 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.961 -179.352 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.526 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.6 OUTLIER -66.35 -56.43 11.13 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.72 179.641 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.669 HG21 ' CB ' ' A' ' 48' ' ' ALA . 10.5 m -52.9 -50.68 63.42 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.987 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -70.28 -27.61 32.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 19.7 tp -66.9 -56.57 9.7 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.003 -179.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 61.2 mt -70.39 -43.23 78.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.596 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.23 -39.51 79.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.979 0.418 . . . . 0.0 110.152 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.79 -40.3 83.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.81 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.72 -50.9 67.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.866 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.4 m -67.98 -34.32 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.63 -0.428 . . . . 0.0 110.59 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -60.24 -44.54 95.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.696 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -66.49 -48.97 68.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -63.75 -50.48 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.219 -179.812 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -60.25 133.9 50.48 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.484 ' C ' ' H ' ' A' ' 34' ' ' GLY . 40.0 ttm180 -76.28 154.59 35.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.541 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 16.0 mt -72.2 38.28 0.07 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.692 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 32' ' ' ARG . . . -179.2 99.07 0.12 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.1 t -165.09 17.01 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.811 0.338 . . . . 0.0 110.522 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.4 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . 47.39 -170.36 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.55 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 52.1 14.09 0.31 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.45 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.4 ' N ' ' C ' ' A' ' 36' ' ' ALA . 17.0 m -63.53 -25.68 38.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.704 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 58.3 tp -46.41 -29.61 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.817 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.98 -50.57 57.3 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.646 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.8 mp -56.79 -48.07 81.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.954 0.407 . . . . 0.0 109.931 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.8 mt -63.58 -29.99 48.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.618 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.3 t -64.85 -47.28 78.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.356 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.5 pt -71.11 -35.43 58.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.323 . . . . 0.0 111.54 -179.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 64.9 t -67.78 -43.85 86.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.196 -0.602 . . . . 0.0 110.36 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.528 ' O ' HG22 ' A' ' 50' ' ' VAL . 3.3 mm? -72.04 -37.52 69.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.72 -179.284 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.2 p -69.4 -31.81 50.82 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.113 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.878 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.669 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.38 -52.14 20.28 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.586 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.8 m -60.22 -42.48 95.25 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.566 -178.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.42 -32.98 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.518 -0.473 . . . . 0.0 112.066 -179.063 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.546 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -68.05 -56.55 8.46 Favored 'General case' 0 CA--C 1.521 -0.146 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.388 -179.694 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.31 -47.68 84.85 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.569 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 96.1 m -61.02 -44.55 97.25 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 95.3 mt -72.33 -43.53 64.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 113.736 1.013 . . . . 0.0 113.736 -177.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.7 m -78.68 -33.72 16.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.171 -0.611 . . . . 0.0 111.565 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -77.86 -39.88 41.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.453 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 13.0 mm -59.75 -54.32 56.88 Favored Pre-proline 0 CA--C 1.541 0.623 0 N-CA-C 113.198 0.814 . . . . 0.0 113.198 -177.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.485 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 16.7 Cg_endo -56.45 -35.76 96.8 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 121.484 1.456 . . . . 0.0 112.045 -179.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -77.28 -61.01 2.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.549 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -48.1 -40.41 23.34 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 120.488 -0.485 . . . . 0.0 109.98 179.664 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -78.74 118.28 20.66 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.828 0.347 . . . . 0.0 110.681 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -70.25 138.8 51.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.574 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--N 1.331 -0.222 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.937 -179.987 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 39.4 m . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 15.0 m -75.92 81.41 2.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.283 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 19.2 p -73.14 166.21 23.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.654 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 27.8 m -149.83 -42.79 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.138 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.529 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -45.39 -63.27 1.27 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.861 179.592 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.5 Cg_endo -59.51 7.43 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.227 1.951 . . . . 0.0 112.35 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -114.05 -66.17 0.45 Allowed Glycine 0 N--CA 1.468 0.772 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.589 HG13 ' N ' ' B' ' 9' ' ' LEU . 11.5 p -63.58 -47.92 89.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.995 0.426 . . . . 0.0 110.306 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.589 ' N ' HG13 ' B' ' 8' ' ' VAL . 33.3 mt -56.74 -38.11 71.94 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.3 -39.09 81.9 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.17 75.74 Favored Glycine 0 CA--C 1.523 0.561 0 CA-C-N 114.491 -1.231 . . . . 0.0 110.786 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.478 HG21 ' HA ' ' A' ' 13' ' ' VAL . 49.8 mm -67.32 -46.13 84.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.063 -0.655 . . . . 0.0 109.615 179.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -55.6 -43.74 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 118.88 -1.128 . . . . 0.0 108.58 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 87.5 t -56.51 -47.92 81.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.294 -0.563 . . . . 0.0 109.542 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -55.5 -30.94 56.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -70.88 -41.91 70.71 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.645 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mp -60.48 -51.55 68.99 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 120.885 0.374 . . . . 0.0 110.196 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.403 HG13 ' N ' ' B' ' 19' ' ' LEU . 2.6 p -58.7 -45.78 90.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.398 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.403 ' N ' HG13 ' B' ' 18' ' ' VAL . 51.8 mt -59.42 -34.91 73.06 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.934 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.8 m -64.27 -41.39 96.94 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.295 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.84 -51.19 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.706 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' LEU . . . . . 0.413 ' N ' HD12 ' B' ' 22' ' ' LEU . 10.3 mp -64.28 -51.4 63.71 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.712 0.291 . . . . 0.0 111.052 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.517 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 82.4 mt -58.63 -51.49 71.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.07 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.6 -48.0 39.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.16 0.505 . . . . 0.0 109.812 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 34.2 tp -57.02 -35.75 69.64 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.1 -36.37 84.07 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.078 179.314 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 45.5 t -60.8 -48.07 90.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -64.42 -37.24 86.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.238 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -59.92 -46.49 89.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.682 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 tp -60.18 -41.45 92.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.318 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 162.52 -119.13 0.86 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.739 0.304 . . . . 0.0 110.371 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.9 p -77.45 156.99 30.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.653 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 11.6 p -81.63 169.28 17.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.426 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.478 ' H ' ' CB ' ' B' ' 5' ' ' SER . 27.0 m 34.64 36.93 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.339 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.484 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -79.36 -48.23 1.52 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.317 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' A' ' 8' ' ' VAL . 46.7 Cg_exo -42.87 -43.42 9.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 122.699 2.266 . . . . 0.0 112.757 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.47 -46.66 0.87 Allowed Glycine 0 N--CA 1.463 0.433 0 N-CA-C 108.84 -1.704 . . . . 0.0 108.84 -179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' PRO . 74.3 t -57.75 -38.73 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.7 mt -55.62 -38.69 69.81 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.27 -40.22 89.59 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.62 -29.22 66.51 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.407 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -66.87 -43.23 89.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.086 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -50.83 74.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 179.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.6 t -57.27 -39.86 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.471 178.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.22 -36.81 91.75 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.62 -47.84 71.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.967 0.413 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 21' ' ' VAL . 41.1 tp -55.53 -51.74 66.04 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.726 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -65.14 -29.15 46.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.373 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.83 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.432 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -60.18 -58.04 10.25 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.738 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.1 m -56.09 -42.37 76.65 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 17' ' ' LEU . 87.4 t -66.51 -32.03 56.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.78 -53.9 13.69 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.404 -178.694 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.9 mt -67.83 -43.17 86.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.365 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.62 -42.94 97.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.891 0.377 . . . . 0.0 110.158 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 30.4 tp -65.56 -42.55 91.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.184 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.51 -48.58 71.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.661 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -64.51 -44.28 96.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.701 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -56.6 -37.58 70.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.662 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -59.91 -48.92 79.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.647 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.1 tp -67.88 -38.41 83.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.489 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -43.32 -69.38 0.66 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.401 ' O ' ' O ' ' A' ' 33' ' ' LEU . 32.7 ttm180 47.42 65.28 1.3 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.774 0.321 . . . . 0.0 110.575 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.58 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.3 mp 52.94 171.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.329 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.18 -24.17 1.37 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.454 ' H ' ' C ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -64.17 -34.37 77.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.796 0.332 . . . . 0.0 110.497 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 51.88 -169.34 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.45 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 48.89 28.68 2.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.483 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.3 m -57.87 -28.28 32.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.561 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.6 tt -49.32 -37.72 25.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.545 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.53 -48.15 76.42 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 92.7 mt -59.63 -40.61 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.064 0.459 . . . . 0.0 110.49 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 91.6 mt -66.84 -35.98 76.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.467 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.3 m -64.18 -51.93 61.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.543 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.5 pt -61.86 -44.53 98.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.966 -179.27 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.47 -43.38 82.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 120.452 -0.499 . . . . 0.0 109.822 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.506 ' O ' HG22 ' A' ' 50' ' ' VAL . 70.5 mt -66.04 -32.14 73.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.201 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.26 -35.78 74.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.412 -0.515 . . . . 0.0 109.658 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.54 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -69.98 -49.05 55.48 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.265 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.3 p -58.92 -48.2 82.32 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.511 -179.325 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.506 HG22 ' O ' ' A' ' 46' ' ' LEU . 14.5 m -71.31 -28.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.603 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.672 ' O ' HG22 ' A' ' 55' ' ' VAL . 5.2 tt -67.12 -53.12 33.69 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.888 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.54 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 37.5 mttp -65.42 -44.83 86.16 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.82 0.343 . . . . 0.0 110.649 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.9 m -63.22 -42.53 99.26 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.515 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 93.8 mt -75.36 -41.96 43.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.672 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.5 m -76.59 -28.62 17.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 120.028 -0.669 . . . . 0.0 111.304 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.1 tp -84.82 -47.13 10.68 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.476 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.3 mp -62.2 -59.38 13.19 Favored Pre-proline 0 N--CA 1.473 0.708 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -175.784 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.515 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -52.02 -27.49 28.93 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 121.392 1.394 . . . . 0.0 111.992 -178.742 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.546 ' CD1' HG11 ' B' ' 8' ' ' VAL . 26.4 m-85 -90.19 -65.94 0.97 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.494 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.2 mm? -59.61 -17.75 35.84 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.29 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ILE . 69.5 mm-40 -141.5 148.9 40.17 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.895 0.379 . . . . 0.0 110.731 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -69.41 -33.59 73.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.544 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.3 t-20 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 -179.96 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.529 ' O ' ' N ' ' B' ' 3' ' ' THR . 97.4 m . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 9.0 t 59.82 -75.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.58 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.529 ' N ' ' O ' ' B' ' 1' ' ' CYS . 26.3 p 45.97 -169.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.727 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 35.4 m -150.91 -29.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.242 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.551 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -62.77 0.98 Allowed Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.908 179.786 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 31.2 Cg_endo -62.43 12.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.209 1.939 . . . . 0.0 111.995 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -125.45 -65.61 0.18 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.465 -0.654 . . . . 0.0 111.465 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.623 HG23 ' N ' ' B' ' 9' ' ' LEU . 18.1 m -60.09 -49.47 83.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.073 0.463 . . . . 0.0 110.461 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.623 ' N ' HG23 ' B' ' 8' ' ' VAL . 28.9 mt -57.41 -42.63 82.67 Favored 'General case' 0 C--O 1.238 0.484 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.66 -37.19 65.42 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 177.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.16 -28.73 73.32 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.347 178.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.2 -43.62 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.377 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.407 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.6 OUTLIER -58.86 -42.34 85.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 119.11 -1.036 . . . . 0.0 108.741 178.773 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.8 t -56.39 -47.42 81.47 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.323 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.86 -32.15 65.67 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.25 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -69.1 -41.75 77.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.804 0.335 . . . . 0.0 110.689 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 36.9 tp -61.07 -53.07 61.72 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.491 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -58.56 -39.85 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.139 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.428 HD22 ' HB2' ' A' ' 48' ' ' ALA . 25.6 mt -60.79 -52.72 63.9 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.733 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.5 m -47.14 -50.56 20.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.877 0.37 . . . . 0.0 110.21 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 60.0 t -61.95 -31.19 50.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.419 179.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 15.5 tp -68.37 -48.19 65.41 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.412 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 18.0 mm -60.64 -44.34 96.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.08 -48.19 79.18 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 121.184 0.516 . . . . 0.0 109.752 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -57.69 -34.93 69.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.55 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.81 -39.39 93.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.081 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -60.59 -45.83 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -62.52 -39.03 92.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -60.4 -44.46 95.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.618 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.0 tp -59.16 -43.38 92.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.369 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.81 116.15 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 50.9 ttm-85 . . . . . 0 C--N 1.328 -0.359 0 CA-C-O 120.737 0.303 . . . . 0.0 110.594 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.7 p -170.03 131.79 1.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.802 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 5' ' ' SER . 41.7 p -80.89 -72.33 0.42 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.456 ' N ' ' OG1' ' A' ' 3' ' ' THR . 10.6 m -69.24 37.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.958 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.18 -40.76 16.17 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.509 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.4 Cg_exo -46.66 -40.53 24.1 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.531 2.154 . . . . 0.0 112.45 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.24 -47.24 0.67 Allowed Glycine 0 N--CA 1.464 0.507 0 N-CA-C 109.125 -1.59 . . . . 0.0 109.125 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 72.7 t -56.26 -39.82 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.612 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.7 mt -55.96 -38.36 70.25 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.28 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.4 -36.1 77.32 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.78 -27.5 70.16 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.65 -42.01 86.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -59.95 -50.93 78.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.997 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.4 t -59.21 -42.32 86.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.904 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.03 -37.1 91.12 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.472 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 59.2 t0 -66.36 -47.4 73.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 110.359 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -55.59 -51.48 67.0 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.884 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.7 m -65.67 -29.02 45.73 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.712 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.475 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -59.38 -58.85 6.83 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.613 179.745 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.586 HG21 HD13 ' B' ' 19' ' ' LEU . 73.5 p -56.32 -42.91 78.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.286 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -64.59 -33.82 65.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.845 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.494 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.86 -52.86 25.3 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.049 -0.261 . . . . 0.0 111.168 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.4 mt -66.36 -43.79 91.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.349 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.8 -42.29 88.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.081 0.467 . . . . 0.0 110.07 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.6 tp -67.97 -31.27 70.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.034 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.81 -51.28 67.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.764 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.4 ' O ' ' N ' ' A' ' 31' ' ' GLY . 14.4 m -65.07 -37.52 80.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -60.98 -48.69 80.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.549 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 78.6 t80 -71.17 -50.97 27.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 30' ' ' LEU . 1.3 tt -63.65 -51.0 67.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.178 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 27' ' ' VAL . . . -71.08 165.32 53.28 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.7 ttm180 -157.94 88.36 0.96 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.822 0.344 . . . . 0.0 110.315 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.572 HD22 ' N ' ' A' ' 33' ' ' LEU . 3.3 mm? 49.58 75.68 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.201 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.99 -154.89 5.32 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.433 ' O ' ' N ' ' A' ' 37' ' ' GLU . 67.5 p -50.96 163.19 0.21 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.783 0.325 . . . . 0.0 110.513 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.85 70.11 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.621 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.433 ' N ' ' O ' ' A' ' 35' ' ' THR . 27.8 tp10 -163.78 49.01 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.478 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.1 m -67.09 -26.0 35.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.485 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.5 tp -45.87 -27.69 0.93 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.727 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.72 -48.28 85.84 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.96 -44.51 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.098 0.475 . . . . 0.0 110.664 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.682 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.8 mp -66.18 -27.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.529 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.503 ' O ' HG23 ' A' ' 47' ' ' VAL . 24.0 p -70.66 -50.48 36.28 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.404 HG12 ' H ' ' A' ' 44' ' ' ILE . 10.5 pt -65.0 -44.85 95.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.032 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.417 HG13 ' N ' ' A' ' 46' ' ' LEU . 6.9 p -63.93 -41.75 93.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.555 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.543 ' O ' HG22 ' A' ' 50' ' ' VAL . 28.9 mt -65.2 -36.09 83.1 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 43' ' ' SER . 47.8 t -67.16 -35.55 74.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.076 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.46 -49.76 62.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.339 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 44.4 p -62.41 -50.57 70.97 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.876 -178.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 46' ' ' LEU . 15.8 m -66.04 -39.01 83.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.719 ' O ' HG22 ' A' ' 55' ' ' VAL . 33.6 tp -65.09 -40.74 95.03 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.598 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.472 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -65.66 -52.17 53.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.753 0.311 . . . . 0.0 110.995 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 m -67.87 -37.34 81.68 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.533 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 89.9 mt -72.28 -44.32 63.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 -177.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.9 m -78.49 -31.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.055 -0.658 . . . . 0.0 111.388 -179.323 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 4.3 tp -79.01 -39.92 32.8 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -177.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.438 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.2 mp -72.42 -60.04 2.3 Favored Pre-proline 0 N--CA 1.475 0.817 0 N-CA-C 113.796 1.036 . . . . 0.0 113.796 -176.237 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.533 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 9.4 Cg_endo -50.72 -25.4 15.05 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 121.736 1.624 . . . . 0.0 112.218 -178.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.533 ' CD1' HG11 ' B' ' 8' ' ' VAL . 1.9 m-85 -88.26 -67.34 0.84 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.54 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? -59.93 -13.38 10.82 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.166 179.476 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.438 ' N ' ' O ' ' A' ' 57' ' ' ILE . 68.8 mt-10 -147.13 137.15 23.24 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -65.56 -44.34 87.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.552 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.563 -179.979 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.44 ' C ' ' H ' ' B' ' 3' ' ' THR . 68.6 m . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.403 ' O ' ' C ' ' B' ' 3' ' ' THR . 22.7 t 56.16 7.94 0.35 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.44 ' H ' ' C ' ' B' ' 1' ' ' CYS . 0.5 OUTLIER 31.98 61.5 0.31 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.665 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.434 HG23 ' N ' ' B' ' 5' ' ' SER . 13.8 m -76.05 -37.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.572 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.509 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -37.75 -65.16 0.38 Allowed Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.923 -179.605 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 28.6 Cg_endo -60.43 6.14 0.12 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.323 2.015 . . . . 0.0 112.145 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -118.46 -64.5 0.3 Allowed Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.628 HG23 ' N ' ' B' ' 9' ' ' LEU . 14.3 m -60.84 -52.18 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 120.572 -0.451 . . . . 0.0 110.343 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.628 ' N ' HG23 ' B' ' 8' ' ' VAL . 36.6 mt -54.29 -40.04 67.5 Favored 'General case' 0 C--O 1.246 0.904 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.425 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.79 -35.41 70.76 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 11' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -63.62 -34.2 89.31 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.374 -1.284 . . . . 0.0 111.137 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.435 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.77 -45.87 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.333 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.53 -46.25 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 C-N-CA 119.095 -1.042 . . . . 0.0 108.856 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.4 t -53.26 -46.41 56.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.21 0.529 . . . . 0.0 109.627 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.78 -40.77 93.41 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.275 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -56.92 -46.37 82.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.709 0.29 . . . . 0.0 110.505 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -58.87 -45.12 90.93 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.3 t -56.34 -47.95 80.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.055 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.586 HD13 HG21 ' A' ' 20' ' ' THR . 98.3 mt -59.13 -39.74 83.3 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.002 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 15.8 m -56.78 -40.13 75.32 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.402 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 89.2 t -67.87 -51.72 47.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.831 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -62.11 -51.68 66.93 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.159 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.446 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -56.87 -50.01 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.55 -0.46 . . . . 0.0 109.998 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -49.13 -46.41 44.98 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.308 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.525 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.79 -40.02 75.16 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.026 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.446 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.25 -37.64 86.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.404 179.47 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.9 -48.06 89.19 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -64.08 -37.89 89.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.277 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -59.88 -51.03 71.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.641 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 20.9 mt -67.29 -42.36 83.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.393 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 158.8 156.01 7.85 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.361 . . . . 0.0 110.512 -179.885 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 55.6 m . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.3 p -167.46 113.86 0.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.782 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 5' ' ' SER . 28.6 p -79.7 -177.24 5.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.368 179.817 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.452 ' H ' ' CB ' ' B' ' 5' ' ' SER . 32.7 m 37.21 26.74 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.203 0.525 . . . . 0.0 111.03 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.627 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.6 OUTLIER -79.72 -35.47 0.96 Allowed Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.684 179.006 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.627 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.7 Cg_exo -49.56 -42.85 41.3 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.158 1.906 . . . . 0.0 112.529 179.81 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.539 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.81 -46.61 0.94 Allowed Glycine 0 CA--C 1.521 0.426 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.474 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -58.97 -40.1 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.59 -38.78 69.85 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.47 -38.91 82.05 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 177.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.04 -28.21 65.99 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.84 -43.62 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.078 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.2 t -55.77 -53.93 32.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -57.61 -36.95 56.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.69 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.08 -39.6 95.99 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -65.1 -46.92 79.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.896 0.379 . . . . 0.0 110.407 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.0 tp -55.74 -50.85 69.27 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -67.76 -25.68 33.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.008 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.57 -56.76 14.88 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 119.984 -0.687 . . . . 0.0 109.396 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.522 HG21 ' CB ' ' A' ' 48' ' ' ALA . 6.7 m -58.52 -44.5 89.55 Favored 'General case' 0 N--CA 1.456 -0.16 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.171 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.73 -32.88 59.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.1 tp -70.34 -54.5 12.29 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 -178.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.546 HG22 HG21 ' B' ' 23' ' ' ILE . 11.5 mm -70.28 -41.58 78.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.314 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.69 -40.3 87.39 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.022 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 32.7 tp -67.6 -37.48 82.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.626 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.18 -51.08 69.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.739 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -67.16 -36.19 76.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 C-N-CA 120.312 -0.555 . . . . 0.0 110.563 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -58.4 -44.38 88.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -66.28 -44.27 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.704 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -62.3 -44.73 95.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.615 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -73.29 137.12 23.31 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -172.26 95.33 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.857 0.36 . . . . 0.0 110.437 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.618 ' N ' HD12 ' A' ' 33' ' ' LEU . 7.4 mp 47.63 76.8 0.1 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.417 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -175.15 -65.68 0.05 OUTLIER Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.475 ' H ' HG22 ' A' ' 35' ' ' THR . 0.0 OUTLIER -61.25 -28.11 68.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.728 0.299 . . . . 0.0 110.563 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 61.85 173.74 0.12 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.531 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 55.99 58.04 4.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.435 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.8 m -69.67 -25.17 28.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.704 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 44.5 tp -46.13 -29.5 1.56 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.854 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.8 -52.82 47.99 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.645 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -40.27 58.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.919 0.39 . . . . 0.0 110.14 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.0 mm -64.54 -41.7 93.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.721 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 11.2 t -59.47 -51.79 68.36 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.69 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.1 tt -61.76 -43.88 97.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.31 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 41' ' ' ILE . 55.7 t -55.99 -43.11 74.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.121 0.486 . . . . 0.0 109.951 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -68.22 -30.8 69.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.935 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.4 t -68.29 -34.36 65.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.816 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.522 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.54 -48.15 42.61 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.474 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.8 m -60.13 -46.75 88.57 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.201 -179.04 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.7 m -68.4 -37.19 77.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 120.652 -0.419 . . . . 0.0 111.115 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.644 ' O ' HG22 ' A' ' 55' ' ' VAL . 34.1 tp -65.7 -41.11 92.76 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.271 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.419 ' NZ ' ' CD1' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -62.96 -53.19 57.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.431 -179.899 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.8 p -63.59 -46.86 83.89 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -61.64 -51.72 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.0 m -73.62 -29.79 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.174 -178.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.401 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 6.5 tt -70.91 -29.95 66.15 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -178.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 mt -61.95 -55.1 44.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.287 -178.713 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.71 -28.63 43.86 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.518 1.479 . . . . 0.0 111.503 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.2 m-30 -56.55 -47.07 80.25 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.349 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.478 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -82.48 26.68 0.55 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 120.846 -0.342 . . . . 0.0 110.437 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -141.2 163.09 33.89 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.892 0.377 . . . . 0.0 110.465 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 -67.44 -26.4 66.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.537 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 65.6 m-20 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.685 -179.972 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.43 ' O ' ' O ' ' B' ' 3' ' ' THR . 41.5 t -59.54 -46.12 89.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.507 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.43 ' O ' ' O ' ' B' ' 2' ' ' SER . 43.8 p 47.36 100.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.83 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.627 HG13 ' N ' ' B' ' 5' ' ' SER . 14.8 p -143.37 -50.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.303 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.627 ' N ' HG13 ' B' ' 4' ' ' VAL . 0.7 OUTLIER -43.31 -64.48 0.75 Allowed Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.515 179.835 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 19.4 Cg_endo -56.86 1.75 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.325 2.017 . . . . 0.0 112.341 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -112.05 -67.05 0.52 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.552 HG23 ' N ' ' B' ' 9' ' ' LEU . 6.8 m -59.24 -48.05 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.154 0.502 . . . . 0.0 110.275 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.552 ' N ' HG23 ' B' ' 8' ' ' VAL . 43.6 mt -57.35 -42.15 81.46 Favored 'General case' 0 C--O 1.242 0.696 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -52.57 -33.46 45.91 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 176.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -37.22 94.17 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.292 178.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.1 tp -58.4 -43.82 87.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.672 -0.811 . . . . 0.0 108.956 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.431 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.9 OUTLIER -59.93 -46.81 93.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 119.256 -0.977 . . . . 0.0 109.487 179.281 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.5 -45.58 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 120.256 -0.577 . . . . 0.0 109.841 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.77 -39.25 96.48 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -59.58 -47.83 84.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.685 0.279 . . . . 0.0 110.712 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -57.79 -45.43 86.07 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -54.83 -46.64 75.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.439 HD22 ' HB2' ' A' ' 48' ' ' ALA . 23.5 mt -61.69 -47.08 86.94 Favored 'General case' 0 C--O 1.223 -0.302 0 C-N-CA 120.659 -0.417 . . . . 0.0 110.295 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.5 m -48.03 -50.73 26.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.8 0.333 . . . . 0.0 110.686 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 99.9 t -61.89 -44.13 98.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.936 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 12.2 tp -59.16 -45.3 91.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.18 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.546 HG21 HG22 ' A' ' 23' ' ' ILE . 4.6 mm -59.52 -49.78 82.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.87 -45.38 30.29 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.332 0.586 . . . . 0.0 109.83 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.561 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -64.76 -35.36 80.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.317 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.34 -55.32 35.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -57.86 -37.04 58.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.4 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 43.1 t80 -59.66 -43.76 93.81 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.82 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -61.15 -41.82 97.44 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.571 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 8.5 mp -59.17 -40.11 84.59 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.23 150.69 5.7 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.362 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 21.1 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 94.5 p -56.85 132.03 51.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.632 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 5' ' ' SER . 32.7 p -83.24 168.17 16.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.424 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.447 ' H ' ' HB3' ' B' ' 5' ' ' SER . 27.0 m 34.59 34.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.442 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -83.98 -40.09 0.73 Allowed Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.361 179.061 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 5' ' ' SER . 86.7 Cg_exo -48.1 -42.73 32.23 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.606 2.204 . . . . 0.0 112.655 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.516 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.86 -46.85 0.75 Allowed Glycine 0 N--CA 1.463 0.438 0 N-CA-C 108.865 -1.694 . . . . 0.0 108.865 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.6 t -55.27 -38.57 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.423 HD23 ' HA ' ' A' ' 9' ' ' LEU . 82.0 mt -55.38 -38.97 69.56 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.182 -1.007 . . . . 0.0 108.388 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.88 -39.86 86.72 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.51 -27.72 63.93 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.53 -42.89 83.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.197 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -56.45 -53.22 43.17 Favored 'Isoleucine or valine' 0 C--O 1.242 0.684 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.7 t -56.92 -39.67 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.357 178.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -54.71 -41.23 74.08 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 61.4 t0 -64.77 -45.85 84.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 110.299 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.434 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 20.8 tp -55.45 -51.08 68.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.894 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -68.53 -24.05 28.8 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.905 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.07 -56.7 14.69 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.032 -0.667 . . . . 0.0 109.382 179.755 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 53.6 m -61.36 -47.36 86.22 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.507 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.8 t -64.4 -34.32 68.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.4 tp -69.22 -54.28 15.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.609 -178.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 64.7 mt -67.57 -41.73 86.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.501 -0.479 . . . . 0.0 110.388 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.01 91.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.138 0.494 . . . . 0.0 110.026 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -67.57 -34.49 77.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.828 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.89 -51.36 70.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.757 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.65 -36.65 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.569 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -59.36 -41.69 89.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.872 0.367 . . . . 0.0 110.577 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -59.42 -46.87 87.49 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.656 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.51 -45.34 91.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.13 149.62 49.67 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -159.31 69.16 0.44 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.779 0.323 . . . . 0.0 110.499 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.584 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.1 mp 51.17 78.3 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.306 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -170.62 -51.58 0.04 OUTLIER Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.2 t -59.3 132.21 53.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.787 0.327 . . . . 0.0 110.721 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -86.23 -179.29 6.68 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.589 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 65.5 mm-40 52.82 32.97 13.24 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.591 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.2 m -49.24 -26.67 2.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.6 tp -48.21 -28.62 3.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.715 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.38 -51.62 57.55 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.647 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -52.68 -49.94 43.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.027 0.441 . . . . 0.0 110.012 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.63 -27.58 43.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.727 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -67.01 -45.52 77.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.432 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.1 pt -71.83 -34.58 51.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.139 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.3 t -68.38 -46.4 80.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.572 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.404 ' O ' HG23 ' A' ' 50' ' ' VAL . 3.4 mm? -69.77 -37.75 76.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.643 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.22 -31.56 47.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.777 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.19 51.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.378 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.9 p -62.38 -43.36 99.0 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.953 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 46' ' ' LEU . 85.1 t -63.99 -43.74 97.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.556 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.5 OUTLIER -64.91 -53.39 47.18 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.018 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.434 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 0.7 OUTLIER -47.21 -51.99 17.03 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.909 179.924 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 31.4 p -59.13 -46.73 87.58 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 87.1 mt -59.82 -52.52 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.58 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 26.7 m -75.31 -30.89 23.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.258 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.7 tt -66.65 -32.79 74.34 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.522 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 7.4 mt -68.16 -54.23 16.37 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.479 -178.415 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.38 -28.44 18.09 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 121.799 1.666 . . . . 0.0 111.566 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.58 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -60.68 -45.43 94.2 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.342 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -57.59 -24.01 53.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.017 0.437 . . . . 0.0 110.141 -179.817 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 73.7 mm-40 -97.28 168.37 10.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.694 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -60.6 -46.77 89.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.416 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 22.2 p-10 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.583 179.965 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' N ' ' B' ' 2' ' ' SER . 29.7 p . . . . . 0 N--CA 1.488 1.458 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.449 ' OG ' ' N ' ' B' ' 3' ' ' THR . 60.7 p -53.66 -64.23 0.89 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.442 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.449 ' N ' ' OG ' ' B' ' 2' ' ' SER . 32.1 p 43.23 53.13 5.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 21.2 m -76.08 -39.31 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.314 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.539 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -40.02 -62.78 0.81 Allowed Pre-proline 0 CA--C 1.536 0.407 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.952 179.763 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.9 Cg_endo -61.02 9.88 0.07 OUTLIER 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.138 1.892 . . . . 0.0 112.073 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -123.64 -66.24 0.21 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.613 HG23 ' N ' ' B' ' 9' ' ' LEU . 15.9 m -58.8 -51.74 68.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 CA-C-O 121.094 0.473 . . . . 0.0 110.61 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.5 mt -56.51 -40.04 74.32 Favored 'General case' 0 C--O 1.242 0.663 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -53.24 -36.97 61.66 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.143 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.16 -34.45 89.12 Favored Glycine 0 CA--C 1.523 0.565 0 CA-C-N 114.425 -1.261 . . . . 0.0 110.447 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.52 -42.26 95.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 C-N-CA 119.701 -0.799 . . . . 0.0 109.341 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.411 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.7 OUTLIER -59.86 -44.42 94.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.32 179.091 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 83.9 t -51.23 -47.52 33.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.615 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.11 93.88 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.161 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -58.78 -45.16 90.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.857 0.361 . . . . 0.0 110.488 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.7 tp -56.77 -45.73 81.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.021 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.42 -46.77 82.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.204 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 14.2 mt -60.25 -39.74 87.84 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.062 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.2 m -57.68 -40.59 79.77 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.388 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.5 t -66.41 -51.8 53.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.474 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 11.1 mp -62.53 -52.95 61.41 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 120.939 -0.304 . . . . 0.0 111.274 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.429 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.9 mt -56.84 -51.33 69.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.111 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.94 -46.46 32.23 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.088 0.47 . . . . 0.0 109.857 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.537 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.91 -39.31 74.19 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.999 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.429 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.83 -38.51 91.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.455 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.53 -47.19 89.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -63.75 -41.37 98.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.206 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -56.44 -46.54 80.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.1 tp -58.05 -45.5 86.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.32 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.63 -100.14 0.15 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 32' ' ' ARG . . . . . 0.546 ' C ' ' HE ' ' B' ' 32' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 110.264 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.0 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.0 m -157.07 136.47 12.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.555 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 8.4 p -80.91 -165.1 0.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.497 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.432 ' H ' ' CB ' ' B' ' 5' ' ' SER . 35.8 m 35.08 36.38 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.346 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -82.23 -40.19 0.92 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.377 179.133 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 72.4 Cg_exo -46.41 -40.45 22.72 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.647 2.232 . . . . 0.0 112.58 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.549 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.31 -48.09 0.7 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.474 ' N ' ' O ' ' A' ' 6' ' ' PRO . 71.3 t -53.83 -39.28 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.465 HD23 HD12 ' A' ' 12' ' ' ILE . 81.2 mt -56.05 -37.99 69.99 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.59 -33.08 73.27 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 177.245 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -63.37 -32.24 83.48 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.732 HG21 HG12 ' B' ' 13' ' ' VAL . 70.8 mt -67.2 -41.98 87.46 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 42.5 t -59.29 -55.17 25.41 Favored 'Isoleucine or valine' 0 C--O 1.241 0.613 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.481 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.425 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.7 t -61.02 -36.86 75.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.498 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.48 -40.47 99.14 Favored Glycine 0 C--O 1.224 -0.513 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -64.16 -51.26 64.68 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.008 0.433 . . . . 0.0 110.281 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 tp -56.86 -47.34 80.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.848 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' VAL . 77.8 t -63.44 -28.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.758 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.461 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -64.53 -56.64 12.74 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.68 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.4 m -56.09 -40.4 73.59 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.649 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.33 -32.52 57.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.727 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.47 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.41 -55.23 9.55 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.15 -178.931 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 80.0 mt -66.66 -43.65 90.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.574 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.41 -41.38 89.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.217 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.2 tp -69.18 -31.79 70.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.273 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.72 -50.51 68.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.799 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -66.32 -38.1 81.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.472 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -61.83 -46.52 89.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.575 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -69.46 -49.13 57.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.744 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.3 tp -62.65 -43.63 98.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.464 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -73.68 124.65 8.77 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -80.09 41.33 0.51 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 0.0 110.544 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 8.8 tp 52.69 82.27 0.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.518 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 164.7 107.79 0.21 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 36' ' ' ALA . 4.4 t -158.63 177.02 11.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.78 0.324 . . . . 0.0 110.626 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 35' ' ' THR . . . -52.26 -104.13 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.6 tp10 -83.14 95.33 8.06 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.573 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.7 t -65.59 -28.98 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.581 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 tp -60.74 -29.29 69.28 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.78 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -54.64 -49.55 60.9 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.8 mm -55.38 -48.51 76.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.028 0.442 . . . . 0.0 110.651 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 74.2 mt -61.53 -34.96 63.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.483 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.433 ' O ' HG23 ' A' ' 47' ' ' VAL . 13.9 m -61.53 -51.7 67.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.692 -179.241 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 12.4 pt -63.06 -42.22 95.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.924 -179.29 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 71.7 t -60.24 -43.99 94.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.375 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.09 -34.7 79.03 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 43' ' ' SER . 50.4 t -66.78 -34.73 71.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.76 -47.98 64.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.457 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 4.5 m -60.87 -48.73 80.47 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.711 -0.396 . . . . 0.0 111.494 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 46' ' ' LEU . 16.9 m -69.91 -33.83 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -178.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.635 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.3 tp -65.69 -52.59 50.22 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.269 -0.572 . . . . 0.0 110.744 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.29 -50.53 72.63 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.312 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 48.5 p -60.34 -43.12 96.75 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.421 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 90.4 mt -72.95 -44.52 57.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.362 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -177.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.635 HG22 ' O ' ' A' ' 51' ' ' LEU . 11.4 m -77.04 -28.34 16.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.384 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.0 tp -82.58 -39.44 22.26 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 114.566 1.321 . . . . 0.0 114.566 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 mm -75.45 -63.79 0.64 Allowed Pre-proline 0 N--CA 1.475 0.824 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.421 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 12.2 Cg_endo -53.09 -38.68 80.91 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.766 1.644 . . . . 0.0 112.146 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -67.33 -59.63 3.25 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 121.055 -0.258 . . . . 0.0 110.666 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.53 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -58.05 -48.04 81.32 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.864 179.685 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -74.55 156.53 36.74 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.848 0.356 . . . . 0.0 110.632 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 19.3 pt20 -155.55 -35.81 0.09 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.477 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.5 p30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.525 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 14.4 m -75.33 172.93 11.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.441 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 2.8 t -156.01 147.56 22.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.64 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.512 HG23 ' N ' ' B' ' 5' ' ' SER . 18.2 m -148.61 -40.77 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.249 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.521 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -40.51 -63.99 0.65 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.37 179.803 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 17.9 Cg_endo -57.9 3.62 0.12 Allowed 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.27 1.98 . . . . 0.0 112.231 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.767 ' O ' ' HB3' ' B' ' 10' ' ' ALA . . . -115.14 -68.07 0.44 Allowed Glycine 0 CA--C 1.527 0.83 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.622 HG23 ' N ' ' B' ' 9' ' ' LEU . 7.4 m -58.19 -52.55 57.35 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.214 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.622 ' N ' HG23 ' B' ' 8' ' ' VAL . 42.1 mt -54.84 -31.76 59.76 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.86 -36.34 72.2 Favored 'General case' 0 C--O 1.244 0.775 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.733 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 11' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -66.71 -30.93 77.04 Favored Glycine 0 CA--C 1.528 0.875 0 CA-C-N 113.768 -1.56 . . . . 0.0 111.319 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.465 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.2 mp -71.32 -39.8 72.71 Favored 'Isoleucine or valine' 0 C--N 1.34 0.194 0 C-N-CA 119.684 -0.807 . . . . 0.0 109.4 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.732 HG12 HG21 ' A' ' 12' ' ' ILE . 1.5 m -57.92 -44.44 86.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.3 t -59.48 -48.85 85.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 CA-C-O 121.18 0.514 . . . . 0.0 110.267 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -34.85 81.27 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -65.76 -39.41 91.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.878 0.37 . . . . 0.0 110.154 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.91 -47.41 86.51 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.86 -35.17 74.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.895 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.43 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -65.59 -48.78 71.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.482 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 99.6 m -59.76 -44.24 93.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.884 0.374 . . . . 0.0 110.542 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.2 t -63.98 -40.72 90.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -59.01 -51.06 71.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.821 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.438 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 66.6 mt -59.06 -48.02 88.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.995 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.53 -46.85 39.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.03 0.443 . . . . 0.0 109.925 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -58.05 -40.48 81.04 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.106 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.65 -37.08 80.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.281 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 50.3 t -62.26 -42.28 94.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 61.5 t80 -63.19 -38.92 93.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.981 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -60.99 -41.07 95.77 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.742 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.7 tp -48.19 -39.21 20.22 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.829 -0.349 . . . . 0.0 110.278 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 77.34 92.63 0.25 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.844 0.354 . . . . 0.0 110.504 179.953 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.7 t . . . . . 0 N--CA 1.462 0.15 0 CA-C-O 120.509 0.195 . . . . 0.0 110.489 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.474 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.22 31.47 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.142 0.496 . . . . 0.0 111.159 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.557 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.5 OUTLIER -84.82 -44.09 0.69 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.262 179.317 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.557 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.0 Cg_exo -45.37 -43.94 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 122.731 2.287 . . . . 0.0 112.871 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -50.45 0.82 Allowed Glycine 0 N--CA 1.464 0.502 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' PRO . 75.8 t -52.8 -35.13 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.9 mt -55.35 -41.7 72.85 Favored 'General case' 0 C--O 1.238 0.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.35 -37.58 75.48 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 177.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.3 -27.96 68.49 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.453 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -68.81 -39.03 79.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.9 t -62.08 -51.32 73.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.846 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.47 -43.04 89.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.72 -38.87 92.75 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.466 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 51.2 t0 -65.57 -46.59 78.88 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.916 0.389 . . . . 0.0 110.685 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.5 tp -56.31 -51.36 68.52 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.766 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 m -65.63 -27.32 41.2 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.323 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.578 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.84 -57.33 13.13 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.515 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -56.98 -42.47 80.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.113 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -65.7 -37.73 80.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.288 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -67.57 -54.47 19.6 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.404 -178.539 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 21.2 mm -66.21 -44.72 91.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.484 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.78 -39.59 77.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.911 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.0 tp -68.52 -34.5 75.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.023 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.58 -50.72 72.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.624 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -68.05 -39.42 81.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -60.58 -33.69 73.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -55.67 -50.09 71.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.75 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.0 tp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.6 -179.959 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.862 0.363 . . . . 0.0 110.361 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 m -57.53 -26.7 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.459 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.0 tp -46.26 -29.12 1.49 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.655 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -55.56 -48.82 68.34 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.666 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.0 mp -56.6 -40.77 71.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.002 0.429 . . . . 0.0 110.104 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -64.9 -41.22 91.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.205 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.7 t -58.1 -51.79 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.618 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.423 ' H ' HG12 ' A' ' 44' ' ' ILE . 6.5 pt -63.14 -39.89 86.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.91 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.0 t -64.71 -30.68 50.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.171 -0.612 . . . . 0.0 109.83 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.559 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -71.21 -47.69 55.9 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.937 -178.905 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.8 p -67.73 -30.49 48.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.626 -178.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.458 ' HB2' HD22 ' B' ' 19' ' ' LEU . . . -70.51 -53.3 16.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.377 -179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.1 m -57.98 -47.1 83.99 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.256 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.5 m -71.11 -28.83 34.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.881 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.606 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.0 tp -67.36 -55.7 12.71 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 119.882 -0.727 . . . . 0.0 110.821 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.466 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.0 OUTLIER -64.8 -45.27 86.98 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.099 179.614 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -60.77 -45.16 95.42 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -178.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.492 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.4 mt -73.45 -43.25 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -177.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.1 m -76.89 -33.13 20.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.365 -178.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.6 tp -79.47 -41.62 27.12 Favored 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 25.9 mt -64.09 -62.11 5.72 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 119.047 -1.061 . . . . 0.0 113.23 -176.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.492 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 7.0 Cg_endo -47.35 -27.14 6.59 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 121.924 1.749 . . . . 0.0 112.504 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.431 ' CD1' HG21 ' B' ' 8' ' ' VAL . 0.9 OUTLIER -90.24 -65.62 1.0 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 120.384 -0.527 . . . . 0.0 109.809 179.52 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.485 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? . . . . . 0 CA--C 1.532 0.256 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.649 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.527 HG23 ' N ' ' B' ' 5' ' ' SER . 32.6 m . . . . . 0 CA--C 1.521 -0.135 0 CA-C-O 120.745 0.307 . . . . 0.0 110.685 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.527 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.1 OUTLIER -38.7 -59.21 1.41 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.177 179.848 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.419 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 33.6 Cg_endo -64.38 13.86 0.09 OUTLIER 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 121.528 1.486 . . . . 0.0 111.783 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -113.01 -66.92 0.49 Allowed Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.431 HG21 ' CD1' ' A' ' 59' ' ' PHE . 0.0 OUTLIER -67.15 -51.92 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 9.6 mt -57.82 -39.15 76.93 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.419 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -58.07 -38.72 76.89 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 108.112 -1.069 . . . . 0.0 108.112 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.88 -30.96 79.38 Favored Glycine 0 CA--C 1.522 0.519 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.099 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 50.5 mm -66.23 -43.34 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 C-N-CA 120.079 -0.648 . . . . 0.0 109.769 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.453 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.9 OUTLIER -60.29 -42.0 89.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.838 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.87 -42.6 89.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.706 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.85 -39.25 97.26 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -61.51 -40.47 94.72 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -62.88 -44.93 94.79 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.102 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.4 -44.34 92.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.301 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.458 HD22 ' HB2' ' A' ' 48' ' ' ALA . 69.8 mt -66.54 -30.3 70.58 Favored 'General case' 0 C--O 1.225 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 110.212 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 21.8 m -62.58 -50.2 72.25 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.239 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 71.8 t -70.42 -43.28 78.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.554 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.45 -53.06 60.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.823 0.344 . . . . 0.0 111.194 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.47 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 76.3 mt -59.45 -50.64 79.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.965 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.39 38.14 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -57.25 -39.39 75.49 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.11 -35.37 78.5 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.133 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.97 -47.05 95.0 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -63.02 -40.43 97.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.125 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -55.67 -44.67 77.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.438 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 28.3 tp . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.216 179.942 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 5' ' ' SER . 8.3 p . . . . . 0 N--CA 1.461 0.107 0 CA-C-O 120.551 0.215 . . . . 0.0 110.621 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.2 m 33.86 34.6 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.198 0.523 . . . . 0.0 111.239 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.578 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -84.94 -42.97 0.68 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.335 179.308 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 5' ' ' SER . 75.5 Cg_exo -46.38 -44.1 20.93 Favored 'Trans proline' 0 N--CA 1.495 1.598 0 C-N-CA 122.745 2.297 . . . . 0.0 112.807 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.496 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -48.33 0.75 Allowed Glycine 0 N--CA 1.464 0.518 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.462 ' H ' ' C ' ' A' ' 6' ' ' PRO . 62.5 t -53.87 -36.38 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' HG22 ' A' ' 12' ' ' ILE . 50.1 mt -55.07 -40.99 70.95 Favored 'General case' 0 C--O 1.238 0.461 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.2 -37.96 75.82 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.34 -28.02 66.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 178.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.427 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -67.8 -41.05 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.304 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 57.4 t -60.0 -53.09 53.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 121.467 0.651 . . . . 0.0 109.573 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.8 t -58.62 -34.63 51.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.964 179.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.32 -34.79 90.38 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -69.25 -44.7 71.42 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.8 tp -66.9 -51.27 57.4 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.42 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 14' ' ' VAL . 22.6 m -59.65 -35.02 57.14 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.328 -179.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.401 HD23 ' OD1' ' B' ' 16' ' ' ASP . 40.8 tp -64.39 -52.84 56.21 Favored 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.537 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.528 HG21 ' CB ' ' A' ' 48' ' ' ALA . 15.0 m -50.48 -49.83 54.24 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.901 -0.319 . . . . 0.0 111.439 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.6 p -70.73 -31.06 44.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 120.197 -0.601 . . . . 0.0 112.464 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.527 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.3 OUTLIER -67.73 -54.6 18.03 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.586 -179.47 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 27.5 mt -63.96 -50.47 77.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.387 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.27 -41.53 68.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.351 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 29.6 tp -63.58 -42.53 98.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.09 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.9 -48.22 70.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.342 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.1 t -63.85 -39.85 86.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.606 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -59.01 -48.02 83.09 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -61.06 -48.53 81.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.683 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.573 -179.859 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 . . . . . 0 C--O 1.23 0.045 0 CA-C-O 121.022 0.439 . . . . 0.0 110.452 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 16.4 m -63.49 -23.52 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.773 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.0 tp -44.03 -28.11 0.44 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.14 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -60.78 -49.51 77.85 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.667 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -49.09 76.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.09 0.472 . . . . 0.0 109.989 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.683 ' N ' HD12 ' A' ' 42' ' ' ILE . 2.0 mp -61.33 -31.4 50.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.981 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.9 t -62.26 -50.99 69.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.438 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.6 pt -66.11 -35.79 75.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.141 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.6 t -67.05 -40.1 84.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.448 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 46' ' ' LEU . 0.8 OUTLIER -68.14 -44.73 75.42 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.841 -178.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.6 p -69.48 -28.71 39.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.817 -178.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.528 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -70.75 -51.76 25.15 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.772 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.7 p -60.09 -40.85 91.03 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.537 -0.465 . . . . 0.0 110.756 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.37 -41.09 78.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.648 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 55' ' ' VAL . 21.5 tp -65.47 -54.91 21.64 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.793 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 56' ' ' LEU . 0.6 OUTLIER -58.58 -43.21 89.4 Favored 'General case' 0 C--O 1.219 -0.518 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.727 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 99.1 m -60.38 -50.74 72.39 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 112.238 0.459 . . . . 0.0 112.238 -179.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.495 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.3 mt -69.23 -43.95 80.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -177.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.526 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.6 m -76.21 -31.18 20.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.148 -0.621 . . . . 0.0 111.85 -178.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.407 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 8.6 tp -75.71 -37.96 58.99 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.23 -51.41 78.48 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.56 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.495 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 59.3 Cg_endo -72.71 -28.73 13.61 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.54 1.493 . . . . 0.0 111.283 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.3 m-30 -67.32 -53.88 25.68 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.131 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.491 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.332 -0.166 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.379 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.431 ' O ' HG22 ' B' ' 8' ' ' VAL . 25.4 m . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.991 0.424 . . . . 0.0 110.336 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.518 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -39.59 -62.15 0.89 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.429 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -62.2 10.61 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.154 1.903 . . . . 0.0 112.388 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.19 -65.52 0.29 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.431 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.0 OUTLIER -60.7 -51.96 67.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 121.215 0.531 . . . . 0.0 110.285 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.6 mt -60.49 -34.38 73.97 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.478 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -58.59 -35.93 73.2 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.2 -40.65 98.18 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.685 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 45.5 mm -58.0 -45.7 87.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.986 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.427 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -57.29 -44.69 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.251 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.96 -41.42 76.93 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.3 -41.72 98.5 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' HD23 ' A' ' 19' ' ' LEU . 24.5 t0 -60.36 -41.4 93.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.359 . . . . 0.0 110.213 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.8 tp -61.2 -43.95 98.06 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.046 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -57.85 -47.97 84.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.048 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 74.7 mt -61.43 -36.28 79.92 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.013 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -57.63 -43.78 85.1 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.215 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -69.24 -47.15 75.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.733 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.0 mp -62.08 -51.9 66.09 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.105 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.449 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -57.58 -50.3 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.9 -45.17 40.94 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 121.256 0.551 . . . . 0.0 109.942 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 4.9 tp -65.19 -30.08 70.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.119 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.17 -50.07 67.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.219 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -64.1 -38.28 82.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 C-N-CA 120.406 -0.518 . . . . 0.0 109.879 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -61.45 -43.11 99.44 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -60.62 -47.09 87.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.676 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.466 -179.706 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 5' ' ' SER . 5.4 p . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.531 0.205 . . . . 0.0 110.629 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.462 ' N ' ' OG ' ' B' ' 5' ' ' SER . 34.8 m 36.62 26.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.252 0.549 . . . . 0.0 111.212 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.62 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 1.6 t -81.74 -35.43 0.75 Allowed Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.61 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.62 ' CD ' ' N ' ' A' ' 5' ' ' SER . 84.2 Cg_exo -49.45 -41.49 43.7 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.336 2.024 . . . . 0.0 112.554 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.517 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.91 -47.01 0.98 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' PRO . 58.1 t -59.28 -40.64 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 12' ' ' ILE . 3.4 mm? -54.37 -43.03 70.99 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -56.12 -37.6 69.66 Favored 'General case' 0 C--O 1.233 0.184 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.08 -27.46 68.93 Favored Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.508 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -68.3 -38.53 79.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.409 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 80.8 t -64.21 -50.89 74.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.15 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.8 t -59.58 -46.1 93.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.18 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.53 -29.2 71.13 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.989 -0.845 . . . . 0.0 110.989 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.512 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 53.3 t0 -67.45 -52.64 37.11 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 110.387 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.3 tp -60.35 -41.23 93.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.127 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.5 -26.45 31.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.468 HD23 ' OD1' ' B' ' 16' ' ' ASP . 37.3 tp -71.43 -57.42 4.45 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.84 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.444 HG23 ' N ' ' A' ' 21' ' ' VAL . 14.0 t -62.3 -40.43 96.26 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.145 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.444 ' N ' HG23 ' A' ' 20' ' ' THR . 53.5 t -69.32 -43.82 80.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.662 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -60.54 -51.6 68.75 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.333 -178.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 63.7 mt -63.08 -42.48 96.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.942 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -43.88 78.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.96 0.41 . . . . 0.0 110.324 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.96 -36.24 82.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.47 -50.79 71.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.795 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.3 m -69.21 -32.56 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.48 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -61.93 -41.31 97.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.716 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -61.73 -45.39 94.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.651 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.5 tp . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.561 -179.879 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.736 0.303 . . . . 0.0 110.563 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 63.5 t -68.17 -28.74 42.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.636 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.6 mm? -63.77 -31.29 72.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -62.23 -50.28 66.56 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.3 mt -58.19 -44.3 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.092 0.473 . . . . 0.0 110.453 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.14 -38.65 82.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.471 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.5 m -59.94 -52.16 66.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.736 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.3 pt -62.11 -42.39 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.649 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.4 t -60.66 -35.24 62.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.0 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.553 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.5 OUTLIER -69.6 -39.16 77.41 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.529 -179.181 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -68.69 -30.46 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.622 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.18 -52.1 25.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.981 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -44.77 90.78 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.622 -0.431 . . . . 0.0 111.8 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.0 m -68.17 -40.32 82.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.563 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.619 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.5 tp -63.33 -45.81 89.54 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.456 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.512 ' NZ ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -62.03 -49.97 73.9 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.742 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.637 ' O ' HD13 ' A' ' 57' ' ' ILE . 25.4 p -62.66 -47.54 83.24 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.605 0.595 . . . . 0.0 112.605 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.482 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 87.4 mt -64.03 -46.05 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.619 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.0 m -76.36 -34.62 25.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.153 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.3 tt -68.27 -35.27 77.63 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 113.574 0.954 . . . . 0.0 113.574 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.637 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -65.42 -52.74 43.33 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 119.456 -0.898 . . . . 0.0 112.127 -177.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 57.6 Cg_endo -71.7 -29.57 15.69 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 121.591 1.527 . . . . 0.0 111.466 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.559 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.7 m-30 -64.28 -48.53 75.37 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.226 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 N--CA 1.463 0.195 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.428 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.536 HG23 ' N ' ' B' ' 5' ' ' SER . 30.0 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.839 0.352 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.536 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.4 OUTLIER -38.49 -64.2 0.49 Allowed Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.584 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.4 Cg_endo -59.31 6.22 0.1 OUTLIER 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.328 2.019 . . . . 0.0 112.296 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -117.78 -66.29 0.34 Allowed Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.451 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -60.68 -51.95 67.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-O 121.091 0.472 . . . . 0.0 110.11 -179.871 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 49.4 mt -57.66 -37.2 73.0 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.23 -34.48 68.63 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 177.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -36.49 91.48 Favored Glycine 0 CA--C 1.524 0.649 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.328 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 11.3 mt -65.42 -41.39 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 119.496 -0.882 . . . . 0.0 109.394 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.508 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.4 m -57.69 -44.2 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -54.29 -50.34 57.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.169 -0.613 . . . . 0.0 109.677 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.17 -31.97 66.57 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.468 ' OD1' HD23 ' A' ' 19' ' ' LEU . 30.5 t0 -69.38 -41.04 77.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.774 0.321 . . . . 0.0 110.835 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -61.49 -52.39 64.7 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 121.008 0.432 . . . . 0.0 110.402 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -58.42 -39.12 73.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.128 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.3 mt -60.85 -53.08 61.72 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.61 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.453 ' OG1' HD21 ' A' ' 19' ' ' LEU . 8.3 m -48.26 -45.84 35.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.528 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 91.8 t -65.37 -33.83 66.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.723 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.9 tp -68.23 -53.76 22.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.49 -179.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 mm -60.83 -47.16 94.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 C-N-CA 120.658 -0.417 . . . . 0.0 109.931 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.12 -45.04 68.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.045 0.45 . . . . 0.0 109.835 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 31.0 tp -58.93 -38.73 79.65 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.18 -38.27 90.51 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.298 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -61.04 -47.75 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.031 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -61.9 -40.88 96.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.048 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -57.21 -48.47 78.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.491 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.8 tp . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.389 -179.977 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 5' ' ' SER . 81.6 p . . . . . 0 C--O 1.23 0.056 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.467 ' H ' ' CB ' ' B' ' 5' ' ' SER . 34.2 m 34.78 32.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 121.158 0.504 . . . . 0.0 111.323 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -81.04 -46.34 1.17 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.093 179.292 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 5' ' ' SER . 50.8 Cg_exo -43.27 -43.78 10.24 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.814 2.343 . . . . 0.0 112.996 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.93 -46.88 0.76 Allowed Glycine 0 N--CA 1.463 0.464 0 N-CA-C 108.932 -1.667 . . . . 0.0 108.932 -179.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.2 t -55.53 -38.95 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.4 HD23 ' HA ' ' A' ' 9' ' ' LEU . 87.6 mt -55.8 -36.79 67.79 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.57 -37.68 84.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -29.21 71.06 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 178.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.69 -42.89 93.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 96.4 t -57.86 -51.13 74.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.3 t -58.47 -30.21 40.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.931 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.43 -38.44 90.99 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -68.2 -44.67 75.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.037 0.446 . . . . 0.0 110.226 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 tp -58.54 -51.38 70.13 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.932 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.6 m -65.0 -29.59 47.85 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.716 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -60.4 -59.57 5.19 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 120.046 -0.662 . . . . 0.0 109.402 179.523 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.45 HG21 ' HB1' ' A' ' 48' ' ' ALA . 70.5 p -52.2 -43.21 64.08 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.005 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.27 -30.02 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 112.103 0.408 . . . . 0.0 112.103 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.7 -55.21 9.2 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.18 -178.869 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 54.5 mt -68.64 -41.01 82.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.254 -0.578 . . . . 0.0 110.352 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.2 -42.83 95.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.138 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -67.82 -32.39 72.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.737 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.45 -51.1 70.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.641 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.5 m -66.54 -36.98 78.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.413 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -60.16 -45.62 92.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.644 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.3 t80 -64.79 -41.12 96.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.745 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.74 -179.791 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.939 0.4 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 20.8 m -68.33 -25.95 32.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -46.43 -30.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.655 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.64 -49.81 62.34 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -58.12 -44.85 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.026 0.441 . . . . 0.0 110.51 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.9 mt -63.43 -36.88 77.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.569 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 47' ' ' VAL . 65.6 m -61.04 -51.47 69.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.506 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.407 HG12 ' H ' ' A' ' 44' ' ' ILE . 9.7 pt -62.66 -43.36 98.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.935 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -58.69 -44.0 88.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.019 0.437 . . . . 0.0 110.233 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -64.62 -36.06 83.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.701 -179.355 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 43' ' ' SER . 53.8 t -65.84 -34.08 67.91 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-O 121.087 0.47 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.602 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -68.45 -53.81 21.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.382 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 6.3 m -55.49 -49.22 73.12 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.075 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 46' ' ' LEU . 13.3 m -70.51 -26.34 28.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.617 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.668 ' O ' HG22 ' A' ' 55' ' ' VAL . 27.6 tp -65.98 -56.06 13.57 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.867 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.602 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 1.4 mppt? -65.16 -44.38 88.71 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.394 -0.522 . . . . 0.0 110.244 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.8 m -60.7 -44.97 95.92 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.474 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.0 mt -74.05 -41.73 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 51' ' ' LEU . 18.9 m -77.23 -32.54 19.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.254 -178.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 tp -78.41 -44.22 25.39 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.9 mt -59.81 -61.9 6.96 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 119.278 -0.969 . . . . 0.0 113.039 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.474 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -49.31 -26.55 11.7 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 C-N-CA 122.135 1.89 . . . . 0.0 112.233 -179.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.663 ' CG ' HG11 ' B' ' 8' ' ' VAL . 2.8 m-85 -92.27 -64.8 1.06 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.499 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 CA--C 1.53 0.194 0 C-N-CA 120.132 -0.627 . . . . 0.0 110.196 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.433 HG23 ' N ' ' B' ' 5' ' ' SER . 22.4 m . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.833 0.349 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.503 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -41.84 -64.69 0.61 Allowed Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.179 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.5 Cg_endo -60.33 6.22 0.12 Allowed 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 122.257 1.971 . . . . 0.0 111.956 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.503 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.46 -65.11 0.28 Allowed Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.663 HG11 ' CG ' ' A' ' 59' ' ' PHE . 16.1 m -59.94 -52.16 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.483 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.636 ' N ' HG23 ' B' ' 8' ' ' VAL . 39.1 mt -54.16 -39.11 66.27 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.27 -36.72 71.36 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.66 -34.53 88.88 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.896 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.426 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.54 -46.96 88.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.302 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -53.56 -42.47 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.047 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 84.2 t -57.92 -44.72 87.16 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.907 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.52 -37.47 94.21 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -61.81 -41.99 98.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 0.0 110.142 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 58.4 tp -61.28 -44.38 97.32 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.35 -41.53 87.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.007 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.464 HD22 ' HB2' ' A' ' 48' ' ' ALA . 20.5 mt -64.55 -35.5 81.19 Favored 'General case' 0 C--O 1.225 -0.208 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.064 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 96.0 m -61.79 -48.83 78.86 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.632 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 61.7 t -68.42 -47.64 76.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.525 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 29.2 tp -60.86 -51.9 67.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.303 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 79.0 mt -57.65 -50.61 76.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.02 37.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.024 0.44 . . . . 0.0 109.934 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.53 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.21 -41.03 78.67 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.113 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.74 -37.21 83.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.403 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.41 -46.51 95.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -61.46 -41.02 96.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.177 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 45.0 t80 -59.34 -44.51 92.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.61 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 30.1 tp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.28 -179.859 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.459 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.14 0 N-CA-C 110.385 -0.228 . . . . 0.0 110.385 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 26.9 m 33.11 34.84 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.082 0.468 . . . . 0.0 111.637 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -86.91 -41.57 0.54 Allowed Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.304 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.2 Cg_exo -47.9 -45.03 25.86 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.659 2.239 . . . . 0.0 112.703 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.76 -49.21 0.82 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 -179.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 6' ' ' PRO . 69.0 t -54.96 -41.72 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 71.4 mt -55.22 -37.9 67.75 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.09 -36.9 75.92 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -61.14 -28.87 69.74 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 178.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -66.6 -40.89 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.51 -50.44 80.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.71 179.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.1 t -58.29 -44.62 88.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.713 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.51 -36.55 78.01 Favored Glycine 0 CA--C 1.525 0.674 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.037 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.2 t0 -65.21 -48.66 72.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.904 0.383 . . . . 0.0 110.592 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 28.7 tp -55.53 -51.64 66.36 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.716 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 m -64.36 -28.72 45.51 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 C-N-CA 120.213 -0.595 . . . . 0.0 110.801 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.424 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -61.26 -56.87 15.61 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.946 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.3 m -55.14 -42.39 72.99 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.415 179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.48 -29.05 44.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.829 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.47 -53.86 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.193 -178.757 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.516 ' CG2' HG21 ' B' ' 23' ' ' ILE . 11.8 mt -66.15 -42.81 91.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.402 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.25 -39.5 90.55 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.992 0.425 . . . . 0.0 110.429 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 33.0 tp -69.14 -37.54 78.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.041 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.61 -50.4 73.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 26.0 m -67.63 -35.69 73.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.634 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -60.31 -41.83 94.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.528 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -65.77 -38.75 89.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.721 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.9 tp . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.539 -179.698 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.871 0.367 . . . . 0.0 110.401 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.0 m -69.17 -23.94 27.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.74 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.566 HD12 ' N ' ' A' ' 39' ' ' LEU . 9.3 mp -46.06 -35.93 5.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.594 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.79 -46.47 89.9 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 58.8 mt -59.2 -38.29 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.016 0.436 . . . . 0.0 110.6 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.4 mm -67.41 -39.45 82.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -61.46 -52.12 65.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.616 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.401 HG22 HD21 ' B' ' 22' ' ' LEU . 7.1 pt -61.62 -44.67 99.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.905 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.8 t -56.72 -43.53 79.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.519 -0.472 . . . . 0.0 109.792 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.458 ' O ' HG22 ' A' ' 50' ' ' VAL . 64.9 mt -65.21 -32.66 74.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.188 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.12 -36.15 76.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.14 -51.13 41.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.145 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.3 m -56.57 -48.45 77.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.455 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 46' ' ' LEU . 12.8 m -71.36 -28.52 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -178.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.682 ' O ' HG22 ' A' ' 55' ' ' VAL . 64.8 tp -67.74 -54.74 16.88 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.839 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.504 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 2.1 mptp? -65.24 -44.84 86.89 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.42 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.642 ' O ' HD13 ' A' ' 57' ' ' ILE . 23.9 m -61.09 -47.19 87.46 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.486 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.1 mt -70.93 -42.95 77.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 51' ' ' LEU . 16.5 m -75.68 -36.58 34.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.509 -178.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -71.85 -39.28 69.81 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 -178.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -60.39 -50.44 85.72 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.371 0.878 . . . . 0.0 113.371 -177.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.486 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 7.4 Cg_endo -50.65 -43.96 42.99 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 CA-C-N 120.718 1.292 . . . . 0.0 111.64 -178.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.71 ' CG ' HG11 ' B' ' 8' ' ' VAL . 24.2 m-85 -74.56 -68.01 0.58 Allowed 'General case' 0 N--CA 1.433 -1.275 0 CA-C-O 120.742 0.306 . . . . 0.0 110.665 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.485 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 C--N 1.331 -0.215 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.298 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.481 ' O ' ' N ' ' B' ' 7' ' ' GLY . 4.7 t . . . . . 0 N--CA 1.465 0.316 0 CA-C-O 120.436 0.16 . . . . 0.0 111.23 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.505 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -33.14 -61.43 0.36 Allowed Pre-proline 0 CA--C 1.535 0.366 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.58 9.39 0.12 Allowed 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.052 1.835 . . . . 0.0 112.194 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -120.69 -63.85 0.25 Allowed Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.964 -0.454 . . . . 0.0 111.964 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.71 HG11 ' CG ' ' A' ' 59' ' ' PHE . 35.2 m -61.52 -55.28 25.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 C-N-CA 120.224 -0.591 . . . . 0.0 110.607 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.8 mt -53.51 -38.1 63.41 Favored 'General case' 0 C--O 1.244 0.788 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.451 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.2 -36.71 71.19 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 177.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.86 -35.75 91.78 Favored Glycine 0 CA--C 1.522 0.472 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.976 179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.47 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.5 mp -65.03 -46.25 92.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.572 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.01 -44.49 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 C-N-CA 118.97 -1.092 . . . . 0.0 109.0 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.18 -43.99 77.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.793 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.08 -36.67 92.68 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -60.65 -46.23 91.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.107 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.474 ' O ' HD13 ' B' ' 17' ' ' LEU . 0.2 OUTLIER -58.22 -49.35 77.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.622 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 70.0 t -54.04 -45.31 64.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.12 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 91.9 mt -60.19 -50.94 71.68 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.967 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -44.97 -49.44 11.18 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.484 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -62.9 -37.64 79.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.547 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . 0.401 HD21 HG22 ' A' ' 44' ' ' ILE . 20.0 tp -63.74 -50.3 69.64 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.516 HG21 ' CG2' ' A' ' 23' ' ' ILE . 24.4 mm -58.85 -46.11 91.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -52.41 -48.7 65.55 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 32.3 tp -56.17 -37.09 69.08 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.39 -37.45 87.32 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.24 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.81 -47.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -61.2 -40.7 94.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.22 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -58.51 -44.8 89.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.557 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.0 tp . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.405 -179.806 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 5' ' ' SER . 60.4 p . . . . . 0 N--CA 1.462 0.166 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.465 ' H ' ' CB ' ' B' ' 5' ' ' SER . 30.4 m 34.85 29.95 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.219 0.533 . . . . 0.0 111.065 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.619 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -91.26 -38.67 0.38 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.215 179.057 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.3 Cg_exo -48.18 -42.19 33.44 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.429 2.086 . . . . 0.0 112.551 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.07 -47.14 0.8 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 108.863 -1.695 . . . . 0.0 108.863 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -56.53 -40.85 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.0 mt -55.69 -35.39 65.98 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -62.63 -37.8 87.75 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 177.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.23 -29.12 70.4 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 178.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.27 -42.58 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.9 t -57.07 -51.89 63.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.103 0.478 . . . . 0.0 109.971 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.4 t -59.2 -43.17 88.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.952 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -36.35 88.08 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.466 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -66.32 -49.75 65.94 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.826 0.346 . . . . 0.0 110.523 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.407 ' O ' HG23 ' A' ' 21' ' ' VAL . 23.0 tp -54.82 -51.02 67.14 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.83 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.5 m -65.18 -29.12 46.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.995 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -61.12 -58.86 6.6 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.999 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -54.9 -40.48 69.84 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.604 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 17' ' ' LEU . 89.9 t -69.57 -30.02 43.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.22 -54.34 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.103 -178.575 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.465 HG22 HG21 ' B' ' 23' ' ' ILE . 22.0 mt -68.14 -41.53 84.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.535 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.36 -41.76 94.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.444 . . . . 0.0 110.094 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.0 tp -68.2 -32.85 73.36 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.909 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.62 -51.09 70.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.627 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.56 -36.36 77.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.506 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -60.64 -46.25 90.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.506 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -69.0 -45.9 69.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.78 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.2 tp . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.552 -179.81 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.855 0.36 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 21.9 m -65.77 -24.7 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.697 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.562 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.2 mp -45.91 -29.22 1.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.404 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.18 -47.48 81.1 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.58 -38.76 72.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.932 0.396 . . . . 0.0 110.598 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -67.13 -43.14 88.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.168 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -58.54 -51.25 70.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.875 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.405 HG22 HD21 ' B' ' 22' ' ' LEU . 7.9 pt -63.04 -45.02 99.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.814 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.59 -36.36 53.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.633 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.532 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -68.55 -38.43 80.79 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.348 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.82 -31.99 56.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.166 -0.614 . . . . 0.0 109.682 -179.383 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.61 -52.36 21.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.482 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.424 ' O ' HG23 ' A' ' 53' ' ' THR . 4.6 m -58.81 -45.26 90.33 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.512 -178.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.51 -31.45 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -179.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.604 ' O ' HG22 ' A' ' 55' ' ' VAL . 56.0 tp -68.07 -53.47 25.32 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 119.816 -0.754 . . . . 0.0 110.954 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 52' ' ' LYS . 11.8 mptt -63.5 -47.12 83.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.732 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 49' ' ' THR . 64.1 p -65.23 -41.92 93.91 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.455 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 97.5 mt -71.52 -46.65 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -177.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 51' ' ' LEU . 8.1 m -74.72 -34.95 35.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.645 -178.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.2 tp -78.35 -41.04 34.64 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.488 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 37.2 mt -53.48 -52.95 62.06 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 57' ' ' ILE . 9.3 Cg_endo -51.1 -44.16 44.09 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 121.228 1.285 . . . . 0.0 112.386 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.485 ' CG ' HG11 ' B' ' 8' ' ' VAL . 9.1 m-85 -75.98 -57.17 4.03 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.532 0.283 0 C-N-CA 120.637 -0.425 . . . . 0.0 109.996 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.564 HG23 ' N ' ' B' ' 5' ' ' SER . 18.4 m . . . . . 0 N--CA 1.461 0.121 0 CA-C-O 120.687 0.28 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.57 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -45.9 -64.81 0.8 Allowed Pre-proline 0 CA--C 1.533 0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.608 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 10.5 Cg_endo -52.95 2.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 121.872 1.715 . . . . 0.0 112.283 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.57 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -99.99 -68.76 0.87 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.485 HG11 ' CG ' ' A' ' 59' ' ' PHE . 0.1 OUTLIER -65.25 -49.61 77.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.826 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.2 mt -55.32 -39.9 70.51 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -61.21 -39.17 89.24 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.5 -29.88 74.8 Favored Glycine 0 CA--C 1.52 0.404 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.159 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -69.09 -47.52 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 C-N-CA 119.661 -0.816 . . . . 0.0 108.976 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -53.86 -42.3 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 118.674 -1.21 . . . . 0.0 108.811 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.58 -42.34 91.22 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.992 179.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.9 -38.45 96.11 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -61.34 -43.2 99.28 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.7 tp -61.16 -46.98 88.29 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.811 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -58.63 -45.49 90.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 89.4 mt -60.87 -50.35 73.77 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.872 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.9 m -45.74 -50.23 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.471 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.28 -36.88 77.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.617 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . 0.405 HD21 HG22 ' A' ' 44' ' ' ILE . 36.1 tp -63.72 -50.67 68.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.571 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 23' ' ' ILE . 28.6 mm -59.39 -44.27 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.27 -47.11 69.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.211 0.529 . . . . 0.0 109.654 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.535 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.93 -38.93 76.81 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.184 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.44 -38.63 87.87 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.258 179.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 73.1 t -60.47 -47.31 93.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -61.2 -40.93 95.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.192 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -58.79 -47.3 85.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.717 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 26.3 tp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.43 -179.785 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.2 t . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.639 0.256 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.533 ' H ' ' CB ' ' B' ' 5' ' ' SER . 26.9 m 34.68 34.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.228 0.537 . . . . 0.0 111.248 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.621 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -86.57 -37.43 0.52 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.36 179.067 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.621 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.1 Cg_exo -48.71 -41.2 38.45 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.359 2.04 . . . . 0.0 112.512 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.532 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.72 -47.21 0.74 Allowed Glycine 0 N--CA 1.463 0.491 0 N-CA-C 108.795 -1.722 . . . . 0.0 108.795 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.8 t -55.0 -38.24 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 9' ' ' LEU . 68.0 mt -55.32 -39.51 70.03 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.532 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.05 -38.45 79.4 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.63 -26.89 67.29 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -68.04 -42.18 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.86 -54.11 39.89 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.733 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.6 t -58.49 -30.25 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.798 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.44 -38.8 93.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.475 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.1 t0 -67.62 -45.88 74.15 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.232 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.0 tp -57.65 -51.01 71.26 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -66.05 -28.71 44.59 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.774 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.518 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -60.19 -56.99 14.76 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 120.297 -0.561 . . . . 0.0 109.545 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.531 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.3 m -57.99 -41.79 83.78 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.292 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.57 -36.76 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.973 0.36 . . . . 0.0 111.973 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.08 -55.36 12.79 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 121.056 -0.258 . . . . 0.0 111.254 -178.526 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.9 mt -66.42 -44.4 90.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.723 -179.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.29 -43.97 88.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.134 0.492 . . . . 0.0 110.231 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.4 tp -67.12 -30.92 71.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.939 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.55 -51.07 68.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -36.11 76.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.365 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -61.82 -48.69 79.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.546 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 61.2 t80 -70.35 -48.47 56.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.669 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.7 tp . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.51 -179.816 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.6 m -62.64 -27.26 42.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.677 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -48.78 -29.38 4.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.921 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.0 -47.96 83.15 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.62 -45.8 79.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.9 0.381 . . . . 0.0 110.079 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.686 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -65.22 -29.48 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.429 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.7 m -65.33 -49.27 70.05 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.543 HD12 HD12 ' B' ' 23' ' ' ILE . 24.4 pt -68.87 -39.2 79.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.473 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.2 t -61.76 -43.05 96.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.125 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.487 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -69.02 -35.93 77.19 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.593 -179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.58 -32.92 59.08 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.954 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.531 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.01 -49.93 32.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -59.55 -48.62 80.94 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.2 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.8 m -64.53 -37.56 80.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.867 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.575 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.3 tp -63.07 -44.15 96.6 Favored 'General case' 0 C--O 1.224 -0.246 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.296 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.475 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 3.8 mptp? -59.79 -52.98 63.16 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.49 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.8 m -63.85 -46.46 84.93 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 -178.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 84.9 mt -62.7 -47.5 92.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.5 m -76.47 -35.91 27.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 120.327 -0.549 . . . . 0.0 111.024 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.5 tt -65.24 -33.07 75.13 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 113.091 0.775 . . . . 0.0 113.091 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.7 mt -66.75 -54.79 20.24 Favored Pre-proline 0 CA--C 1.544 0.75 0 C-N-CA 119.549 -0.86 . . . . 0.0 112.692 -178.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 55.9 Cg_endo -70.09 -28.57 23.5 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.726 1.617 . . . . 0.0 111.033 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.98 -52.0 64.67 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.523 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.446 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.7 mm? . . . . . 0 C--N 1.331 -0.224 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.507 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.463 HG23 ' N ' ' B' ' 5' ' ' SER . 28.3 m . . . . . 0 C--O 1.23 0.047 0 CA-C-O 120.943 0.401 . . . . 0.0 110.433 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.533 ' CB ' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -38.67 -62.86 0.65 Allowed Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.505 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -59.93 6.99 0.09 OUTLIER 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.197 1.931 . . . . 0.0 112.229 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -116.99 -66.44 0.37 Allowed Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.45 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -58.2 -51.88 65.62 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 121.007 0.432 . . . . 0.0 110.3 -179.898 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 32.2 mt -56.79 -38.42 72.5 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.68 -34.23 67.19 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.13 -36.84 93.42 Favored Glycine 0 CA--C 1.522 0.498 0 CA-C-N 114.135 -1.393 . . . . 0.0 110.884 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 19.6 mt -63.96 -42.53 96.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.567 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.403 HG13 ' H ' ' B' ' 13' ' ' VAL . 1.1 m -56.64 -46.05 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.833 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.8 t -52.44 -45.12 45.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 C-N-CA 120.081 -0.647 . . . . 0.0 109.474 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.3 -37.45 91.91 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -60.58 -47.0 88.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.094 0.474 . . . . 0.0 110.175 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.5 tp -56.61 -47.22 80.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.155 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -56.35 -45.54 81.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.272 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 30.0 mt -59.67 -52.84 63.78 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.588 -0.445 . . . . 0.0 109.977 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.1 m -44.64 -47.4 10.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.574 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -63.45 -38.43 82.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.485 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 39.7 tp -64.58 -54.86 25.37 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.67 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.543 HD12 HD12 ' A' ' 44' ' ' ILE . 8.5 mm -55.13 -47.48 77.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.893 -179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -50.98 -49.14 60.78 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 121.118 0.485 . . . . 0.0 109.781 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -55.86 -36.46 67.58 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.76 -37.72 88.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.19 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -60.62 -47.69 91.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -62.35 -40.04 95.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.053 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -59.14 -43.8 92.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.551 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.9 tp . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.462 -179.935 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.1 t . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.62 0.248 . . . . 0.0 110.448 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.502 ' H ' ' HB2' ' B' ' 5' ' ' SER . 29.5 m 32.23 34.44 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.561 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -85.49 -40.77 0.62 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.442 179.345 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 90.1 Cg_exo -47.77 -43.01 29.97 Favored 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.695 2.264 . . . . 0.0 112.801 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 69.98 -52.18 0.75 Allowed Glycine 0 N--CA 1.465 0.568 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' PRO . 63.1 t -50.73 -36.12 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 177.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.412 ' O ' HG22 ' A' ' 12' ' ' ILE . 36.2 mt -55.4 -40.93 72.03 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.524 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -56.18 -39.07 71.8 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 177.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.9 -27.53 67.03 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.444 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -69.03 -37.15 76.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.398 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.1 t -65.6 -52.65 48.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.22 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.4 t -59.77 -42.63 89.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.138 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.43 73.14 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.346 -0.701 . . . . 0.0 111.346 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -69.94 -54.08 14.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.771 0.319 . . . . 0.0 110.487 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.42 ' O ' HG23 ' A' ' 21' ' ' VAL . 50.2 tp -61.05 -40.71 94.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.204 0.526 . . . . 0.0 109.815 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.6 t -69.23 -27.63 35.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.272 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 tp -72.16 -55.87 6.54 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.802 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 m -62.51 -39.09 92.4 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.235 -0.586 . . . . 0.0 110.975 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 17' ' ' LEU . 94.6 t -70.85 -39.36 75.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.658 -0.246 . . . . 0.0 111.521 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.3 -52.8 56.77 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.387 -178.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.486 HG22 HG21 ' B' ' 23' ' ' ILE . 50.2 mt -65.67 -43.7 93.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.363 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -40.21 81.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.023 0.439 . . . . 0.0 110.404 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -71.1 -35.82 71.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.258 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.75 -50.19 70.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.996 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.435 HG11 ' CG2' ' B' ' 27' ' ' VAL . 29.6 m -69.17 -33.84 60.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.357 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -63.39 -45.26 91.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.456 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -61.18 -50.83 71.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.428 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 28.7 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.25 179.758 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.9 tp10 . . . . . 0 CA--C 1.529 0.15 0 CA-C-O 120.985 0.422 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.2 m -56.63 -26.54 23.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.544 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.9 tp -47.79 -32.57 6.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.643 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.0 -53.16 42.55 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.9 mm -56.38 -46.41 81.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-O 121.055 0.455 . . . . 0.0 110.436 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 95.7 mt -55.02 -45.25 76.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.171 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.7 t -60.12 -41.14 92.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.041 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 47' ' ' VAL . 5.3 mm -57.44 -53.9 37.98 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.278 0.561 . . . . 0.0 111.125 -179.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 p -64.65 -27.64 43.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.184 -0.606 . . . . 0.0 110.279 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.534 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.2 OUTLIER -66.9 -46.42 74.95 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.276 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 44' ' ' ILE . 3.7 p -67.61 -33.44 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.626 -179.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.59 -44.62 77.69 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.633 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.5 p -66.56 -52.06 49.69 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.836 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 46' ' ' LEU . 25.3 m -65.35 -37.33 79.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.244 -179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.666 ' O ' HG22 ' A' ' 55' ' ' VAL . 6.1 tt -65.35 -42.19 93.1 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.591 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 14.6 tptm -62.98 -52.43 63.04 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.884 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 75.5 p -65.95 -44.02 86.23 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 112.807 0.669 . . . . 0.0 112.807 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.477 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 88.5 mt -64.93 -45.97 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.3 m -77.64 -36.34 22.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.135 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.1 tt -67.27 -31.93 72.6 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.401 HD13 ' HA ' ' A' ' 57' ' ' ILE . 3.5 mm -67.74 -54.19 18.44 Favored Pre-proline 0 CA--C 1.544 0.729 0 C-N-CA 119.663 -0.815 . . . . 0.0 112.669 -178.009 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 53.7 Cg_endo -69.54 -28.05 26.77 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 121.729 1.619 . . . . 0.0 111.0 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.81 -54.62 36.17 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.6 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.458 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.523 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.499 ' O ' HG22 ' B' ' 8' ' ' VAL . 7.7 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.761 0.315 . . . . 0.0 111.254 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.502 ' HB2' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -40.21 -63.93 0.64 Allowed Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.783 -179.071 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.523 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 30.8 Cg_endo -61.6 0.73 0.97 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.099 1.866 . . . . 0.0 112.02 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -107.29 -64.02 0.59 Allowed Glycine 0 N--CA 1.466 0.7 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.522 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 0.2 OUTLIER -64.11 -50.95 74.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.091 0.472 . . . . 0.0 109.859 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.38 -38.96 81.84 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -57.19 -32.77 66.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -38.34 93.91 Favored Glycine 0 CA--C 1.525 0.713 0 CA-C-N 114.449 -1.251 . . . . 0.0 111.625 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 8.2 mt -65.73 -42.31 92.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 C-N-CA 119.555 -0.858 . . . . 0.0 109.61 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.444 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.5 m -55.75 -45.27 79.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.0 t -53.73 -50.18 52.9 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.674 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.46 -31.22 62.83 Favored Glycine 0 CA--C 1.527 0.844 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -70.93 -40.38 72.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.742 0.306 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 tp -61.53 -51.39 68.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -59.03 -44.43 91.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.353 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 26.8 mt -58.45 -51.94 67.73 Favored 'General case' 0 C--O 1.227 -0.117 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.925 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -48.07 -50.85 26.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 0.0 110.456 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.2 t -60.82 -31.26 49.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.137 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 13.9 tp -67.86 -44.74 76.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.894 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.486 HG21 HG22 ' A' ' 23' ' ' ILE . 28.4 mm -61.53 -51.23 75.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.035 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.86 -42.25 75.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.144 0.497 . . . . 0.0 109.92 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.2 tp -60.02 -37.38 79.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.709 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.81 94.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.204 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.435 ' CG2' HG11 ' A' ' 27' ' ' VAL . 87.3 t -60.13 -48.11 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.059 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -63.66 -38.95 93.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.221 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 44.0 t80 -58.26 -46.96 85.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.8 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.227 179.974 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.462 0.137 0 CA-C-O 120.598 0.237 . . . . 0.0 110.374 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.453 ' N ' ' OG ' ' B' ' 5' ' ' SER . 26.8 m 34.61 31.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.173 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.616 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -85.71 -38.33 0.58 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.432 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.616 ' CD ' ' N ' ' A' ' 5' ' ' SER . 97.9 Cg_exo -48.43 -42.4 34.77 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 122.405 2.07 . . . . 0.0 112.572 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.28 -48.39 0.71 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 6' ' ' PRO . 76.7 t -53.68 -35.94 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 177.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.424 ' O ' HG22 ' A' ' 12' ' ' ILE . 34.0 mt -54.84 -41.88 71.27 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.67 -37.98 77.21 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.82 -26.02 64.63 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.506 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -70.9 -38.38 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.6 t -61.42 -54.6 32.79 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-O 121.355 0.598 . . . . 0.0 109.521 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.401 ' O ' HG22 ' A' ' 18' ' ' VAL . 14.9 t -60.57 -36.26 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.284 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.11 -38.75 96.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -67.92 -47.75 67.86 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.889 0.376 . . . . 0.0 110.382 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.805 ' N ' ' HZ1' ' A' ' 52' ' ' LYS . 23.5 tp -58.91 -50.67 73.15 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.044 -179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.401 HG22 ' O ' ' A' ' 14' ' ' VAL . 16.9 m -68.33 -26.33 33.56 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.292 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.764 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.5 mt -62.81 -54.99 30.47 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.469 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.421 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.1 m -60.39 -43.99 96.1 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.298 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 17' ' ' LEU . 98.6 t -62.75 -49.36 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.511 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -62.33 -53.51 53.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.143 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.45 ' CG2' HG21 ' B' ' 23' ' ' ILE . 59.1 mt -58.8 -44.34 90.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.159 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.13 -38.02 81.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.286 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -65.39 -48.05 74.23 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.642 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.93 -46.85 64.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.512 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.2 t -62.06 -45.21 99.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -55.22 -43.67 74.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.636 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -59.21 -48.47 81.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.3 tt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.435 179.951 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.778 0.323 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.7 m -56.34 -24.48 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.563 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.1 mp -46.9 -32.54 3.87 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.394 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 -50.89 42.7 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 61.0 mt -60.74 -41.05 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.669 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 82.1 mt -66.27 -39.44 84.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.398 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.4 t -60.53 -50.83 71.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.794 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 8.3 pt -64.51 -44.11 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -57.52 -42.97 82.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.128 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.68 -39.71 91.59 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.694 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.24 -30.24 49.67 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.067 0 C-N-CA 120.396 -0.521 . . . . 0.0 109.658 -179.21 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.421 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.73 -50.18 32.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.546 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.7 m -58.5 -47.04 85.44 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.352 -0.539 . . . . 0.0 111.108 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.526 HG23 ' N ' ' A' ' 51' ' ' LEU . 26.7 m -69.0 -44.69 81.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.596 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.572 ' O ' HG22 ' A' ' 55' ' ' VAL . 37.9 tp -53.41 -51.81 61.38 Favored 'General case' 0 CA--C 1.519 -0.218 0 C-N-CA 120.114 -0.634 . . . . 0.0 110.302 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.805 ' HZ1' ' N ' ' A' ' 17' ' ' LEU . 3.4 mmmm -60.45 -43.94 96.34 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.825 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.2 m -59.68 -49.82 76.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.483 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 2.8 mp -70.97 -44.84 75.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.572 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.0 m -74.92 -34.18 32.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.887 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.404 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 10.8 tp -75.33 -37.33 60.79 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -178.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.1 mt -57.59 -52.64 72.81 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.483 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 49.5 Cg_endo -69.59 -27.58 27.11 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.434 1.423 . . . . 0.0 111.216 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.519 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.4 m-30 -63.98 -56.37 15.63 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.28 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.55 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.331 -0.234 0 CA-C-O 120.932 0.396 . . . . 0.0 110.096 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.401 ' O ' HG22 ' B' ' 8' ' ' VAL . 26.6 m . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.767 0.318 . . . . 0.0 110.456 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.528 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -40.49 -62.75 0.87 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.213 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -61.85 11.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 122.09 1.86 . . . . 0.0 112.235 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.74 -66.14 0.28 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.401 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.2 OUTLIER -61.85 -50.86 78.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-O 121.055 0.455 . . . . 0.0 110.224 -179.807 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.8 mt -60.13 -37.14 79.16 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.52 -34.15 66.73 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.02 -43.4 97.41 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.946 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 42.6 mm -57.82 -41.72 80.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.195 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.506 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -60.75 -43.02 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.395 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -57.44 -47.2 85.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 120.338 -0.545 . . . . 0.0 109.913 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.37 -36.3 90.68 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -63.18 -41.19 99.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.147 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.9 tp -61.77 -45.73 92.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.917 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.91 -48.0 82.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.384 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 49.9 mt -61.24 -49.13 78.36 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.105 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -46.1 -50.33 15.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.504 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 97.1 t -66.01 -31.72 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.501 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.6 tp -66.22 -51.83 53.78 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.482 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.45 HG21 ' CG2' ' A' ' 23' ' ' ILE . 20.9 mm -61.4 -50.71 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.3 -44.35 61.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.176 0.512 . . . . 0.0 109.677 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.33 -38.47 80.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.478 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.43 -39.0 91.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.088 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 84.1 t -60.86 -46.0 97.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.987 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -60.84 -41.74 96.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.162 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -58.02 -49.99 74.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.409 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 19.9 mt . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.406 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.6 t . . . . . 0 N--CA 1.462 0.125 0 CA-C-O 120.574 0.226 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.41 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.11 34.3 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.502 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.593 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -78.24 -41.15 1.95 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.469 179.402 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 5' ' ' SER . 78.7 Cg_exo -47.57 -41.98 29.57 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.727 2.285 . . . . 0.0 112.748 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.548 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.26 -47.37 0.85 Allowed Glycine 0 N--CA 1.462 0.416 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -179.226 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.477 ' H ' ' C ' ' A' ' 6' ' ' PRO . 70.8 t -56.1 -39.47 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 9' ' ' LEU . 72.5 mt -55.86 -38.1 69.66 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.23 -38.51 83.63 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.024 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.13 -29.76 71.96 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.42 -42.87 94.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.478 ' HA ' HG21 ' B' ' 12' ' ' ILE . 60.6 t -57.81 -51.64 67.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 84.8 t -57.79 -30.12 36.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.758 178.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.35 -38.12 86.84 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -68.03 -43.79 77.95 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.87 0.367 . . . . 0.0 110.648 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 27.5 tp -63.5 -48.72 76.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.417 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 14' ' ' VAL . 31.9 m -65.49 -29.81 48.26 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.124 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.961 -179.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.526 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.6 OUTLIER -66.35 -56.43 11.13 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.72 179.641 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.669 HG21 ' CB ' ' A' ' 48' ' ' ALA . 10.5 m -52.9 -50.68 63.42 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.987 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -70.28 -27.61 32.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 19.7 tp -66.9 -56.57 9.7 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.003 -179.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 61.2 mt -70.39 -43.23 78.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.596 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.23 -39.51 79.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.979 0.418 . . . . 0.0 110.152 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.79 -40.3 83.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.81 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.72 -50.9 67.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.866 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.4 m -67.98 -34.32 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.63 -0.428 . . . . 0.0 110.59 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -60.24 -44.54 95.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.696 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -66.49 -48.97 68.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 30' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.219 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.887 0.375 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.53 -25.68 38.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.704 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 58.3 tp -46.41 -29.61 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.817 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.98 -50.57 57.3 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.646 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.8 mp -56.79 -48.07 81.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.954 0.407 . . . . 0.0 109.931 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.8 mt -63.58 -29.99 48.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.618 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.3 t -64.85 -47.28 78.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.356 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.5 pt -71.11 -35.43 58.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.323 . . . . 0.0 111.54 -179.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 64.9 t -67.78 -43.85 86.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.196 -0.602 . . . . 0.0 110.36 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.528 ' O ' HG22 ' A' ' 50' ' ' VAL . 3.3 mm? -72.04 -37.52 69.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.72 -179.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.2 p -69.4 -31.81 50.82 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.113 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.878 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.669 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.38 -52.14 20.28 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.586 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.8 m -60.22 -42.48 95.25 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.566 -178.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.42 -32.98 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.518 -0.473 . . . . 0.0 112.066 -179.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.546 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -68.05 -56.55 8.46 Favored 'General case' 0 CA--C 1.521 -0.146 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.388 -179.694 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.31 -47.68 84.85 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.569 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 96.1 m -61.02 -44.55 97.25 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 95.3 mt -72.33 -43.53 64.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 113.736 1.013 . . . . 0.0 113.736 -177.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.7 m -78.68 -33.72 16.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.171 -0.611 . . . . 0.0 111.565 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -77.86 -39.88 41.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.453 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 13.0 mm -59.75 -54.32 56.88 Favored Pre-proline 0 CA--C 1.541 0.623 0 N-CA-C 113.198 0.814 . . . . 0.0 113.198 -177.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.485 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 16.7 Cg_endo -56.45 -35.76 96.8 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 121.484 1.456 . . . . 0.0 112.045 -179.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -77.28 -61.01 2.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.549 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.532 0.251 0 C-N-CA 120.488 -0.485 . . . . 0.0 109.98 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 27.8 m . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.887 0.375 . . . . 0.0 110.138 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.529 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -45.39 -63.27 1.27 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.861 179.592 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.5 Cg_endo -59.51 7.43 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.227 1.951 . . . . 0.0 112.35 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -114.05 -66.17 0.45 Allowed Glycine 0 N--CA 1.468 0.772 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.589 HG13 ' N ' ' B' ' 9' ' ' LEU . 11.5 p -63.58 -47.92 89.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.995 0.426 . . . . 0.0 110.306 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.589 ' N ' HG13 ' B' ' 8' ' ' VAL . 33.3 mt -56.74 -38.11 71.94 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.3 -39.09 81.9 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.17 75.74 Favored Glycine 0 CA--C 1.523 0.561 0 CA-C-N 114.491 -1.231 . . . . 0.0 110.786 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.478 HG21 ' HA ' ' A' ' 13' ' ' VAL . 49.8 mm -67.32 -46.13 84.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.063 -0.655 . . . . 0.0 109.615 179.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -55.6 -43.74 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 118.88 -1.128 . . . . 0.0 108.58 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 87.5 t -56.51 -47.92 81.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.294 -0.563 . . . . 0.0 109.542 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -55.5 -30.94 56.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -70.88 -41.91 70.71 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.645 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mp -60.48 -51.55 68.99 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 120.885 0.374 . . . . 0.0 110.196 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.403 HG13 ' N ' ' B' ' 19' ' ' LEU . 2.6 p -58.7 -45.78 90.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.398 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.403 ' N ' HG13 ' B' ' 18' ' ' VAL . 51.8 mt -59.42 -34.91 73.06 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.934 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.8 m -64.27 -41.39 96.94 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.295 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.84 -51.19 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.706 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . 0.413 ' N ' HD12 ' B' ' 22' ' ' LEU . 10.3 mp -64.28 -51.4 63.71 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.712 0.291 . . . . 0.0 111.052 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.517 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 82.4 mt -58.63 -51.49 71.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.07 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.6 -48.0 39.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.16 0.505 . . . . 0.0 109.812 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 34.2 tp -57.02 -35.75 69.64 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.1 -36.37 84.07 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.078 179.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 45.5 t -60.8 -48.07 90.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -64.42 -37.24 86.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.238 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -59.92 -46.49 89.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.682 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 tp . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.318 -179.836 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 11.6 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.572 0.225 . . . . 0.0 110.426 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.478 ' H ' ' CB ' ' B' ' 5' ' ' SER . 27.0 m 34.64 36.93 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.339 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.484 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -79.36 -48.23 1.52 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.317 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' A' ' 8' ' ' VAL . 46.7 Cg_exo -42.87 -43.42 9.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 122.699 2.266 . . . . 0.0 112.757 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.47 -46.66 0.87 Allowed Glycine 0 N--CA 1.463 0.433 0 N-CA-C 108.84 -1.704 . . . . 0.0 108.84 -179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' PRO . 74.3 t -57.75 -38.73 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.7 mt -55.62 -38.69 69.81 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.27 -40.22 89.59 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.62 -29.22 66.51 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.407 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -66.87 -43.23 89.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.086 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -50.83 74.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 179.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.6 t -57.27 -39.86 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.471 178.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.22 -36.81 91.75 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.62 -47.84 71.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.967 0.413 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 21' ' ' VAL . 41.1 tp -55.53 -51.74 66.04 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.726 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -65.14 -29.15 46.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.373 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.83 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.432 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -60.18 -58.04 10.25 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.738 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.1 m -56.09 -42.37 76.65 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 17' ' ' LEU . 87.4 t -66.51 -32.03 56.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.78 -53.9 13.69 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.404 -178.694 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.9 mt -67.83 -43.17 86.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.365 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.62 -42.94 97.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.891 0.377 . . . . 0.0 110.158 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 30.4 tp -65.56 -42.55 91.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.184 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.51 -48.58 71.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.661 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -64.51 -44.28 96.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.701 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -56.6 -37.58 70.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.662 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -59.91 -48.92 79.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.647 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.1 tp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.489 -179.994 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.856 0.36 . . . . 0.0 110.483 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.3 m -57.87 -28.28 32.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.561 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.6 tt -49.32 -37.72 25.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.545 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.53 -48.15 76.42 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 92.7 mt -59.63 -40.61 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.064 0.459 . . . . 0.0 110.49 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 91.6 mt -66.84 -35.98 76.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.467 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.3 m -64.18 -51.93 61.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.543 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.5 pt -61.86 -44.53 98.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.966 -179.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.47 -43.38 82.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 120.452 -0.499 . . . . 0.0 109.822 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.506 ' O ' HG22 ' A' ' 50' ' ' VAL . 70.5 mt -66.04 -32.14 73.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.201 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.26 -35.78 74.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.412 -0.515 . . . . 0.0 109.658 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.54 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -69.98 -49.05 55.48 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.265 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.3 p -58.92 -48.2 82.32 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.511 -179.325 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.506 HG22 ' O ' ' A' ' 46' ' ' LEU . 14.5 m -71.31 -28.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.603 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.672 ' O ' HG22 ' A' ' 55' ' ' VAL . 5.2 tt -67.12 -53.12 33.69 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.888 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.54 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 37.5 mttp -65.42 -44.83 86.16 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.82 0.343 . . . . 0.0 110.649 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.9 m -63.22 -42.53 99.26 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.515 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 93.8 mt -75.36 -41.96 43.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.672 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.5 m -76.59 -28.62 17.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 120.028 -0.669 . . . . 0.0 111.304 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.1 tp -84.82 -47.13 10.68 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.2 -59.38 13.19 Favored Pre-proline 0 N--CA 1.473 0.708 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -175.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.515 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -52.02 -27.49 28.93 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 121.392 1.394 . . . . 0.0 111.992 -178.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.546 ' CD1' HG11 ' B' ' 8' ' ' VAL . 26.4 m-85 -90.19 -65.94 0.97 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.494 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.2 mm? . . . . . 0 CA--C 1.53 0.205 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.29 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.462 0.136 0 CA-C-O 120.855 0.359 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.551 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -62.77 0.98 Allowed Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.908 179.786 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 31.2 Cg_endo -62.43 12.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.209 1.939 . . . . 0.0 111.995 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -125.45 -65.61 0.18 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.465 -0.654 . . . . 0.0 111.465 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.623 HG23 ' N ' ' B' ' 9' ' ' LEU . 18.1 m -60.09 -49.47 83.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.073 0.463 . . . . 0.0 110.461 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.623 ' N ' HG23 ' B' ' 8' ' ' VAL . 28.9 mt -57.41 -42.63 82.67 Favored 'General case' 0 C--O 1.238 0.484 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.66 -37.19 65.42 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 177.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.16 -28.73 73.32 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.347 178.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.2 -43.62 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.377 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.407 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.6 OUTLIER -58.86 -42.34 85.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 119.11 -1.036 . . . . 0.0 108.741 178.773 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.8 t -56.39 -47.42 81.47 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.86 -32.15 65.67 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -69.1 -41.75 77.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.804 0.335 . . . . 0.0 110.689 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 36.9 tp -61.07 -53.07 61.72 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.491 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -58.56 -39.85 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.139 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.428 HD22 ' HB2' ' A' ' 48' ' ' ALA . 25.6 mt -60.79 -52.72 63.9 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.733 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.5 m -47.14 -50.56 20.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.877 0.37 . . . . 0.0 110.21 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 60.0 t -61.95 -31.19 50.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.419 179.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 15.5 tp -68.37 -48.19 65.41 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.412 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 18.0 mm -60.64 -44.34 96.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.08 -48.19 79.18 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 121.184 0.516 . . . . 0.0 109.752 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -57.69 -34.93 69.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.55 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.81 -39.39 93.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.081 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -60.59 -45.83 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -62.52 -39.03 92.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -60.4 -44.46 95.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.618 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.0 tp . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.369 -179.848 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 5' ' ' SER . 41.7 p . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.791 0.329 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.456 ' N ' ' OG1' ' A' ' 3' ' ' THR . 10.6 m -69.24 37.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.958 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.18 -40.76 16.17 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.509 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.4 Cg_exo -46.66 -40.53 24.1 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.531 2.154 . . . . 0.0 112.45 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.24 -47.24 0.67 Allowed Glycine 0 N--CA 1.464 0.507 0 N-CA-C 109.125 -1.59 . . . . 0.0 109.125 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 72.7 t -56.26 -39.82 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.612 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.7 mt -55.96 -38.36 70.25 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.4 -36.1 77.32 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.78 -27.5 70.16 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.65 -42.01 86.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -59.95 -50.93 78.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.997 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.4 t -59.21 -42.32 86.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.904 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.03 -37.1 91.12 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.472 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 59.2 t0 -66.36 -47.4 73.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 110.359 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -55.59 -51.48 67.0 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.884 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.7 m -65.67 -29.02 45.73 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.712 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.475 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -59.38 -58.85 6.83 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.613 179.745 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.586 HG21 HD13 ' B' ' 19' ' ' LEU . 73.5 p -56.32 -42.91 78.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.286 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -64.59 -33.82 65.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.845 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.494 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.86 -52.86 25.3 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.049 -0.261 . . . . 0.0 111.168 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.4 mt -66.36 -43.79 91.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.349 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.8 -42.29 88.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.081 0.467 . . . . 0.0 110.07 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.6 tp -67.97 -31.27 70.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.034 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.81 -51.28 67.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.764 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.4 m -65.07 -37.52 80.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.432 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -60.98 -48.69 80.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.549 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 78.6 t80 -71.17 -50.97 27.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 30' ' ' LEU . 1.3 tt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.178 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.899 0.38 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.1 m -67.09 -26.0 35.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.485 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.5 tp -45.87 -27.69 0.93 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.727 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.72 -48.28 85.84 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.96 -44.51 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.098 0.475 . . . . 0.0 110.664 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.682 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.8 mp -66.18 -27.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.529 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.503 ' O ' HG23 ' A' ' 47' ' ' VAL . 24.0 p -70.66 -50.48 36.28 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.404 HG12 ' H ' ' A' ' 44' ' ' ILE . 10.5 pt -65.0 -44.85 95.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.032 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.417 HG13 ' N ' ' A' ' 46' ' ' LEU . 6.9 p -63.93 -41.75 93.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.555 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.543 ' O ' HG22 ' A' ' 50' ' ' VAL . 28.9 mt -65.2 -36.09 83.1 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 43' ' ' SER . 47.8 t -67.16 -35.55 74.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.076 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.46 -49.76 62.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.339 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 44.4 p -62.41 -50.57 70.97 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.876 -178.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 46' ' ' LEU . 15.8 m -66.04 -39.01 83.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.719 ' O ' HG22 ' A' ' 55' ' ' VAL . 33.6 tp -65.09 -40.74 95.03 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.598 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.472 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -65.66 -52.17 53.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.753 0.311 . . . . 0.0 110.995 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 m -67.87 -37.34 81.68 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.533 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 89.9 mt -72.28 -44.32 63.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 -177.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.9 m -78.49 -31.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.055 -0.658 . . . . 0.0 111.388 -179.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 4.3 tp -79.01 -39.92 32.8 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -177.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.2 mp -72.42 -60.04 2.3 Favored Pre-proline 0 N--CA 1.475 0.817 0 N-CA-C 113.796 1.036 . . . . 0.0 113.796 -176.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.533 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 9.4 Cg_endo -50.72 -25.4 15.05 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 121.736 1.624 . . . . 0.0 112.218 -178.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.533 ' CD1' HG11 ' B' ' 8' ' ' VAL . 1.9 m-85 -88.26 -67.34 0.84 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.54 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? . . . . . 0 C--O 1.231 0.122 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.166 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.434 HG23 ' N ' ' B' ' 5' ' ' SER . 13.8 m . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.815 0.34 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.509 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -37.75 -65.16 0.38 Allowed Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.923 -179.605 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 28.6 Cg_endo -60.43 6.14 0.12 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.323 2.015 . . . . 0.0 112.145 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -118.46 -64.5 0.3 Allowed Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.628 HG23 ' N ' ' B' ' 9' ' ' LEU . 14.3 m -60.84 -52.18 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 120.572 -0.451 . . . . 0.0 110.343 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.628 ' N ' HG23 ' B' ' 8' ' ' VAL . 36.6 mt -54.29 -40.04 67.5 Favored 'General case' 0 C--O 1.246 0.904 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.425 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.79 -35.41 70.76 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -63.62 -34.2 89.31 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.374 -1.284 . . . . 0.0 111.137 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.435 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.77 -45.87 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.333 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.53 -46.25 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 C-N-CA 119.095 -1.042 . . . . 0.0 108.856 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.4 t -53.26 -46.41 56.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.21 0.529 . . . . 0.0 109.627 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.78 -40.77 93.41 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -56.92 -46.37 82.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.709 0.29 . . . . 0.0 110.505 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -58.87 -45.12 90.93 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.3 t -56.34 -47.95 80.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.055 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.586 HD13 HG21 ' A' ' 20' ' ' THR . 98.3 mt -59.13 -39.74 83.3 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.002 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 15.8 m -56.78 -40.13 75.32 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.402 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 89.2 t -67.87 -51.72 47.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.831 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -62.11 -51.68 66.93 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.159 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.446 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -56.87 -50.01 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.55 -0.46 . . . . 0.0 109.998 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -49.13 -46.41 44.98 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.525 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.79 -40.02 75.16 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.026 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.446 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.25 -37.64 86.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.404 179.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.9 -48.06 89.19 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -64.08 -37.89 89.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.277 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -59.88 -51.03 71.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.641 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 20.9 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.393 179.861 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 5' ' ' SER . 28.6 p . . . . . 0 C--O 1.231 0.113 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.452 ' H ' ' CB ' ' B' ' 5' ' ' SER . 32.7 m 37.21 26.74 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.203 0.525 . . . . 0.0 111.03 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.627 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.6 OUTLIER -79.72 -35.47 0.96 Allowed Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.684 179.006 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.627 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.7 Cg_exo -49.56 -42.85 41.3 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.158 1.906 . . . . 0.0 112.529 179.81 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.539 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.81 -46.61 0.94 Allowed Glycine 0 CA--C 1.521 0.426 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.474 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -58.97 -40.1 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.59 -38.78 69.85 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.47 -38.91 82.05 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 177.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.04 -28.21 65.99 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.84 -43.62 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.2 t -55.77 -53.93 32.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -57.61 -36.95 56.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.69 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.08 -39.6 95.99 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -65.1 -46.92 79.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.896 0.379 . . . . 0.0 110.407 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.0 tp -55.74 -50.85 69.27 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -67.76 -25.68 33.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.008 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.57 -56.76 14.88 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 119.984 -0.687 . . . . 0.0 109.396 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.522 HG21 ' CB ' ' A' ' 48' ' ' ALA . 6.7 m -58.52 -44.5 89.55 Favored 'General case' 0 N--CA 1.456 -0.16 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.171 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.73 -32.88 59.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.1 tp -70.34 -54.5 12.29 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 -178.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.546 HG22 HG21 ' B' ' 23' ' ' ILE . 11.5 mm -70.28 -41.58 78.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.314 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.69 -40.3 87.39 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.022 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 32.7 tp -67.6 -37.48 82.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.626 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.18 -51.08 69.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.739 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -67.16 -36.19 76.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 C-N-CA 120.312 -0.555 . . . . 0.0 110.563 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -58.4 -44.38 88.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -66.28 -44.27 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.704 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.615 -179.803 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.908 0.385 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.8 m -69.67 -25.17 28.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.704 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 44.5 tp -46.13 -29.5 1.56 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.854 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.8 -52.82 47.99 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.645 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -40.27 58.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.919 0.39 . . . . 0.0 110.14 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.0 mm -64.54 -41.7 93.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.721 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 11.2 t -59.47 -51.79 68.36 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.69 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.1 tt -61.76 -43.88 97.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.31 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 41' ' ' ILE . 55.7 t -55.99 -43.11 74.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.121 0.486 . . . . 0.0 109.951 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -68.22 -30.8 69.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.935 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.4 t -68.29 -34.36 65.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.816 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.522 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.54 -48.15 42.61 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.474 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.8 m -60.13 -46.75 88.57 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.201 -179.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.7 m -68.4 -37.19 77.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 120.652 -0.419 . . . . 0.0 111.115 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.644 ' O ' HG22 ' A' ' 55' ' ' VAL . 34.1 tp -65.7 -41.11 92.76 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.271 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.419 ' NZ ' ' CD1' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -62.96 -53.19 57.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.431 -179.899 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.8 p -63.59 -46.86 83.89 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -61.64 -51.72 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.0 m -73.62 -29.79 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.174 -178.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.401 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 6.5 tt -70.91 -29.95 66.15 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -178.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 mt -61.95 -55.1 44.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.287 -178.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.71 -28.63 43.86 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.518 1.479 . . . . 0.0 111.503 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.2 m-30 -56.55 -47.07 80.25 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.349 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.478 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? . . . . . 0 N--CA 1.462 0.135 0 C-N-CA 120.846 -0.342 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.627 HG13 ' N ' ' B' ' 5' ' ' SER . 14.8 p . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 120.805 0.336 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.627 ' N ' HG13 ' B' ' 4' ' ' VAL . 0.7 OUTLIER -43.31 -64.48 0.75 Allowed Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.515 179.835 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 19.4 Cg_endo -56.86 1.75 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.325 2.017 . . . . 0.0 112.341 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -112.05 -67.05 0.52 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.552 HG23 ' N ' ' B' ' 9' ' ' LEU . 6.8 m -59.24 -48.05 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.154 0.502 . . . . 0.0 110.275 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.552 ' N ' HG23 ' B' ' 8' ' ' VAL . 43.6 mt -57.35 -42.15 81.46 Favored 'General case' 0 C--O 1.242 0.696 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -52.57 -33.46 45.91 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 176.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -37.22 94.17 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.292 178.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.1 tp -58.4 -43.82 87.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.672 -0.811 . . . . 0.0 108.956 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.431 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.9 OUTLIER -59.93 -46.81 93.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 119.256 -0.977 . . . . 0.0 109.487 179.281 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.5 -45.58 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 120.256 -0.577 . . . . 0.0 109.841 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.77 -39.25 96.48 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -59.58 -47.83 84.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.685 0.279 . . . . 0.0 110.712 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -57.79 -45.43 86.07 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -54.83 -46.64 75.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.439 HD22 ' HB2' ' A' ' 48' ' ' ALA . 23.5 mt -61.69 -47.08 86.94 Favored 'General case' 0 C--O 1.223 -0.302 0 C-N-CA 120.659 -0.417 . . . . 0.0 110.295 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.5 m -48.03 -50.73 26.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.8 0.333 . . . . 0.0 110.686 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 99.9 t -61.89 -44.13 98.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.936 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 12.2 tp -59.16 -45.3 91.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.18 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.546 HG21 HG22 ' A' ' 23' ' ' ILE . 4.6 mm -59.52 -49.78 82.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.87 -45.38 30.29 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.332 0.586 . . . . 0.0 109.83 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.561 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -64.76 -35.36 80.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.317 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.34 -55.32 35.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -57.86 -37.04 58.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.4 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 43.1 t80 -59.66 -43.76 93.81 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.82 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -61.15 -41.82 97.44 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.571 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 8.5 mp . . . . . 0 C--N 1.329 -0.299 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 5' ' ' SER . 32.7 p . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.621 0.248 . . . . 0.0 110.424 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.447 ' H ' ' HB3' ' B' ' 5' ' ' SER . 27.0 m 34.59 34.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.442 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -83.98 -40.09 0.73 Allowed Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.361 179.061 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 5' ' ' SER . 86.7 Cg_exo -48.1 -42.73 32.23 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.606 2.204 . . . . 0.0 112.655 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.516 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.86 -46.85 0.75 Allowed Glycine 0 N--CA 1.463 0.438 0 N-CA-C 108.865 -1.694 . . . . 0.0 108.865 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.6 t -55.27 -38.57 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.423 HD23 ' HA ' ' A' ' 9' ' ' LEU . 82.0 mt -55.38 -38.97 69.56 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.182 -1.007 . . . . 0.0 108.388 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.88 -39.86 86.72 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.51 -27.72 63.93 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.53 -42.89 83.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.197 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -56.45 -53.22 43.17 Favored 'Isoleucine or valine' 0 C--O 1.242 0.684 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.7 t -56.92 -39.67 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.357 178.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -54.71 -41.23 74.08 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 61.4 t0 -64.77 -45.85 84.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 110.299 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.434 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 20.8 tp -55.45 -51.08 68.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.894 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -68.53 -24.05 28.8 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.905 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.07 -56.7 14.69 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.032 -0.667 . . . . 0.0 109.382 179.755 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 53.6 m -61.36 -47.36 86.22 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.507 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.8 t -64.4 -34.32 68.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.4 tp -69.22 -54.28 15.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.609 -178.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 64.7 mt -67.57 -41.73 86.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.501 -0.479 . . . . 0.0 110.388 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.01 91.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.138 0.494 . . . . 0.0 110.026 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -67.57 -34.49 77.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.828 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.89 -51.36 70.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.757 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.65 -36.65 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.569 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -59.36 -41.69 89.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.872 0.367 . . . . 0.0 110.577 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -59.42 -46.87 87.49 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.656 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.4 tp . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -179.892 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 65.5 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.814 0.34 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.2 m -49.24 -26.67 2.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.6 tp -48.21 -28.62 3.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.715 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.38 -51.62 57.55 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.647 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -52.68 -49.94 43.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.027 0.441 . . . . 0.0 110.012 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.63 -27.58 43.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.727 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -67.01 -45.52 77.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.432 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.1 pt -71.83 -34.58 51.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.139 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.3 t -68.38 -46.4 80.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.572 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.404 ' O ' HG23 ' A' ' 50' ' ' VAL . 3.4 mm? -69.77 -37.75 76.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.643 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.22 -31.56 47.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.777 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.19 51.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.378 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.9 p -62.38 -43.36 99.0 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.953 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 46' ' ' LEU . 85.1 t -63.99 -43.74 97.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.556 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.5 OUTLIER -64.91 -53.39 47.18 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.018 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.434 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 0.7 OUTLIER -47.21 -51.99 17.03 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.909 179.924 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 31.4 p -59.13 -46.73 87.58 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 87.1 mt -59.82 -52.52 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.58 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 26.7 m -75.31 -30.89 23.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.258 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.7 tt -66.65 -32.79 74.34 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 7.4 mt -68.16 -54.23 16.37 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.479 -178.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.38 -28.44 18.09 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 121.799 1.666 . . . . 0.0 111.566 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.58 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -60.68 -45.43 94.2 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.342 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 121.017 0.437 . . . . 0.0 110.141 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 21.2 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.897 0.379 . . . . 0.0 110.314 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.539 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -40.02 -62.78 0.81 Allowed Pre-proline 0 CA--C 1.536 0.407 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.952 179.763 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.9 Cg_endo -61.02 9.88 0.07 OUTLIER 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.138 1.892 . . . . 0.0 112.073 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -123.64 -66.24 0.21 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.613 HG23 ' N ' ' B' ' 9' ' ' LEU . 15.9 m -58.8 -51.74 68.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 CA-C-O 121.094 0.473 . . . . 0.0 110.61 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.5 mt -56.51 -40.04 74.32 Favored 'General case' 0 C--O 1.242 0.663 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -53.24 -36.97 61.66 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.16 -34.45 89.12 Favored Glycine 0 CA--C 1.523 0.565 0 CA-C-N 114.425 -1.261 . . . . 0.0 110.447 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.52 -42.26 95.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 C-N-CA 119.701 -0.799 . . . . 0.0 109.341 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.411 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.7 OUTLIER -59.86 -44.42 94.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.32 179.091 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 83.9 t -51.23 -47.52 33.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.615 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.11 93.88 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -58.78 -45.16 90.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.857 0.361 . . . . 0.0 110.488 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.7 tp -56.77 -45.73 81.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.021 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.42 -46.77 82.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.204 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 14.2 mt -60.25 -39.74 87.84 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.062 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.2 m -57.68 -40.59 79.77 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.388 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.5 t -66.41 -51.8 53.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.474 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 11.1 mp -62.53 -52.95 61.41 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 120.939 -0.304 . . . . 0.0 111.274 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.429 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.9 mt -56.84 -51.33 69.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.111 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.94 -46.46 32.23 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.088 0.47 . . . . 0.0 109.857 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.537 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.91 -39.31 74.19 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.429 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.83 -38.51 91.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.455 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.53 -47.19 89.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -63.75 -41.37 98.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.206 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -56.44 -46.54 80.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.1 tp . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.32 -179.763 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 8.4 p . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.613 0.244 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.432 ' H ' ' CB ' ' B' ' 5' ' ' SER . 35.8 m 35.08 36.38 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.346 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -82.23 -40.19 0.92 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.377 179.133 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 72.4 Cg_exo -46.41 -40.45 22.72 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.647 2.232 . . . . 0.0 112.58 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.549 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.31 -48.09 0.7 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.474 ' N ' ' O ' ' A' ' 6' ' ' PRO . 71.3 t -53.83 -39.28 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.465 HD23 HD12 ' A' ' 12' ' ' ILE . 81.2 mt -56.05 -37.99 69.99 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.59 -33.08 73.27 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 177.245 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -63.37 -32.24 83.48 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.732 HG21 HG12 ' B' ' 13' ' ' VAL . 70.8 mt -67.2 -41.98 87.46 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 42.5 t -59.29 -55.17 25.41 Favored 'Isoleucine or valine' 0 C--O 1.241 0.613 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.481 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.425 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.7 t -61.02 -36.86 75.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.498 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.48 -40.47 99.14 Favored Glycine 0 C--O 1.224 -0.513 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -64.16 -51.26 64.68 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.008 0.433 . . . . 0.0 110.281 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 tp -56.86 -47.34 80.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.848 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' VAL . 77.8 t -63.44 -28.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.758 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.461 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -64.53 -56.64 12.74 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.68 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.4 m -56.09 -40.4 73.59 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.649 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.33 -32.52 57.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.727 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.47 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.41 -55.23 9.55 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.15 -178.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 80.0 mt -66.66 -43.65 90.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.574 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.41 -41.38 89.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.217 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.2 tp -69.18 -31.79 70.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.273 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.72 -50.51 68.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.799 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -66.32 -38.1 81.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.472 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -61.83 -46.52 89.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.575 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -69.46 -49.13 57.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.744 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.3 tp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.464 -179.977 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.6 tp10 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.839 0.352 . . . . 0.0 110.573 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.7 t -65.59 -28.98 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.581 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 tp -60.74 -29.29 69.28 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.78 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -54.64 -49.55 60.9 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.8 mm -55.38 -48.51 76.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.028 0.442 . . . . 0.0 110.651 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 74.2 mt -61.53 -34.96 63.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.483 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.433 ' O ' HG23 ' A' ' 47' ' ' VAL . 13.9 m -61.53 -51.7 67.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.692 -179.241 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 12.4 pt -63.06 -42.22 95.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.924 -179.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 71.7 t -60.24 -43.99 94.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.375 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.09 -34.7 79.03 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 43' ' ' SER . 50.4 t -66.78 -34.73 71.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.76 -47.98 64.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.457 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 4.5 m -60.87 -48.73 80.47 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.711 -0.396 . . . . 0.0 111.494 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 46' ' ' LEU . 16.9 m -69.91 -33.83 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -178.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.635 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.3 tp -65.69 -52.59 50.22 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.269 -0.572 . . . . 0.0 110.744 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.29 -50.53 72.63 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.312 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 48.5 p -60.34 -43.12 96.75 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.421 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 90.4 mt -72.95 -44.52 57.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.362 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -177.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.635 HG22 ' O ' ' A' ' 51' ' ' LEU . 11.4 m -77.04 -28.34 16.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.384 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.0 tp -82.58 -39.44 22.26 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 114.566 1.321 . . . . 0.0 114.566 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 mm -75.45 -63.79 0.64 Allowed Pre-proline 0 N--CA 1.475 0.824 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.421 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 12.2 Cg_endo -53.09 -38.68 80.91 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.766 1.644 . . . . 0.0 112.146 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -67.33 -59.63 3.25 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 121.055 -0.258 . . . . 0.0 110.666 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.53 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.531 0.219 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.864 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 4' ' ' VAL . . . . . 0.512 HG23 ' N ' ' B' ' 5' ' ' SER . 18.2 m . . . . . 0 N--CA 1.462 0.15 0 CA-C-O 120.953 0.406 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 5' ' ' SER . . . . . 0.521 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -40.51 -63.99 0.65 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.37 179.803 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 17.9 Cg_endo -57.9 3.62 0.12 Allowed 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.27 1.98 . . . . 0.0 112.231 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . 0.767 ' O ' ' HB3' ' B' ' 10' ' ' ALA . . . -115.14 -68.07 0.44 Allowed Glycine 0 CA--C 1.527 0.83 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.622 HG23 ' N ' ' B' ' 9' ' ' LEU . 7.4 m -58.19 -52.55 57.35 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.214 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.622 ' N ' HG23 ' B' ' 8' ' ' VAL . 42.1 mt -54.84 -31.76 59.76 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.86 -36.34 72.2 Favored 'General case' 0 C--O 1.244 0.775 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -66.71 -30.93 77.04 Favored Glycine 0 CA--C 1.528 0.875 0 CA-C-N 113.768 -1.56 . . . . 0.0 111.319 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.465 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.2 mp -71.32 -39.8 72.71 Favored 'Isoleucine or valine' 0 C--N 1.34 0.194 0 C-N-CA 119.684 -0.807 . . . . 0.0 109.4 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.732 HG12 HG21 ' A' ' 12' ' ' ILE . 1.5 m -57.92 -44.44 86.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.3 t -59.48 -48.85 85.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 CA-C-O 121.18 0.514 . . . . 0.0 110.267 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -34.85 81.27 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -65.76 -39.41 91.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.878 0.37 . . . . 0.0 110.154 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.91 -47.41 86.51 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.86 -35.17 74.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.895 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.43 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -65.59 -48.78 71.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.482 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 99.6 m -59.76 -44.24 93.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.884 0.374 . . . . 0.0 110.542 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.2 t -63.98 -40.72 90.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -59.01 -51.06 71.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.821 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.438 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 66.6 mt -59.06 -48.02 88.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.995 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.53 -46.85 39.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.03 0.443 . . . . 0.0 109.925 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -58.05 -40.48 81.04 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.65 -37.08 80.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.281 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 50.3 t -62.26 -42.28 94.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 61.5 t80 -63.19 -38.92 93.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.981 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -60.99 -41.07 95.77 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.742 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.7 tp . . . . . 0 C--N 1.329 -0.294 0 C-N-CA 120.829 -0.349 . . . . 0.0 110.278 -179.858 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.667 ' HB2' ' H1 ' ' B' ' 1' ' ' CYS . 40.4 t . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.1 m -160.56 170.17 21.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.575 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.7 t -152.07 145.23 24.61 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.489 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.474 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.22 31.47 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.142 0.496 . . . . 0.0 111.159 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.557 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.5 OUTLIER -84.82 -44.09 0.69 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.262 179.317 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.557 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.0 Cg_exo -45.37 -43.94 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 122.731 2.287 . . . . 0.0 112.871 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -50.45 0.82 Allowed Glycine 0 N--CA 1.464 0.502 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' PRO . 75.8 t -52.8 -35.13 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.9 mt -55.35 -41.7 72.85 Favored 'General case' 0 C--O 1.238 0.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.35 -37.58 75.48 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 177.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.3 -27.96 68.49 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.453 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -68.81 -39.03 79.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.9 t -62.08 -51.32 73.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.846 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.47 -43.04 89.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.72 -38.87 92.75 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.466 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 51.2 t0 -65.57 -46.59 78.88 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.916 0.389 . . . . 0.0 110.685 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.5 tp -56.31 -51.36 68.52 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.766 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 m -65.63 -27.32 41.2 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.323 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.578 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.84 -57.33 13.13 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.515 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -56.98 -42.47 80.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.113 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -65.7 -37.73 80.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.288 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -67.57 -54.47 19.6 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.404 -178.539 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 21.2 mm -66.21 -44.72 91.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.484 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.78 -39.59 77.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.911 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.0 tp -68.52 -34.5 75.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.023 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.58 -50.72 72.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.624 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -68.05 -39.42 81.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -60.58 -33.69 73.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -55.67 -50.09 71.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.75 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.0 tp -67.94 -43.61 78.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.6 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.96 41.73 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -163.7 67.76 0.18 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.599 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.59 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.9 mp 46.31 87.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.41 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 165.25 -34.14 0.25 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 61.3 p -74.93 -19.01 60.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.779 0.323 . . . . 0.0 110.555 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 58.99 177.95 0.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.397 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 53.96 15.23 0.81 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.361 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 m -57.53 -26.7 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.459 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.0 tp -46.26 -29.12 1.49 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.655 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -55.56 -48.82 68.34 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.666 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.0 mp -56.6 -40.77 71.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.002 0.429 . . . . 0.0 110.104 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -64.9 -41.22 91.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.205 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.7 t -58.1 -51.79 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.618 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.423 ' H ' HG12 ' A' ' 44' ' ' ILE . 6.5 pt -63.14 -39.89 86.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.91 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.0 t -64.71 -30.68 50.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.171 -0.612 . . . . 0.0 109.83 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.559 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -71.21 -47.69 55.9 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.937 -178.905 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.8 p -67.73 -30.49 48.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.626 -178.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.458 ' HB2' HD22 ' B' ' 19' ' ' LEU . . . -70.51 -53.3 16.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.377 -179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.1 m -57.98 -47.1 83.99 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.256 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.5 m -71.11 -28.83 34.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.881 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.606 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.0 tp -67.36 -55.7 12.71 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 119.882 -0.727 . . . . 0.0 110.821 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.466 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.0 OUTLIER -64.8 -45.27 86.98 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.099 179.614 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -60.77 -45.16 95.42 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -178.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.492 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.4 mt -73.45 -43.25 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -177.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.1 m -76.89 -33.13 20.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.365 -178.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.6 tp -79.47 -41.62 27.12 Favored 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.428 ' O ' ' CB ' ' A' ' 61' ' ' GLU . 25.9 mt -64.09 -62.11 5.72 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 119.047 -1.061 . . . . 0.0 113.23 -176.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.492 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 7.0 Cg_endo -47.35 -27.14 6.59 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 121.924 1.749 . . . . 0.0 112.504 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.431 ' CD1' HG21 ' B' ' 8' ' ' VAL . 0.9 OUTLIER -90.24 -65.62 1.0 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 120.384 -0.527 . . . . 0.0 109.809 179.52 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.485 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? -57.16 -15.99 6.88 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.649 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.428 ' CB ' ' O ' ' A' ' 57' ' ' ILE . 34.7 tt0 -77.94 139.61 39.2 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.657 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -67.94 85.9 0.23 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.436 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 60.9 t30 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.576 -179.857 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.667 ' H1 ' ' HB2' ' A' ' 1' ' ' CYS . 85.8 m . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.406 ' O ' ' OG1' ' B' ' 3' ' ' THR . 18.5 t -71.72 -24.28 61.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.538 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.406 ' OG1' ' O ' ' B' ' 2' ' ' SER . 36.3 p 52.28 100.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.669 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.527 HG23 ' N ' ' B' ' 5' ' ' SER . 32.6 m -79.15 -42.72 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.685 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.527 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.1 OUTLIER -38.7 -59.21 1.41 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.177 179.848 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.419 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 33.6 Cg_endo -64.38 13.86 0.09 OUTLIER 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 121.528 1.486 . . . . 0.0 111.783 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.513 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -113.01 -66.92 0.49 Allowed Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.431 HG21 ' CD1' ' A' ' 59' ' ' PHE . 0.0 OUTLIER -67.15 -51.92 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 9.6 mt -57.82 -39.15 76.93 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.419 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -58.07 -38.72 76.89 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 108.112 -1.069 . . . . 0.0 108.112 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.88 -30.96 79.38 Favored Glycine 0 CA--C 1.522 0.519 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.099 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 50.5 mm -66.23 -43.34 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 C-N-CA 120.079 -0.648 . . . . 0.0 109.769 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.453 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.9 OUTLIER -60.29 -42.0 89.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.838 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.87 -42.6 89.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.706 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.85 -39.25 97.26 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -61.51 -40.47 94.72 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -62.88 -44.93 94.79 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.102 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.4 -44.34 92.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.301 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.458 HD22 ' HB2' ' A' ' 48' ' ' ALA . 69.8 mt -66.54 -30.3 70.58 Favored 'General case' 0 C--O 1.225 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 110.212 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 21.8 m -62.58 -50.2 72.25 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.519 -0.472 . . . . 0.0 110.239 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 71.8 t -70.42 -43.28 78.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.554 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.45 -53.06 60.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.823 0.344 . . . . 0.0 111.194 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.47 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 76.3 mt -59.45 -50.64 79.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.965 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.39 38.14 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -57.25 -39.39 75.49 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.11 -35.37 78.5 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.133 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.97 -47.05 95.0 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.2 t80 -63.02 -40.43 97.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.125 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -55.67 -44.67 77.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.438 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 28.3 tp -59.88 -44.07 94.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.216 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 70.72 140.87 0.19 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 . . . . . 0 C--N 1.328 -0.352 0 CA-C-O 120.844 0.354 . . . . 0.0 110.532 -179.932 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 42.3 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.5 t -161.09 125.25 3.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.537 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 5' ' ' SER . 8.3 p -83.62 163.29 20.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.621 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.2 m 33.86 34.6 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.198 0.523 . . . . 0.0 111.239 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.578 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -84.94 -42.97 0.68 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.335 179.308 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 5' ' ' SER . 75.5 Cg_exo -46.38 -44.1 20.93 Favored 'Trans proline' 0 N--CA 1.495 1.598 0 C-N-CA 122.745 2.297 . . . . 0.0 112.807 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.496 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.55 -48.33 0.75 Allowed Glycine 0 N--CA 1.464 0.518 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.462 ' H ' ' C ' ' A' ' 6' ' ' PRO . 62.5 t -53.87 -36.38 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' HG22 ' A' ' 12' ' ' ILE . 50.1 mt -55.07 -40.99 70.95 Favored 'General case' 0 C--O 1.238 0.461 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.2 -37.96 75.82 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.34 -28.02 66.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 178.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.427 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -67.8 -41.05 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.304 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 57.4 t -60.0 -53.09 53.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 121.467 0.651 . . . . 0.0 109.573 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.8 t -58.62 -34.63 51.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.964 179.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.32 -34.79 90.38 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -69.25 -44.7 71.42 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.8 tp -66.9 -51.27 57.4 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.42 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 14' ' ' VAL . 22.6 m -59.65 -35.02 57.14 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.328 -179.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.401 HD23 ' OD1' ' B' ' 16' ' ' ASP . 40.8 tp -64.39 -52.84 56.21 Favored 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.537 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.528 HG21 ' CB ' ' A' ' 48' ' ' ALA . 15.0 m -50.48 -49.83 54.24 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.901 -0.319 . . . . 0.0 111.439 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.6 p -70.73 -31.06 44.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 120.197 -0.601 . . . . 0.0 112.464 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.527 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.3 OUTLIER -67.73 -54.6 18.03 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.586 -179.47 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 27.5 mt -63.96 -50.47 77.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.387 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.27 -41.53 68.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.351 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 29.6 tp -63.58 -42.53 98.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.09 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.9 -48.22 70.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.342 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.1 t -63.85 -39.85 86.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.606 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -59.01 -48.02 83.09 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -61.06 -48.53 81.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.683 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.7 tp -66.7 -39.35 88.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.573 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -76.99 -106.45 0.15 Allowed Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 60.61 80.64 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.86 0.362 . . . . 0.0 110.475 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.576 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.4 mp 55.22 179.34 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.4 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.61 1.33 90.5 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 69.8 p -151.72 -4.3 0.27 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.735 0.302 . . . . 0.0 110.488 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 46.37 -162.09 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.597 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 54.25 31.44 14.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.452 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 16.4 m -63.49 -23.52 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.773 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.0 tp -44.03 -28.11 0.44 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.14 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -60.78 -49.51 77.85 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.667 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -49.09 76.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.09 0.472 . . . . 0.0 109.989 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.683 ' N ' HD12 ' A' ' 42' ' ' ILE . 2.0 mp -61.33 -31.4 50.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.981 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.9 t -62.26 -50.99 69.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.438 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.6 pt -66.11 -35.79 75.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.141 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.6 t -67.05 -40.1 84.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.448 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 46' ' ' LEU . 0.8 OUTLIER -68.14 -44.73 75.42 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.841 -178.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 3.6 p -69.48 -28.71 39.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.817 -178.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.528 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -70.75 -51.76 25.15 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.772 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.7 p -60.09 -40.85 91.03 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.537 -0.465 . . . . 0.0 110.756 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.37 -41.09 78.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.648 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.509 ' O ' HG22 ' A' ' 55' ' ' VAL . 21.5 tp -65.47 -54.91 21.64 Favored 'General case' 0 CA--C 1.517 -0.295 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.793 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 56' ' ' LEU . 0.6 OUTLIER -58.58 -43.21 89.4 Favored 'General case' 0 C--O 1.219 -0.518 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.727 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 99.1 m -60.38 -50.74 72.39 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 112.238 0.459 . . . . 0.0 112.238 -179.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.495 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.3 mt -69.23 -43.95 80.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -177.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.526 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 6.6 m -76.21 -31.18 20.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.148 -0.621 . . . . 0.0 111.85 -178.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.407 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 8.6 tp -75.71 -37.96 58.99 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 113.202 0.815 . . . . 0.0 113.202 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.23 -51.41 78.48 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.56 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.495 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 59.3 Cg_endo -72.71 -28.73 13.61 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.54 1.493 . . . . 0.0 111.283 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.3 m-30 -67.32 -53.88 25.68 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.131 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.491 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -78.36 21.98 0.34 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.379 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 59' ' ' PHE . 89.4 mt-10 -148.66 159.51 44.04 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.523 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.49 ' OE1' ' ND2' ' A' ' 63' ' ' ASN . 7.8 tm0? -68.09 -41.63 81.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.378 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.49 ' ND2' ' OE1' ' A' ' 62' ' ' GLN . 2.5 p30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.549 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.526 ' O ' ' N ' ' B' ' 3' ' ' THR . 10.3 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.419 ' O ' ' OG1' ' B' ' 3' ' ' THR . 6.4 t 62.21 -70.93 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.614 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.526 ' N ' ' O ' ' B' ' 1' ' ' CYS . 8.3 p 57.84 63.62 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.84 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.431 ' O ' HG22 ' B' ' 8' ' ' VAL . 25.4 m -75.3 -34.66 31.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.336 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.518 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.2 OUTLIER -39.59 -62.15 0.89 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.429 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -62.2 10.61 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.154 1.903 . . . . 0.0 112.388 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.19 -65.52 0.29 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.431 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.0 OUTLIER -60.7 -51.96 67.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 121.215 0.531 . . . . 0.0 110.285 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.6 mt -60.49 -34.38 73.97 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.478 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -58.59 -35.93 73.2 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.2 -40.65 98.18 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.685 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 45.5 mm -58.0 -45.7 87.97 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.986 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.427 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -57.29 -44.69 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 C-N-CA 119.625 -0.83 . . . . 0.0 109.251 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.96 -41.42 76.93 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.3 -41.72 98.5 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' HD23 ' A' ' 19' ' ' LEU . 24.5 t0 -60.36 -41.4 93.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.359 . . . . 0.0 110.213 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.8 tp -61.2 -43.95 98.06 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.046 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -57.85 -47.97 84.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.048 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 74.7 mt -61.43 -36.28 79.92 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.013 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -57.63 -43.78 85.1 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.215 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -69.24 -47.15 75.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.733 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 10.0 mp -62.08 -51.9 66.09 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.105 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.449 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -57.58 -50.3 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.9 -45.17 40.94 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 121.256 0.551 . . . . 0.0 109.942 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 4.9 tp -65.19 -30.08 70.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.119 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.17 -50.07 67.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.219 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -64.1 -38.28 82.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 C-N-CA 120.406 -0.518 . . . . 0.0 109.879 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -61.45 -43.11 99.44 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -60.62 -47.09 87.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.676 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 4.9 tp -61.06 -40.68 94.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.466 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -165.83 -89.23 0.07 OUTLIER Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.8 ttt85 . . . . . 0 C--N 1.328 -0.348 0 CA-C-O 120.778 0.323 . . . . 0.0 110.481 179.959 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 47.5 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.6 t -158.59 114.15 2.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.635 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 5' ' ' SER . 5.4 p -82.68 174.7 10.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.629 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.462 ' N ' ' OG ' ' B' ' 5' ' ' SER . 34.8 m 36.62 26.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.252 0.549 . . . . 0.0 111.212 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.62 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 1.6 t -81.74 -35.43 0.75 Allowed Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.61 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.62 ' CD ' ' N ' ' A' ' 5' ' ' SER . 84.2 Cg_exo -49.45 -41.49 43.7 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.336 2.024 . . . . 0.0 112.554 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.517 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.91 -47.01 0.98 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' PRO . 58.1 t -59.28 -40.64 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.434 ' O ' HG22 ' A' ' 12' ' ' ILE . 3.4 mm? -54.37 -43.03 70.99 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -56.12 -37.6 69.66 Favored 'General case' 0 C--O 1.233 0.184 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.08 -27.46 68.93 Favored Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 178.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.508 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -68.3 -38.53 79.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.409 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 80.8 t -64.21 -50.89 74.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.15 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.8 t -59.58 -46.1 93.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.18 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.53 -29.2 71.13 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.989 -0.845 . . . . 0.0 110.989 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.512 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 53.3 t0 -67.45 -52.64 37.11 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 110.387 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 36.3 tp -60.35 -41.23 93.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.127 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.5 -26.45 31.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.468 HD23 ' OD1' ' B' ' 16' ' ' ASP . 37.3 tp -71.43 -57.42 4.45 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.84 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.444 HG23 ' N ' ' A' ' 21' ' ' VAL . 14.0 t -62.3 -40.43 96.26 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.383 -0.527 . . . . 0.0 111.145 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.444 ' N ' HG23 ' A' ' 20' ' ' THR . 53.5 t -69.32 -43.82 80.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.662 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -60.54 -51.6 68.75 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.333 -178.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 63.7 mt -63.08 -42.48 96.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.942 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -43.88 78.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.96 0.41 . . . . 0.0 110.324 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.1 tp -65.96 -36.24 82.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.47 -50.79 71.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.795 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.3 m -69.21 -32.56 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.48 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -61.93 -41.31 97.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.716 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -61.73 -45.39 94.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.651 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.04 -43.66 98.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.561 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.19 156.19 52.96 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -162.54 89.67 0.69 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.78 0.324 . . . . 0.0 110.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.7 mt 51.75 38.18 22.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.567 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 176.32 111.95 0.3 Allowed Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.4 t -161.04 173.63 14.93 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.787 0.327 . . . . 0.0 110.634 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.444 ' H ' HD13 ' B' ' 30' ' ' LEU . . . -74.2 106.43 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.581 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 36' ' ' ALA . 50.1 mt-10 49.85 100.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.563 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 63.5 t -68.17 -28.74 42.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.636 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.6 mm? -63.77 -31.29 72.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -62.23 -50.28 66.56 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.3 mt -58.19 -44.3 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.092 0.473 . . . . 0.0 110.453 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.14 -38.65 82.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.471 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.5 m -59.94 -52.16 66.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.736 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.3 pt -62.11 -42.39 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.649 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.4 t -60.66 -35.24 62.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.0 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.553 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.5 OUTLIER -69.6 -39.16 77.41 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.529 -179.181 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -68.69 -30.46 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.622 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.18 -52.1 25.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.981 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -44.77 90.78 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.622 -0.431 . . . . 0.0 111.8 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.0 m -68.17 -40.32 82.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.563 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.619 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.5 tp -63.33 -45.81 89.54 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.456 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.512 ' NZ ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -62.03 -49.97 73.9 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.742 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.637 ' O ' HD13 ' A' ' 57' ' ' ILE . 25.4 p -62.66 -47.54 83.24 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.605 0.595 . . . . 0.0 112.605 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.482 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 87.4 mt -64.03 -46.05 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.619 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.0 m -76.36 -34.62 25.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.153 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.3 tt -68.27 -35.27 77.63 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 113.574 0.954 . . . . 0.0 113.574 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.637 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -65.42 -52.74 43.33 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 119.456 -0.898 . . . . 0.0 112.127 -177.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 57.6 Cg_endo -71.7 -29.57 15.69 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 121.591 1.527 . . . . 0.0 111.466 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.559 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.7 m-30 -64.28 -48.53 75.37 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.226 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -84.12 26.34 0.76 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.428 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -139.82 147.54 40.88 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.347 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.2 mm-40 -73.03 143.95 47.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.65 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 18.8 p30 . . . . . 0 C--N 1.331 -0.211 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.848 179.947 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 9.9 m . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 40.4 m -159.74 -35.33 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.371 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p 45.78 72.86 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.922 179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.536 HG23 ' N ' ' B' ' 5' ' ' SER . 30.0 m -81.78 -43.44 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.349 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.536 ' N ' HG23 ' B' ' 4' ' ' VAL . 0.4 OUTLIER -38.49 -64.2 0.49 Allowed Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.584 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.4 Cg_endo -59.31 6.22 0.1 OUTLIER 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.328 2.019 . . . . 0.0 112.296 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.518 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -117.78 -66.29 0.34 Allowed Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.451 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -60.68 -51.95 67.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-O 121.091 0.472 . . . . 0.0 110.11 -179.871 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 49.4 mt -57.66 -37.2 73.0 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.23 -34.48 68.63 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 177.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -36.49 91.48 Favored Glycine 0 CA--C 1.524 0.649 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.328 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 11.3 mt -65.42 -41.39 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 119.496 -0.882 . . . . 0.0 109.394 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.508 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.4 m -57.69 -44.2 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -54.29 -50.34 57.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.169 -0.613 . . . . 0.0 109.677 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -58.17 -31.97 66.57 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.468 ' OD1' HD23 ' A' ' 19' ' ' LEU . 30.5 t0 -69.38 -41.04 77.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.774 0.321 . . . . 0.0 110.835 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 20.7 tp -61.49 -52.39 64.7 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 121.008 0.432 . . . . 0.0 110.402 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -58.42 -39.12 73.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.128 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.3 mt -60.85 -53.08 61.72 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.61 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.453 ' OG1' HD21 ' A' ' 19' ' ' LEU . 8.3 m -48.26 -45.84 35.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.528 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 91.8 t -65.37 -33.83 66.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.723 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.9 tp -68.23 -53.76 22.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.49 -179.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 mm -60.83 -47.16 94.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 C-N-CA 120.658 -0.417 . . . . 0.0 109.931 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.12 -45.04 68.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.045 0.45 . . . . 0.0 109.835 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 31.0 tp -58.93 -38.73 79.65 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.18 -38.27 90.51 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.298 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -61.04 -47.75 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.031 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -61.9 -40.88 96.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.048 179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -57.21 -48.47 78.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.491 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . 0.444 HD13 ' H ' ' A' ' 36' ' ' ALA . 29.8 tp -61.97 -43.14 99.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.389 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.17 120.59 0.01 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 . . . . . 0 C--N 1.328 -0.335 0 CA-C-O 120.771 0.32 . . . . 0.0 110.58 -179.985 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 10.5 m . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.8 m -160.59 67.59 0.34 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.735 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 5' ' ' SER . 81.6 p -82.41 160.51 22.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.314 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.467 ' H ' ' CB ' ' B' ' 5' ' ' SER . 34.2 m 34.78 32.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 121.158 0.504 . . . . 0.0 111.323 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -81.04 -46.34 1.17 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.093 179.292 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 5' ' ' SER . 50.8 Cg_exo -43.27 -43.78 10.24 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.814 2.343 . . . . 0.0 112.996 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.93 -46.88 0.76 Allowed Glycine 0 N--CA 1.463 0.464 0 N-CA-C 108.932 -1.667 . . . . 0.0 108.932 -179.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' PRO . 75.2 t -55.53 -38.95 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.4 HD23 ' HA ' ' A' ' 9' ' ' LEU . 87.6 mt -55.8 -36.79 67.79 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.57 -37.68 84.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 177.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -29.21 71.06 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 178.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.69 -42.89 93.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 96.4 t -57.86 -51.13 74.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.3 t -58.47 -30.21 40.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.931 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.43 -38.44 90.99 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -68.2 -44.67 75.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.037 0.446 . . . . 0.0 110.226 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 21.9 tp -58.54 -51.38 70.13 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.932 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.6 m -65.0 -29.59 47.85 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.317 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.716 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -60.4 -59.57 5.19 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 120.046 -0.662 . . . . 0.0 109.402 179.523 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.45 HG21 ' HB1' ' A' ' 48' ' ' ALA . 70.5 p -52.2 -43.21 64.08 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.005 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.27 -30.02 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 112.103 0.408 . . . . 0.0 112.103 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.7 -55.21 9.2 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.18 -178.869 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 54.5 mt -68.64 -41.01 82.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.254 -0.578 . . . . 0.0 110.352 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.2 -42.83 95.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.138 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -67.82 -32.39 72.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.737 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.45 -51.1 70.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.641 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.5 m -66.54 -36.98 78.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.413 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -60.16 -45.62 92.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.644 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.3 t80 -64.79 -41.12 96.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.745 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.15 -41.29 92.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.74 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -48.2 147.39 4.71 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -171.77 71.69 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 33' ' ' LEU . 7.7 mp 51.01 62.94 2.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.321 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -172.96 1.43 0.03 OUTLIER Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.1 t -73.35 177.95 4.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.742 0.306 . . . . 0.0 110.519 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -158.28 134.1 9.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.551 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 55.62 65.22 1.52 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.551 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 20.8 m -68.33 -25.95 32.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -46.43 -30.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.655 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.64 -49.81 62.34 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -58.12 -44.85 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.026 0.441 . . . . 0.0 110.51 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.9 mt -63.43 -36.88 77.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.569 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 47' ' ' VAL . 65.6 m -61.04 -51.47 69.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.506 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.407 HG12 ' H ' ' A' ' 44' ' ' ILE . 9.7 pt -62.66 -43.36 98.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.935 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -58.69 -44.0 88.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.019 0.437 . . . . 0.0 110.233 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -64.62 -36.06 83.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.701 -179.355 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 43' ' ' SER . 53.8 t -65.84 -34.08 67.91 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-O 121.087 0.47 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.602 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -68.45 -53.81 21.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.382 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 6.3 m -55.49 -49.22 73.12 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.075 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 46' ' ' LEU . 13.3 m -70.51 -26.34 28.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.617 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.668 ' O ' HG22 ' A' ' 55' ' ' VAL . 27.6 tp -65.98 -56.06 13.57 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.036 -0.666 . . . . 0.0 110.867 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.602 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 1.4 mppt? -65.16 -44.38 88.71 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.394 -0.522 . . . . 0.0 110.244 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.8 m -60.7 -44.97 95.92 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.474 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 96.0 mt -74.05 -41.73 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 51' ' ' LEU . 18.9 m -77.23 -32.54 19.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.254 -178.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 tp -78.41 -44.22 25.39 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.452 ' O ' ' N ' ' A' ' 61' ' ' GLU . 33.9 mt -59.81 -61.9 6.96 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 119.278 -0.969 . . . . 0.0 113.039 -176.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.474 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -49.31 -26.55 11.7 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 C-N-CA 122.135 1.89 . . . . 0.0 112.233 -179.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.663 ' CG ' HG11 ' B' ' 8' ' ' VAL . 2.8 m-85 -92.27 -64.8 1.06 Allowed 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.499 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -60.4 -11.09 5.81 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.132 -0.627 . . . . 0.0 110.196 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 57' ' ' ILE . 31.5 mm-40 -135.02 110.56 9.15 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.928 0.394 . . . . 0.0 110.543 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -72.4 -36.95 68.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.477 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 17.8 m120 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.525 179.984 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.413 ' OG ' ' N ' ' B' ' 3' ' ' THR . 3.3 p 72.58 -53.1 0.7 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.449 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.413 ' N ' ' OG ' ' B' ' 2' ' ' SER . 64.9 p 45.37 61.44 2.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.813 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.433 HG23 ' N ' ' B' ' 5' ' ' SER . 22.4 m -72.28 -37.21 58.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.326 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.503 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -41.84 -64.69 0.61 Allowed Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.179 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.5 Cg_endo -60.33 6.22 0.12 Allowed 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 122.257 1.971 . . . . 0.0 111.956 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.503 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.46 -65.11 0.28 Allowed Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.663 HG11 ' CG ' ' A' ' 59' ' ' PHE . 16.1 m -59.94 -52.16 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.483 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.636 ' N ' HG23 ' B' ' 8' ' ' VAL . 39.1 mt -54.16 -39.11 66.27 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.27 -36.72 71.36 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.66 -34.53 88.88 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.896 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.426 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.54 -46.96 88.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 119.438 -0.905 . . . . 0.0 109.302 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -53.56 -42.47 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.047 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 84.2 t -57.92 -44.72 87.16 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.907 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.52 -37.47 94.21 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -61.81 -41.99 98.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 0.0 110.142 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 58.4 tp -61.28 -44.38 97.32 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.35 -41.53 87.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.007 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.464 HD22 ' HB2' ' A' ' 48' ' ' ALA . 20.5 mt -64.55 -35.5 81.19 Favored 'General case' 0 C--O 1.225 -0.208 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.064 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 96.0 m -61.79 -48.83 78.86 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.632 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 61.7 t -68.42 -47.64 76.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.525 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 29.2 tp -60.86 -51.9 67.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.303 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 79.0 mt -57.65 -50.61 76.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.48 -46.02 37.58 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.024 0.44 . . . . 0.0 109.934 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.53 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.21 -41.03 78.67 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.113 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.74 -37.21 83.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.403 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.41 -46.51 95.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -61.46 -41.02 96.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.177 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 45.0 t80 -59.34 -44.51 92.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.61 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 30.1 tp -55.87 -41.83 74.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.28 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 78.89 161.16 19.74 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 64.3 mtp85 . . . . . 0 C--N 1.331 -0.236 0 CA-C-O 120.787 0.327 . . . . 0.0 110.572 179.997 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.527 ' SG ' ' N ' ' B' ' 1' ' ' CYS . 55.9 m . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.0 t -76.7 115.52 16.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.668 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.459 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.6 OUTLIER -82.48 169.73 16.04 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.385 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.466 ' H ' ' HB2' ' B' ' 5' ' ' SER . 26.9 m 33.11 34.84 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.082 0.468 . . . . 0.0 111.637 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -86.91 -41.57 0.54 Allowed Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.304 179.313 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.2 Cg_exo -47.9 -45.03 25.86 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.659 2.239 . . . . 0.0 112.703 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.76 -49.21 0.82 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 -179.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 6' ' ' PRO . 69.0 t -54.96 -41.72 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 71.4 mt -55.22 -37.9 67.75 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.09 -36.9 75.92 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -61.14 -28.87 69.74 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 178.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -66.6 -40.89 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.51 -50.44 80.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.71 179.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.1 t -58.29 -44.62 88.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.713 179.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.51 -36.55 78.01 Favored Glycine 0 CA--C 1.525 0.674 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.037 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.2 t0 -65.21 -48.66 72.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.904 0.383 . . . . 0.0 110.592 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 28.7 tp -55.53 -51.64 66.36 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.716 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 m -64.36 -28.72 45.51 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 C-N-CA 120.213 -0.595 . . . . 0.0 110.801 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.424 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -61.26 -56.87 15.61 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.946 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.3 m -55.14 -42.39 72.99 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.415 179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.48 -29.05 44.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.829 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.47 -53.86 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 121.012 -0.275 . . . . 0.0 111.193 -178.757 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.516 ' CG2' HG21 ' B' ' 23' ' ' ILE . 11.8 mt -66.15 -42.81 91.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.402 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.25 -39.5 90.55 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.992 0.425 . . . . 0.0 110.429 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 33.0 tp -69.14 -37.54 78.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.041 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.61 -50.4 73.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 26.0 m -67.63 -35.69 73.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.634 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -60.31 -41.83 94.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.528 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -65.77 -38.75 89.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.721 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.9 tp -59.78 -43.33 94.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.539 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.98 115.69 4.58 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.9 mmt85 -81.21 44.89 0.8 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.76 0.314 . . . . 0.0 110.482 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.4 mt 58.75 158.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.487 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.58 12.15 84.78 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 29.0 p -78.57 -11.8 59.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.779 0.323 . . . . 0.0 110.496 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 52.46 -175.13 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.539 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 47.36 22.78 0.29 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.401 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.0 m -69.17 -23.94 27.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.74 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.566 HD12 ' N ' ' A' ' 39' ' ' LEU . 9.3 mp -46.06 -35.93 5.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.594 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.79 -46.47 89.9 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 58.8 mt -59.2 -38.29 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.016 0.436 . . . . 0.0 110.6 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.4 mm -67.41 -39.45 82.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -61.46 -52.12 65.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.616 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.401 HG22 HD21 ' B' ' 22' ' ' LEU . 7.1 pt -61.62 -44.67 99.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.905 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.8 t -56.72 -43.53 79.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.519 -0.472 . . . . 0.0 109.792 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.458 ' O ' HG22 ' A' ' 50' ' ' VAL . 64.9 mt -65.21 -32.66 74.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.188 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.12 -36.15 76.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.14 -51.13 41.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.145 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.3 m -56.57 -48.45 77.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.455 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 46' ' ' LEU . 12.8 m -71.36 -28.52 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -178.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.682 ' O ' HG22 ' A' ' 55' ' ' VAL . 64.8 tp -67.74 -54.74 16.88 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 119.856 -0.738 . . . . 0.0 110.839 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.504 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 2.1 mptp? -65.24 -44.84 86.89 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.42 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.642 ' O ' HD13 ' A' ' 57' ' ' ILE . 23.9 m -61.09 -47.19 87.46 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.486 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 96.1 mt -70.93 -42.95 77.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 51' ' ' LEU . 16.5 m -75.68 -36.58 34.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.509 -178.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -71.85 -39.28 69.81 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 -178.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 53' ' ' THR . 1.4 mp -60.39 -50.44 85.72 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.371 0.878 . . . . 0.0 113.371 -177.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.486 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 7.4 Cg_endo -50.65 -43.96 42.99 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 CA-C-N 120.718 1.292 . . . . 0.0 111.64 -178.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.71 ' CG ' HG11 ' B' ' 8' ' ' VAL . 24.2 m-85 -74.56 -68.01 0.58 Allowed 'General case' 0 N--CA 1.433 -1.275 0 CA-C-O 120.742 0.306 . . . . 0.0 110.665 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.485 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -53.24 -22.62 7.13 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.298 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 57' ' ' ILE . 66.1 mm-40 -143.92 111.05 5.77 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.86 0.362 . . . . 0.0 110.268 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -72.84 -31.27 64.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.684 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.2 p30 . . . . . 0 C--N 1.332 -0.194 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.811 -179.917 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.527 ' N ' ' SG ' ' A' ' 1' ' ' CYS . 23.9 p . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.528 ' C ' ' H ' ' B' ' 4' ' ' VAL . 8.1 t 60.22 -75.0 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.647 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.527 ' N ' ' O ' ' B' ' 1' ' ' CYS . 5.9 m 67.69 -30.59 0.17 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.488 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.528 ' H ' ' C ' ' B' ' 2' ' ' SER . 4.7 t 64.57 -66.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.818 -0.174 . . . . 0.0 111.23 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.505 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -33.14 -61.43 0.36 Allowed Pre-proline 0 CA--C 1.535 0.366 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.58 9.39 0.12 Allowed 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.052 1.835 . . . . 0.0 112.194 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -120.69 -63.85 0.25 Allowed Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.964 -0.454 . . . . 0.0 111.964 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.71 HG11 ' CG ' ' A' ' 59' ' ' PHE . 35.2 m -61.52 -55.28 25.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 C-N-CA 120.224 -0.591 . . . . 0.0 110.607 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.8 mt -53.51 -38.1 63.41 Favored 'General case' 0 C--O 1.244 0.788 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.451 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.2 -36.71 71.19 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 177.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -61.86 -35.75 91.78 Favored Glycine 0 CA--C 1.522 0.472 0 CA-C-N 114.194 -1.366 . . . . 0.0 110.976 179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.47 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.5 mp -65.03 -46.25 92.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.572 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.01 -44.49 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 C-N-CA 118.97 -1.092 . . . . 0.0 109.0 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.18 -43.99 77.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.793 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.08 -36.67 92.68 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -60.65 -46.23 91.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.932 0.396 . . . . 0.0 110.107 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.474 ' O ' HD13 ' B' ' 17' ' ' LEU . 0.2 OUTLIER -58.22 -49.35 77.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.622 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 70.0 t -54.04 -45.31 64.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.12 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 91.9 mt -60.19 -50.94 71.68 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.967 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 17.4 m -44.97 -49.44 11.18 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.484 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -62.9 -37.64 79.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.547 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . 0.401 HD21 HG22 ' A' ' 44' ' ' ILE . 20.0 tp -63.74 -50.3 69.64 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.516 HG21 ' CG2' ' A' ' 23' ' ' ILE . 24.4 mm -58.85 -46.11 91.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -52.41 -48.7 65.55 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 32.3 tp -56.17 -37.09 69.08 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.39 -37.45 87.32 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.24 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.81 -47.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -61.2 -40.7 94.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.22 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -58.51 -44.8 89.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.557 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.0 tp -58.17 -40.61 81.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.405 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.99 150.38 8.21 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.784 0.326 . . . . 0.0 110.549 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 45.4 m . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.5 m -80.89 70.74 7.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.653 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 5' ' ' SER . 60.4 p -148.97 132.2 16.45 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.363 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.465 ' H ' ' CB ' ' B' ' 5' ' ' SER . 30.4 m 34.85 29.95 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.219 0.533 . . . . 0.0 111.065 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.619 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -91.26 -38.67 0.38 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.215 179.057 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.3 Cg_exo -48.18 -42.19 33.44 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.429 2.086 . . . . 0.0 112.551 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.606 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.07 -47.14 0.8 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 108.863 -1.695 . . . . 0.0 108.863 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -56.53 -40.85 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.0 mt -55.69 -35.39 65.98 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -62.63 -37.8 87.75 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 177.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.23 -29.12 70.4 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.186 -1.565 . . . . 0.0 109.186 178.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -67.27 -42.58 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.9 t -57.07 -51.89 63.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.103 0.478 . . . . 0.0 109.971 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.4 t -59.2 -43.17 88.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.952 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -36.35 88.08 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.466 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -66.32 -49.75 65.94 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.826 0.346 . . . . 0.0 110.523 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.407 ' O ' HG23 ' A' ' 21' ' ' VAL . 23.0 tp -54.82 -51.02 67.14 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.83 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.5 m -65.18 -29.12 46.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.421 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.995 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -61.12 -58.86 6.6 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 120.33 -0.548 . . . . 0.0 109.999 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -54.9 -40.48 69.84 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.604 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 17' ' ' LEU . 89.9 t -69.57 -30.02 43.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.22 -54.34 13.19 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.103 -178.575 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.465 HG22 HG21 ' B' ' 23' ' ' ILE . 22.0 mt -68.14 -41.53 84.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.535 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.36 -41.76 94.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.444 . . . . 0.0 110.094 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.0 tp -68.2 -32.85 73.36 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.909 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.62 -51.09 70.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.627 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.56 -36.36 77.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.506 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -60.64 -46.25 90.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.506 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -69.0 -45.9 69.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.78 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.2 tp -61.34 -43.72 98.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.552 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -82.25 79.26 1.89 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -63.41 82.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.467 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.582 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.2 mp 45.48 64.15 1.53 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.4 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -73.73 -152.31 2.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.425 ' O ' ' O ' ' A' ' 36' ' ' ALA . 9.5 t -72.55 177.95 4.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.767 0.318 . . . . 0.0 110.536 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.472 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . -60.27 -139.57 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.498 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 54.56 8.0 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.472 ' H ' ' C ' ' A' ' 36' ' ' ALA . 21.9 m -65.77 -24.7 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.697 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.562 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.2 mp -45.91 -29.22 1.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.404 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -56.18 -47.48 81.1 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.58 -38.76 72.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.932 0.396 . . . . 0.0 110.598 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -67.13 -43.14 88.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.168 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -58.54 -51.25 70.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.875 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.405 HG22 HD21 ' B' ' 22' ' ' LEU . 7.9 pt -63.04 -45.02 99.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.814 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.59 -36.36 53.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.633 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.532 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -68.55 -38.43 80.79 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.348 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.82 -31.99 56.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 C-N-CA 120.166 -0.614 . . . . 0.0 109.682 -179.383 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -70.61 -52.36 21.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.482 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.424 ' O ' HG23 ' A' ' 53' ' ' THR . 4.6 m -58.81 -45.26 90.33 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.512 -178.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.51 -31.45 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -179.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.604 ' O ' HG22 ' A' ' 55' ' ' VAL . 56.0 tp -68.07 -53.47 25.32 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 119.816 -0.754 . . . . 0.0 110.954 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 52' ' ' LYS . 11.8 mptt -63.5 -47.12 83.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.732 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 49' ' ' THR . 64.1 p -65.23 -41.92 93.91 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.455 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 97.5 mt -71.52 -46.65 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -177.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 51' ' ' LEU . 8.1 m -74.72 -34.95 35.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.126 -0.63 . . . . 0.0 111.645 -178.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.2 tp -78.35 -41.04 34.64 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.488 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 37.2 mt -53.48 -52.95 62.06 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 57' ' ' ILE . 9.3 Cg_endo -51.1 -44.16 44.09 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 121.228 1.285 . . . . 0.0 112.386 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.485 ' CG ' HG11 ' B' ' 8' ' ' VAL . 9.1 m-85 -75.98 -57.17 4.03 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -45.29 -38.23 5.47 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 120.637 -0.425 . . . . 0.0 109.996 179.494 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -81.61 110.61 17.14 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.529 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -69.76 -23.71 63.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.496 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 30.0 m120 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.498 -179.991 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.415 ' O ' ' O ' ' B' ' 2' ' ' SER . 24.2 m . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.415 ' O ' ' O ' ' B' ' 1' ' ' CYS . 16.3 m 55.76 108.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.491 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 30.8 p -68.69 143.25 54.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.501 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.564 HG23 ' N ' ' B' ' 5' ' ' SER . 18.4 m -147.37 -46.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.57 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -45.9 -64.81 0.8 Allowed Pre-proline 0 CA--C 1.533 0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.608 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 10.5 Cg_endo -52.95 2.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 121.872 1.715 . . . . 0.0 112.283 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.57 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -99.99 -68.76 0.87 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.485 HG11 ' CG ' ' A' ' 59' ' ' PHE . 0.1 OUTLIER -65.25 -49.61 77.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.826 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.2 mt -55.32 -39.9 70.51 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -61.21 -39.17 89.24 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.5 -29.88 74.8 Favored Glycine 0 CA--C 1.52 0.404 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.159 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -69.09 -47.52 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 C-N-CA 119.661 -0.816 . . . . 0.0 108.976 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -53.86 -42.3 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 118.674 -1.21 . . . . 0.0 108.811 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 90.9 t -60.58 -42.34 91.22 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.992 179.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.9 -38.45 96.11 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -61.34 -43.2 99.28 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.7 tp -61.16 -46.98 88.29 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.811 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -58.63 -45.49 90.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 89.4 mt -60.87 -50.35 73.77 Favored 'General case' 0 C--O 1.222 -0.353 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.872 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.9 m -45.74 -50.23 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.471 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.28 -36.88 77.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.617 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . 0.405 HD21 HG22 ' A' ' 44' ' ' ILE . 36.1 tp -63.72 -50.67 68.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.571 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 23' ' ' ILE . 28.6 mm -59.39 -44.27 92.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.27 -47.11 69.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.211 0.529 . . . . 0.0 109.654 179.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.535 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -57.93 -38.93 76.81 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.184 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -61.44 -38.63 87.87 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.258 179.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 73.1 t -60.47 -47.31 93.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -61.2 -40.93 95.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.192 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -58.79 -47.3 85.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.717 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 26.3 tp -59.17 -46.88 87.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.43 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.95 112.32 0.75 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 . . . . . 0 C--N 1.328 -0.366 0 CA-C-O 120.827 0.346 . . . . 0.0 110.47 179.975 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.0 t . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.3 p -73.29 151.01 41.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.545 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.2 t -163.1 165.0 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.613 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.533 ' H ' ' CB ' ' B' ' 5' ' ' SER . 26.9 m 34.68 34.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.228 0.537 . . . . 0.0 111.248 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.621 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -86.57 -37.43 0.52 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.36 179.067 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.621 ' CD ' ' N ' ' A' ' 5' ' ' SER . 99.1 Cg_exo -48.71 -41.2 38.45 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.359 2.04 . . . . 0.0 112.512 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.532 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.72 -47.21 0.74 Allowed Glycine 0 N--CA 1.463 0.491 0 N-CA-C 108.795 -1.722 . . . . 0.0 108.795 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 69.8 t -55.0 -38.24 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 9' ' ' LEU . 68.0 mt -55.32 -39.51 70.03 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.532 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.05 -38.45 79.4 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.63 -26.89 67.29 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -68.04 -42.18 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.86 -54.11 39.89 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.733 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.6 t -58.49 -30.25 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.798 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.44 -38.8 93.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.475 ' OD2' ' NZ ' ' A' ' 52' ' ' LYS . 45.1 t0 -67.62 -45.88 74.15 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.232 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 26.0 tp -57.65 -51.01 71.26 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -66.05 -28.71 44.59 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.774 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.518 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -60.19 -56.99 14.76 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 120.297 -0.561 . . . . 0.0 109.545 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.531 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.3 m -57.99 -41.79 83.78 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.292 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.57 -36.76 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.973 0.36 . . . . 0.0 111.973 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.08 -55.36 12.79 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 121.056 -0.258 . . . . 0.0 111.254 -178.526 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.9 mt -66.42 -44.4 90.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.723 -179.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.29 -43.97 88.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.134 0.492 . . . . 0.0 110.231 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 57.4 tp -67.12 -30.92 71.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.939 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.55 -51.07 68.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.04 -36.11 76.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.365 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -61.82 -48.69 79.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.546 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 61.2 t80 -70.35 -48.47 56.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.669 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.7 tp -62.59 -42.89 99.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.51 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.72 112.37 4.93 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -72.84 149.51 43.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.798 0.332 . . . . 0.0 110.423 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.589 HD22 ' N ' ' A' ' 33' ' ' LEU . 3.2 mm? -73.73 109.86 7.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.215 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 160.88 43.31 0.02 OUTLIER Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -165.05 132.02 2.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.627 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.42 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . -73.26 -140.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.455 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 47.24 19.02 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.474 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.42 ' N ' ' C ' ' A' ' 36' ' ' ALA . 19.6 m -62.64 -27.26 42.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.677 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -48.78 -29.38 4.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.921 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.0 -47.96 83.15 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.62 -45.8 79.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.9 0.381 . . . . 0.0 110.079 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.686 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.9 mp -65.22 -29.48 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.429 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.7 m -65.33 -49.27 70.05 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.543 HD12 HD12 ' B' ' 23' ' ' ILE . 24.4 pt -68.87 -39.2 79.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.473 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.2 t -61.76 -43.05 96.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.125 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.487 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -69.02 -35.93 77.19 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.593 -179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -67.58 -32.92 59.08 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.954 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.531 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.01 -49.93 32.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.6 m -59.55 -48.62 80.94 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.2 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.8 m -64.53 -37.56 80.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.867 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.575 ' O ' HG22 ' A' ' 55' ' ' VAL . 35.3 tp -63.07 -44.15 96.6 Favored 'General case' 0 C--O 1.224 -0.246 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.296 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.475 ' NZ ' ' OD2' ' A' ' 16' ' ' ASP . 3.8 mptp? -59.79 -52.98 63.16 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.49 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.8 m -63.85 -46.46 84.93 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 -178.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 84.9 mt -62.7 -47.5 92.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.5 m -76.47 -35.91 27.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 120.327 -0.549 . . . . 0.0 111.024 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.5 tt -65.24 -33.07 75.13 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 113.091 0.775 . . . . 0.0 113.091 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.438 ' O ' ' OE1' ' A' ' 61' ' ' GLU . 9.7 mt -66.75 -54.79 20.24 Favored Pre-proline 0 CA--C 1.544 0.75 0 C-N-CA 119.549 -0.86 . . . . 0.0 112.692 -178.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' A' ' 61' ' ' GLU . 55.9 Cg_endo -70.09 -28.57 23.5 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.726 1.617 . . . . 0.0 111.033 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.98 -52.0 64.67 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.523 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.446 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.7 mm? -79.21 -3.01 43.69 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.507 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 57' ' ' ILE . 56.9 mp0 -145.01 109.22 4.83 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.281 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 89.3 mm-40 -62.97 -41.64 99.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.554 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.616 -179.938 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 77.5 m . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 5.1 m 53.92 18.08 1.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.588 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p 52.83 94.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.818 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.463 HG23 ' N ' ' B' ' 5' ' ' SER . 28.3 m -74.52 -38.95 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.433 179.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.533 ' CB ' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -38.67 -62.86 0.65 Allowed Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.505 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -59.93 6.99 0.09 OUTLIER 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.197 1.931 . . . . 0.0 112.229 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -116.99 -66.44 0.37 Allowed Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.45 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.1 OUTLIER -58.2 -51.88 65.62 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 121.007 0.432 . . . . 0.0 110.3 -179.898 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 32.2 mt -56.79 -38.42 72.5 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.68 -34.23 67.19 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.13 -36.84 93.42 Favored Glycine 0 CA--C 1.522 0.498 0 CA-C-N 114.135 -1.393 . . . . 0.0 110.884 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 19.6 mt -63.96 -42.53 96.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.567 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.403 HG13 ' H ' ' B' ' 13' ' ' VAL . 1.1 m -56.64 -46.05 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.833 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 86.8 t -52.44 -45.12 45.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 C-N-CA 120.081 -0.647 . . . . 0.0 109.474 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.3 -37.45 91.91 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -60.58 -47.0 88.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.094 0.474 . . . . 0.0 110.175 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.5 tp -56.61 -47.22 80.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.155 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -56.35 -45.54 81.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.272 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 30.0 mt -59.67 -52.84 63.78 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.588 -0.445 . . . . 0.0 109.977 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.1 m -44.64 -47.4 10.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.574 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -63.45 -38.43 82.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.485 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 39.7 tp -64.58 -54.86 25.37 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.67 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.543 HD12 HD12 ' A' ' 44' ' ' ILE . 8.5 mm -55.13 -47.48 77.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.893 -179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -50.98 -49.14 60.78 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 121.118 0.485 . . . . 0.0 109.781 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.1 tp -55.86 -36.46 67.58 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.76 -37.72 88.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.19 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -60.62 -47.69 91.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -62.35 -40.04 95.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.053 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -59.14 -43.8 92.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.551 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.9 tp -59.75 -43.09 94.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.462 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 74.98 142.76 0.89 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 22.0 ttm105 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.783 0.325 . . . . 0.0 110.533 -179.913 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 2' ' ' SER . 31.1 t . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.483 ' N ' ' SG ' ' A' ' 1' ' ' CYS . 42.8 m 51.66 54.95 10.1 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.608 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.1 t -67.39 145.58 54.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.448 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.502 ' H ' ' HB2' ' B' ' 5' ' ' SER . 29.5 m 32.23 34.44 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.561 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -85.49 -40.77 0.62 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.442 179.345 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 90.1 Cg_exo -47.77 -43.01 29.97 Favored 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.695 2.264 . . . . 0.0 112.801 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 10' ' ' ALA . . . 69.98 -52.18 0.75 Allowed Glycine 0 N--CA 1.465 0.568 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' PRO . 63.1 t -50.73 -36.12 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 177.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.412 ' O ' HG22 ' A' ' 12' ' ' ILE . 36.2 mt -55.4 -40.93 72.03 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.524 ' N ' ' O ' ' A' ' 7' ' ' GLY . . . -56.18 -39.07 71.8 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 177.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.9 -27.53 67.03 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.444 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -69.03 -37.15 76.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.398 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.1 t -65.6 -52.65 48.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.22 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.4 t -59.77 -42.63 89.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.138 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.43 73.14 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.346 -0.701 . . . . 0.0 111.346 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -69.94 -54.08 14.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.771 0.319 . . . . 0.0 110.487 -179.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.42 ' O ' HG23 ' A' ' 21' ' ' VAL . 50.2 tp -61.05 -40.71 94.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.204 0.526 . . . . 0.0 109.815 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.6 t -69.23 -27.63 35.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.272 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 tp -72.16 -55.87 6.54 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.802 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 m -62.51 -39.09 92.4 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.235 -0.586 . . . . 0.0 110.975 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 17' ' ' LEU . 94.6 t -70.85 -39.36 75.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.658 -0.246 . . . . 0.0 111.521 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.3 -52.8 56.77 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.387 -178.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.486 HG22 HG21 ' B' ' 23' ' ' ILE . 50.2 mt -65.67 -43.7 93.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.363 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -40.21 81.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.023 0.439 . . . . 0.0 110.404 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -71.1 -35.82 71.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.258 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.75 -50.19 70.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.996 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.435 HG11 ' CG2' ' B' ' 27' ' ' VAL . 29.6 m -69.17 -33.84 60.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.357 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -63.39 -45.26 91.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.456 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -61.18 -50.83 71.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.428 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' GLY . 28.7 mt -70.05 -34.82 73.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.25 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 30' ' ' LEU . . . -55.99 -160.23 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -159.8 127.12 4.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.835 0.35 . . . . 0.0 110.722 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.572 ' H ' HD23 ' A' ' 33' ' ' LEU . 0.2 OUTLIER -84.17 -177.61 6.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.126 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.62 -15.93 3.42 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.445 ' H ' ' C ' ' A' ' 33' ' ' LEU . 11.4 t -80.44 23.72 0.49 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.809 0.338 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.43 ' C ' ' H ' ' A' ' 38' ' ' VAL . . . 51.17 -171.58 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.9 tp10 58.2 7.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.119 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.43 ' H ' ' C ' ' A' ' 36' ' ' ALA . 27.2 m -56.63 -26.54 23.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.544 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.9 tp -47.79 -32.57 6.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.643 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.0 -53.16 42.55 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.9 mm -56.38 -46.41 81.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-O 121.055 0.455 . . . . 0.0 110.436 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 95.7 mt -55.02 -45.25 76.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.171 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.7 t -60.12 -41.14 92.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.041 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 47' ' ' VAL . 5.3 mm -57.44 -53.9 37.98 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.278 0.561 . . . . 0.0 111.125 -179.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 p -64.65 -27.64 43.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.184 -0.606 . . . . 0.0 110.279 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.534 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.2 OUTLIER -66.9 -46.42 74.95 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.276 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 44' ' ' ILE . 3.7 p -67.61 -33.44 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.626 -179.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.59 -44.62 77.69 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.633 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.5 p -66.56 -52.06 49.69 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.836 -178.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 46' ' ' LEU . 25.3 m -65.35 -37.33 79.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.244 -179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.666 ' O ' HG22 ' A' ' 55' ' ' VAL . 6.1 tt -65.35 -42.19 93.1 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.591 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 14.6 tptm -62.98 -52.43 63.04 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.884 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 75.5 p -65.95 -44.02 86.23 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 112.807 0.669 . . . . 0.0 112.807 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.477 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 88.5 mt -64.93 -45.97 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.3 m -77.64 -36.34 22.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.135 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.1 tt -67.27 -31.93 72.6 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.401 HD13 ' HA ' ' A' ' 57' ' ' ILE . 3.5 mm -67.74 -54.19 18.44 Favored Pre-proline 0 CA--C 1.544 0.729 0 C-N-CA 119.663 -0.815 . . . . 0.0 112.669 -178.009 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 53.7 Cg_endo -69.54 -28.05 26.77 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 121.729 1.619 . . . . 0.0 111.0 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.538 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -62.81 -54.62 36.17 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.6 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.458 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -76.36 -20.99 56.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.523 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 58' ' ' PRO . 69.3 mm-40 -99.65 115.26 29.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.461 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -67.05 -67.18 0.47 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.569 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.522 179.98 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.51 ' O ' HG23 ' B' ' 4' ' ' VAL . 32.9 p -163.36 102.9 0.95 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.394 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.472 ' OG1' ' N ' ' B' ' 4' ' ' VAL . 44.7 p 57.19 -101.95 0.14 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.864 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.51 HG23 ' O ' ' B' ' 2' ' ' SER . 7.7 t 66.33 -79.79 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.254 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.502 ' HB2' ' H ' ' A' ' 4' ' ' VAL . 0.2 OUTLIER -40.21 -63.93 0.64 Allowed Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.783 -179.071 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.523 ' O ' ' HB2' ' B' ' 10' ' ' ALA . 30.8 Cg_endo -61.6 0.73 0.97 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.099 1.866 . . . . 0.0 112.02 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -107.29 -64.02 0.59 Allowed Glycine 0 N--CA 1.466 0.7 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.522 ' O ' ' CE2' ' A' ' 59' ' ' PHE . 0.2 OUTLIER -64.11 -50.95 74.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.091 0.472 . . . . 0.0 109.859 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.38 -38.96 81.84 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' B' ' 6' ' ' PRO . . . -57.19 -32.77 66.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -38.34 93.91 Favored Glycine 0 CA--C 1.525 0.713 0 CA-C-N 114.449 -1.251 . . . . 0.0 111.625 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 8.2 mt -65.73 -42.31 92.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 C-N-CA 119.555 -0.858 . . . . 0.0 109.61 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.444 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.5 m -55.75 -45.27 79.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.0 t -53.73 -50.18 52.9 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.674 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.46 -31.22 62.83 Favored Glycine 0 CA--C 1.527 0.844 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -70.93 -40.38 72.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.742 0.306 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 22.8 tp -61.53 -51.39 68.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -59.03 -44.43 91.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.353 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 26.8 mt -58.45 -51.94 67.73 Favored 'General case' 0 C--O 1.227 -0.117 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.925 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -48.07 -50.85 26.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 0.0 110.456 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 94.2 t -60.82 -31.26 49.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.137 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 13.9 tp -67.86 -44.74 76.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.894 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.486 HG21 HG22 ' A' ' 23' ' ' ILE . 28.4 mm -61.53 -51.23 75.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.035 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.86 -42.25 75.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.144 0.497 . . . . 0.0 109.92 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.2 tp -60.02 -37.38 79.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.709 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.44 -39.81 94.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.204 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.435 ' CG2' HG11 ' A' ' 27' ' ' VAL . 87.3 t -60.13 -48.11 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.059 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -63.66 -38.95 93.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.221 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 44.0 t80 -58.26 -46.96 85.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.6 -40.28 96.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.227 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 84.73 176.97 51.05 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 82.1 mtt85 . . . . . 0 C--N 1.329 -0.309 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 -179.966 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 53.8 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.41 ' C ' ' HG ' ' A' ' 5' ' ' SER . 17.6 p -52.87 113.07 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.58 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 5' ' ' SER . 0.0 OUTLIER -87.28 167.38 14.14 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.374 179.844 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.453 ' N ' ' OG ' ' B' ' 5' ' ' SER . 26.8 m 34.61 31.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.173 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.616 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.7 OUTLIER -85.71 -38.33 0.58 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.432 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.616 ' CD ' ' N ' ' A' ' 5' ' ' SER . 97.9 Cg_exo -48.43 -42.4 34.77 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 122.405 2.07 . . . . 0.0 112.572 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.28 -48.39 0.71 Allowed Glycine 0 N--CA 1.463 0.467 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 6' ' ' PRO . 76.7 t -53.68 -35.94 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 177.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.424 ' O ' HG22 ' A' ' 12' ' ' ILE . 34.0 mt -54.84 -41.88 71.27 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 178.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -58.67 -37.98 77.21 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.82 -26.02 64.63 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.506 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.4 OUTLIER -70.9 -38.38 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.6 t -61.42 -54.6 32.79 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-O 121.355 0.598 . . . . 0.0 109.521 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.401 ' O ' HG22 ' A' ' 18' ' ' VAL . 14.9 t -60.57 -36.26 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.284 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.11 -38.75 96.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -67.92 -47.75 67.86 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.889 0.376 . . . . 0.0 110.382 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.805 ' N ' ' HZ1' ' A' ' 52' ' ' LYS . 23.5 tp -58.91 -50.67 73.15 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.044 -179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.401 HG22 ' O ' ' A' ' 14' ' ' VAL . 16.9 m -68.33 -26.33 33.56 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.292 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.764 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.5 mt -62.81 -54.99 30.47 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.469 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.421 HG21 ' CB ' ' A' ' 48' ' ' ALA . 7.1 m -60.39 -43.99 96.1 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.298 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 17' ' ' LEU . 98.6 t -62.75 -49.36 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.511 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -62.33 -53.51 53.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.143 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.45 ' CG2' HG21 ' B' ' 23' ' ' ILE . 59.1 mt -58.8 -44.34 90.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.389 -0.524 . . . . 0.0 110.159 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.13 -38.02 81.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.286 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -65.39 -48.05 74.23 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.642 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.93 -46.85 64.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.512 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.2 t -62.06 -45.21 99.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -55.22 -43.67 74.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.636 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -59.21 -48.47 81.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.3 tt -64.35 -43.17 95.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.435 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.01 94.99 0.19 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -76.89 41.84 0.29 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.838 0.351 . . . . 0.0 110.587 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.577 HD22 ' N ' ' A' ' 33' ' ' LEU . 3.3 mm? 48.69 -175.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.92 -20.17 3.9 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 35' ' ' THR . 3.3 t -80.42 -12.7 59.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.823 0.344 . . . . 0.0 110.449 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.421 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . 49.76 -143.83 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.467 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 48.63 17.96 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.48 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.421 ' N ' ' C ' ' A' ' 36' ' ' ALA . 23.7 m -56.34 -24.48 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.563 HD12 ' N ' ' A' ' 39' ' ' LEU . 10.1 mp -46.9 -32.54 3.87 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.394 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 -50.89 42.7 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 61.0 mt -60.74 -41.05 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.669 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 82.1 mt -66.27 -39.44 84.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.398 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.4 t -60.53 -50.83 71.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.794 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 8.3 pt -64.51 -44.11 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -57.52 -42.97 82.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.128 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.468 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.68 -39.71 91.59 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.694 -178.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -65.24 -30.24 49.67 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.067 0 C-N-CA 120.396 -0.521 . . . . 0.0 109.658 -179.21 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.421 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.73 -50.18 32.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.546 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.7 m -58.5 -47.04 85.44 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.352 -0.539 . . . . 0.0 111.108 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.526 HG23 ' N ' ' A' ' 51' ' ' LEU . 26.7 m -69.0 -44.69 81.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.596 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.572 ' O ' HG22 ' A' ' 55' ' ' VAL . 37.9 tp -53.41 -51.81 61.38 Favored 'General case' 0 CA--C 1.519 -0.218 0 C-N-CA 120.114 -0.634 . . . . 0.0 110.302 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.805 ' HZ1' ' N ' ' A' ' 17' ' ' LEU . 3.4 mmmm -60.45 -43.94 96.34 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.825 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.2 m -59.68 -49.82 76.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.483 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 2.8 mp -70.97 -44.84 75.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.572 HG22 ' O ' ' A' ' 51' ' ' LEU . 6.0 m -74.92 -34.18 32.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.887 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.404 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 10.8 tp -75.33 -37.33 60.79 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -178.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.1 mt -57.59 -52.64 72.81 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 49.5 Cg_endo -69.59 -27.58 27.11 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.434 1.423 . . . . 0.0 111.216 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.519 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.4 m-30 -63.98 -56.37 15.63 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.28 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.55 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.4 mm? -77.7 18.79 0.42 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.932 0.396 . . . . 0.0 110.096 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.425 ' H ' ' C ' ' A' ' 59' ' ' PHE . 32.9 tp10 -173.25 78.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.598 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -55.47 -46.3 76.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.647 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 16.2 p30 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.508 -179.982 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 25.7 p -66.02 -46.94 76.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.467 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 71.2 p 43.18 45.49 4.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.103 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.401 ' O ' HG22 ' B' ' 8' ' ' VAL . 26.6 m -73.93 -33.27 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.767 0.318 . . . . 0.0 110.456 179.592 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.528 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.4 OUTLIER -40.49 -62.75 0.87 Allowed Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.213 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -61.85 11.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 122.09 1.86 . . . . 0.0 112.235 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -119.74 -66.14 0.28 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.401 HG22 ' O ' ' B' ' 4' ' ' VAL . 0.2 OUTLIER -61.85 -50.86 78.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-O 121.055 0.455 . . . . 0.0 110.224 -179.807 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 15.8 mt -60.13 -37.14 79.16 Favored 'General case' 0 C--O 1.244 0.783 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -56.52 -34.15 66.73 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.02 -43.4 97.41 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.946 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 42.6 mm -57.82 -41.72 80.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.195 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.506 ' CG1' HD13 ' A' ' 12' ' ' ILE . 1.3 m -60.75 -43.02 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.395 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -57.44 -47.2 85.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 120.338 -0.545 . . . . 0.0 109.913 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.37 -36.3 90.68 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -63.18 -41.19 99.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.147 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.9 tp -61.77 -45.73 92.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.917 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.91 -48.0 82.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.384 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 49.9 mt -61.24 -49.13 78.36 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.105 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -46.1 -50.33 15.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.504 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 97.1 t -66.01 -31.72 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.501 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 14.6 tp -66.22 -51.83 53.78 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.482 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.45 HG21 ' CG2' ' A' ' 23' ' ' ILE . 20.9 mm -61.4 -50.71 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.3 -44.35 61.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.176 0.512 . . . . 0.0 109.677 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.33 -38.47 80.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.478 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.43 -39.0 91.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.088 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 84.1 t -60.86 -46.0 97.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.987 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -60.84 -41.74 96.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.162 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -58.02 -49.99 74.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.409 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 19.9 mt -63.48 -39.01 93.33 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.406 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 76.97 -140.99 25.61 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-O 120.86 0.362 . . . . 0.0 110.361 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.1 t . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.2 p -79.4 151.41 30.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.638 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.444 ' O ' ' N ' ' A' ' 5' ' ' SER . 1.6 t -87.91 159.54 18.31 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.474 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.41 ' H ' ' HB2' ' B' ' 5' ' ' SER . 27.1 m 34.11 34.3 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.502 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.593 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -78.24 -41.15 1.95 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.469 179.402 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 5' ' ' SER . 78.7 Cg_exo -47.57 -41.98 29.57 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.727 2.285 . . . . 0.0 112.748 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.548 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.26 -47.37 0.85 Allowed Glycine 0 N--CA 1.462 0.416 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -179.226 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.477 ' H ' ' C ' ' A' ' 6' ' ' PRO . 70.8 t -56.1 -39.47 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 9' ' ' LEU . 72.5 mt -55.86 -38.1 69.66 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.23 -38.51 83.63 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.024 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.13 -29.76 71.96 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 178.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.42 -42.87 94.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.478 ' HA ' HG21 ' B' ' 12' ' ' ILE . 60.6 t -57.81 -51.64 67.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 84.8 t -57.79 -30.12 36.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.758 178.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.35 -38.12 86.84 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -68.03 -43.79 77.95 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.87 0.367 . . . . 0.0 110.648 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 27.5 tp -63.5 -48.72 76.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.417 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 14' ' ' VAL . 31.9 m -65.49 -29.81 48.26 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.124 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.961 -179.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.526 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.6 OUTLIER -66.35 -56.43 11.13 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.72 179.641 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.669 HG21 ' CB ' ' A' ' 48' ' ' ALA . 10.5 m -52.9 -50.68 63.42 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.987 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -70.28 -27.61 32.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 19.7 tp -66.9 -56.57 9.7 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.003 -179.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 61.2 mt -70.39 -43.23 78.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.596 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.23 -39.51 79.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.979 0.418 . . . . 0.0 110.152 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.79 -40.3 83.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.81 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.72 -50.9 67.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.866 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.4 m -67.98 -34.32 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.63 -0.428 . . . . 0.0 110.59 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -60.24 -44.54 95.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.696 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -66.49 -48.97 68.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -63.75 -50.48 68.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.219 -179.812 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -60.25 133.9 50.48 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.484 ' C ' ' H ' ' A' ' 34' ' ' GLY . 40.0 ttm180 -76.28 154.59 35.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.541 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 16.0 mt -72.2 38.28 0.07 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.692 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 32' ' ' ARG . . . -179.2 99.07 0.12 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.1 t -165.09 17.01 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.811 0.338 . . . . 0.0 110.522 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.4 ' C ' ' N ' ' A' ' 38' ' ' VAL . . . 47.39 -170.36 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.55 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 52.1 14.09 0.31 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.45 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.4 ' N ' ' C ' ' A' ' 36' ' ' ALA . 17.0 m -63.53 -25.68 38.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.704 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 58.3 tp -46.41 -29.61 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.817 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.98 -50.57 57.3 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.646 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.8 mp -56.79 -48.07 81.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.954 0.407 . . . . 0.0 109.931 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 68.8 mt -63.58 -29.99 48.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.618 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.3 t -64.85 -47.28 78.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.356 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.5 pt -71.11 -35.43 58.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.323 . . . . 0.0 111.54 -179.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 64.9 t -67.78 -43.85 86.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.196 -0.602 . . . . 0.0 110.36 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.528 ' O ' HG22 ' A' ' 50' ' ' VAL . 3.3 mm? -72.04 -37.52 69.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.72 -179.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.2 p -69.4 -31.81 50.82 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.113 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.878 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.669 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -71.38 -52.14 20.28 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.586 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.8 m -60.22 -42.48 95.25 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.566 -178.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 46' ' ' LEU . 18.8 m -71.42 -32.98 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 C-N-CA 120.518 -0.473 . . . . 0.0 112.066 -179.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.546 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -68.05 -56.55 8.46 Favored 'General case' 0 CA--C 1.521 -0.146 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.388 -179.694 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.31 -47.68 84.85 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.569 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 96.1 m -61.02 -44.55 97.25 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' CD ' ' A' ' 58' ' ' PRO . 95.3 mt -72.33 -43.53 64.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 113.736 1.013 . . . . 0.0 113.736 -177.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.7 m -78.68 -33.72 16.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.171 -0.611 . . . . 0.0 111.565 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.0 tp -77.86 -39.88 41.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.453 ' N ' ' HD2' ' A' ' 58' ' ' PRO . 13.0 mm -59.75 -54.32 56.88 Favored Pre-proline 0 CA--C 1.541 0.623 0 N-CA-C 113.198 0.814 . . . . 0.0 113.198 -177.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.485 ' CD ' ' O ' ' A' ' 54' ' ' ILE . 16.7 Cg_endo -56.45 -35.76 96.8 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 121.484 1.456 . . . . 0.0 112.045 -179.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -77.28 -61.01 2.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.549 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -48.1 -40.41 23.34 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 120.488 -0.485 . . . . 0.0 109.98 179.664 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -78.74 118.28 20.66 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.828 0.347 . . . . 0.0 110.681 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -70.25 138.8 51.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.574 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 14.7 p30 . . . . . 0 C--N 1.331 -0.222 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.937 -179.987 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 39.4 m . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 15.0 m -75.92 81.41 2.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.283 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 19.2 p -73.14 166.21 23.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.654 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 27.8 m -149.83 -42.79 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.138 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.529 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -45.39 -63.27 1.27 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.861 179.592 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 21.5 Cg_endo -59.51 7.43 0.08 OUTLIER 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.227 1.951 . . . . 0.0 112.35 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -114.05 -66.17 0.45 Allowed Glycine 0 N--CA 1.468 0.772 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.589 HG13 ' N ' ' B' ' 9' ' ' LEU . 11.5 p -63.58 -47.92 89.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.995 0.426 . . . . 0.0 110.306 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.589 ' N ' HG13 ' B' ' 8' ' ' VAL . 33.3 mt -56.74 -38.11 71.94 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.3 -39.09 81.9 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.17 75.74 Favored Glycine 0 CA--C 1.523 0.561 0 CA-C-N 114.491 -1.231 . . . . 0.0 110.786 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.478 HG21 ' HA ' ' A' ' 13' ' ' VAL . 49.8 mm -67.32 -46.13 84.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.063 -0.655 . . . . 0.0 109.615 179.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.403 ' H ' HG13 ' B' ' 13' ' ' VAL . 0.7 OUTLIER -55.6 -43.74 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 C-N-CA 118.88 -1.128 . . . . 0.0 108.58 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 87.5 t -56.51 -47.92 81.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.294 -0.563 . . . . 0.0 109.542 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -55.5 -30.94 56.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -70.88 -41.91 70.71 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.645 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.2 mp -60.48 -51.55 68.99 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 120.885 0.374 . . . . 0.0 110.196 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.403 HG13 ' N ' ' B' ' 19' ' ' LEU . 2.6 p -58.7 -45.78 90.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.398 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.403 ' N ' HG13 ' B' ' 18' ' ' VAL . 51.8 mt -59.42 -34.91 73.06 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.934 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.8 m -64.27 -41.39 96.94 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.295 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.84 -51.19 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.706 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . 0.413 ' N ' HD12 ' B' ' 22' ' ' LEU . 10.3 mp -64.28 -51.4 63.71 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.712 0.291 . . . . 0.0 111.052 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.517 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 82.4 mt -58.63 -51.49 71.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.07 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.6 -48.0 39.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.16 0.505 . . . . 0.0 109.812 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 34.2 tp -57.02 -35.75 69.64 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -65.1 -36.37 84.07 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.078 179.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 45.5 t -60.8 -48.07 90.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -64.42 -37.24 86.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.238 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -59.92 -46.49 89.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.682 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 tp -60.18 -41.45 92.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.318 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 162.52 -119.13 0.86 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.739 0.304 . . . . 0.0 110.371 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.9 p -77.45 156.99 30.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.653 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 11.6 p -81.63 169.28 17.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.426 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.478 ' H ' ' CB ' ' B' ' 5' ' ' SER . 27.0 m 34.64 36.93 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.339 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.484 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -79.36 -48.23 1.52 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.317 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' A' ' 8' ' ' VAL . 46.7 Cg_exo -42.87 -43.42 9.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 122.699 2.266 . . . . 0.0 112.757 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.47 -46.66 0.87 Allowed Glycine 0 N--CA 1.463 0.433 0 N-CA-C 108.84 -1.704 . . . . 0.0 108.84 -179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' PRO . 74.3 t -57.75 -38.73 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.7 mt -55.62 -38.69 69.81 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 178.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.27 -40.22 89.59 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.62 -29.22 66.51 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.407 HD13 ' CG1' ' B' ' 13' ' ' VAL . 0.3 OUTLIER -66.87 -43.23 89.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.086 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -50.83 74.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 179.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.6 t -57.27 -39.86 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.471 178.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.22 -36.81 91.75 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.62 -47.84 71.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.967 0.413 . . . . 0.0 110.441 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 21' ' ' VAL . 41.1 tp -55.53 -51.74 66.04 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.726 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -65.14 -29.15 46.47 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.373 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.83 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.432 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -60.18 -58.04 10.25 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.738 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 73.1 m -56.09 -42.37 76.65 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 17' ' ' LEU . 87.4 t -66.51 -32.03 56.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.78 -53.9 13.69 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.404 -178.694 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 47.9 mt -67.83 -43.17 86.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.365 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.62 -42.94 97.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.891 0.377 . . . . 0.0 110.158 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 30.4 tp -65.56 -42.55 91.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.184 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.51 -48.58 71.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.661 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -64.51 -44.28 96.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.701 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -56.6 -37.58 70.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.662 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -59.91 -48.92 79.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.647 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.1 tp -67.88 -38.41 83.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.489 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -43.32 -69.38 0.66 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.401 ' O ' ' O ' ' A' ' 33' ' ' LEU . 32.7 ttm180 47.42 65.28 1.3 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.774 0.321 . . . . 0.0 110.575 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.58 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.3 mp 52.94 171.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.329 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.18 -24.17 1.37 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.454 ' H ' ' C ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -64.17 -34.37 77.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.796 0.332 . . . . 0.0 110.497 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 51.88 -169.34 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.45 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 48.89 28.68 2.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.483 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.3 m -57.87 -28.28 32.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.561 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.6 tt -49.32 -37.72 25.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.545 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.53 -48.15 76.42 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 92.7 mt -59.63 -40.61 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.064 0.459 . . . . 0.0 110.49 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 91.6 mt -66.84 -35.98 76.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.467 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.3 m -64.18 -51.93 61.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.543 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 7.5 pt -61.86 -44.53 98.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.966 -179.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.47 -43.38 82.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 120.452 -0.499 . . . . 0.0 109.822 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.506 ' O ' HG22 ' A' ' 50' ' ' VAL . 70.5 mt -66.04 -32.14 73.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.201 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.9 t -67.26 -35.78 74.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.412 -0.515 . . . . 0.0 109.658 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.54 ' HB1' ' NZ ' ' A' ' 52' ' ' LYS . . . -69.98 -49.05 55.48 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.265 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.3 p -58.92 -48.2 82.32 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.511 -179.325 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.506 HG22 ' O ' ' A' ' 46' ' ' LEU . 14.5 m -71.31 -28.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.975 -0.29 . . . . 0.0 111.603 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.672 ' O ' HG22 ' A' ' 55' ' ' VAL . 5.2 tt -67.12 -53.12 33.69 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.888 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.54 ' NZ ' ' HB1' ' A' ' 48' ' ' ALA . 37.5 mttp -65.42 -44.83 86.16 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.82 0.343 . . . . 0.0 110.649 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 25.9 m -63.22 -42.53 99.26 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.515 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 93.8 mt -75.36 -41.96 43.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.672 HG22 ' O ' ' A' ' 51' ' ' LEU . 13.5 m -76.59 -28.62 17.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 120.028 -0.669 . . . . 0.0 111.304 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.1 tp -84.82 -47.13 10.68 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.476 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.3 mp -62.2 -59.38 13.19 Favored Pre-proline 0 N--CA 1.473 0.708 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -175.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.515 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 10.1 Cg_endo -52.02 -27.49 28.93 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 121.392 1.394 . . . . 0.0 111.992 -178.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.546 ' CD1' HG11 ' B' ' 8' ' ' VAL . 26.4 m-85 -90.19 -65.94 0.97 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.494 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.2 mm? -59.61 -17.75 35.84 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.29 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ILE . 69.5 mm-40 -141.5 148.9 40.17 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.895 0.379 . . . . 0.0 110.731 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -69.41 -33.59 73.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.544 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.3 t-20 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 -179.96 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.529 ' O ' ' N ' ' B' ' 3' ' ' THR . 97.4 m . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 9.0 t 59.82 -75.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.58 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.529 ' N ' ' O ' ' B' ' 1' ' ' CYS . 26.3 p 45.97 -169.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.727 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 35.4 m -150.91 -29.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.242 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.551 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -62.77 0.98 Allowed Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.908 179.786 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 31.2 Cg_endo -62.43 12.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.209 1.939 . . . . 0.0 111.995 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -125.45 -65.61 0.18 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.465 -0.654 . . . . 0.0 111.465 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.623 HG23 ' N ' ' B' ' 9' ' ' LEU . 18.1 m -60.09 -49.47 83.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.073 0.463 . . . . 0.0 110.461 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.623 ' N ' HG23 ' B' ' 8' ' ' VAL . 28.9 mt -57.41 -42.63 82.67 Favored 'General case' 0 C--O 1.238 0.484 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.66 -37.19 65.42 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 177.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.16 -28.73 73.32 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 114.351 -1.295 . . . . 0.0 110.347 178.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.2 -43.62 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.377 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.407 ' CG1' HD13 ' A' ' 12' ' ' ILE . 0.6 OUTLIER -58.86 -42.34 85.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 119.11 -1.036 . . . . 0.0 108.741 178.773 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 75.8 t -56.39 -47.42 81.47 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.86 -32.15 65.67 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -69.1 -41.75 77.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.804 0.335 . . . . 0.0 110.689 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 36.9 tp -61.07 -53.07 61.72 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.491 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -58.56 -39.85 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.139 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.428 HD22 ' HB2' ' A' ' 48' ' ' ALA . 25.6 mt -60.79 -52.72 63.9 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.733 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 88.5 m -47.14 -50.56 20.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.877 0.37 . . . . 0.0 110.21 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 60.0 t -61.95 -31.19 50.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.419 179.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 15.5 tp -68.37 -48.19 65.41 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.412 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 18.0 mm -60.64 -44.34 96.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.08 -48.19 79.18 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 121.184 0.516 . . . . 0.0 109.752 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -57.69 -34.93 69.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.55 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -64.81 -39.39 93.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.081 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 98.2 t -60.59 -45.83 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -62.52 -39.03 92.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -60.4 -44.46 95.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.618 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 29.0 tp -59.16 -43.38 92.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.369 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.81 116.15 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 50.9 ttm-85 . . . . . 0 C--N 1.328 -0.359 0 CA-C-O 120.737 0.303 . . . . 0.0 110.594 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.7 p -170.03 131.79 1.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.802 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.513 ' C ' ' H ' ' A' ' 5' ' ' SER . 41.7 p -80.89 -72.33 0.42 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.456 ' N ' ' OG1' ' A' ' 3' ' ' THR . 10.6 m -69.24 37.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.958 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.586 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.18 -40.76 16.17 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.509 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 5' ' ' SER . 70.4 Cg_exo -46.66 -40.53 24.1 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.531 2.154 . . . . 0.0 112.45 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.24 -47.24 0.67 Allowed Glycine 0 N--CA 1.464 0.507 0 N-CA-C 109.125 -1.59 . . . . 0.0 109.125 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.482 ' H ' ' C ' ' A' ' 6' ' ' PRO . 72.7 t -56.26 -39.82 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.612 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.7 mt -55.96 -38.36 70.25 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -60.4 -36.1 77.32 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.78 -27.5 70.16 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.65 -42.01 86.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -59.95 -50.93 78.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.997 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.4 t -59.21 -42.32 86.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.904 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.03 -37.1 91.12 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.472 ' CG ' ' NZ ' ' A' ' 52' ' ' LYS . 59.2 t0 -66.36 -47.4 73.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 110.359 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -55.59 -51.48 67.0 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.884 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.7 m -65.67 -29.02 45.73 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.712 -179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.475 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -59.38 -58.85 6.83 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.613 179.745 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.586 HG21 HD13 ' B' ' 19' ' ' LEU . 73.5 p -56.32 -42.91 78.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.286 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.7 t -64.59 -33.82 65.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.845 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.494 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -68.86 -52.86 25.3 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.049 -0.261 . . . . 0.0 111.168 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 59.4 mt -66.36 -43.79 91.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.349 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.8 -42.29 88.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.081 0.467 . . . . 0.0 110.07 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 36.6 tp -67.97 -31.27 70.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.034 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.81 -51.28 67.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.764 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.4 ' O ' ' N ' ' A' ' 31' ' ' GLY . 14.4 m -65.07 -37.52 80.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.432 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -60.98 -48.69 80.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.549 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 78.6 t80 -71.17 -50.97 27.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 30' ' ' LEU . 1.3 tt -63.65 -51.0 67.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.178 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 27' ' ' VAL . . . -71.08 165.32 53.28 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.7 ttm180 -157.94 88.36 0.96 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.822 0.344 . . . . 0.0 110.315 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.572 HD22 ' N ' ' A' ' 33' ' ' LEU . 3.3 mm? 49.58 75.68 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.201 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.99 -154.89 5.32 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.433 ' O ' ' N ' ' A' ' 37' ' ' GLU . 67.5 p -50.96 163.19 0.21 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.783 0.325 . . . . 0.0 110.513 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.85 70.11 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.621 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.433 ' N ' ' O ' ' A' ' 35' ' ' THR . 27.8 tp10 -163.78 49.01 0.13 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.478 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.1 m -67.09 -26.0 35.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.485 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.5 tp -45.87 -27.69 0.93 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.727 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.72 -48.28 85.84 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.96 -44.51 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.098 0.475 . . . . 0.0 110.664 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.682 ' N ' HD12 ' A' ' 42' ' ' ILE . 1.8 mp -66.18 -27.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.529 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.503 ' O ' HG23 ' A' ' 47' ' ' VAL . 24.0 p -70.66 -50.48 36.28 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.404 HG12 ' H ' ' A' ' 44' ' ' ILE . 10.5 pt -65.0 -44.85 95.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.032 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.417 HG13 ' N ' ' A' ' 46' ' ' LEU . 6.9 p -63.93 -41.75 93.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.555 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.543 ' O ' HG22 ' A' ' 50' ' ' VAL . 28.9 mt -65.2 -36.09 83.1 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 43' ' ' SER . 47.8 t -67.16 -35.55 74.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.076 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.46 -49.76 62.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.339 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 44.4 p -62.41 -50.57 70.97 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.876 -178.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 46' ' ' LEU . 15.8 m -66.04 -39.01 83.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.719 ' O ' HG22 ' A' ' 55' ' ' VAL . 33.6 tp -65.09 -40.74 95.03 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.598 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.472 ' NZ ' ' CG ' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -65.66 -52.17 53.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.753 0.311 . . . . 0.0 110.995 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 m -67.87 -37.34 81.68 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.533 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 89.9 mt -72.28 -44.32 63.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 -177.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 51' ' ' LEU . 10.9 m -78.49 -31.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 C-N-CA 120.055 -0.658 . . . . 0.0 111.388 -179.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 4.3 tp -79.01 -39.92 32.8 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -177.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.438 ' O ' ' N ' ' A' ' 61' ' ' GLU . 1.2 mp -72.42 -60.04 2.3 Favored Pre-proline 0 N--CA 1.475 0.817 0 N-CA-C 113.796 1.036 . . . . 0.0 113.796 -176.237 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.533 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 9.4 Cg_endo -50.72 -25.4 15.05 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 121.736 1.624 . . . . 0.0 112.218 -178.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.533 ' CD1' HG11 ' B' ' 8' ' ' VAL . 1.9 m-85 -88.26 -67.34 0.84 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.54 HD22 ' N ' ' A' ' 60' ' ' LEU . 3.3 mm? -59.93 -13.38 10.82 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.166 179.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.438 ' N ' ' O ' ' A' ' 57' ' ' ILE . 68.8 mt-10 -147.13 137.15 23.24 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -65.56 -44.34 87.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.552 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.563 -179.979 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.44 ' C ' ' H ' ' B' ' 3' ' ' THR . 68.6 m . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.403 ' O ' ' C ' ' B' ' 3' ' ' THR . 22.7 t 56.16 7.94 0.35 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.44 ' H ' ' C ' ' B' ' 1' ' ' CYS . 0.5 OUTLIER 31.98 61.5 0.31 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.665 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.434 HG23 ' N ' ' B' ' 5' ' ' SER . 13.8 m -76.05 -37.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.572 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.509 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -37.75 -65.16 0.38 Allowed Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.923 -179.605 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 28.6 Cg_endo -60.43 6.14 0.12 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.323 2.015 . . . . 0.0 112.145 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -118.46 -64.5 0.3 Allowed Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.628 HG23 ' N ' ' B' ' 9' ' ' LEU . 14.3 m -60.84 -52.18 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 120.572 -0.451 . . . . 0.0 110.343 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.628 ' N ' HG23 ' B' ' 8' ' ' VAL . 36.6 mt -54.29 -40.04 67.5 Favored 'General case' 0 C--O 1.246 0.904 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.425 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.79 -35.41 70.76 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -63.62 -34.2 89.31 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.374 -1.284 . . . . 0.0 111.137 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.435 ' N ' HD12 ' B' ' 12' ' ' ILE . 1.6 mp -65.77 -45.87 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.333 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -54.53 -46.25 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 C-N-CA 119.095 -1.042 . . . . 0.0 108.856 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 77.4 t -53.26 -46.41 56.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.21 0.529 . . . . 0.0 109.627 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.78 -40.77 93.41 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -56.92 -46.37 82.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.709 0.29 . . . . 0.0 110.505 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -58.87 -45.12 90.93 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.3 t -56.34 -47.95 80.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.055 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.586 HD13 HG21 ' A' ' 20' ' ' THR . 98.3 mt -59.13 -39.74 83.3 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.002 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 15.8 m -56.78 -40.13 75.32 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.402 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 89.2 t -67.87 -51.72 47.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.831 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -62.11 -51.68 66.93 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.159 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.446 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.0 mt -56.87 -50.01 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.55 -0.46 . . . . 0.0 109.998 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -49.13 -46.41 44.98 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.525 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.79 -40.02 75.16 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.026 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.446 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -62.25 -37.64 86.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.404 179.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.9 -48.06 89.19 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -64.08 -37.89 89.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.277 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -59.88 -51.03 71.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.641 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 20.9 mt -67.29 -42.36 83.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.393 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 158.8 156.01 7.85 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.361 . . . . 0.0 110.512 -179.885 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 55.6 m . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.3 p -167.46 113.86 0.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.782 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 5' ' ' SER . 28.6 p -79.7 -177.24 5.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.368 179.817 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.452 ' H ' ' CB ' ' B' ' 5' ' ' SER . 32.7 m 37.21 26.74 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-O 121.203 0.525 . . . . 0.0 111.03 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.627 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.6 OUTLIER -79.72 -35.47 0.96 Allowed Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.684 179.006 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.627 ' CD ' ' N ' ' A' ' 5' ' ' SER . 87.7 Cg_exo -49.56 -42.85 41.3 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.158 1.906 . . . . 0.0 112.529 179.81 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.539 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 71.81 -46.61 0.94 Allowed Glycine 0 CA--C 1.521 0.426 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.474 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.0 t -58.97 -40.1 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.59 -38.78 69.85 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.47 -38.91 82.05 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 177.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.04 -28.21 65.99 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.84 -43.62 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.2 t -55.77 -53.93 32.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -57.61 -36.95 56.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.69 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.08 -39.6 95.99 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -65.1 -46.92 79.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.896 0.379 . . . . 0.0 110.407 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.0 tp -55.74 -50.85 69.27 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -67.76 -25.68 33.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.008 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.57 -56.76 14.88 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 119.984 -0.687 . . . . 0.0 109.396 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.522 HG21 ' CB ' ' A' ' 48' ' ' ALA . 6.7 m -58.52 -44.5 89.55 Favored 'General case' 0 N--CA 1.456 -0.16 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.171 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.73 -32.88 59.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.1 tp -70.34 -54.5 12.29 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 -178.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.546 HG22 HG21 ' B' ' 23' ' ' ILE . 11.5 mm -70.28 -41.58 78.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.314 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.69 -40.3 87.39 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.022 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 32.7 tp -67.6 -37.48 82.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.626 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.18 -51.08 69.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.739 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -67.16 -36.19 76.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 C-N-CA 120.312 -0.555 . . . . 0.0 110.563 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -58.4 -44.38 88.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.434 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -66.28 -44.27 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.704 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -62.3 -44.73 95.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.615 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -73.29 137.12 23.31 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -172.26 95.33 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.857 0.36 . . . . 0.0 110.437 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.618 ' N ' HD12 ' A' ' 33' ' ' LEU . 7.4 mp 47.63 76.8 0.1 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.417 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -175.15 -65.68 0.05 OUTLIER Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.475 ' H ' HG22 ' A' ' 35' ' ' THR . 0.0 OUTLIER -61.25 -28.11 68.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.728 0.299 . . . . 0.0 110.563 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . 61.85 173.74 0.12 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.531 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 55.99 58.04 4.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.435 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.8 m -69.67 -25.17 28.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.704 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 44.5 tp -46.13 -29.5 1.56 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.854 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.8 -52.82 47.99 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.645 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -55.56 -40.27 58.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.919 0.39 . . . . 0.0 110.14 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.0 mm -64.54 -41.7 93.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.721 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 11.2 t -59.47 -51.79 68.36 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.69 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.1 tt -61.76 -43.88 97.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.31 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 41' ' ' ILE . 55.7 t -55.99 -43.11 74.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.121 0.486 . . . . 0.0 109.951 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 50' ' ' VAL . 2.9 mm? -68.22 -30.8 69.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.935 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 53.4 t -68.29 -34.36 65.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.512 -0.475 . . . . 0.0 109.816 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.522 ' CB ' HG21 ' A' ' 20' ' ' THR . . . -72.54 -48.15 42.61 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.474 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.8 m -60.13 -46.75 88.57 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.201 -179.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 46' ' ' LEU . 17.7 m -68.4 -37.19 77.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 120.652 -0.419 . . . . 0.0 111.115 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.644 ' O ' HG22 ' A' ' 55' ' ' VAL . 34.1 tp -65.7 -41.11 92.76 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.271 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.419 ' NZ ' ' CD1' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -62.96 -53.19 57.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.431 -179.899 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.8 p -63.59 -46.86 83.89 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -61.64 -51.72 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 51' ' ' LEU . 5.0 m -73.62 -29.79 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.174 -178.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.401 ' CB ' ' O ' ' A' ' 52' ' ' LYS . 6.5 tt -70.91 -29.95 66.15 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -178.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 mt -61.95 -55.1 44.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.287 -178.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.71 -28.63 43.86 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.518 1.479 . . . . 0.0 111.503 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 55' ' ' VAL . 5.2 m-30 -56.55 -47.07 80.25 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.349 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.478 ' CD2' ' N ' ' A' ' 60' ' ' LEU . 3.6 mm? -82.48 26.68 0.55 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 120.846 -0.342 . . . . 0.0 110.437 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -141.2 163.09 33.89 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.892 0.377 . . . . 0.0 110.465 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 -67.44 -26.4 66.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.537 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 65.6 m-20 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.685 -179.972 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.43 ' O ' ' O ' ' B' ' 3' ' ' THR . 41.5 t -59.54 -46.12 89.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.507 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.43 ' O ' ' O ' ' B' ' 2' ' ' SER . 43.8 p 47.36 100.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.83 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.627 HG13 ' N ' ' B' ' 5' ' ' SER . 14.8 p -143.37 -50.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.303 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.627 ' N ' HG13 ' B' ' 4' ' ' VAL . 0.7 OUTLIER -43.31 -64.48 0.75 Allowed Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.515 179.835 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.425 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 19.4 Cg_endo -56.86 1.75 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.325 2.017 . . . . 0.0 112.341 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.501 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -112.05 -67.05 0.52 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.552 HG23 ' N ' ' B' ' 9' ' ' LEU . 6.8 m -59.24 -48.05 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.154 0.502 . . . . 0.0 110.275 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.552 ' N ' HG23 ' B' ' 8' ' ' VAL . 43.6 mt -57.35 -42.15 81.46 Favored 'General case' 0 C--O 1.242 0.696 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -52.57 -33.46 45.91 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 176.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -37.22 94.17 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.292 178.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.1 tp -58.4 -43.82 87.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.672 -0.811 . . . . 0.0 108.956 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.431 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.9 OUTLIER -59.93 -46.81 93.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 119.256 -0.977 . . . . 0.0 109.487 179.281 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.5 -45.58 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 120.256 -0.577 . . . . 0.0 109.841 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.77 -39.25 96.48 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -59.58 -47.83 84.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.685 0.279 . . . . 0.0 110.712 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -57.79 -45.43 86.07 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -54.83 -46.64 75.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.227 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.439 HD22 ' HB2' ' A' ' 48' ' ' ALA . 23.5 mt -61.69 -47.08 86.94 Favored 'General case' 0 C--O 1.223 -0.302 0 C-N-CA 120.659 -0.417 . . . . 0.0 110.295 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.5 m -48.03 -50.73 26.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.8 0.333 . . . . 0.0 110.686 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 99.9 t -61.89 -44.13 98.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.936 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 12.2 tp -59.16 -45.3 91.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.18 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.546 HG21 HG22 ' A' ' 23' ' ' ILE . 4.6 mm -59.52 -49.78 82.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.87 -45.38 30.29 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.332 0.586 . . . . 0.0 109.83 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.561 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -64.76 -35.36 80.84 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.317 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.34 -55.32 35.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 2.7 p -57.86 -37.04 58.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 C-N-CA 120.149 -0.62 . . . . 0.0 109.4 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 43.1 t80 -59.66 -43.76 93.81 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.82 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -61.15 -41.82 97.44 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.571 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 8.5 mp -59.17 -40.11 84.59 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.23 150.69 5.7 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.362 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 21.1 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 94.5 p -56.85 132.03 51.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.632 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 5' ' ' SER . 32.7 p -83.24 168.17 16.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.424 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.447 ' H ' ' HB3' ' B' ' 5' ' ' SER . 27.0 m 34.59 34.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.442 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.6 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.3 OUTLIER -83.98 -40.09 0.73 Allowed Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.361 179.061 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.6 ' CD ' ' N ' ' A' ' 5' ' ' SER . 86.7 Cg_exo -48.1 -42.73 32.23 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.606 2.204 . . . . 0.0 112.655 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.516 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.86 -46.85 0.75 Allowed Glycine 0 N--CA 1.463 0.438 0 N-CA-C 108.865 -1.694 . . . . 0.0 108.865 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 6' ' ' PRO . 78.6 t -55.27 -38.57 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.423 HD23 ' HA ' ' A' ' 9' ' ' LEU . 82.0 mt -55.38 -38.97 69.56 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.182 -1.007 . . . . 0.0 108.388 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -59.88 -39.86 86.72 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.51 -27.72 63.93 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.53 -42.89 83.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.197 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -56.45 -53.22 43.17 Favored 'Isoleucine or valine' 0 C--O 1.242 0.684 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.7 t -56.92 -39.67 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.357 178.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -54.71 -41.23 74.08 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 61.4 t0 -64.77 -45.85 84.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.924 0.393 . . . . 0.0 110.299 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.434 ' N ' ' HZ3' ' A' ' 52' ' ' LYS . 20.8 tp -55.45 -51.08 68.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.894 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.0 m -68.53 -24.05 28.8 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.905 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.07 -56.7 14.69 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.032 -0.667 . . . . 0.0 109.382 179.755 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 53.6 m -61.36 -47.36 86.22 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.507 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.8 t -64.4 -34.32 68.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.4 tp -69.22 -54.28 15.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.609 -178.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 64.7 mt -67.57 -41.73 86.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.501 -0.479 . . . . 0.0 110.388 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.01 91.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.138 0.494 . . . . 0.0 110.026 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 tp -67.57 -34.49 77.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.828 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.89 -51.36 70.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.757 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.65 -36.65 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.569 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -59.36 -41.69 89.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.872 0.367 . . . . 0.0 110.577 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -59.42 -46.87 87.49 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.656 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.51 -45.34 91.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.13 149.62 49.67 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -159.31 69.16 0.44 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.779 0.323 . . . . 0.0 110.499 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.584 ' N ' HD12 ' A' ' 33' ' ' LEU . 9.1 mp 51.17 78.3 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.306 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -170.62 -51.58 0.04 OUTLIER Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.2 t -59.3 132.21 53.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.787 0.327 . . . . 0.0 110.721 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -86.23 -179.29 6.68 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.589 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 65.5 mm-40 52.82 32.97 13.24 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.591 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.2 m -49.24 -26.67 2.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.6 tp -48.21 -28.62 3.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.715 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.38 -51.62 57.55 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.647 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.9 mp -52.68 -49.94 43.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.027 0.441 . . . . 0.0 110.012 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.63 -27.58 43.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.727 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.0 t -67.01 -45.52 77.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.432 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.1 pt -71.83 -34.58 51.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.139 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 78.3 t -68.38 -46.4 80.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.572 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.404 ' O ' HG23 ' A' ' 50' ' ' VAL . 3.4 mm? -69.77 -37.75 76.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.643 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.22 -31.56 47.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.777 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.19 51.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.378 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.9 p -62.38 -43.36 99.0 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.953 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 46' ' ' LEU . 85.1 t -63.99 -43.74 97.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.556 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 51' ' ' LEU . 0.5 OUTLIER -64.91 -53.39 47.18 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.018 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.434 ' HZ3' ' N ' ' A' ' 17' ' ' LEU . 0.7 OUTLIER -47.21 -51.99 17.03 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.909 179.924 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 31.4 p -59.13 -46.73 87.58 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 87.1 mt -59.82 -52.52 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.58 ' O ' ' CG ' ' A' ' 59' ' ' PHE . 26.7 m -75.31 -30.89 23.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.258 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.7 tt -66.65 -32.79 74.34 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 7.4 mt -68.16 -54.23 16.37 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.479 -178.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.38 -28.44 18.09 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 121.799 1.666 . . . . 0.0 111.566 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.58 ' CG ' ' O ' ' A' ' 55' ' ' VAL . 4.5 m-30 -60.68 -45.43 94.2 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.342 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -57.59 -24.01 53.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.017 0.437 . . . . 0.0 110.141 -179.817 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 73.7 mm-40 -97.28 168.37 10.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.694 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -60.6 -46.77 89.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.416 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 22.2 p-10 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.583 179.965 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' N ' ' B' ' 2' ' ' SER . 29.7 p . . . . . 0 N--CA 1.488 1.458 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.449 ' OG ' ' N ' ' B' ' 3' ' ' THR . 60.7 p -53.66 -64.23 0.89 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.442 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.449 ' N ' ' OG ' ' B' ' 2' ' ' SER . 32.1 p 43.23 53.13 5.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.471 HG23 ' N ' ' B' ' 5' ' ' SER . 21.2 m -76.08 -39.31 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.314 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.539 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.1 OUTLIER -40.02 -62.78 0.81 Allowed Pre-proline 0 CA--C 1.536 0.407 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.952 179.763 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 26.9 Cg_endo -61.02 9.88 0.07 OUTLIER 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.138 1.892 . . . . 0.0 112.073 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' B' ' 5' ' ' SER . . . -123.64 -66.24 0.21 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.613 HG23 ' N ' ' B' ' 9' ' ' LEU . 15.9 m -58.8 -51.74 68.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 CA-C-O 121.094 0.473 . . . . 0.0 110.61 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.613 ' N ' HG23 ' B' ' 8' ' ' VAL . 40.5 mt -56.51 -40.04 74.32 Favored 'General case' 0 C--O 1.242 0.663 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -53.24 -36.97 61.66 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.16 -34.45 89.12 Favored Glycine 0 CA--C 1.523 0.565 0 CA-C-N 114.425 -1.261 . . . . 0.0 110.447 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -62.52 -42.26 95.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 C-N-CA 119.701 -0.799 . . . . 0.0 109.341 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.411 HG13 ' H ' ' B' ' 13' ' ' VAL . 0.7 OUTLIER -59.86 -44.42 94.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.32 179.091 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 83.9 t -51.23 -47.52 33.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.615 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.11 93.88 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -58.78 -45.16 90.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.857 0.361 . . . . 0.0 110.488 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 29.7 tp -56.77 -45.73 81.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.021 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.42 -46.77 82.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.204 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 14.2 mt -60.25 -39.74 87.84 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.062 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.2 m -57.68 -40.59 79.77 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.388 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.5 t -66.41 -51.8 53.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.474 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 11.1 mp -62.53 -52.95 61.41 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 120.939 -0.304 . . . . 0.0 111.274 -178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.429 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 61.9 mt -56.84 -51.33 69.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.111 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -47.94 -46.46 32.23 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.088 0.47 . . . . 0.0 109.857 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.537 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -56.91 -39.31 74.19 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.429 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -63.83 -38.51 91.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.455 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.53 -47.19 89.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -63.75 -41.37 98.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.206 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -56.44 -46.54 80.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 31.1 tp -58.05 -45.5 86.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.32 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.63 -100.14 0.15 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . 0.546 ' C ' ' HE ' ' B' ' 32' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 110.264 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.0 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.0 m -157.07 136.47 12.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.555 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 8.4 p -80.91 -165.1 0.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.497 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.432 ' H ' ' CB ' ' B' ' 5' ' ' SER . 35.8 m 35.08 36.38 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.346 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.598 ' N ' ' CD ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -82.23 -40.19 0.92 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.377 179.133 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 5' ' ' SER . 72.4 Cg_exo -46.41 -40.45 22.72 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.647 2.232 . . . . 0.0 112.58 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.549 ' O ' ' HB3' ' A' ' 10' ' ' ALA . . . 70.31 -48.09 0.7 Allowed Glycine 0 N--CA 1.464 0.506 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.474 ' N ' ' O ' ' A' ' 6' ' ' PRO . 71.3 t -53.83 -39.28 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.465 HD23 HD12 ' A' ' 12' ' ' ILE . 81.2 mt -56.05 -37.99 69.99 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 7' ' ' GLY . . . -61.59 -33.08 73.27 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 177.245 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 8' ' ' VAL . . . -63.37 -32.24 83.48 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.732 HG21 HG12 ' B' ' 13' ' ' VAL . 70.8 mt -67.2 -41.98 87.46 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 42.5 t -59.29 -55.17 25.41 Favored 'Isoleucine or valine' 0 C--O 1.241 0.613 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.481 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.425 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.7 t -61.02 -36.86 75.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.498 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.48 -40.47 99.14 Favored Glycine 0 C--O 1.224 -0.513 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -64.16 -51.26 64.68 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.008 0.433 . . . . 0.0 110.281 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.0 tp -56.86 -47.34 80.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.848 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' VAL . 77.8 t -63.44 -28.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.758 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.461 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -64.53 -56.64 12.74 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.68 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.4 m -56.09 -40.4 73.59 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.649 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.33 -32.52 57.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.727 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.47 HD13 ' O ' ' A' ' 22' ' ' LEU . 0.2 OUTLIER -70.41 -55.23 9.55 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.15 -178.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 80.0 mt -66.66 -43.65 90.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.574 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.41 -41.38 89.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.217 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.2 tp -69.18 -31.79 70.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.273 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.72 -50.51 68.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.799 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 m -66.32 -38.1 81.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.472 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -61.83 -46.52 89.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.575 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -69.46 -49.13 57.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.744 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.3 tp -62.65 -43.63 98.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.464 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -73.68 124.65 8.77 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -80.09 41.33 0.51 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 0.0 110.544 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 8.8 tp 52.69 82.27 0.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.518 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 164.7 107.79 0.21 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 36' ' ' ALA . 4.4 t -158.63 177.02 11.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.78 0.324 . . . . 0.0 110.626 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 35' ' ' THR . . . -52.26 -104.13 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.6 tp10 -83.14 95.33 8.06 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.573 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.7 t -65.59 -28.98 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.581 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 tp -60.74 -29.29 69.28 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.78 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -54.64 -49.55 60.9 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.8 mm -55.38 -48.51 76.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.028 0.442 . . . . 0.0 110.651 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 74.2 mt -61.53 -34.96 63.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.483 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.433 ' O ' HG23 ' A' ' 47' ' ' VAL . 13.9 m -61.53 -51.7 67.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.692 -179.241 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 12.4 pt -63.06 -42.22 95.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.924 -179.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 71.7 t -60.24 -43.99 94.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.375 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 50' ' ' VAL . 0.1 OUTLIER -65.09 -34.7 79.03 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 43' ' ' SER . 50.4 t -66.78 -34.73 71.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.76 -47.98 64.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.457 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 4.5 m -60.87 -48.73 80.47 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.711 -0.396 . . . . 0.0 111.494 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 46' ' ' LEU . 16.9 m -69.91 -33.83 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -178.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.635 ' O ' HG22 ' A' ' 55' ' ' VAL . 49.3 tp -65.69 -52.59 50.22 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.269 -0.572 . . . . 0.0 110.744 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.29 -50.53 72.63 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.312 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 48.5 p -60.34 -43.12 96.75 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.421 ' O ' ' CG ' ' A' ' 58' ' ' PRO . 90.4 mt -72.95 -44.52 57.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.362 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -177.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.635 HG22 ' O ' ' A' ' 51' ' ' LEU . 11.4 m -77.04 -28.34 16.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.384 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.0 tp -82.58 -39.44 22.26 Favored 'General case' 0 CA--C 1.538 0.489 0 N-CA-C 114.566 1.321 . . . . 0.0 114.566 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 mm -75.45 -63.79 0.64 Allowed Pre-proline 0 N--CA 1.475 0.824 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.421 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 12.2 Cg_endo -53.09 -38.68 80.91 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.766 1.644 . . . . 0.0 112.146 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -67.33 -59.63 3.25 Favored 'General case' 0 N--CA 1.441 -0.885 0 C-N-CA 121.055 -0.258 . . . . 0.0 110.666 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.53 HD13 ' O ' ' A' ' 60' ' ' LEU . 0.2 OUTLIER -58.05 -48.04 81.32 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.864 179.685 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -74.55 156.53 36.74 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.848 0.356 . . . . 0.0 110.632 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -155.55 -35.81 0.09 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.477 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.5 p30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.525 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 14.4 m -75.33 172.93 11.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.441 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 2.8 t -156.01 147.56 22.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.64 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.512 HG23 ' N ' ' B' ' 5' ' ' SER . 18.2 m -148.61 -40.77 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.249 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.521 ' C ' ' H ' ' B' ' 7' ' ' GLY . 0.3 OUTLIER -40.51 -63.99 0.65 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.37 179.803 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' B' ' 5' ' ' SER . 17.9 Cg_endo -57.9 3.62 0.12 Allowed 'Trans proline' 0 N--CA 1.495 1.601 0 C-N-CA 122.27 1.98 . . . . 0.0 112.231 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.767 ' O ' ' HB3' ' B' ' 10' ' ' ALA . . . -115.14 -68.07 0.44 Allowed Glycine 0 CA--C 1.527 0.83 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.622 HG23 ' N ' ' B' ' 9' ' ' LEU . 7.4 m -58.19 -52.55 57.35 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.214 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.622 ' N ' HG23 ' B' ' 8' ' ' VAL . 42.1 mt -54.84 -31.76 59.76 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' B' ' 7' ' ' GLY . . . -57.86 -36.34 72.2 Favored 'General case' 0 C--O 1.244 0.775 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' B' ' 8' ' ' VAL . . . -66.71 -30.93 77.04 Favored Glycine 0 CA--C 1.528 0.875 0 CA-C-N 113.768 -1.56 . . . . 0.0 111.319 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.465 ' N ' ' CD1' ' B' ' 12' ' ' ILE . 1.2 mp -71.32 -39.8 72.71 Favored 'Isoleucine or valine' 0 C--N 1.34 0.194 0 C-N-CA 119.684 -0.807 . . . . 0.0 109.4 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.732 HG12 HG21 ' A' ' 12' ' ' ILE . 1.5 m -57.92 -44.44 86.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 78.3 t -59.48 -48.85 85.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 CA-C-O 121.18 0.514 . . . . 0.0 110.267 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -59.07 -34.85 81.27 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -65.76 -39.41 91.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.878 0.37 . . . . 0.0 110.154 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.91 -47.41 86.51 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.86 -35.17 74.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.895 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.43 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -65.59 -48.78 71.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.482 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 99.6 m -59.76 -44.24 93.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.884 0.374 . . . . 0.0 110.542 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.2 t -63.98 -40.72 90.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -59.01 -51.06 71.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.821 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.438 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 66.6 mt -59.06 -48.02 88.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.484 -0.486 . . . . 0.0 109.995 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -48.53 -46.85 39.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.03 0.443 . . . . 0.0 109.925 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -58.05 -40.48 81.04 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -60.65 -37.08 80.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.281 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 50.3 t -62.26 -42.28 94.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 61.5 t80 -63.19 -38.92 93.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.981 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -60.99 -41.07 95.77 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.742 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 32.7 tp -48.19 -39.21 20.22 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.829 -0.349 . . . . 0.0 110.278 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 77.34 92.63 0.25 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.844 0.354 . . . . 0.0 110.504 179.953 . . . . . . . . 0 0 . 1 stop_ save_